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SUMMARY 
 
Transmissible spongiform encephalopathies (TSE), also known as prion diseases, comprise a class 
of neurological lethal disorders, affecting both humans and animals. TSEs are commonly associated 
with the formation of abnormal protein aggregates and plaques observed in the central nervous 
system (CNS) of the affected individual leading to neuronal cell death. The observed aggregates 
originate from accumulation of the abnormal isoform (PrPSc) of the host encoded cellular prion 
protein (PrPc) mainly responsible for the pathology of the disease. Several functions have been 
described for PrPc, however, little is known about the exact role of PrPc in the disease and the 
underlying mechanisms of accumulation and neurodegeneration, respectively.  
The 37 kDa/67 kDa laminin receptor LRP/LR has been identified as a cellular surface receptor for 
both PrPc and PrPSc. In addition, LRP/LR is thought to participate in the prion protein uptake in 
intestinal cells such as enterocytes suggesting an implication in the oral prion protein uptake. The 
crucial role of LRP/LR in the prion life cycle indicates new possibilities for the development of an 
alternative therapy for prion diseases. Tools directed against or downregulating the laminin receptor 
have been developed. Among them, anti-LRP/LR antibodies have been proven to block the PrP- 
LRP/LR interaction and their potential in prion disease therapy using experimental prion infection 
of mice was demonstrated: Passive immunotransfer (intraperitoneal (i.p.) injection) of the 
polyclonal antibody W3 into scrapie infected mice reduced the peripheral prion propagation and 
prolonged their survival. Furthermore, i.p. treatment of prion infected mice with single chain 
antibodies (scFvs) directed against LRP, reduced also the peripheral prion propagation in scrapie 
infected mice. Delivery of the scFvs via recombinant Adeno-Associated Viral vectors (rAAVs) 
resulted in an efficient expression of these antibodies and reduced also the peripheral prion 
propagation of scrapie infected mice, due to trafficking of the i.c microinjected viruses to the spleen. 
LRP/LR plays a crucial role in the metastatic process of tumor cells, proliferation and angiogenesis, 
mainly due to laminin1-LRP/LR interaction. Tools directed against LRP/LR, such as single chain 
antibodies (scFvs) and full-length IgG antibodies have been proven to interfere with the laminin-1 
binding to LRP/LR and hampered the invasion process of tumorigenic cells, therefore providing 
efficient tools targeting the metastasis of tumor cells. 
Anti-LRP/LR antibodies might represent alternative promising therapeutics for the treatment of 
cancer, especially for preventing metastatic spread, and prion diseases. 
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1. Transmissible spongiform encephalopathies 
 
Prion diseases or transmissible spongiform encephalopathies (TSEs) comprise a rare group of 
neurodegenerative disorders affecting both humans and animals. Histopathological changes in the 
brain of the affected individuals exhibit vacuolization, also termed spongiosis, reactive changes of 
astrocytes (gliosis) and variable loss of neurons. The central feature is the conversion of the host 
encoded cellular prion protein (PrPc) into an abnormal aggregated isoform, designated PrPSc (Bolton 
and Bendheim, 1988; Prusiner, 1998; Telling et al., 1996). The mechanism of neurodegeneration 
that accompanies the accumulation of the PrPSc is still not clarified. Characteristic 
neurodegenerative symptoms like dementia, convulations, ataxia, balance and coordination 
dysfunction and behavioral personality changes occur in most cases after a long incubation phase 
without clinical signs. In humans, incubation periods can vary from 1.5 to 40 years. To date, there is 
no therapy available to cure the individuals. 
 
1.1 Human TSEs 
 
In the early 1920s the first human prion-like disease was described by Creutzfeldt and Jakob, 
(Creutzfeldt, 1920; Jakob, 1921), followed by the discovery of an unusual inherited progressive 
cerebellar ataxia associated with amyloid plaque formation in the brain by Gerstmann, Sträussler 
and Scheinker, (Gerstmann, 1936), later termed Gerstmann-Sträussler-Scheinker syndrome (GSS). 
Kuru and fatal familial insomnia (FFI) have been discovered later and also classified as human prion 
diseases (Table 1). All of them are related to the abnormal form of the cellular prion protein PrPc 
and share spongiform degeneration of neurons in the brain concomitant with amyloid plaque 
formation, which can vary among the prion diseases. 
Experimental transmission of prion diseases has been successfully reported (Cuillé, 1936; Gajdusek 
et al., 1966; Gajdusek et al., 1968; Gibbs et al., 1968), thus justifying the term transmissible 
spongiform encephalopathy (TSE). Creutzfeldt-Jakob disease (CJD), which is the most frequent 
human prion disease, can be classified into four categories comprising a sporadic, a genetic, an 
iatrogenic and a variant type (Prusiner, 1993), respectively. 
- The sporadic form (sCJD) (Johnson and Gibbs, 1998) represents approx. 85% of all CJD 
cases and affects women and men equally (Kretzschmar, 1993). Disease outcome occurs at 
the median age of 60 years with a duration time from onset to death of approx. 5 months 
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(Collins et al., 2006). sCJD is characterized by rapidly progressive and multifocal dementia 
and cerebellar degeneration usually with myoclonus (Collinge, 2001). The classical form is 
supposed to occur through spontaneous misfolding of the cellular prion protein PrPc 
resulting in a conformational altered form designated PrPSc (PrP scrapie). Additionally, at 
codon position 129 in the prion protein gene PRNP, homozygosity for amino acid 
methionine or valine have been identified as a predisposing factor in the majority of 
sporadic CJD cases (Palmer et al., 1991). sCJD is currently divided into further clinical 
subtypes depending on the biochemical phenotype (Yuan et al., 2006). 
- The iatrogenic form of CJD (iCJD) represents a rare disease resulting from neurosurgery, 
corneal grafting or human dura mater implants which have been contaminated with 
infectious prions (Boutoleau et al., 2003; Yamada et al., 1994). A correlation between 
valine homozygosity at position 129 on the PRNP gene (Collinge et al., 1991) and 
susceptibility for iCJD has also been found. Contaminated human growth hormone (hGH) 
or pituitary derived gonadotropin (hGNH) actually represents the main source of iCJD 
reported in UK (Swerdlow et al., 2003), Netherlands (Croes et al., 2001) and France 
(Huillard d'Aignaux et al., 1999). The disease was first discovered in 1974 in a US patient 
having received a corneal transplant from a donor who had suffered from CJD (Duffy et al., 
1974). The incubation period, or latent period (time from exposure to the agent until clinical 
onset) ranges from two years to more than ten years.  
- Genetic or familial CJD (fCJD) is associated with mutations within the prion protein gene 
PRNP, sometimes supposed to be inherited (Hsiao et al., 1989). The former used term 
“inherited” or “familial” CJD is not always appropiate, since not all patients with PRNP 
mutations appear to have affected familiy members. Therefore TSE cases associated with a 
PRNP mutation are termed “genetic TSE” (gTSE) (EuroCJD, 2001; Goldman et al., 2004) 
and include also cases without an apparent family history. The clinical and pathological 
symptoms as well as the onset age and duration depend on the mutational background into 
the PRNP gene. The majority of familial CJD is associated with a mutation in the PRNP 
gene at codon 200 (E200K) (Bertoni et al., 1992; Chapman et al., 1994; Goldfarb et al., 
1991b; Rene et al., 2007) or with a mutation at position 178 (D178N) (Haltia et al., 1991).  
- A new variant of CJD (vCJD) was first described in the UK in 1996 (Will et al., 1996) and 
is thought to originate from the consumption of cattle products contaminated with bovine 
spongiform encephalopathy (BSE) prions (Bruce et al., 1997). Experimental transmission of 
BSE to mice confirmed that vCJD is caused by the same prion strain that has led to BSE 
(Bruce et al., 1997). In addition, incubation period and neuropathological changes observed 
in mice transgenic for bovine PrP displayed similarities between BSE and CJD (Scott et al., 
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1999) confirming that the BSE agent has crossed the species barrier and caused a zoonotic 
disease in humans (Bosque et al., 2002; Butler, 2002). Long incubation periods in prion 
diseases and the resulting late detection of the disease in an affected individual, 
respectively, raised concerns of an epidemic (Cousens et al., 1997; Ghani et al., 1998). 
vCJD can be distinguished from sCJD by a longer disease duration (up to 22 month versus 6 
month), and distinct neuropathological features (e.g. earlier onset of the disease (age 19-
39)). Despite the UK, where most vCJD cases have been reported, vCJD was also observed 
in many other countries worldwide, like France (Streichenberger et al., 2000), Spain 
(EuroSurveillance (Watt et al., 2005)), USA, Japan and Saudi-Arabia 
(EUROCJD/NEUROCJD). To date, no vCJD case has been reported for Germany (CJD 
Surveillance Unit Munich/Göttingen). Characteristic features comprise psychiatric 
symptoms and after a median period of 6 months ataxia, involuntary movements and 
cognitive impairment become apparent (Will et al., 2000). In contrast to other TSE forms, 
the abnormal prion protein isoform was additionally detected outside the CNS in tonsils 
(Hill et al., 1997) and lymphatic tissue (Ironside, 1998). For the development of secondary 
vCJD, which is distinct from the BSE originated vCJD, another source has been postulated 
based on sheep transmission experiments. BSE was efficiently transmitted via blood 
transfusion causing vCJD (Houston et al., 2000; Hunter et al., 2002). Despite blood 
products, tissue or organ transplantation might also transmit prion disease to humans 
causing vCJD (Peden et al., 2004; Wroe et al., 2006). Recently, efficient transmission of 
prion infection was observed in mice transgenic for human PrP inoculated with vCJD rectal 
tissue (Wadsworth et al., 2007), suggesting a possible risk for disease transmission via 
transplantation of gastrointestinal tissue. All reported vCJD cases displayed homozygosity 
for methionine at codon 129 in the PRNP gene (Collinge et al., 1996a; Collinge et al., 
1996b) (Robert Will, CJD surveillance Unit Edinburgh, may 2008, personal 
communication). However, it is assumed that in principle all individuals, irrespective of the 
PRNP codon 129, might be susceptible to secondary transmission of vCJD through routes 
such as blood transfusion (Bishop et al., 2006). 
Gerstmann-Sträussler-Scheinker syndrome (GSS) is mostly described in a familial context. To 
date only few sporadic cases have been reported (Masters et al., 1981). The syndrome was first 
described in 1928 by the Austrian neurologist Josef Gerstmann followed by a detailed report in 
collaboration with the colleagues Isaak Scheinker and Erwin Sträussler in 1936 (Gerstmann, 1936). 
This class of prion disease represents a chronic cerebellar ataxia concomitant with multicentric 
amyloid plaques. The majority of the affected families display PRNP point mutations at codon 102 
(Hsiao et al., 1989). However, mutations e.g. on positions 198 (F198S), 117 (A117V) (Piccardo et 
al., 2001), 131 (G131V) (Panegyres et al., 2001) or 105 (P105L) (Kubo et al., 1995) have been 
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found in GSS patients. Mice carrying a substitution of leucine for proline at codon 102 (P102L) 
within the PRNP gene, spontaneously developed GSS-like neurologic symptoms of ataxia, lethargy, 
and rigidity accompanied by spongiform degeneration throughout the brain and served as a model 
for studying and reproducing GSS (Hsiao and Prusiner, 1991).  
Fatal familial Insomnia (FFI) has been found to be worldwide distributed e.g. in Austria, (Almer 
et al., 1999), Italy (Padovani et al., 1998), Australia (McLean et al., 1997), Japan (Nagayama et al., 
1996) and China (Spacey et al., 2004). Its occurrence is associated with a PRNP mutation at position 
178 (D178N) (Medori et al., 1992a), which has also been observed in a subtype of familiar CJD 
(fCJD) (Medori et al., 1992b). FFI is characterized by thalamic degeneration, dysautonomia, 
dementia and insomnia. Although FFI and fCJD are linked to the same PRNP mutation at position 
178, they can be distinguished by the methionine/valine polymorphism at 129 (Goldfarb et al., 
1992). A sporadic form (sFI) has been reported in two patients displaying homozygocity for 
methionine at position 129 without any mutations in the PRNP gene locus (Scaravilli et al., 2000). 
An atypical case of FFI has been reported recently harbouring neither mutation nor homozygocity 
for methionine at codon 129 (Piao et al., 2005). 
Kuru (means “trembling with fear“ in the native language) resulted from transmission of prions by 
ritualistic cannibalism (Gajdusek, 1977). Restricted to the ‘Fore’ people in the eastern highlands of 
New Guinea, the disease occurred mostly in children and women due to consumption of brain from 
deceased familiy members (Alpers and Gajdusek, 1965). In 1959, the government banned the 
cannibalistic practice. Lesions observed in the brain of patients were similar to those found in 
scrapie infected animals (Gajdusek, 1967; Gajdusek et al., 1966). 
 
Table 1. Human prion diseases  
Human TSE Origin  Initial description 
sporadic CJD Somatic mutation in the PRNP gene or spontaneous 
conversion of PrPc to PrPSc 
1921 
iatrogenic CJD Infectious origin (transmission through neurosurgery or 
contaminated hormons) 
1974 
genetic/familial 
CJD 
4-9 additional octarepeat insertions in the  PRNP gene, point 
mutations at position 178 
1924 
variant CJD Infectious origin (transmission through contaminated food) 1996 
FFI Point mutation in the PRNP gene at codon 178 1986 
GSS Mutation in the PRNP gene at codon 102, 117, 198 or 217 1928  
Kuru Infectious origin (transmission through cannibalistic practice) 1955 
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1.1.1 Genetic background of human prion diseases 
 
In genetic prion disorders, the disease phenotype seems to be determined by the combined effects of 
the PRNP polymorphism at the coding region 129 (two variant alleles: methionine or valine), other 
pathogenic mutations and the type of the abnormal prion protein (PrPSc). Three types of pathogenic 
PRNP mutations can be distinguished (i) point mutations leading to an amino acid substitution (ii) a 
premature stop codon or (iii) the insertion of additional octarepeats (Collinge, 2001; Collinge et al., 
1992). Several subtypes of familial CJD have been associated with variable numbers of octapeptide 
coding repeats in the region of codon 51 to 91 (Goldfarb et al., 1991a). Point mutations are mainly 
located in the central and C-terminal region of PrP, and deletion and insertion mutations can be 
detected in the N-terminal region (Gambetti et al., 2003). The PRNP polymorphism at position 129 
is suggested to correlate with the different disease types and might influence the clinical course and 
pathological findings in CJD patients (Gambetti et al., 1995; Miyazono et al., 1992). For instance, 
patients heterozygous for PRNP 129 (M/V) exhibit a later disease onset. CJD patients 
predominantly displayed homozygosity for either methionine (M/M) or valine (V/V). The incidence 
of methionine homozygosity was found to correlate with increased susceptibility to the development 
of sporadic CJD, with the relative risks for the three genotypes M/M: V/V: M/V being 11:4:1 
(Windl et al., 1996). Recent studies suggest that a single nucleotide polymorphism at position 101 
(C/G) in the regulatory region of the PRNP gene might be a risk factor for sCJD among M/V 
heterozygous patients (Bratosiewicz-Wasik et al., 2007). Additional data originating from transgenic 
mice suggest that human PRNP 129 heterozygotes might be more susceptible to a secondary vCJD 
infection than to cattle BSE prions and may represent a neuropathological phenotype distinct from 
vCJD (Asante et al., 2006). The variant CJD phenotype was also observed in mice transgenic for 
human PRNP 129 methionine homozygosity (Wadsworth et al., 2004) suggesting that the presence 
of valine at 129 may prevent vCJD. Recently, data on worldwide genetic TSEs between 1993 and 
2002 have been collected and analysed (EUROCJD group) regarding PRNP mutations, pathological 
findings and phenotype (Kovacs et al., 2005). This study reported for example that (i) the majority 
of gTSE patients display methionine at codon 129 (M/M 67,9%; M/V 25.8%; V/V 6.3%) in 
combination with E200K, and (ii) that the distribution of gCJD is geographically heterogenous. 
Base pair insertions for example, associated with the gCJD phenotype, GSS and FFI cases, revealed 
longer disease duration compared to cases with point mutations. In addition, the PRNP 129 
polymorphism seems to influence the phenotype of gCJD (Kovacs et al., 2005). 
The polymorphic variation at position 129 on PRNP has been supposed to remarkably influence the 
ability of the protein to form amyloid fibrils spontaneously (Lewis et al., 2006b). Kinetic studies 
suggest that valine in contrast to methionine accelerates amyloid formation (Baskakov et al., 2005). 
 10 
Further in vitro studies evidenced that polymorphism at 129 strongly influences the conformation of 
the amyloid fibrils (Jones et al., 2006).  
1.2 Animal TSEs 
 
Prion diseases have also been observed in a variety of animal species (Table 2), posing a risk for 
transmission to humans via prion contaminated food. 
Scrapie has been discovered over 300 years ago (Brown and Bradley, 1998). It has been described 
as a slowly progressive disease causing neurodegeneration in the central nervous system (CNS), 
mainly in sheep and goats. The term “scrapie“ originates from the tendency of affected sheep to 
scrape off their wool. The first atypical scrapie case was discovered in Norway 1998 (Benestad et 
al., 2003) newly classified as Nor98. The discovery was followed by reports of further unusual cases 
displaying distinct neuropathological findings (Klingeborn et al., 2006) for example in Portugal 
(Orge et al., 2004), in Germany and France (Buschmann et al., 2004), in Sweden (Gavier-Widen et 
al., 2004) and Belgium (De Bosschere et al., 2004), respectively. 
 Table 2. Animal prion diseases 
Animal TSE  Origin Initial 
description 
Scrapie in sheep and goats sporadic 1732 
BSE in cattle Infectious origin (transmission through scrapie 
contaminated food) 
1987 
CWD in captive mule, deer and 
elk 
unknown 1967/1978 
FSE in captive and domestic 
cats 
Infectious origin (transmission through BSE 
contaminated food) 
1986/1990 
TME in minks infectious origin (transmission through BSE 
contaminated food) 
1947 
PSE in non human primates 
e.g. macaques, lemur 
unknown 1996 
EUE in zoo antelopes Infectious origin (transmission through 
contaminated food, probably BSE) 
1986 
 
Although sheep scrapie is the most common animal prion disease, bovine spongiform 
encephalopathy (BSE) has gained prominent attention, since oral uptake of infected meat evoked a 
 11 
new zoonotic disease in humans. The first BSE case in cattle has been reported 1986 in the UK 
(Wells et al., 1987). After a long incubation period (four to five years), spongiform degeneration in 
the brain leads to a neurological disorder. BSE is supposed to originate from scrapie contaminated 
food prepared from rendered carcasses (Wilesmith et al., 1988). Different “prion” types have been 
identified, revealing distinct biochemical and histopathological properties concerning the abnormal 
prion protein. BASE (bovine amyloidotic spongiform encephalopathy) (Casalone et al., 2004), a 
recently discovered subtype of BSE, displays similarities to the human sCJD suggesting to originate 
from a distinct prion strain. Experimental serial transmission studies using inbred mouse lines 
indicated that BASE might represent the origin of BSE (Capobianco et al., 2007). 
Chronic wasting disease (CWD) affecting captive and wild cervids including white tailed deer, 
mule deer, elk and moose has become economically important for North America. The disorder was 
first recognized in Colorado in 1967 and characterized in 1978 as a TSE (Williams and Young, 
1980). In contrast to BSE no evidence from a possible transmission of CWD prions to humans 
causing a zoonotic disease could be found yet (Belay et al., 2004), but cannot be excluded. 
Transmissible mink encephalopathy (TME) appeared in farmed mink in 1947 in Wisconsin and 
Minnesota (USA), probably through ingestion of scrapie contaminated meat (Marsh and Bessen, 
1993). 
Ingestion of BSE infected material has obviously caused feline spongiform encephalopathy (FSE) 
in captive cheetah, puma, ocelot, tiger and lion (Kirkwood and Cunningham, 1994). Also domestic 
cats have been diagnosed with FSE (Ryder et al., 2001). It is widely proposed that the observed FSE 
cases were caused by BSE contaminated commercial cat food. A ban on bovine spleen and CNS 
tissue in pet food was initiated in 1990 and all except one of the FSE cases to date occurred in cats 
born prior to the ban. 
In 1996, a first case of spontaneously developed spongiform encephalopathy has been observed in a 
rhesus monkey (macaca mulatta) (primate spongiform encephalopathy, PSE) in France (Bons et al., 
1996). Primates like lemurs infected with BSE displayed similar neuropathology to spontaneous 
infected zoo lemurs (Bons et al., 1999). 
Exotic ungulate encephalopathy (EUE) cases were diagnosed in hoofed zoo species like greater 
kudu, eland, nyala, gemsbok, Arabian oryx, a scimitar horned oryx and a bison (Kirkwood et al., 
1994) in British zoos. 
Small animals like hamsters, mice or bank voles (Piening et al., 2006) can be infected 
experimentally and serve currently as models for the analysis of molecular and biochemical 
mechanisms in prion pathology. 
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In parallel to human polymorphisms and genetic susceptibility for the development of a prion 
disease, association studies of PRNP and TSE aquisition have also been reported for animals 
(Goldmann, 2008). For example, the ovine PRNP polymorphism have been found to influence the 
susceptibility to scrapie and BSE and modulates disease progression in sheep (Goldmann et al., 
1990). Single amino acid changes as well as insertions/deletions within the octarepeat region of the 
N-terminus of the prion protein have been associated with the outcome of prion disease. In sheep, 
there are three PRNP codons (136, 154 and 171) that are of particular interest for both scrapie and 
BSE susceptibility. Ovine PrP allels comprise A136R154Q171 (ARQ) and V136R154Q171 (VRQ) 
(Goldmann, 2008). In elk, a polymorphism at codon 132 (methionine/leucine) of the PRNP gene, 
corresponding to the human 129 polymorphism, has been detected. Elk expressing 132 M/L and 132 
L/L seemed to be overrepresented among CWD infected individuals concluding that this 
polymorphism might also influence susceptibility to prion disease (O'Rourke et al., 1999).  
 
2. The cellular prion protein 
 
The cellular prion protein (PrPc) represents the central key player in prion diseases, which is during 
the course of disease proposed to be converted into an abnormal isoform, termed PrPSc (scrapie), 
PrPd (disease associated) or PrPTSE, respectively. Accumulation of the misfolded prion protein 
occurs mainly in the CNS, associated with neuronal cell death and plaque formation. 
PrPc is a monomeric N-glycosylated protein (30-35kDa) linked to cellular membranes via a glycosyl 
phosphatidylinositol (GPI) anchor (Stahl et al., 1987). There is evidence that PrPc occurs also in the 
chimeric form (Hundt et al., 2003; Kaimann et al., 2008). Like other GPI-linked proteins, it is 
enriched in detergent-resistant membranes (DRM) or sphingolipid-cholesterol-rich membrane 
microdomains (SCRMs) (Vey et al., 1996). While expressed in nearly all cell types, PrPc is 
abundantly expressed in neurons (Kretzschmar et al., 1986). In addition PrPc expression has been 
reported in astrocytes (Moser et al., 1995), in the periphery on lymphoid tissues and leukocytes (Li 
et al., 2001; Paltrinieri et al., 2004) as well as in follicular dendritic cells (FDCs) (McBride et al., 
1992; Thielen et al., 2001). Substantial amounts were also found in heart (Brown et al., 1990) and 
skeletal muscle (Bosque et al., 2002), intestinal tissues (Morel et al., 2004). In situ hybridization 
detected PrPc mRNA also in uterus and testis (Tanji et al., 1995). PrPc represents a highly conserved 
protein among mammals (Schatzl et al., 1995) (>85% homology between mouse and human 
sequence) and is universally expressed in vertebrate species (Wopfner et al., 1999). The 
corresponding PRNP gene was identified in 1986 (Basler et al., 1986; Chesebro et al., 1985) and has 
been mapped to 20p12-pter on the short arm of human chromosome 20 (Liao et al., 1986) and on 
mouse chromosome 2 (Sparkes et al., 1986). 
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2.1 Functional domains of the cellular prion protein 
 
PrPc (Figure 1) is composed of an N-terminal domain which contains a segment of four repeats of 
an octameric amino acid sequence (octapeptide repeat region) and one nonarepeat implicated in 
copper ion binding (Hornshaw et al., 1995). At the very N-terminus a 22 aa secretory signal peptide 
resides. A highly hydrophobic and conserved region, originally proposed as a transmembrane region 
(Yost et al., 1990) follows the octapeptide region. The amino acid length as well as position of prion 
proteins can vary among species to a small extend (Wopfner et al., 1999). In Syrian hamster and 
mice for example, PrPc is synthesized as a precursor of 254 amino acids (aa), whereas the human 
equivalent consists of 253 aa. PrPc can be present in distinct isoforms depending on proteolytic 
processing (full length and truncated), topology (GPI-anchored, transmembrane or soluble (see 2.2)) 
and glycosylation (non-, mono- and di-glycosylated). Glycosylation sites are variably occupied 
leading to non-, mono- or digylcosylated forms (Stahl et al., 1993). 
 
 
Figure 1. Primary structure of the Syrian hamster prion protein and posttranslational modifications. The 
hamster prion protein (254 aa) contains at the N-terminus a repeat region of four octarepeats and one 
nonarepeat (OR) implicated in copper binding. The highly structured C-terminus harbours two glycosylation 
sites (CHO) at Asparagin 181 (N-181) and 197 (N-197). During processing, a 22 amino acid long signal 
peptide at the N-terminus is cleaved and at the C- terminus 23 residues is removed upon addition of a GPI 
anchor to serin residue (Ser-231). Upon proteinase K digestion a resistant core remains designated as PrPres. A 
loop is generated by the disulfide bond between two cystein residues (C179 - C214). MA, membrane anchor 
region; HC, hydrophobic core; CC, charged cluster. adopted from (Aguzzi et al., 2007a). 
 
2.2 Trafficking of the prion protein 
 
A newly synthesized PrPc undergoes cleavage of the hydrophobic N-terminal signal peptide (22 
amino acids) and is targeted to the rER, where it is co- and posttranscriptionally modified including 
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N-glycosylation at two potential sites and the replacement of the hydrophobic carboxy terminal 
signal peptide by a GPI lipidic moiety.  
Due to the lack of a cytoplasmic domain, PrPc is believed to be endocytosed through clathrin-coated 
pits (Figure 2) by binding extracellularly to a transmembrane receptor harbouring endocytic motifs 
on its cytoplasmic domain. In this context it has been recently reported that the low density related 
protein LRP-1 mediates PrP endocytosis and is important for trafficking of PrPc in neurons (Parkyn 
et al., 2008). In addition, the 37 kDa/67 kDa laminin receptor LRP/LR, which is also a receptor for 
the prion protein (Gauczynski et al., 2001) is thought to be implicated in clathrin mediated prion 
endocytosis (Rieger et al., 1999).  
It has been reported that the chicken homologue of the mammalian prion protein (chPrP) cycles 
between the cell surface and an endocytic compartment with a transit time of approx. 60 min. 
(Shyng et al., 1993). More than 95% of the internalized protein is returned to the cell surface intact, 
and the remainder is proteolytically cleaved within the highly conserved region in the NH2-terminal 
half of the molecule (Sunyach et al., 2003). The N-terminal half of the chPrP polypeptide chain is 
essential for its endocytosis via clathrin-coated pits (Shyng et al., 1995). Studies on primary cultured 
neurons and N2a neuroblastoma cell line demonstrated also that PrPc is rapidly and constitutively 
endocytosed. While it is on the cell surface, prion protein leaves the lipid raft domains to enter non 
raft-membrane domains from which it enters coated pits (Sunyach et al., 2003). The GPI anchor is 
thought to be responsible for the lipid raft association of PrPc (Taraboulos et al., 1995). 
Cryoimmunogold electron microscopy studies revealed that PrP is also highly enriched in caveolae 
and caveolae-containing endocytic structures in CHO (Chinese hamster ovary) cells stably 
transfected with Syrian hamster PrP raising the possibility of another non-clathrin mediated uptake 
mechanism for PrPc (Peters et al., 2003) (Figure 2). In addition to the cellular PrP (Harmey et al., 
1995), the proteinase K resistant PrP was found in caveolae like domains (CLD) (Vey et al., 1996). 
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Figure 2. Trafficking of PrPc demonstrating three possible endocytotic mechanism of PrPc internalization. 
Both clathrin-mediated as well as caveolae mediated endocytosis are suggested to be implicated in prion 
protein life cycle since PrPc was found to be associated with caveolin and clathrin. PrPc transits through the 
secretory pathway to reach the cell surface. Finally, an additional non-clathrin and non-caveolin, but raft 
dependent endocytotic pathway has been proposed. 
 
In contrast to the majority of glycoproteins which are synthesized in a single orientation with respect 
to the endoplasmatic reticulum (ER) membrane, PrPc can be synthesized in different topological 
forms (Lopez et al., 1990; Yost et al., 1990): the fully translocated form secPrP (Hay et al., 1987) and 
two transmembrane configurations NtmPrP and CtmPrP, respectively (Hegde et al., 1998; Lehmann 
and Harris, 1995). NtmPrP and CtmPrP, span the lipid bilayer once, via a highly conserved 
hydrophobic region (amino acid residue 11-134), with either the N- or the C- terminus, respectively, 
on the extracytoplasmatic site of the membrane. In addition, CtmPrP has been proposed as a key 
neurotoxic intermediate for example in Gerstmann-Sträussler-Scheinker syndrome, suggested to 
cause neurodegeneration (Hegde et al., 1999; Stewart et al., 2001). 
 
 
2.3 Tertiary structure of PrPc 
 
NMR measurements on prion proteins from various species including mouse (Riek et al., 1996), 
Syrian hamster (Donne et al., 1997) human (Zahn et al., 2000), cattle (Lopez Garcia et al., 2000), 
sheep, cat, dog and pig (Lysek et al., 2005), chicken turtle frog (Calzolai et al., 2005), elk (Gossert 
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et al., 2005) and african lion (Maj et al., 2008) share a common architecture. The structure of PrPc is 
composed of a flexible unstructured N-terminal region (aa 23-124) and a well-ordered C-terminal 
globular domain (aa 125-228) including three α-helices and a two stranded antiparallel β-sheets that 
flank the first α-helix (Figure 3).  
 
 
 
 
 
2.4 Interaction partners for the cellular prion protein 
 
Several PrPc-mediated functions are related to the interaction with receptors, other proteins or 
chemical compounds (Vana et al., 2007). 
PrPc is a cell surface receptor for glycosaminoglycans (GAGs) (Gabizon et al., 1993; Pan et al., 
2002). Binding of the prion protein to GAGs, laminin and the 37 kDa/67 kDa laminin receptor 
LRP/LR, along with the neuronal cell adhesion molecule (NCAM) mediates the contact between 
neurons and other cells and the extracellular matrix (Caughey and Baron, 2006). In addition 
interaction with LRP/LR together with heparan sulfate proteoglycanes (HSPGs) is an important 
event in binding and internalization of the cellular prion protein (Hundt et al., 2001).  
The neuroprotective activity exerted by PrPc (Chiarini et al., 2002) is associated with the binding 
to laminin (Graner et al., 2000) and/or to the precursor of the laminin receptor LRP/LR (Rieger et 
al., 1997). In addition, molecular chaperone and stress protein binding (Edenhofer et al., 1996; Jin et 
al., 2000; Zanata et al., 2002), or interaction with members of the antiapoptotic Bcl-2 family 
Figure 3. Model of the tertiary structure of the cellular 
prion protein deduced from NMR spectroscopy 
inserted into a lipid bilayer, including the unstructured 
N-terminal tail and the GPI anchor. Two antiparallel β-
strands are indicated in blue, three α-helices are shown 
in red. Sugar residues are depicted as yellow circles. 
The indicated loop connects the second β-strand and 
the third α-helix. (adopted from (Aguzzi et al., 2007b) 
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(Kurschner and Morgan, 1995) has been reported. Interaction with the stress inducible protein 1 
(ST-1) elicits neuroprotective signals that rescue cells from apoptosis (Zanata et al., 2002). 
Furthermore, the PrPc-ST-1 interaction modulates short-term memory as well as long-term memory 
consolidation in rats (Coitinho et al., 2007). Direct interaction at the neuronal cell surface and 
association of PrPc with the neural cell adhesion molecule (NCAM) in lipid rafts (Schmitt-Ulms et 
al., 2001), has been shown to be important for neurite outgrowth (Santuccione et al., 2005). 
Additionally, interaction with laminin in the hippocampus, suggests a critical role for PrP in 
memory processing by activation of both PKA and ERK1/2 signaling pathways (Coitinho et al., 
2006). 
 
2.5 The physiological function of the cellular prion protein 
 
Although PRNP knock out mice (PrP0/0) developed normal (Bueler et al., 1992) and display only 
minor phenotypic anomalies (Tobler et al., 1996), important physiological functions have been 
attributed to PrPc including the regulation of immune responses, signal transduction and pro- as well 
as antiapoptotic functions (Hu et al., 2007) (Table 3 and Table III in (Vana et al., 2007)). Many 
functions have been studied using transgenic mouse models. Prion protein knock out mice (PrP0/0 
mice) exhibited no obvious alterations in synaptic transmission and neuronal excitability (Lledo et 
al., 1996). However, PrPc knock out mice displayed alterations in nerve fiber organization (Colling 
et al., 1997), circadian rhythm (Tobler et al., 1996) and spatial learning (Criado et al., 2005), 
memory formation (Coitinho et al., 2006) or cognitive function. The functions seem to vary and 
depend on the cell type and location.  
A variety of functions have been found concomitant with PrPc expression. For example it has been 
suggested that PrPc acts as a positive regulator of neural precursor proliferation during 
developmental and adult mammalian neurogenesis (Steele et al., 2006). Present on hematopoetic 
stem cells (Zhang et al., 2006), PrPc is supposed to support their self renewal. 
A regulatory role in apoptotic pathways within the photoreceptor has been also attributed to the 
prion protein. Studies demonstrated that the in vivo expression level of PrPc in the retina of mice 
inversely correlated with the susceptibility of photoreceptors to light damage. Therefore PrPc 
expression may execute neuroprotective activity for the receptors in the retina (Frigg et al., 2006). 
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Table 3. Physiological functions of the cellular prion protein PrPc 
Function interaction partner/mode of action Reference 
Neuroprotection PrPc transduces neuroprotective signals  (Chiarini et al., 2002) 
(Roucou et al., 2004) 
Survival and cell to 
cell interaction 
PrPc on astrocytes interacts with 
laminin and ST-1 
(Lima et al., 2007) (Zanata 
et al., 2002) 
Antiapoptotic  PrPc inhibits Bax-induced cell death in 
human primary neurons  
PrPc binds to bcl-2 
(Bounhar et al., 2001) 
(Kuwahara et al., 1999) 
Proapoptotic PrPc increases levels of p53 (Roucou and LeBlanc, 
2005) 
Modulation of T-
cell response 
Association with cytokine production (Bainbridge and Walker, 
2005) 
T-cell development 
and activation 
PrPc inducec signal pathway: ZAP 
70/Fyn; MAPK association 
(Cashman et al., 1990; 
Mabbott et al., 1997; Mattei 
et al., 2004) 
Synaptic function Binding of PrPc to copper  (Brown, 1999; Collinge et 
al., 1994) 
Memory 
consolidation 
PrPc interacts with ST-1 (Coitinho et al., 2007) 
Cell adhesion PrPc interacts with NCAM and 
LRP/LR 
(Mange et al., 2002; 
Schmitt-Ulms et al., 2001) 
Oxidative stress PrPc protects against ROS species 
mediated DNA damage 
(Watt et al., 2007) 
SOD activity PrPc binds to copper (Vassallo and Herms, 2003) 
Cell redox 
homeostasis 
PrPc activates signaling pathway: 
Fyn/ERK1/2 activation 
(Schneider et al., 2003) 
Copper uptake Expression of PrPc at the synapse (Brown et al., 1997a; 
Kretzschmar et al., 2000) 
Nervous system 
development 
PrPc interacts with NCAM (Santuccione et al., 2005) 
Phagocytosis/ 
inflammatory 
response 
PrPc expression on leucocytes 
activation of signaling pathways 
(de Almeida et al., 2005) 
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PrPc has been demonstrated to play a role in other neurodegenerative diseases such as Alzheimers 
disease or Chorea Huntington. Overexpression of cellular prion protein protects cells from 
huntingtin aggregation by increasing the proteasomal activity and reducing the reactive oxygen 
species (ROS) (Lee et al., 2007). Since prion protein deposits have been found in senile plaques in 
the brain of Alzheimer patients (Ferrer et al., 2001), a role for PrP in Amyloid beta (Aβ) plaque 
formation has been proposed (Schwarze-Eicker et al., 2005). In addition, it has been shown that the 
prion protein regulates the ß-secretase activity (Parkin et al., 2007), an enzyme which is responsible 
for the proteolytic processing of the amyloid precursor protein (APP) leading to beta amyloid plaque 
formation in Alzheimer patients (Vassar et al., 1999).  
It has been demonstrated, that the octapeptide repeat region of the prion protein is able to bind 
metal ions such as Zinc (II) (Gaggelli et al., 2005) or manganese (II) (Jackson et al., 2001) and up to 
four copper ions (Viles et al., 1999). Furthermore, the binding ability of PrPc to copper in vivo 
(Brown et al., 1997a) is related to an anti-oxidant activity (Brown et al., 2001) and stimulates 
endocytosis of PrPc (Pauly and Harris, 1998) via clathrin coated pits. It has been recently reported 
that the transmembrane LRP1 (LDL receptor-related protein 1) is required for the Cu2+-mediated 
endocytosis of PrPc in neuronal cells (Taylor and Hooper, 2007). A role as a copper sensor in 
synaptic transmission has also been proposed for PrPc (Vassallo and Herms, 2003). An additional 
site within aa residues 91-111 is controversially discussed as the so-called fifth site implicated in 
copper binding (Burns et al., 2003). Deletion of the copper binding octapeptide region has been 
reported to impair SOD like activity of PrPc (Brown et al., 1999a), confirming the neuroprotective 
effect of PrPc (Kuwahara et al., 1999). It has been reported that PrPc protects cells against reactive-
oxygen-species-mediated DNA damage requiring the octapeptide repeat region (Watt et al., 2007). 
In a process termed beta-cleavage, PrPc is cleaved at the end of the copper-binding octapeptide 
repeats through the action of reactive oxygen species (ROS). Lack of ROS-mediated beta-cleavage 
of PrP has been demonstrated to correlate with the sensitivity of the cells to oxidative stress (Watt et 
al., 2005). However, the SOD activity is under discussion since in vivo experiments did not confirm 
such an activity (Hutter et al., 2003), as well as recombinant PrP has not been proven to exhibit 
SOD activity, suggesting that the role in oxidative stress might be an indirect one (Jones et al., 
2005). 
Recently, it has been demonstrated that PrPc might serve as a receptor for neurotrophins, mediating 
additional neuroprotective effects (Chiarini et al., 2002) probably through the inhibition of the 
mitochondrial proapoptotic pathway (Marciano et al., 2004). PrPc activation on the cell surface 
through antibodies led to contradictory results. On the one hand, in vitro, antibody-mediated PrPc 
dimerization led to a rapid phosphorylation of extracellular regulated kinases (ERK) 1 and 2, and 
promoted neuronal survival (Schneider et al., 2003). On the other hand, cross-linking of PrPc by 
monoclonal antibodies in vivo was found to induce rapid and extensive apoptotic cell death of 
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hippocampal and cerebellar neurons suggesting a role of PrP in the control for neuronal survival 
(Solforosi et al., 2004). Since PrPc is present in synaptic plasma membrane and in synaptic vesicles 
(Herms et al., 1999), it appears to be partly responsible for early synaptic transmission in neurons 
and reorganization of neuronal circuitry in the hippocampus (Colling et al., 1997).  
 
Pro as well as antiapoptotic functions have been attributed to the prion protein (for review 
(Roucou and LeBlanc, 2005)). The absence of PrPc in hippocampal neurons led to apoptotic cell 
death in vitro (Kuwahara et al., 1999). A structural similarity between PrPc and the BH2 domain of 
B-cell lymphoma (Bcl)-2 family members have been observed and it could be demonstrated that 
PrPc protects human neurons against Bax (Bcl-2-associated X protein)-mediated cell death in an in 
vitro culture system (Bounhar et al., 2001). The pro-apoptotic protein Bax is expressed in neurons 
and initiates the release of apoptotic factors by mitochondria, accelerating cell death (Martinou and 
Green, 2001). Expression of Bcl-2 prevents Bax-induced apoptosis in human neurons. Coexpression 
of PrPc also completely prevented Bax-induced cell death. Therefore, PrPc in the CNS might protect 
neurons against Bax-mediated cell death (Bounhar et al., 2001; Roucou et al., 2004).  
PrPc expression was also found in correlation to cancer. For example an antiapoptotic activity of 
PrPc has been demonstrated in a human breast carcinoma cell line (Diarra-Mehrpour et al., 2004). 
Liang et al discovered a Bcl-2 dependent antiapoptotic effect of PrPc (Liang et al., 2006). 
Expression of PrPc in a gastric cancer cell line led to an upregulation of Bcl-2 whereas p53 and Bax 
were downregulated. In another study the same group demonstrated that PrPc is overexpressed in 
metastatic cell lines compared to nonmetastatic ones (Liang et al., 2007). The N-terminal fragment 
(amino acid 24-90) was suggested to be an indispensable region for signal transduction and 
invasion-promoting function of PrPc. It has been suggested that the existence of the N-terminal 
region of PrPc might promote the invasive and metastatic abilities of gastric cancer cells. In 
addition, this group proposed that PrPc expression might be required for transcriptional activation of 
Cyclin D1 to regulate the G1/S phase transition, mediated by the octapeptide region. 
 
2.6 The prion protein and its relation to prion diseases  
 
Although the physiological functions of the prion protein remain unclear, it is widely accepted that 
the pathogenesis of prion diseases requires the expression of PrPc. The finding that knockout mice 
carrying a homozygous deletion of the PRNP gene fail to develop disease upon inoculation with 
infectious brain homogenates (Bueler et al., 1993) demonstrated that the presence of the prion 
protein is important for the development of the disease. In addition, brain tissues of PrPc deficient 
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cattle (Richt et al., 2007) were resistant to prion propagation confirming that the presence of PrPc is 
crucial for the development of BSE in cattle. Furthermore, all cases of familial TSE cases are 
characterized by genetic mutations within the PRNP gene (Hsiao and Prusiner, 1990), which argues 
for a major role of the PrPc in this class of neurodegenerative disorders.  
 
2.6.1 The nature of the prion agent 
 
The theory of a self propagating proteinaceous agent (Prusiner, 1982) was proposed after the 
isolation of a proteinase K resistant glycoprotein from scrapie infected hamster brain. It was 
associated with infectivity and identified as the scrapie agent designated the prion protein PrPSc 
(Bolton et al., 1982). Due to the observed resistance to UV, high pressure/temperature or nucleases, 
the agent had been proposed to be devoid of nucleic acids (Alper et al., 1967; Griffith, 1967; 
Weissmann, 1991). Prusiner, who gained the novel price for medicine in 1997 (Bonn and Ault, 
1997), defined the term prion as a “small proteinaceous infectious particle that resists inactivation 
by procedures which modify nucleic acids” (Prusiner, 1982). It was the first time that a hypothesis 
suggested that a disease causing agent is composed of a single protein only. The second hypothesis 
termed “virino hypothesis” (Dickinson and Outram, 1988) postulates that the infectious agent is 
composed of a scrapie specific nucleic acid associated or coated with the host encoded protein PrPc. 
However no striking evidence was found which argues for a TSE specific nucleic acids (Safar et al., 
2005). For example virus like particles have been found in neuroblastoma cells infected with 
Creutzfeldt Jakob disease agent (Manuelidis et al., 2007) which might exclude a solely prionic 
nature.  
 
2.6.2 Generation of PrPSc – mechanisms of conversion 
 
The largely accepted hypothesis for the prion propagation describes that an abnormal prion protein 
conformation, which propagates itself in an autocatalytic manner, binds to the cellular form 
(corresponding to the substrate) and converts it to the infectious isoform. Two models have been 
postulated to explain the mechanism covering the generation of the aggregated prion protein termed 
PrPSc or PrPd. 
The template directed refolding model (Figure 4) postulates an interaction between endogenous PrPc 
and the exogenously produced PrPSc resulting in a heterodimer, promoting the conformational 
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conversion of the cellular prion protein into the PrPSc conformation (Prusiner, 1991). Although the 
conversion process is extremely slow in the absence of PrPSc, it is irreversible. This is due to the 
extremely stable PrPSc, which is kinetically inaccessible. PrPSc initiates a catalytic cascade using 
PrPc or a partially unfolded intermediate (PrP*) converting it by conformational change into a more 
stable beta rich structure. The newly formed PrPSc turns again another PrPc molecule to a PK 
resistant PrP molecule.  
The seeding or nucleation model (Figure 4) proposes that the formation of PrPSc is initiated by a 
seed of aggregated PrPSc triggering a nucleation-dependent polymerization process (Come et al., 
1993; Jarrett and Lansbury, 1993). Conversion between the two forms is extremely fast. However, 
the PrPc conformation is thermodynamically favored. The presence of an aggregated seed, the 
“nucleus” stabilizes the unfavoured conformation. Recent studies indicate that the seeding model is 
actually the favoured model for prion conversion (Lee and Caughey, 2007). 
 
(Lansbury and Caughey, 
1995) 
Figure 4. Models explaining the PrPSc generation and propagation. The catalytic model (A) proposes that PrPSc 
promotes the conversion of PrPc into PrPSc. The generated stable molecule is now able to bind and catalyse the 
conversion of further PrPc into the disease associated PrPSc form. The nucleation-polymerisation (seeding) 
model (B) postulates that polymerization of PrPSc molecules result in an infectious seed, which is able to 
recruit further PrP molecules to build an amyloid structure. Fragmentation of large seeds results in several 
aggregates, acting themselves as a new seed. (adopted from (Aguzzi and Polymenidou, 2004)) 
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2.6.3 Characteristics of proteinase K resistant PrP fragments 
 
The conversion of the cellular form to the infectivity associated PrPSc involves changes in the 
secondary structure characterized by protease resistant, aggregated PrP (multimeric) and higher beta 
sheet content. Infrared spectroscopy and circular dichroism demonstrated that the secondary 
structure of PrPc is mainly composed of α-helices (42%), whereas PrPSc consists mainly of β-sheets 
(45%) (Cohen et al., 1994) (Table 4). The acquisition of the high beta sheet content enhances the 
resistance to PK (proteinase K) digestion (Caughey et al., 1991b; Pan et al., 1993) and renders it 
insoluble, which is the main reason that the three dimensional structure has not yet been resolved. In 
addition this protein has the tendency to form large, heterogenous aggregates. Based on the higher 
β-sheet content, several models have been hypothesized, whereas the model of Cohen and 
colleagues is one of the most favoured (Figure 5). The C-terminal portion of the prion protein, 
corresponding to the reported protease-resistant core fragment of the abnormal isoform PrPSc, was 
found to be essential for prion propagation. This is supported by the finding that antibodies to the C-
terminal portion of PrP inhibit PrPSc accumulation in cells persistently infected with prions (Enari et 
al., 2001; Peretz et al., 2001). 
 
 
Figure 5. Postulated model of the three dimensional PrPSc structure (right) compared with already solved PrPc 
structure) (left) The amino acid region 90-160 has been modeled onto α-helical architecture, while the C-
terminal helices are preserved from PrPc. (adopted from http://scienceblogs.com/retrospectacle/2007/2/basic 
_concepts_prions.php). 
 
It has been reported that Proteinase K digestion of scrapie infected hamster brain extract and, to a 
lesser extent normal brain homogenate, yielded a fragment designated PrP27-30 in infected brain 
(Figure 6a) (Oesch et al., 1985). Under conditions where PrPc and most other proteins are degraded, 
PrPSc is cleaved between aa residues 87 and 91 (depending on the prion protein species). This results 
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in a fragment (aa90-233) with the molecular weight of 27-30 kDa. PrP27-30 displays a characteristic 
electrophoretic mobility shift of the three bands corresponding to nonn-, mono- and diglycosylated 
forms, which is resistant to proteinase K digestion (therefore also termed PrPres) (Figure 6a). 
Depending on the disease, distinct biochemical glycosylation pattern can be observed designating 
different prion strains (different PrP species) (Figure 6b). The relative ratios of the three 
glycosylation forms among the various disease phenotypes are used for prion strain phenotyping 
(Aguzzi et al., 2007a). PrP27-30 has been reported to accumulate in rod-shaped polymers (McKinley 
et al., 1991) that are insoluble in aqueous, organic solvents as well as in nonionic detergents 
(Caughey et al., 1991b) and is able to build amyloid fibrils. In contrast PrPSc has a tendency to form 
aggregates (McKinley and Prusiner, 1991) (Table 4). 
Table. 4. Biochemical properties of cellular prion protein and Proteinase K cleaved derivatives 
isoform α-helix (%) β-sheet (%) solubility Proteinase K digestion aggregation status 
PrPc 43 ~3% soluble     sensitive monomeric/chimeric 
PrPSc 20 34 insoluble     partially resitant aggregates 
PrP27-30 29 31 insoluble     resistant amyloid fibrils 
 
 
            
Figure 6. The glycosylation pattern enables discrimination between PrPSc and PrPc, as well as between 
different prion strains. PrPc can be distinguished from PrPSc by limited proteolysis under conditions where 
PrPc is hydrolyzed and PrPSc is resistant. (a) To determine the PrPSc presence, tissues are digested with 
Proteinase K, which cleaves approx. 70 amino-terminal residues, resulting in a shift in the molecular mass (b) 
Different “prion” strains reveal distinct fragment pattern prion strains vary in their proteinase K cleavage sites, 
leading in differences in the molecular mass of the three glycoforms observed by western blotting. (modified 
from (Lawson et al., 2005)) 
 
a b 
Strain A 
Strain B 
glycosylation 
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2.6.4 Methods for the prion conversion mechanism  
 
To elucidate the in vivo conversion mechanism as well as the required components, techniques such 
as the cell free conversion assay or the protein misfolding cyclic amplification (PMCA) have been 
developed. In 1995, Caughey and colleagues demonstrated that PrPc can be converted into the PK 
resistant form PrPres, in the presence of PrPSc in a cell free system (Caughey et al., 1999; Horiuchi 
and Caughey, 1999). The in vitro generated PrPres has been confirmed to be infectious. Therefore, it 
has been concluded that PrPSc is formated through a nucleation dependent polymerization 
mechanism, which is inconsistent with a heterodimer mechanism (Caughey et al., 1995). The 
invention of the PMCA method in 2001 (Saborio et al., 2001) provided strong evidence for the 
protein-only hypothesis. PrPSc is amplified by incubation with brain homogenates followed by 
cycles of sonication (Figure 7a). Sonication is required to fractionate PrPSc aggregates into smaller 
units, which serve themselves as a seed. Interestingly, these small seeds were reported to be more 
infectious than larger amyloid fibrils (Silveira et al., 2005). During PMCA, disruption of growing 
PrPSc molecules by repeated sonication in the presence of detergent occurs. In addition, PMCA 
reactions have been compared with reactions lacking the sonication step concluding that aggregate 
breakage is essential for prion propagation (Piening et al., 2005). Soto and coworkers employed the 
PMCA method for bioassays (Figure 7b) and found that in vitro generated PrPres by PMCA led to a 
scrapie disease in hamster identical to the illness produced by brain infectious material (Castilla et 
al., 2005a). This cell free amplification method is currently used for the detection of extremely low 
PrPSc amounts in different tissues (e.g. in blood (Castilla et al., 2005b)) and for diagnostic purposes 
(Atarashi et al., 2007; Jones et al., 2007). Since brain homogenate as a template is required for 
PMCA, other factors involved in the conversion process are not excluded.  
 
 26 
 
Figure 7. Schematic presentation of the procedure of the protein misfolding cyclic amplification (PMCA) 
method. A) (adopted from (Watts et al., 2006)) This method is used to amplify prion proteins which are below 
detection level. PrPSc can be subsequently determined by western blot analysis or infection with animals. 
Brain homogenate from a healthy donor is first incubated with a PrPSc seed which might derive from a TSE 
infected brain. After alternating cycles of incubation followed by sonication (should mimic fragmentation) the 
infectivity can be determined by injection of the PMCA mix into animals (bioassay) (b) adopted from 
(Enserink, 2005). For subsequent serial amplification the PMCA product is diluted into a new brain 
homogenate.  
 
2.6.5 Prion conversion – involvement of cofactors and localisation 
 
Posttranslational modifications of PrPc such as the GPI anchor (Campana et al., 2007) or 
glycosylated site chains  have been proposed to influence the conversion ability of PrPc into PrPSc 
(Ermonval et al., 2003). The conversion process itself is thought to take place at the cell surface, in 
endosomes or lysosomal compartments (Arnold et al., 1995; Magalhaes et al., 2002). In 1992, 
abnormal high numbers of lysosomes and lysosome related structures (multivesicular and 
tubulovesicular dense bodies) have been detected in neuronal cells of scrapie infected brains, 
containing PrP (Laszlo et al., 1992). Cell culture studies using scrapie infected neuroblastoma cells 
indicate that conversion occurs in the plasma membrane or along with the endocytic pathway 
(Caughey et al., 1991a). Both PrPc and PrPSc have been found in caveolae like domains, suggesting 
that the conversion may occur within these compartments (Vey et al., 1996). However, since 
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immunogold labeling of disease specific PrP in scrapie infected mice revealed the presence of the 
prion protein in the extracellular space (Jeffrey et al., 1994), it has been suggested that conversion 
does not exclusively occur inside the cell. Lipid rafts have been reported to be involved in 
conformational conversion of PrPc to PrPSc. In the brain of different mammalian species a PrPc C-
terminal fragment was present in detergent-resistant raft domains (DRM) (Laffont-Proust et al., 
2006). Raft domains are recently proposed to play a critical role in the conversion process (Baron et 
al., 2002). For example it has been demonstrated that sphingolipid-rich rafts play an essential role in 
the posttranslational (Borchelt et al., 1990) formation of the scrapie prion protein PrPSc (Taraboulos 
et al., 1995). It has been proposed that for conversion both the PrPc and the infectious PrPSc has to 
be inserted into the raft membrane (Baron et al., 2002). Recent biophysical studies indicate that for 
conversion not the raft itself is required but rather other factors, e.g. increased local PrP 
concentrations or high concentrations of membrane-associated conversion factors (Eberl et al., 
2004).  
To date no report confirmed that the TSE agent is exclusively composed of the protein alone, 
pointing out that other molecules might be crucial for prion conversion and infectivity propagation. 
Several groups reported the involvement of additional factors in the conversion process. A potential 
factor termed protein X, which might act as a chaperone participating in prion formation, has been 
postulated for an involvement in the conversion process (Telling et al., 1995).  
Several reports argue for participation of metal ions in the conversion process. For example 
manganese has been demonstrated to reveal a pro-aggregatory effect on PrPc, whereas copper seem 
to counteract aggregation of PrP (Giese et al., 2004). Host encoded factors proposed to be involved 
in the conversion process should stabilize PrPSc structure on the one hand or might help triggering 
the conversion on the other hand. For example polysaccharides are found as prion rod components 
in scrapie infected brain (Appel et al., 1999). In addition, lipids have been observed as components 
surrounding the “prion environment” (Klein et al., 1998). Scrapie associated PrP was captured by an 
anti-DNA antibody suggesting that nucleic acids represent possible components in the infectious 
prion agent (Zou et al., 2004). Indeed, DNA has been reported to convert PrP into a beta sheet 
conformation (Cordeiro et al., 2001) proposing a catalytic action of host derived nucleic acids 
(Cordeiro and Silva, 2005). Recently, find nucleic acids, which might trigger infection, were not 
confirmed to be prion specific but host derived (Safar et al., 2005).  
Several studies demonstrated that polyanionic compounds such as host encoded RNA (Deleault et 
al., 2003) or proteoglycan molecules (e.g. heparan sulfate) (Wong et al., 2001) were able to support 
prion seeded conversion of PrPc to PrPSc in vitro. Recently, PMCA triggered de novo formation of 
PrPSc from purified brain derived hamster PrP was reported to require only synthetic poly(A)+ RNA 
and lipid molecules (Deleault et al., 2007). In addition, these in vitro generated purified PrPSc 
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molecules were infectious in vivo. Infectivity could be generated spontaneously, without the 
addition of brain derived PrPSc seeds, which might explain the spontaneous development of sporadic 
Creutzfeldt Jakob disease. Since the conversion process is suggested to occur at the plasma 
membrane and/or in endocytic vesicles of infected cells (Borchelt et al., 1992; Caughey and 
Raymond, 1991), Glycosaminoglycans (GAGs), for example, present at the plasma membrane, are 
likely to be the in vivo counterparts of polyanionic compounds. In contrast single stranded nucleic 
acids are usually not present at the cell surface or in endosomes. In addition, GAGs are found in 
PrPSc deposits in vivo (Snow et al., 1990), and heparan sulfate proteoglycanes (HSPGs) act as 
receptors for PrPSc (Ben-Zaken et al., 2003; Hijazi et al., 2005; Horonchik et al., 2005). Since the 37 
kDa/67 kDa laminin receptor LRP/LR represents a cell surface receptor for PrPc (Gauczynski et al., 
2001) and PrPSc (Gauczynski et al., 2006), the hypothesis that conversion takes place at the cell 
surface is supported. However, direct participation of LRP/LR has not yet been proven. 
 
2.6.6 Infectivity does not always correlate with proteinase K resistant PrP 
 
Infectivity is not in all cases associated with PrPSc depositions. In 1997, Lasmezas and colleagues 
demonstrated that upon intracerebral BSE infection, more than half of the infected mice exhibited 
no detectable PrPres although displaying neurological disease (Lasmezas et al., 1997). In addition, 
Barron and coworkers confirmed that tissues containing little or no proteinase K-resistant PrP are 
also infectious and harbour high titers of TSE infectivity (Barron et al., 2007), suggesting that, 
supplementory transmissible infectious agents in addition to PrPres might exist. Beside PrPSc, 
aberrant regulation of protein biogenesis and topology at the endoplasmic reticulum can also result 
in neurodegeneration as demonstrated by Hegde and colleagues, who found that ctmPrP is 
responsible for the pathology in the absence of proteinas K resistant PrPSc (Hegde et al., 1998). 
A reliabable test for infectivity remains to be the bioassay in animals. For example, in 2005, Nazor 
et al could demonstrate that a protease sensitive PrPSc is associated with the GSS disease in 
transgenic mice (Nazor et al., 2005). 
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2.6.7 Mechanisms of neurodegeneration 
 
Several mechanisms or a combination of different processes are proposed to be responsible for 
neurodegeneration in prion diseases, (i) the loss of PrPc function, (ii) toxic intermediates and/or side 
effects involved in/resulting from conversion of PrPc, and (iii) the toxic gain of function (Figure 8). 
It is suggested that the normal neuroprotective function of PrPc is lost (Figure 8) during 
conversion or interaction with PrPSc and is involved in the mechanism of neurodegeneration.  
Overexpression of PrP was demonstrated to rescue cells from death (Kuwahara et al., 1999) and to 
protect cells from oxidative stress (Brown et al., 2002). Due to the suggested action as an effective 
anti-apoptotic protein, the loss of function might result in a reduction of the anti-apoptotic capacity 
of PrPc contributing to the pathogenic mechanism (Kim et al., 2004). In addition, the prion protein is 
necessary for normal synaptic transmission, a loss of function may contribute also to the early 
synaptic loss and neuronal degeneration (Collinge et al., 1994).  
The Cu2+ binding ability (Brown et al., 1997a) plays a critical role regarding the function of PrPc. 
Copper binding to the octarepeat region of PrP has been suggested to inhibit prion pathogenesis 
(Harris and True, 2006; Hijazi et al., 2003). In addition the in vitro conversion of the prion protein 
into amyloid fibrils was inhibited through Cu2+ binding indicating that the copper mediated 
physiological PrP function contributes to the neuropathogenesis of prion disease (Bocharova et al., 
2005). The role of copper in prion disease pathology is not entirely clear, since it was also shown 
that copper ions stabilize the disease-specific isoform against proteolytic clearance and enhanced the 
resistance of amyloid (Kuczius et al., 2004). In addition, PrPc has been implicated in higher 
resistance of cells to oxidative stress or copper toxicity (Brown et al., 1997b), suggesting that the 
loss of PrPc correlates with the lack of prevention of copper toxicity due to an impaired Cu2+ 
metabolism. The octarepeat region has been reported to play a role in generation of the proteinase K 
resistant fragment PrPSc since cells expressing PrPc devoid of this region did not produce PrPSc 
(Sakudo et al., 2008). Transgenic mice expressing an N-terminally truncated form of PrP 
spontaneously develop a neurodegenerative phenotype (Li et al., 2007b). Another study reported 
that transgenic mice expressing the mouse homolog of a mutant human PrP which contained a nine 
octapeptide insertion, display a prion disease accompanied by neurological disorders (Chiesa et al., 
1998).  
An additional mechanism contributing to the neurodegenerative phenotype represents the toxic gain 
of function. This implicates that after conversion of the prion protein to the abnormal form the prion 
agent receives toxic properties for example a neurotoxic activity (Figure 8). Additional deposition of 
amyloid plaques and blockage of axonal transport might result from PrPSc aggregates, likely leading 
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to perturbation of the normal physiological activity. The central region of the prion protein 
stretching from 105-125 (in humans 106-126) is suggested to be implicated in neurotoxicity. Mice 
carrying deletions in this region spontaneously developed a neuropathological phenotype 
(Shmerling et al., 1998) and neonatal lethality (Li et al., 2007a). The corresponding synthetic 
peptide PrP 106-126 shares many characteristics with PrPSc and is largely used to elucidate the toxic 
mechanisms underlying prion diseases. PrP 106-126 reveals a high tendency to aggregate into fibrils 
and lead to neuronal death of primary rat hippocampal cultures (Forloni et al., 1993). Furthermore, 
the peptide has been demonstrated to induce oxidative stress by free radicals (Brown, 2005) and 
trigger endoplasmic reticulum stress-induced apoptotic cell death (Ferreiro et al., 2008). However, 
small amounts of detergent-insoluble proteinase K resistant PrP aggregates were also found in 
healthy human brains suggesting that this PrP form is not necessarily neurotoxic (Yuan et al., 2006). 
Transgenic mice expressing PrP lacking the C-terminal GPI anchor displayed abnormal protease-
resistant PrPres deposition in amyloid plaques but only minimal scrapie neuropathology proposing 
that membrane attachment of PrPc is essential for transducing PrPSc derived neurotoxic signal 
(Chesebro et al., 2005) (Figure 8). A contradictory study demonstrated that the cleavage of the GPI 
anchor did not alter infectivity in a mouse bioassay (Lewis et al., 2006a).  
 
 
Figure 8. Possible relationship between PrPc and PrPSc interactions on the cell surface. Neuronal loss is 
suggested to result from toxic signal delivered by PrPSc (toxic gain of function) (A), PrPc looses 
neuroprotective activity upon conversion top PrPSc (loss of function) (B), or subversion of PrPc by PrPSc 
generating a toxic signal of the original protective one (C). Data from GPI anchorless mice suggest that PrPc 
lacking the GPI anchor delivers no signal and is therefore not toxic (D). (modified from (Harris and True, 
2006)) 
Another proposal for the pathogenic mechanism involves subversion of the normal 
neuroprotective functions of PrPc (Figure 8). PrPc is converted by the action of PrPSc into a 
transducer of neurotoxic signals (Harris and True, 2006). This might probably result from PrPSc 
induced aggregation of PrP on the cell surface. Consistent with this, it has been demonstrated that 
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cross-linking of PrPc on the cell surface by antibodies results in apoptotic death in CNS neurons 
(Solforosi et al., 2004). Another possibility would be that PrPSc bind and block specific regions on 
PrPc, which are required for the delivery of a neuroprotective signal or just alter the normal 
signaling properties (Westergard et al., 2007). 
 
Astrocytosis as well as microglial activation are observed features in prion diseases, since these cells 
are for example increased in the brain of CJD patients (Van Everbroeck et al., 2002). Microglia are 
associated with amyloid plaques and supposed to contribute to the development of spongiform 
vacuoles (Rezaie and Lantos, 2001). In addition, in scrapie infected mice microglial activation has 
been demonstrated to be involved in the neurotoxicity of PrPSc (Giese et al., 1998). Neuronal cell 
death in the brain is associated with chronic inflammatory response dominated by microglia, which 
is suggested to contribute to the spread of infection for the whole symptomatic period of the disease 
(Szpak et al., 2006). Through microglial activation, which has been found to be upregulated in CJD 
or GSS, inflammatory proteins such as prostaglandin E are released and elevated in the 
cerebrospinal fluid (CSF) of CJD patients (Minghetti and Pocchiari, 2007). Astrocytes have also 
been reported to participate in the formation of amyloid plaques (Liberski and Brown, 2004).  
Neuronal loss is suggested to occur through an apoptotic process. Examination of brain areals 
originating from different CJD patients revealed apoptotic neurons in all disease types, found mostly 
in damaged regions (Gray et al., 1999). Their abundant presence seemed to correlate closely with 
neuronal loss. Neuronal autophagy, like apoptosis, is one of the mechanisms of the programmed cell 
death (PCD). It is also implicated in TSE pathogenesis and might participate in the formation of 
spongiform changes (Liberski et al., 2004). Autophagy is an important step in the cellular turnover 
of proteins and organelles. It is known to occur in neurons under physiological as under pathological 
conditions. Large autophagic vacuoles have been observed in hamsters experimentally infected with 
scrapie (Boellaard et al., 1991) and in CJD infected mice (Boellaard et al., 1989). 
Several groups demonstrated the involvement of endoplasmatic reticulum (ER) stress in prion 
replication (Hetz et al., 2007). Kristiansen et al provided evidence that soluble aggregates of a toxic 
might cause prion disease by the inhibition of the proteasomal activity, concluding a strong 
involvement of the degradation machinery. In addition the authors demonstrated that scrapie 
infected neurons display a reduced proteasomal activity confirming that this is one toxic mechanism 
contributing to neuronal loss (Kristiansen et al., 2007).  
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2.6.8 Route of prion infection 
 
The spread of prions depends on the site of entry, strain and species as well as the PrP genotype of 
the host. Following exposure to the infectious agent PrPSc, infection is thought to propagate in 
lymphoid tissues (Fraser, 1996) prior to neuroinvasion and spread within the central nervous system.  
BSE, CWD Kuru or vCJD are assumed to originate from oral infection. After oral ingestion, the 
infectious agent has to cross the intestinal epithelium to accumulate in lymphoid tissues (Kimberlin 
and Walker, 1989a). Subsequently it spreads to the peripheral nervous system (Kimberlin and 
Walker, 1980), termed neuroinvasion (Figure 9). Kimberlin and Walker reported very early the 
prion spread in mice after intragastric challenge and observed propagation in the cervical lymph 
nodes and spleen (Kimberlin and Walker, 1989a). However, splenectomy of these mice did not alter 
the incubation time of the infected mice, suggesting that the spleen seems to play rather a minor role 
in prion spread after oral infection. A more prominent involvement of the spleen has been observed 
in other infection routes, such as intraperitoneal (i.p.) or intravenous (i.v.) infection (Fraser and 
Dickinson, 1978; Kimberlin and Walker, 1989b). Tissue examination of vCJD patients revealed 
PrPSc presence in the spleen (Hill et al., 1999), concluding that the spleen is important for prion 
propagation but not always required for an efficient spread of prions. 
Feeding of the scrapie agent lead to accumulation of prions in peyers patches and mesenteric lymph 
nodes followed by the lymphoreticular system (LRS) as a secondary site of replication (Maignien et 
al., 1999). The gut associated lymphoid tissue (GALT) was found to play a role in the early stages 
of a prion infection (Beekes and McBride, 2000). Different types of cells, e.g. dendritic cells, 
macrophages, microfold cells (M-cells) and follicular dendritic cells (FDC) of the GALT and are 
implicated in the transfer of the prion agent. In addition, enterocytes representing the major 
population in the intestine, expressing PrPc (Morel et al., 2004), are also implicated in prion uptake 
(Morel et al., 2005); Kolodziejczak et al., submitted). M-cells have been demonstrated to 
transcytose the prion agent (Heppner et al., 2001), whereas intestinal dendritic cells are able to 
transport the PrPSc to the mesenteric lymph nodes (Huang et al., 2002). Especially FDCs seem to be 
important for peripheral prion propagation. In transgenic mice, replication of the scrapie agent in 
lymphoid tissues such as the spleen, was demonstrated to depend on PrPc-expressing FDCs (Brown 
et al., 1999b). Depletion of FDCs from the spleen of mice hampered neuroinvasion (Mackay and 
Browning, 1998), suggesting that FDCs transport the prion agent to sympathetic nerves.  
The peripheral nervous system (PNS) is suggested to be involved in further prion neuroinvasion 
(Blattler et al., 1997). It has been confirmed that transmission of the prion agent within the PNS 
requires prion protein expression (Glatzel and Aguzzi, 2000). Recently, in cattle orally infected with 
BSE, PrPSc was found to accumulate in parts of the peripheric nervous system (Masujin et al., 2007). 
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It has been suggested that prion contact between immune cells and nerve tissue occurs in the 
innervated lymphoid tissue (Defaweux et al., 2005). Detailed analysis of the disease specific PrP 
distribution within the nervous system of orally infected rodents indicated that the scrapie agent 
spreads from the GALT to the CNS through the enteric nervous system (Beekes and McBride, 
2000).  
Several possible routes from the PNS to the brain have been implicated (Figure 9). 
Immunocytochemistry data from scrapie infected hamsters indicate that both parasympathetic (e.g. 
nervus vagus) as well as sympathetic nerves are suggested to provide a pathway to the brain 
(McBride et al., 2001). In the hamster scrapie model, a spinal cord independent infection route has 
been discovered, most likely terminating in the medulla oblongata (Baldauf et al., 1997) occuring 
via the vagus nerve (Beekes et al., 1998). A permanent depletion of sympathetic nerves has been 
demonstrated to hamper scrapie agent neuroinvasion arguing for a major role of sympathetic 
nervous system in prion neuroinvasion (Glatzel et al., 2001).  
 
.  
Figure 9. Model of the prion transport through the body. Orally ingested prions are intestinally absorbed via 
enterocytes or M-cells/Dendritic cells (DC) and transported through different pathways lymphoid tissues or 
blood. Peripheral replication/propagation takes place in the spleen, appendix, tonsils or other lymphoid 
tissues. Subsequently, prions are transported through the peripheral nervous system via two pathways 
(sympathetic or parasympathetic) to the CNS, independently or dependently of the spinal cord. Since the 
spleen has no afferent lymphatic connection, hematogenous spread seem to be most likely, either directly or 
via superficial cevical lymph nodes. Intraperitoneal infection with prions results in PrPSc accumuation in the 
spleen. It is not elucidated how prions get access from the spleen to the CNS, probably either via the blood 
stream, through B-or T-cells, or via other lymphatic routes e.g. FDCs (folicular dendritic cells). GALT = gut 
associated lymphoid tissue; M-cells (microfold cells). 
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An alternative prion spread may involve blood constituents, since PrPc was detected in the blood of 
different individuals, e.g. scrapie infected hamsters during presymptomatic phase of the disease (Saa 
et al., 2006), or in vCJD patients (Ramasamy et al., 2003). The TSE agent might pass the blood 
brain barrier (BBB) through lymphocytes as possible TSE carriers. During preclinical TSE stages it 
has been observed that T-cells (Lewicki et al., 2003) as well as DCs (Rosicarelli et al., 2005) cross 
the BBB. However there is no striking evidence for the importance of these cells as so called prion 
transporters responsible for the spread (Armstrong et al., 2003). Blood is rather suggested to act as a 
TSE source through transmission (Llewelyn et al., 2004).  
Muscle tissue has been implicated in the centrifugal spread of prions after CNS infection and 
provides a possible infectious source. Since PrPTSE has been detected in muscle spindles, which act 
as mechanoreceptors, sensory nerve fibers may also provide an additional pathway for infection 
(Beekes and McBride, 2007). Thomzig and coworkers demonstrated that hamsters orally infected 
with scrapie displayed substantial amounts of PrPTSE in a variety of muscles providing evidence for 
the spread of infection to muscle tissue after oral infection (Thomzig et al., 2003). Prion invasion of 
muscle tissue was also observed in TSEs with an origin other than oral infection e.g. in sCJD 
patients and iatrogenic CJD patients (Peden et al., 2006) suggesting a potential risk of iatrogenic 
spread via contaminated surgical instruments. 
 
2.7 Transmission, Prion strains and transmission barriers 
 
Prion disease transmission can occur horizontal, between members of the same species, 
(intraspecies transmission) as well as between different species (interspecies transmission). Efficient 
horizontal transmission has been suggested to occur through contaminated saliva (Vascellari et al., 
2007), blood, urine (Murayama et al., 2007) or feces. In case of the latter, it has been recently 
demonstrated that cohabitation of uninfected hamsters to the bedding of hamsters orally infected 
with Sc237 lead to horizontal infection (Safar et al., 2008). This was most likely due to consumption 
of prion contaminated feces (coprophagy), since substantial amounts of PrPSc have been detected. It 
has been reported that CWD is efficiently transmitted horizontally and maternally among captive 
mule deer (Miller and Williams, 2003). 
It has been discovered that clinical TSE symptoms and biochemical PrP properties differ among 
infected individuals (Ironside et al., 2005; Lowenstein et al., 1990) suggesting that different prion 
strains exist. They can be distinguished by neuropathological profiles, sensitivity to proteinase K 
digestion (Kuczius and Groschup, 1999), plaque morphology, incubation period and differences in 
the PrPSc tissue distribution and time point of occurrence (Farquhar et al., 1996). Different PrPSc 
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types displaying distinct glycosylation pattern, have been detected in humans associated with 
different phenotypes of CJD (Collinge et al., 1996b; Parchi et al., 1996). Molecular strain typing, 
including glycosylation pattern and PrPSc types, is used for diagnosis of the different types in CJD 
and subtypes in sporadic CJD (Cali et al., 2006; Heinemann et al., 2007; Notari et al., 2004). New 
prion strains have been generated over the past years by passaging prion strains from one animal 
species to another (experimental interspecies transmission). For example, mouse scrapie has been 
transmitted to hamster and passaged resulting in hamster adapted scrapie prions (Kimberlin et al., 
1987). Several TSE strains have been generated upon transmission to mice or hamsters. RML, 
Chandler (Chandler, 1961), 22L or ME7 (Kuczius et al., 1998) are for example commonly used 
scrapie strains adopted in mice. Other TSE species like BSE, CJD or TME have been adapted in 
both mice and hamster. It has been early proposed that the infected tissue used for transmission of 
the disease, contains a prion strain mixture and adaptation from one species to another may involve 
the selection of a single strain which is specifically pathogenic for the infected species (Kimberlin 
and Walker, 1978). Upon transmission of prion diseases between different mammalian species, 
altered incubation periods or even a resistance to the disease has been observed. This phenomenon 
has been described as the so-called species barrier (Pattison, 1965). Mice that are normally 
resistant to a hamster adapted scrapie strain 236K have been demonstrated to become susceptible by 
the introduction of a hamster PrP gene (Scott et al., 1989). Interspecies transmission is widely 
studied using transgenic mouse models. For example mice expressing either human PrP (Telling et 
al., 1994), bovine PrP (Buschmann et al., 2000) or ovine PrP (Vilotte et al., 2001) displayed reduced 
incubation times and survival following inoculation with human, bovine or sheep prions, 
respectively. Furthermore, a reduction of the incubation period upon scrapie transmission has been 
observed in transgenic mice (tga20) expressing a 10-fold higher level of PrPc than wild type mice 
(Thackray et al., 2002). Beside the prion protein sequence (Kupfer et al., 2007) and the infectivity 
dose, also the route of infection (Beekes and McBride, 2007) is supposed to determine interspecies 
transmission ability (Beringue et al., 2008).  
Current studies focus on the oral transmission (Davies et al., 2006; Sales, 2006), since the natural 
route of prion infection occurs mostly orally. Recently, it has been suggested that human intestinal 
cells (Caco-2/TC7) play a crucial role in the species barrier via the oral prion uptake and therefore 
might influence the susceptibility for prion infection (Mishra et al., 2004). Prion protein binding 
studies on different enterocyte species provided evidence for a LRP/LR dependent prion uptake 
(Kolodziejczak et al., submitted;) Moreover, data obtained from immunofluorescence colocalistion 
studies of CWD prions on human enterocytes, suggest a possible transmission of CWD via the oral 
route to humans, leading to a possible new zoonotic disease. 
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2.8 Prion like proteins 
 
Two paralogs of the prion protein have been discovered, however the complete function is not 
clarified yet. Doppel (Dpl) is a testis expressed protein which appears to play an important role in 
the proper function in the male reproduction system (Behrens et al., 2002). The tertiary structure is 
very similar to the C-terminus of PrPc sharing 25% sequence identity. Doppel resembles the C-
terminal domain of PrPc but lacks the hydrophobic domain and the N-terminal octapeptide regions 
(Figure 10) (Watts et al., 2007). Like PrPc, Doppel is localized to lipid rafts harbouring a GPI 
anchor. It has been reported that Bax signaling associated apoptosis of Purkinje cells can be induced 
by Doppel (Heitz et al., 2007). In contrast to PrPc, Dpl does not seem to support prion replication. 
Furthermore, expression in the brain caused a neurodegenerative phenotype distinct from that of 
PrPc (Mo et al., 2001). There is no evidence for a role of doppel in prion pathogenesis (Watts and 
Westaway, 2007). The second prion protein paralog, Shadoo (Sho) is a hypothetical GPI-anchored 
protein encoded by the SPRN gene (shadow of prion protein) (Premzl et al., 2003) exhibiting 
homology and domain organization similar to the N-terminus of PrP (Figure 10). Shadoo represents 
a CNS-expressed protein harbouring similar properties as PrPc and is thought to retain overlapping 
activity (Premzl et al., 2003). It has been found to be significantly reduced in prion infected mice 
(Watts et al., 2007). However, the exact physiological role in the CNS as well as a potential role in 
prion pathogenesis remains still unclear.  
 
 
Figure 10. Domain architecture of the prion protein family members. Both PrP paralogs Doppel (Dpl) and 
Shadoo (Sho) contain a GPI anchor. Dpl reveal similar C-terminal domains to PrPc consisting of three α-
helices and two short β-strands. Disulfide bridges and N-glycosylation sites are depicted. Sho exhibits 
repetitive elements, similar to the octapeptide region of PrP. However, in contrast to PrPc the repetitive motif 
consists of arginin and glycine rich tetrarepeats. The hydrophobic region is conserved in both proteins. 
(adopted from (Watts and Westaway, 2007) 
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3. The 37 kDa/67 kDa Laminin receptor (LRP/LR) 
 
In 1983, several groups isolated the laminin receptor as a laminin binding protein from different cell 
lines, including human breast carcinoma (Terranova et al., 1983), murine melanoma cells (Rao et 
al., 1983) and normal muscle cells (Lesot et al., 1983). Purification and isolation identified a protein 
with an apparent molecular mass of approx. 67 kDa (according to SDS-PAGE) and was therefore 
termed high affinity 67 kDa Laminin receptor (LR), due to its strong binding to laminin . The full 
length protein sequence could not yet been identified, however, cleavage of the purified protein with 
cyanogen bromide followed by microsequence analysis revealed an octapeptide fragment 
(MLAREVLR) (Wewer et al., 1986), which enabled the identification of the cDNA encoding a 
295aa long peptide with an approx. molecular mass of 32.8kDa. It appeared at approx. 37 kDa in 
western blot analysis of cell lysates. The remarkable discrepancy between the observed mass 
isolated from tumors and the protein resulting from its corresponding gene is still not clarified. A 
pulse chase experiment using 37 kDa LRP from 35S methionine labeled human melanoma cells 
indicated that the 37 kDa form represents the precursor of the laminin receptor (LRP), which might 
undergo modifications prior to maturation to the surface protein 67 kDa LR (Rao et al., 1989). Fatty 
acylation might occur during the proposed conversion of LRP to LR (Buto et al., 1998; Landowski 
et al., 1995). A suggested homodimerization was not confirmed by yeast two hybrid studies and size 
exclusion chromatography of recombinant LRP (Hundt et al., 2001). Since the 67 kDa form 
harbours lectin epitopes, heterodimerization with another laminin binding protein carrying epitopes 
from galectin-3 (Hinek et al., 1993) has been proposed. However, the finding that both receptor 
forms are present on the surface of N2a (mouse neuroblastoma) cells which do not express galectin-
3, (Gauczynski et al., 2001), suggested that heterodimerization between gal-3 and LRP is unlikely. 
Fluorescent in situ hybridization localized the 37LRP/p40 active gene on chromosome 3 in the locus 
3p21.3 which represents a hot spot for genetic alterations in several cancers and particularly in small 
cell lung carcinoma (Jackers et al., 1996b). Multiple copies of the LRP gene exist among mammals, 
whereas the human genome harbours 26 copies and the mouse contains 6 copies, respectively 
(Jackers et al., 1996a). 
 
3.1 The 37 kDa/67 kDa LRP/LR and its correlation to prion disease 
 
A yeast two hybrid screen employing a complex HeLa cDNA library, identified the 37 kDa laminin 
receptor precursor (LRP) as an interaction partner for the prion protein (Rieger et al., 1997). 
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Additional in vitro studies in neuronal and non-neuronal cells revealed that LRP/LR acts as the 
receptor for PrPc (Gauczynski et al., 2001). Mapping analysis identified two PrP binding domains 
for LRP (Hundt et al., 2001): a direct binding domain (PrPLRPbd1, aa144-179) and an indirect one 
(PrPLRPbd2, aa53-93), which is dependent on the presence of heparan sulfate proteoglycanes 
(HSPGs) (Hundt et al., 2001; Warner et al., 2002)). Further binding sides on PrPc for HSPGS have 
been identified (Warner et al., 2002). Hence, HSPGs, known as interaction partners for PrPc 
(Gabizon et al., 1993), have been proposed to act as co-receptors for PrPc (Hundt et al., 2001) and 
the glycosaminoglycane moiety heparan sulfates act as receptors for the scrapie prion protein PrPSc, 
since heparinase III treatment prevents binding of prion rods to neuronal cells(Horonchik et al., 
2005). In addition to HSPGs LRP/LR has been demonstrated as coreceptor for PrPSc (Gauczynski et 
al., 2006). The corresponding binding sites for PrP on LRP have been mapped between aa residues 
161 and 179, whereas the second indirect binding domain is located between aa180-285 (Figure 11) 
(Hundt et al., 2001). PrP has been confirmed to specifically bind to LRP/LR and becomes 
internalized mediated by LRP/LR (Gauczynski et al., 2001). Several isoforms corresponding to 
different maturation stages of the receptor have been detected in mouse brain, including a 42 kDa, a 
60 kDa, a 67 kDa and a 220 kDa form (Simoneau et al., 2003). In addition, all isoforms were able to 
bind to PrP. Immunocytochemistry studies demonstrated that the 67 kDa LR is expressed in adult 
rat brain and spinal cord within the cytoplasm and at the plasma membrane of most neurons and in a 
subset of glial cells (Baloui et al., 2004). The overall distribution of LR was found to correlate with 
brain regions classically associated with prion-related neurodegeneration (Baloui et al., 2004). In 
contrast, the 37 kDa form was detected in cortical interneurons, which are known to degenerate 
during the early stages of Creutzfeldt-Jakob disease (Belichenko et al., 1999). Interestingly, LRP 
levels have been found to be elevated in scrapie infected mouse and hamster brain and splenic 
tissues (Rieger et al., 1997). LRP/LR acts also as a receptor for PrPSc supporting prion replication, 
due the binding of PrPres (Gauczynski et al., 2006) and the observed hampererd PrPSc propagation by 
the usage of tools directed against or downregulating LRP/LR, including polysulfated glycanes, 
such as pentosan polysulfate or heparan mimetics (for reviews (Vana et al., 2007); (Ludewigs et al., 
2007; Vana, in press; Zuber et al., 2007a). Especially, antibodies directed against the 37 kDa/67 kDa 
LRP/LR have been demonstrated in mice experiments to be promising for prion disease therapy 
(Zuber et al., 2008a; Zuber et al., 2007a; Zuber et al., 2007b; Zuber et al., 2008c). In addition, 
LRP/LR was found to bind and internalize PrPBSE in human enterocytes (Kolodziejcak et al., 
submitted). 
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Figure 11. Schematic model of the 37 kDa LRP. The human LRP represents a 295 aa long peptide, displaying 
the C-terminal part on the extracellular site. A hydrophobic region stretching from aa 86-101 is proposed to 
serve as the transmembrane region. LRP has been demonstrated to bind laminin via three different regions, 
including (i) a heparan-dependent binding region, termed Peptide G (aa161-180), which contains the 
palindromic sequence LMWWML, (ii) TWEDS like repeats at the C-terminal part and (iii) a direct laminin-
binding domain (205-229). Two prion protein (PrPc) binding sites exist on LRP, whereas one represents a 
heparan sulfate proteoglycan-dependent region (aa180-285) and the other stretches from aa161-179. 
 
3.2 Localization of LRP/LR 
 
In 1988, a polypeptide identified from mouse tumor cells, termed p40 (an acidic ribosomal protein 
with a molecular mass of approx. 40 kDa) (Makrides et al., 1988) was found to share identical 
sequence to human 37 kDa LRP (Auth and Brawerman, 1992). Sucrose gradient sedimentation of 
cytoplasmic fractions from murine sarcoma and erythroleukaemia cells detected the 37 kDa form 
associated with ribosomal 40S subunits. Gene expression analysis of different human tissues 
detected the 37 kDa LRP gene product (RPSA) in ribosomes of all investigated organs, such as 
brain, liver, skeletal muscle, ovary, retina and uterus (Bortoluzzi et al., 2001). LRP was also found 
in heart tissue associated with the mitochondrial proteome (Taylor et al., 2003). Comparative 
modeling of the N-terminal domain using crystal structures from prokaryotic p40 homologues 
suggests that the N-terminal domain is implicated in ribosomal function (Kazmin et al., 2003). In 
addition to mammals, LRP was found in mitochondrial ribosomes in other species such as budding 
yeast (Saccharomyces cerevisiae) (Davis et al., 1992). Interestingly, the disruption of the 
corresponding yeast genes encoding for proteins similar to 37 kDa LRP, resulted in reduced cell 
proliferation and deletion of both was lethal, suggesting that p40/LRP homologues support 
ribosomal stability or assembly of the 40S subunit (Demianova et al., 1996).  
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LRP has been also detected in cytoplasmic (Grosso et al., 1991), perinuclear and perichromosomal 
regions of the cell (Sato et al., 1996). In addition, in vitro analysis using cellulose affinity column 
revealed that p40/LRP is tightly associated with histone H1 and in particular the core histones H2A, 
H2B, and H4 (Kinoshita et al., 1998). However, the exact role of LRP in the nucleus as well as on 
ribosomal structures is not clear. Introduction of antisense cDNA against p40 has been demonstrated 
to induce apoptosis (Kaneda et al., 1998), demonstrating a protective role of LRP. It has been 
suggested that 37 kDa/p40 might be required for translation or stabilization of chromatin. A role for 
LRP in cell viability has been proposed via interaction with midkine, a cell survival and migration 
mediating protein (Salama et al., 2001). Midkine binding to the 37 kDa LRP leads to nuclear 
translocation. Furthermore, downregulation of LRP via siRNAs demonstrated an anti-apoptotic 
function of LRP (Susantad and Smith, 2008), confirming that LRP/LR contributes to cell viability. 
 
3.3 Function of LRP/LR 
 
Besides the described function in prion protein binding and cell viability, LRP/LR binds to laminin, 
elastins and carbohydrates (Mecham, 1991) and acts as a receptor for a variety of viruses, such as 
the Sindbis Virus (Wang et al., 1992), Dengue Virus (Thepparit and Smith, 2004), Venezuelan 
Enquine Encephalitis Virus (Ludwig et al., 1996) and Adeno Associated Virus serotype 2, 3, 8 and 9 
(Akache et al., 2006). The receptor might also be important for bacterial infection, since 37 kDa 
LRP binds to the bacterial toxin cytotoxic necrotizing factor 1 (CNF1) (Chung et al., 2003; 
McNichol et al., 2007). The 67 kDa form has also been proven to promote internalization of a 
CNF1-expressing E.coli strain into human brain microvascular endothelial cells (HBMEC) (Kim et 
al., 2005). 
Vascular smooth muscle cells have been demonstrated to produce and secrete LRP into the 
extracellular matrix for cell attachment (Hu et al., 2001). LRP is supposed to mediate the interaction 
between smooth muscle and endothelial cells and might therefore contribute to angiogenetic 
processes like blood vessel formation.  
Furthermore, LRP/LR is strongly implicated in the metastatic process of tumor cells discussed in 
section 3.5. 
In addition a differential expression of the 67 kDa LR between dividing and contact-inhibited cells 
has been detected indicating a role for this receptor during proliferative processes (Donaldson et al., 
2000; Stitt et al., 1998). An involvement in mobilization of hematopoetic stem cells (HSCs) by the 
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granulocyte–colony-stimulating factor (G-CSF) has been suggested, since LR expression correlated 
with mobilization efficiency of HSCs (Selleri et al., 2006). 
 
3.4 Functional laminin binding domains and structure of LRP/LR 
 
LRP/LR is a type II receptor, whereas the C-terminus is suggested to represent the extracellular 
laminin binding domain and the N-terminal part locates inside the cell (Figure 11). A hydrophobic 
domain stretching from aa 86-101 has been proposed as a putative transmembrane region 
(Castronovo et al., 1991; Menard et al., 1997). Phylogenetic protein sequence analysis revealed that 
the C-terminal region, containing the laminin binding palindromic sequence LMWWML, appeared 
during evolution concomitant with laminin and the basement membrane (Ardini et al., 1998). Thus, 
the original 37 kDa ribosomal protein acquired during evolution a laminin receptor function, which 
is linked to multicellular tissue formation of higher organisms. Additional laminin binding sites in 
the C-terminal domain of LRP/LR have been identified (Figure 11). A sequence YIGSR, 
corresponding to the region on LRP between aa 205-229 has been proven to bind laminin directly 
(Graf et al., 1987; Starkey et al., 1999). A heparan sulfate dependent laminin binding region 
stretching from aa 161-180 has been identified (Castronovo et al., 1991). The palindromic motif 
LMWWML is also termed Peptide G and is strongly implicated in laminin binding on cancer cells 
(Magnifico et al., 1996). In addition, a third laminin binding site has been proposed at the very 
ultimate C-terminus involving TWEDS like repeats (Kazmin et al., 2000).  
Recently, the crystal structure of the aa region 1-220 of the human 37 kDa LRP has been solved 
(Figure 12) (Jamieson et al., 2008). According to this, the former proposed transmembrane region 
(86-101) is unlikely to serve as a transmembrane region. In addition, the peptide G epitope has been 
discussed to be only in part accessible for the binding to laminin-1. 
 
Figure 12. Structure model of human 37 kDa LRP 
peptide 1-220. The structure was determined based on 
the Archeoglobus fulgidus homologue, the 30S 
ribosomal protein S2p. The overall structure is 
composed of 5 parallel β and 2 antiparallel β sheets 
(colored yellow). The N-terminal region (residue 1-8) 
and the C-terminus (residues 206-220) are disordered. 
Five α-Helices are indicated in red (A-E). 
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3.5 The role of the LRP/LR in cancer 
 
3.5.1 Cancer 
 
Cancer describes a class of diseases in which host cells start to display uncontrolled growth and 
invasive potential. Most of the affected individuals die from metastasis designating cancer spread to 
other locations via lymph or blood and its formation of metastases at the secondary sites. Cancer is 
usually classified according to the tissue from which the cancerous cells originate, the primary 
tumor, as well as the normal cell type they most resemble (Table 4). Tumorigenic cells describe 
malignant neoplasms, designating abnormal proliferation of genetically altered cells. They are 
distinguished from benign neoplasms, which are able to stop growing by themselves and do not 
invade other tissues and do not form metastases, respectively. 
 
Table 4. Cancer types and their original tissue 
Type Derived tumor Location/tissue 
Epithelium adenocarcinoma, squamous cell 
carcinoma 
breast, liver, skin, intestinal 
mucosae, bladder, lung, cervix 
Connective tissue osteosarcoma, chondrosarcoma, 
rhabdomyosarcoma, angiosarcoma 
chondrae, bone, muscle, blood 
vessels 
Haematopoetic 
system 
lymphoma, myeloma, 
erythroleukaemia, lymphoid or 
myeloid lymphoma 
bone marrow, spleen 
Nervous tissue neuroblastoma, glioma, astrocytoma, 
schwannoma, neuroma, 
medulloblastoma 
PNS; CNS 
 
 
Tumorigenesis is a multistep process involving genetic alterations leading to transformation of 
normal human cells into highly malignant derivates. Tumor development and progression is 
accompanied by the change in the genomic and proteomic expression profile resulting in 
physiological changes: (i) self-sufficiency in growth signals, (ii) insensitivity, to growth-inhibitory 
(antigrowth) signals, (iii) evasion of apoptosis, (iv) limitless replicative potential, (v) sustained 
angiogenesis, and (vi) tissue invasion and metastasis (Hanahan and Weinberg, 2000). Tumorigenic 
cells aquire defense mechanisms and display reduced dependence on exogenous growth stimulation 
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disrupting the critically important homeostatic mechanism that normally operates to ensure proper 
behavior of a cell type within a tissue. 
 
3.5.1.2 Metastatic process of tumorigenic cells – involvement of the 
laminin receptor and binding to laminin 
 
The metastatic process is a highly complex process including attachment of cells to the extracellular 
matrix components through several receptors, degradation of extracellular matrix (ECM) 
components by local secretion of proteolytic enzymes and migration into adjacent tissues (Makale, 
2007; Pauli et al., 1983). Components of the ECM comprise laminin, fibronectin, type IV collagens 
and proteoglycanes (Vracko, 1974). An important feature of a tumorigenic cell is the initiation of 
local invasion and neovascularization, which marks the beginning of the metastatic process (Meyer 
and Hart, 1998). Formation of new blood vessels is important for nutritional support of the tumor 
cell and for entering the blood circulation, respectively (Bikfalvi, 1995). A variety of molecules are 
implicated in the angiogenetic process including fibroblast growth factors (bFGF), angiogenin, 
vascular permeability factor (VPF) and transforming growth factor α and β (TGF α and β) 
(Folkman and Klagsbrun, 1987). Several reports argue for a role of LRP/LR in the angiogenetic 
process (Tanaka et al., 2000), observed for example in melanocyte tumor progression (Vacca et al., 
1993) and in retinal angiogenesis (McKenna et al., 2001; Stitt et al., 1998). Interaction of 67 kDa 
LR with laminin has been suggested to be crucial for adhesion during angiogenesis (Berno et al., 
2005). Expression analysis of mice revealed a bi-phasic expression pattern of LR in retinal 
vasculature, which correlated with key stages of retinal vascular development in the murine retina 
(McKenna et al., 2001). In addition, shedding of 67 kDa LR from malignant cells has been 
observed, concomitant with laminin-1 binding suggesting that the laminin receptor modulates 
angiogenesis (Moss et al., 2006). This process enables the invasion of adjacent tissues along with 
the formation of new colonies distant from the origin tumor.  
LRP/LR plays a major role in cancer, since increased expression of the 67 kDa laminin receptor 
correlates with cell proliferation (Stitt et al., 1998), migration (Chen et al., 2002; Vande Broek et al., 
2001) and invasion capacity (van den Brule et al., 1994b). Overexpression of 67 kDa LR has been 
observed in several human cancer cell type associated with metastasis (Table 5) and implicated in 
tumor progression (Givant-Horwitz et al., 2005). 
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Due to the strong binding capacity to the glycoprotein laminin, the 67 kDa form is termed the high 
affinity laminin receptor. The binding of laminin is concomitant with many functions attributed to 
the receptor, e.g. cell attachment to the basement membrane, cell adhesion, migration (Wewer et al., 
1987) and invasion of tumorigenic cells (Menard et al., 1997). Laminin is the major noncollagenous 
component of the extracellular matrix mediating cell adhesion, movement, extravasation, growth, 
differentiation, maintainence of tissue phenotype and survival (Aumailley and Krieg, 1996; 
Kleinman et al., 1985). More than 14 laminin isoforms exist (Patarroyo et al., 2002), whereas 
laminin-1 has been prominently implicated in LRP/LR binding (Wewer et al., 1987). Laminin is a 
cross-shaped heterotrimer of three subunits (α, β and γ chains) held together by a disulphide bond 
(Nomizu et al., 1994). Different laminin isoforms exhibit different tissue distribution and distinct 
developmental functions (Engvall and Wewer, 1996). Laminin-1–LRP/LR interaction is a crucial 
step in tumor cell migration (Wewer et al., 1987). In addition, it has been demonstrated that the 67 
kDa LR functions in the proteolytic cleavage of laminin-1, resulting in basement membrane 
degradation and tumor dissemination (Ardini et al., 2002; Berno et al., 2005). It has been reported 
that LR mediates laminin-1 induced proteolytic activity of extracellular matrix degrading enzymes 
(Givant-Horwitz et al., 2004), such as matrix metalloproteinases (MMPs) (Chambers and Matrisian, 
1997) which are implicated in the destruction of adjacent tissue. Analysis of laminin induced 
receptor signaling demonstrated an involvement of the MAP kinase pathway as well as the initiation 
of MMP-2 (Givant-Horwitz et al., 2004).  
 
Table 5. Human tumors reported to overexpress 67 kDa LR 
Human tumors with LR expression Reference 
Colorectal carcinoma (Sanjuan et al., 1996) 
Colon cancer  (Campo et al., 1992) 
Cervical preneoplastic and neoplastic 
squamous epithelial lesions 
(al-Saleh et al., 1997) 
Gastric adenocarcinoma  (Lee et al., 1996) 
Breast carcinoma  (Martignone et al., 1993; Nadji et al., 1999) 
Acute myeloid leukemia (AML) (Montuori et al., 1999) 
Human laryngeal sqamous cell carcinoma (Zhou et al., 2006) 
Human small cell lung cancer (Satoh et al., 1992) 
Prostate cancer (Waltregny et al., 1997) 
Ovarian carcinoma (van den Brule et al., 1994a) 
Uterine adenocarcinoma  (van den Brule et al., 1996) 
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The 37 kDa LRP was found to interact with Midkine, a protein which is well correlated with a poor 
cancer prognosis, when overexpressed (O'Brien et al., 1996). Through binding to LRP, Midkine is 
transported into the nucleus (Salama et al., 2001). The complex of both proteins might therefore also 
contribute to tumor progression.  
 
3.5.1.3 LRP/LR as a prognostic marker for tumor progression 
 
The 67 kDa LR has been proposed to be one important determinant in the invasive progression of 
cancer. Some tumorigenic cell lines isolated from cancer patients are currently studied for the 
presence of LRP/LR and its correlation to metastasis and/or progression (Menard et al., 1998). A 
prognostic significance has been discussed in several human cancers (Menard et al., 1998). In 
human breast cancer for example, a correlation between tumor size as well as onset age and the 67 
kDa LR was found (Martignone et al., 1993). In addition, the presence of LR correlated with poor 
prognosis. Immunohistochemistry analyses following the morphological phases in breast carcinoma 
progression suggested that the expression is related to tumor progression (Viacava et al., 1997). A 
correlation has been also demonstrated for colorectal carcinoma (Sanjuan et al., 1996). Furthermore, 
67 kDa LR expression in primary tumors has been found to correlate with bone marrow metastases 
(Menard et al., 1994). Proteomic analyses of differentially expressed proteins on tumor tissues from 
different esophageal squamous cell carcinoma patients identified the 67 kDa LR as a stage specific 
marker (Fu et al., 2007). Although expression did not correlate with lymph node metastases or 
patients age, a clinical significance of the association with the tumor stage was found. A significant 
correlation between 67 kDa LR overexpression and tumor progression has also been found with 
lymph node metastasis in gastric carcinoma (Lee et al., 1996).  
However, a recent study on cervical carcinoma did not support the prognostic relevance of the 
receptor in cervical carcinoma (Branca et al., 2006). Upon immunohistochemical staining of lesions, 
Branca and coworkers failed to prove that upregulation of the LR is a predisposing factor for an 
invasive phenotype. However, elevated expression was found to correlate with an increasing grade 
of lesions (Branca et al., 2006). During transition to an invasive phenotype, LR was upregulated 
implicating a role in cell proliferation. In addition, 67 kDa LR expression did not predict the 
outcome of cervical cancer (Branca et al., 2006). Contradictory studies with prostate cancer have 
been conducted, whereas a first study found that 67 kDa LR expression independently predicted 
poor prognosis for relapse (Waltregny et al., 1997). In contrast, in a second study, no correlation 
between the 67 kDa LR expression and the prognosis of relapse has been detected (Waltregny et al., 
2001). 
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3.5.1.4 Therapy of cancer through targeting LRP/LR 
 
Therapeutic strategies in cancer describe surgery, chemotherapy, radiation therapy and actually 
monoclonal antibody therapy (Chapter 4, Table 7) depending on the tumor. A prominent example 
for currently used antibodies represents the anti-HER2/neu antibody trastuzumab (Herceptin) 
(Chapter 4) used in breast cancer, targeting the epidermal growth factor receptor (EGFR) to inhibit 
uncontrolled tumor cell growth. Since a variety of antibodies are available directed against surface 
receptors, anti-LRP/LR antibodies might be promising therapeutic tools for cancer therapy. Since 
LRP/LR plays a prominent role in tumor cell migration, proliferation, angiogenesis and metastasis, 
it exhibits a valuable target for the development of therapeutics in cancer. In addition, LRP/LR 
seems to play a role in apoptotic processes, since downregulation of LRP via siRNAs was 
concomitant with apoptosis (Susantad and Smith, 2008). Together with the finding that LRP/LR is 
overexpressed in metastatic tumors, it can be concluded, that tumor cells prevent apoptosis by 
increasing the LRP/LR level. Specific targeting of LRP/LR on tumor cells to induce apoptosis, 
might therefore be an additional therapeutic strategy besides other approaches in cancer targeting 
apoptosis (Fesik, 2005; Fulda and Debatin, 2006).  
Inhibition of laminin-1 - LRP/LR interaction has been achieved by incubation of cells with anti-LRP 
antibodies (Zuber et al., 2008b). Single chain antibodies (scFv) as well as full length monoclonal 
IgG1 antibodies directed against LRP/LR are directed against the TWEDS region at the C-terminus 
on LRP, which have been reported to be implicated in tumor cell adhesion (Kazmin et al., 2000). 
Therefore, these antibodies were able to reduce invasion of tumorigenic cells (Zuber et al., 2008b). 
The inhibition of LRP/LR-laminin binding represents therefore a promising strategy for the 
treatment of invasive cancers. Blocking of the LRP/LR via antibodies has been reported to be 
efficient in mice. For example, experimental lung metastasis was inhibited by preincubation of 
tumorinducing cells with the anti-LRP antibodiy P4G prior to injection (Narumi et al., 1999). 
Furthermore, downregulation of 37 kDa LRP has been confirmed to reduce the capability of lung 
tumor formation in balbc nu/nu mice (Satoh et al., 1999). 
 
In summary, targeting LRP/LR for cancer intervention may act through several mechanisms due to 
the multifunctional properties of LRP/LR. 
First, tumorigenic cells exhibit remarkably elevated 67kDa LR levels on the cell surface, which 
enables discrimination from normal cells. LR can be therefore used as a marker for specific 
targeting of cancer cells, for example in gene therapeutic delivery approaches.  
The laminin1-LRP/LR interaction exhibits a second application point interfering with the metastatic 
process of tumorigenic cells. Antibodies recognising specifically the laminin binding TWEDS 
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region on the C-terminus were able to reduce the invasion of tumorigenic fibrosarcoma cells (Zuber 
et al., 2008a; Zuber et al., 2008b). 
Third, the observed overexpression of 67kDa LR in tumorigenic cells together with the proposed 
protective role in apoptosis (Susantad and Smith, 2008), suggests that the increased LR level on 
tumor cells serves as a protective mechanism of the cancer cell to prevent apoptosis. Targeting 
LRP/LR, for example by downregulation of LRP/LR, might re-induce apoptosis of the tumorigenic 
cell 
 
4. Antibodies 
 
Antibodies are synthesized and secreted during humoral immune response by plasma cells, which 
are derived from B-lymphocytes (B-cells). They recognize and bind selectively foreign molecules 
and serve as markers for signaling and defense of pathogenic invasion. Antibodies exhibit specific 
affinity for a particular part of the target molecule, which is called epitope or antigenic determinant.  
 
4.1 Structure and function of antibodies 
 
The first immunoglobulin (Ig) structure was published in 1979 (Amzel and Poljak, 1979). A typical 
antibody, or immunoglobulin (Figure 13) represents a compactly folded globular unit of approx. 110 
amino acids. The monomer is composed of two identical polypeptide light and heavy chains folded 
into a immunoglobulin like structure (Figure 13). The whole molecule consists of two antigen 
binding fragments termed Fabs (Fragment antigen binding), which are linked via a flexible hinge 
region to the Fc part (crystallizable). The Fc portion determines the Ig isotype (IgG and subclasses, 
IgA, IgD, IgE and IgM) and is able to bind to various effector molecules of the immune system e.g. 
Fc receptors, complement receptors or other compounds that influence the biodistribution and 
clearance of the antibody.  
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Figure 13 Monomer structure  and domain organization of an immunoglobulin. Light chains consist of one 
constant (CL) domain and one variable (VL), whereas the heavy chain is composed of three constant region 
(CH1, CH2, CH3) and one variable chain (VH). Two variable domains are responsible for the antigen binding 
and harbour three loops (hypervariable loops) designating complementary determining regions (CDR) 1, 2 and 
3. These domains confine the specifity of the antibody for epitope recognition and the highest diversity is 
found within CDR 3.The immunoglobulin fold consist of a pair of antiparallel beta sheets Fab = fragment 
antigen binding; Fc = crystallizable. (adopted from (Brekke and Sandlie, 2003)). 
The ability of antibodies to activate complement cascade or the antibody dependent cellular 
cytotoxicty (ADCC) depends on the isotype. In humans, the IgG1 is the most prominent 
one. Through binding to a receptor the antibody is able to induce signaling cascades e.g. 
induction of apoptotic pathways. 
 
4.2 Passive Antibody therapy 
 
Passive antibody therapy was used since 1890s, after the discovery, that immune sera are able to 
prevent certain infections in experimental animals (Casadevall and Scharff, 1994). In 1920 and 
1930, several sera, originating from rabbit or horse, were used for treatment of pneumococcal 
pneumonia, meningococcal meningitis, diphtheria, scarlet fever or measles (Casadevall and Scharff, 
1994). However, administration was associated with toxic side effects, due to contaminations and 
animal origin, which elicited immune respone. In addition, a polyclonal serum contains a variety of 
antibodies with different specifities and affinities. The invention of the hybridoma technology 
(Kohler and Milstein, 1975) allowed the production of monoclonal antibodies, comprising a specific 
isotype with one specifity and marked an important step in the development of antibody therapies. A 
splenic derived B-cell is fused to a plasmacytoma to combine the antibody synthese function with 
immortality. The potential of a produced mouse monoclonal antibody (mAb) (Figure 14) was 
limited due to a short half life, the inability to trigger human effector functions and the HAMA 
 49 
response (Schroff et al., 1985), which results in the production of reactive human anti-mouse 
antibodies. In the following, genetically engineered antibodies were designed (Morrison et al., 1984; 
Wright et al., 1992) comprising a human constant part and a mouse variable region. However, a so-
called HACA response, a human anti-chimeric antibody response, was observed after application 
(Kuus-Reichel et al., 1994; Sandborn and Hanauer, 1999). To minimize the mouse component, 
further CDR (complementary determining region) grafting has been used (Jones et al., 1986). 
Hence, mouse CDR regions are inserted into human constant and variable regions of the antibody 
construct, resulting in humanized antibodies (Figure 14). The selection of human antibody 
fragments from in vitro libraries or transgenic mice finally enabled the construction of complete 
human antibodies (Figure 14). Transgenic mice able to express human immunoglobulins, can be 
immunized against the desired antigen and the B-cells are subsequently isolated and fused to a 
myeloma cell. The resulting hybridomas are screened for specific human antibodies (hu mAb).  
 
 
Figure 14. Schematic representation of modified monoclonal antibodies. Antibodies can be generated through 
mouse hybridoma technology resulting in murine antibodies (ending: -mumab), chimeric (-ximab) and 
humanized (-zumab) antibodies (Table 6). Cloning of mouse variable regions into human constant region 
genes generates chimeric antibodies. Humanized antibodies can be generated by insertion of mouse CDRs into 
human constant and variable domain frameworks. Entire or full length human antibodies are generated by 
selection of human antibody fragments from in vitro libraries or transgenic mice. (modified from 
http://www.biologie.de/biowiki/ Monoklonaler_Antik%C3%B6rper) 
 
4.2.1 Antibodies and derived fragments – therapeutic implications 
 
Besides monoclonal antibodies, different antibody fragments have been developed for therapeutic 
purposes. Fab fragments and single chain antibodies (scFvs) (Figure 15), represent also promising 
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therapeutic antibody formats, lacking the Fc region and exhibit in contrast to full length IgGs a 
better tissue penetration as well as possible faster distribution in the organism due to the smaller size 
(approx. 35kDa). ScFvs or Fabs can be polymerized into dia-, triabodies or modified through 
PEGylation (Yang et al., 2003). The chemical coupling of a polyethylene glycol group (PEG) 
reduces the immunogenicity and prolongs the serum half life. Bispecific antibodies can consist of 
two different Fab fragments, one binding to the host immune complement component, which is 
often a receptor. The other fragment recognizes the pathogen (microbial epitope). A bispecific mAb 
crosslinking the erythrocyte complement receptor with an anti-bacterial antigen specific for 
Pseudomonas aeroginosa has been reported to clear primates effectively from bacterial infection 
(Lindorfer et al., 2001). In contrast to scFv, which cannot be rescued from degradation due to the 
lack of the Fc part, full-length antibodies are more stable and exhibit a longer serum half life. The 
long survival of IgG relative to the other plasma proteins has been associated with the binding to the 
FcRn or Brambell receptor (Brambell et al., 1964; Junghans and Anderson, 1996). The Fc portion of 
a full length IgG binds to this neonatal Fc receptor (FcRn), expressed on human placenta and blood 
vessels, which is able to transport IgGs. It has been demonstrated that upon binding to FcRn in 
endosomes, IgGs can be prevented from lysosomal degradation and recycled to the blood circulation 
(Hinton et al., 2006). Approaches to modify the Fc region of therapeutic antibodies for a higher 
binding affinity to FcRn have been reported, aiming at an increase in the serum half life (Petkova et 
al., 2006). 
 
  
Figure 15. Schematic representation of antigen-binding fragments derived from Ig. The Fab fragment 
represents the antigen-binding portion without the Fc part. A single chain antibody (scFv) consists of the 
variable regions of the heavy and light chains which are linked by a small peptide linker molecule e.g. 
Gly4Ser3 or yol consisting of 8-15 amino acids.  
4.2.2 Manufacture of antibodies and antibody fragments 
 
For antibody selection, the prominent in vitro technology describes the phage display technique 
(McCafferty et al., 1990) (Figure 16), which enabled the design of antibodies composed only of the 
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variable regions, termed single chain antibodies scFv (single chain Fragment variable). Both human 
and synthetic gene repertoires can be cloned into specific expression vectors, which are 
subsequently transfected into phages producing E.coli (in vitro library) (Gram et al., 1992). The 
variable genes encoding antibody variable domains are expressed on the surface of filamentous 
bacteriophages as fusion products to the coat proteins of the phage (Figure 16). The fragments are 
selected for the antigenbinding, the corresponding gene is cloned into an expression vector and 
produced in E.coli (scFv) or in mammalian cells (Fab-IgG), respectively. The first monoclonal 
antibody, which was generated by phage display was adalimumab (Humira®, anti-TNFα) (Table 6) 
approved at the end of 2002 for the treatment of rheumatoid arthritis. Chain-shuffling can be 
additionally used to improve the binding affinity of an antibody, through the introduction of point 
mutations in the CDR. The light chain repertoire is substituted by a new light chain repertoire, 
retaining the variable heavy chain. Panning of such chain-shuffled libraries by stringent conditions 
generates antibodies with higher affinities than the original one. Further approaches generate an 
antibody library, with mutations within the variable regions through error prone polymerase chain 
reaction (Pannekoek et al., 1993) or site specific mutagenesis (Miyazaki et al., 1999). 
 
 
 
Figure 16. Schematic overview of the phage display technique. From a large pool of lymphocyte DNA a 
library of variable region genes is isolated and inserted by random combination into the phage DNA. 
Following infection and amplification of the phage in E. coli, a huge number of different specificities are 
expressed on the surface. After binding to the purified antigen, the phage can be amplified by replication in 
the bacterial host. Following several cycles of selection and amplification, a population of antigen-specific 
phages is obtained, each containing the specific DNA, which encodes for the expressed Fv fragment. The 
DNA is subsequently cloned into vectors for amplification and expression in bacteria (in case of scFv) or 
mammalian cells (full-length IgG).               
(adopted from http://juang.bst.ntu.edu.tw/ECX/images/phage%20display.jpg) 
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4.2.3 Features of antibodies for therapy  
 
A striking feature of antibodies is the high specificity, targeting only the microorganism that causes 
the disease or the tumorigenic cell, which displays distinct properties in contrast to normal cells. The 
design of an antibody (isotype, coupling of chemical compounds, scFv of IgG) depends on the 
target, disease and mode of action. Antibodies can function through several mechanisms: selective 
killing of the target cell by either delivery of toxic payload (radioisotope, catalytic toxins, drugs, 
cytokines and enzymes) (i), or inducing apoptotic signaling (ii), antibody dependent cellular 
cytotoxicity (ADCC) (iii), complement dependent cellular cytotoxicity (CDC) (iv), or simply 
blocking the binding of molecules to a target e.g. a receptor (v).  
The isotype offers a variety of possibilities for the design of antibodies to achieve a specific effect. 
Most therapeutic monoclonal antibodies (mAb) contain the IgG1 isotype, which is able to mediate 
Fc domain-based functions, such as ADCC and complement fixation. Other isotypes e.g. IgG2 act 
only through antigen-binding e.g. mAb directed against growth factor receptors on tumor cells.  
Since antibodies are produced in cell lines or other expression systems, a possible contamination 
with viruses or other infectious agents cannot be excluded. A further challenge is the appropriate 
therapeutical antibody concentration, which is crucial for a successful therapy, since the so-called 
prozone effect occuring after excessive antibody administration, can be detrimental for the host 
(Taborda et al., 2003). The prozone effect describes the lack of agglutination at high concentrations 
of antibodies. Since protection against bacterial infection is hampered as a result of high antibody 
concentration, the appropriate antibody concentration has to be considered for the treatment for 
infectious diseases. 
 
4.2.3.1 Antibodies for cancer therapy 
 
Several monoclonal antibodies are currently used for therapy of several cancer types (Table 6). The 
first humanized antibody was alemtuzumab (Campath® anti-CD52) (Albitar et al., 2004; Osterborg 
et al., 1997), which is now used for the treatment of chronic lymphocytic leukemia (Alinari et al., 
2007). In contrast to most anti-cancer antibodies, which are coupled to toxic substances, so-called 
naked antibodies are in therapeutic use, acting through Fc receptor or complement activation, which 
induces crosslinking of surface receptors leading to apoptotic signaling. Many solid tumors 
overexpress growth factor receptors such as EGFR (epidermal growth factor receptor) stimulating 
cell growth in an autocrine manner. A series of mAbs were shown to inhibit ligand binding and 
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therefore, receptor activation (Teramoto et al., 1996). Healing from established tumors was achieved 
when anti-EGFR mAbs were combined with chemotherapeutic agents such as cisplatin (Fan et al., 
1993). A novel strategy in mAb tumor therapy describes the antibody-directed enzyme prodrug 
therapy (ADEPT). Here, an enzyme is conjugated to the antibody. After antibody binding to the 
tumor cell, the enzyme cleaves a subsequently delivered prodrug, which becomes then active in the 
tumor cell. This leads to highly specific deposition of an active drug solely in the tumor cell. 
Clinical study, employing this strategy, have been investigated for colorectal cancer (Francis et al., 
2002) (Mayer et al., 2004).  
Lymphomas are targeted by mAbs directed against cell surface receptors like e.g. CD20 acting 
through mechanisms like activation of ADCC, CDC and apoptosis. The affinity of an antibody can 
also be modified according to the desired effect. For example, in tumor therapy a higher affinity of 
the antibody to the antigen is not recommended since this correlates with an impeded penetration 
ability into the tumor mass (van Osdol et al., 1991; Weinstein et al., 1987). This finding was 
proposed as the binding site barrier, which describes the fact that high affinity interactions between 
the antibody and its target block the diffusion of the antibody through the tumor mass. The use of a 
high affinity scFv directed aginst EGF (epidermal growth factor) which exhibited diminished 
penetration into solid tumor compared to their lower affinity counterparts (Adams et al., 2001) 
supported this effect. In contrast, if an ADCC response should be achieved, a higher affinity is 
required. In combination with multivalency, which is also an important feature, the ADCC response 
can be more efficient. For example bispecific antibodies targeting both EGFR and a distinct Fc 
receptor reveal more effective mediators of ADCC, in case the antibody affinity is higher (Weiner 
and Carter, 2005). 
 
4.2.3.2 Antibody based therapy for infectious diseases and other 
implications 
 
Passive antibody therapy is currently used to treat and prevent diseases caused by severeal viruses 
and bacteria. Besides the general properties such as ADCC or CDC, antibodies exhibit also direct 
toxin neutralization and microbial properties (e.g. generation of oxidants). Human mAb have been 
generated against e.g. fungal antigens (Matthews et al., 2003). Antiviral active antibodies have been 
designed against respiratory syncitical virus (RSV) infection, available for prophylaxis (Wang and 
Tang, 2000) and for treatment (Domachowske and Rosenberg, 1999). Prophylactic antibodies 
against Hepatitis B virus are currently used (Zuckerman, 2007). A protective effect against the 
tetanus toxin has been discovered 1993 after the isolation of toxin-neutralizing human monoclonal 
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antibodies (Lang et al., 1993). Recently, immunization of transgenic mice resulted in the generation 
of shiga-toxin 1 neutralizing human mAbs (Mukherjee et al., 2002). Additionally, in mice, high 
affinity scFvs have been demonstrated to be protective against anthrax toxin in mice (Maynard et 
al., 2002). Furthermore, neutralizing Fab fragments against measles virus have been isolated by 
phage display (de Carvalho Nicacio et al., 2002). Moreover, some antibodies seem to be able to kill 
bacteria directly by altering their surface structures (Connolly and Benach, 2001). 
Radioimmunotherapy, succesfully used in cancer treatment, has also been described for treatment of 
fungal infection (Dadachova et al., 2003). 
Antibodies encompassing high affinity can be developed to bind cytokines and their receptors to 
reduce the inflammatory response. Patients with rheumatoid arthritis for example, can be treated 
with chimeric anti-TNF α antibodies (e.g. Infliximab; Table 6), which are also available for the 
treatment of Crohn’s disease (Mikula, 1999). 
Fc-IgG interaction has been reported to reduce the inflammatory response and diseasae related 
damages (Samuelsson et al., 2001).  
Antibodies can be applied not only for disease treatment or vaccination, but also for other 
implications (Table 6). For instance, in organ transplantation, immunsuppression is required and 
achieved by targeting CD3 (Wilde and Goa, 1996), a T-cell surface receptor required for T-cell 
activation. Furthermore, antibodies directed against the 37 kDa/67 kDa LRP/LR block both the 
binding of the prion protein (Leucht et al., 2003; Zuber et al., 2008a; Zuber et al., 2007b) and the 
binding of laminin-1 to the laminin receptor (Zuber et al., 2008b). Thus, these antibodies can be 
used for therapeutic application in prion disease (Chapter II-IX) and intervention of metastatic 
potential of tumor cells (CHAPTER XI). 
 
4.2.3.3 Rediscovery of polyclonal antibodies for therapy 
 
Although designed monoclonal antibodies, Fabs and scFvs are widely used and generated for 
therapeutic purposes, also the polyclonal format becomes again interesting for therapeutic 
applications. Polyclonal antibodies (pAb) are recommended for the treatment of diseases associated 
with complex antigens such as sepsis (Kreymann et al., 2007). A polyclonal ovine anti-TNF 
fragment antigen binding (Fab) fragment was effective for sepsis (Rice et al., 2006). Additionally, 
an oligoclonal antibody cocktail has been proven to efficiently neutralize and clear patients from 
botulinum neurotoxin (Nowakowski et al., 2002). The polyclonal anti-LRP/LR antibody displayed 
also a more prominent therapeutic effect compared to the single chain format (Zuber et al., 2007b). 
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Intraperitoneal (ip.) administration in scrapie infected mice prolonged the survival of these mice 
compared to another study where scFvs were delivered i.p. into prion infected mice. For cancer 
therapy the polyclonal format is believed to be more efficient in mediating effector functions and 
escape variants are thought to be minimized by multi-targeting through the polyclonal format 
(Sharon et al., 2005). Polyclonal antibodies can be produced in transgenic animals or via the 
combination with mAb production technology. For this, polyclonal antibody libraries (pALs) have 
been generated (McNichol et al., 2007; Sarantopoulos et al., 1994). Heavy and light chain variable 
region genes are obtained from immune B cell-containing tissues, by RT-PCR, and cloned in pairs 
in a Fab phage display vector. The resulting Fab phage display library is then selected for desired 
specificities and the selected VL–VH region gene pairs are transferred from the phage display vector 
to a mammalian expression vector. Full-length antibodies can be produced by transfection of the 
mammalian expression vector library into mammalian cells (Sharon et al., 2005; Sharon et al., 
2002). 
Table 6. Available therapeutic antibodies 
Generic name / 
Trade name 
type target indication 
Cancer    
Alemtuzumab / 
MabCampath® 
humanized CD52-antigen on 
lymphocytes  
Chronic lymphatic 
leukemia, T-cell-lymphoma 
Bevacizumab / 
Avastin® 
humanized VEGF (Vascular 
Endothelial Growth Factor)  
colorectal cancer, lung 
cancer  
Cetuximab / 
Erbitux® 
chimeric  EGF-receptor (Epidermal 
Growth Factor Receptor)  
colorectal cancer 
2Epratuzumab / 
LymphoCide® 
humanized CD22-antigen  Non-Hodgkin-Lymphoma, 
Autoimmune diseases 
1Gemtuzumab / 
Mylotarg® 
humanized, 
conjugared to 
calicheamicin  
CD33-antigen  acute myelogenous 
leukemia 
Ibritumomab / 
Zevalin® 
murine, 90Y-
radiolabeled  
CD20 on B-lymphocytes  non-Hodgkin-lymphoma 
Panitumumab / 
ABX-EGF 
humanized EGF (Epidermal Growth 
Factor Receptor)  
non-small cell lung cancer 
(not approved yet) (Phase 
I/II-Studien) 
Rituximab / 
MabThera® 
chimeric  CD20 on B-lymphocytes non-Hodgkin-lymphoma 
1Tositumomab / murine, 131I- CD20 on B-lymphocytes non-Hodgkin-lymphoma 
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Bexxar® labeled  
Trastuzumab / 
Herceptin® 
 humanized HER2/neu-Rezeptor  breast cancer 
Autoimmune 
diseases 
   
Adalimumab / 
Humira® 
humanized Tumor Nekrose factor α 
(TNF-α)  
rheumatoid arthritis 
Basiliximab / 
Simulect® 
chimeric  CD25-antigen (Interleukin-
2-receptor)  
Prophylaxis in kidney 
transplant rejection  
Daclizumab / 
Zenapax® 
humanized CD25-antigen (Interleukin-
2-receptor) 
Prophylaxis in kidney 
transplant rejection  
Infliximab / 
Remicade® 
chimeric  tumor Nekrose factor α 
(TNF-α)  
Crohn’s disease, 
rheumatoid arthritis 
Muromonab / 
Orthoclon OKT3® 
murine CD3-antigen (T-
lymphocytes)  
Prophylaxis in 
kidney/heart/liver 
transplant rejection 
1Natalizumab / 
Tysabri® (FDA 
appproved) 
humanized CD49d (VLA-4, integrin)  multiple sclerosis  
Cardiovascular 
disease 
   
Abciximab / 
ReoPro® 
chimeric, Fab2-
fragment, anti-
platelet  
GPIIb/IIIa on thrombocytes Coronary intervention and 
angioplasty 
Infectious disease    
Palivizumab / 
Synagis® 
humanized anti-F protein, component 
of  respiratory syncytial 
virus (RSV)  
Prophylaxis of RSV-
pneumonia  
others    
Efalizumab / 
Raptiva® 
humanized  CD11a-antigen  psoriasis 
1Omalizumab / 
Xolair ® 
humanized IgE (Fc-Teil)  Allergy, severe asthma 
bronchiale 
(1not approved for Germany), indicated types are all full length Igs except Abciximab 
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SUMMARY
1. Prion diseases are a group of rare, fatal neurodegenerative diseases, also known as
transmissible spongiform encephalopathies (TSEs), that affect both animals and humans
and include bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, chronic
wasting disease (CWD) in deer and elk, and Creutzfeldt–Jakob disease (CJD) in humans.
TSEs are usually rapidly progressive and clinical symptoms comprise dementia and loss of
movement coordination due to the accumulation of an abnormal isoform (PrPSc) of the
host-encoded prion protein (PrPc).
2. This article reviews the current knowledge on PrPc and PrPSc, prion replication
mechanisms, interaction partners of prions, and their cell surface receptors. Several strate-
gies, summarized in this article, have been investigated for an effective antiprion treatment
including development of a vaccination therapy and screening for potent chemical com-
pounds. Currently, no effective treatment for prion diseases is available.
3. The identification of the 37 kDa/67 kDa laminin receptor (LRP/LR) and heparan
sulfate as cell surface receptors for prions, however, opens new avenues for the develop-
ment of alternative TSE therapies.
KEY WORDS: bovine spongiform encephalopathy; Creutzfeldt–Jakob disease; hep-
aran sulfate; 37 kDa/67 kDa laminin receptor; LRP/LR; prion; PrP therapy; transmissible
spongiform encephalopathy.
INTRODUCTION
Prion diseases or transmissible spongiform encephalopathies are incurable neu-
rodegenerative disorders, which occur both in humans and animals. Human TSEs
include Kuru (Gajdusek and Zigas, 1957), Gerstmann–Sträussler–Scheinker syn-
drome (GSS) (Gerstmann et al., 1936), fatal familial insomnia (FFI) (Lugaresi
et al., 1986), and Creutzfeldt–Jakob disease (CJD) (Creutzfeldt, 1920), which is the
most prominent prion disease in humans. However, all of them (as summarized in
Table I) are a group of rapidly progressive disorders characterized by a defined spec-
trum of clinical abnormalities. They share a spongiform degeneration of the brain
1 Laboratorium für Molekulare Biologie, Genzentrum, Institut für Biochemie der Ludwig-Maximilians-
Universität München, Feodor-Lynen-Str. 25, 81377, München, Germany.
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Table I. Summary of the Initial Description of Human TSEs
TSE
Initially
described Reference
Creutzfeldt–Jakob disease (CJD) 1920 (Creutzfeldt, 1920)
Sporadic Creutzfeldt–Jakob disease (sCJD) 1921 (Jakob, 1921)
Familial Ceutzfeldt–Jakob disease (fCJD) 1924 (Kirschbaum, 1924)
Iatrogenic Creutzfeldt–Jakob disease (iCJD) 1974 (Duffy et al., 1974)
New variant Creutzfeldt–Jakob disease (vCJD) 1996 (Will et al., 1996)
Gerstmann–Sträussler–Scheinker syndrome (GSS) 1928 (Gerstmann et al., 1936)
Kuru 1957 (Gajdusek and Zigas, 1957)
Fatal familial insomnia (FFI) 1986 (Lugaresi et al., 1986)
Sporadic fatal insomnia (sFI) 1999 (Mastrianni et al., 1999;
Parchi et al., 1999)
and a variable amyloid plaque formation and can appear as sporadic, inherited, or
iatrogenic disorders.
Transmissible spongiform encephalopathies (TSEs) also frequently occur in
different animal species. Scrapie in sheep and goats (McGowan, 1922), feline
spongiform encephalopathy (FSE) in cats (Wyatt, 1990), transmissible mink en-
cephalopathy (TME) (Burger and Hartsough, 1965), chronic wasting disease in wild
ruminants (CWD) (Williams and Young, 1980), bovine spongiform encephalopathy
(BSE) in cattle (Wells et al., 1987), and encephalopathies of a number of zoo an-
imals (exotic ungulate encephalopathy, EUE) (Jeffrey and Wells, 1988; Kirkwood
et al., 1990) have been described. A hallmark of all prion diseases is the accumu-
lation of an abnormal, partially proteinase-resistant isoform of the cellular prion
protein (PrPc), which represents a cell-surface glycosylphosphatidyl inositol (GPI)
anchored protein (Stahl and Prusiner, 1991). PrPc is highly conserved among mam-
mals (Schätzl et al., 1995) and is expressed in many tissues with notably high levels
in the brain of animals and humans (Kretzschmar et al., 1986; Moudjou et al., 2001).
The conversion of the host-encoded PrPc into the abnormal disease-inducing iso-
form (PrPSc) involves a conformational change and is important in the pathogenesis
of these diseases (Prusiner, 1994). Several hypotheses about the nature of the in-
fectious agent have been proposed. Initially, the agent was thought to be a slow
virus (Sigurdsson, 1954; Thormar, 1971). In 1967, J. S. Griffith postulated the hy-
pothesis that the causative agent might be a protein (Griffith, 1967). The theory of
a self-propagating proteinaceous agent (Bolton et al., 1982) was proposed after the
isolation of a protease-resistant sialoglycoprotein specifically associated with infec-
tivity, designated the prion protein (PrP) (Bolton et al., 1982). The term prion, which
was devised by Stanley Prusiner, is the abbreviation for “proteinaceous infectious
particle” and was defined as “small proteinaceous infectious particle that resists in-
activation by procedures which modify nucleic acids” (Bolton et al., 1982; Prusiner,
1982).
THE CELLULAR PRION PROTEIN PrPc
The prion protein (PrPc) is a normal cellular glycosylphosphatidyl inositol
(GPI) anchored protein and is highly conserved among mammalian species (Schätzl
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Fig. 1. Schematic view of structural elements of the murine cellular prion protein. The depicted murine
cellular PrP (PrPc) is a GPI-anchored protein of 254 amino acid residues. During PrPc processing, a
22 amino acid N-terminal signal peptide (SP) is removed and 23 carboxy-terminal amino acid residues
(signal sequence (SS)) are cleaved upon the addition of the glycosylphosphatidyl inositol anchor to Ser-
231. The N-terminal region contains a series of four octapeptide repeats that have been implicated in the
binding of metal ions (Whittal et al., 2000). The first repeat represents a nonarepeat due to an additional
glycin residue. The repeat has a histidine residue substituted by a glutamine and, therefore, fails to bind
copper (Leliveld et al., 2006). The globular C-terminus of the molecule folds into three α-helices and an
antiparallel ß-sheet, whereas the N-terminal part of the protein is flexible as determined in solution. The
structure of the murine PrP 121-231 was initially solved by Riek and colleagues (Riek et al., 1996), and
that of hamster PrP 29-231 by Donne and colleagues (Donne et al., 1997).
et al., 1995; Wopfner et al., 1999). It has been identified in various animals in-
cluding birds (Harris et al., 1993), pisces (Gibbs and Bolis, 1997), and marsupials
(Windl et al., 1995), and may be present in all vertebrates. PrP mRNA is consti-
tutively expressed in the brains of adult animals with a high expression in neurons
(Kretzschmar et al., 1986). Substantial amounts have also been found in heart
(Brown et al., 1990), skeletal muscle (Brown et al., 1998; Bosque et al., 2002),
lymphoid tissue and leukocytes (Liu et al., 2001; Paltrinieri et al., 2004), intestinal
tissues (Morel et al., 2004), and uterus and testis (Tanji et al., 1995). In 1986, the
human PrP gene (Prn-p) has been mapped to 20p12-pter (Liao et al., 1986; Robakis
et al., 1986; Sparkes et al., 1986). The conformation of the cellular isoform of murine
PrP was first determined by nuclear magnetic resonance (NMR) studies (Riek et al.,
1996). Since then, NMR measurements on the prion protein from various species
were performed and revealed that they all have global architecture similarities.
The prion protein has a flexible, unstructured N-terminal region and a well-ordered
C-terminal globular domain, which includes three α-helices and two antiparallel
β-sheet structures (Riek et al., 1996). The N-terminal region contains a segment of
several octapeptide-repeat regions that preferentially bind copper (Hornshaw et al.,
1995) (Fig. 1). Infrared spectroscopy and circular dichroism demonstrated that the
secondary structure of PrPc is mainly composed of α-helices (42%), whereas PrPSc
consists mainly of β-sheets (Table II) (Cohen et al., 1994). In Syrian hamster and
Table II. Comparison of Biochemical Features of PrPc, PrPSc, and PrP27-30
PrP isoform PrPc PrPSc PrP27-30
Infectivity Noninfectious Infectious Infectious
Protease status Sensitive Partially resistant Resistant
Solubility Soluble Insoluble Insoluble
Aggregation status Monomer/dimer/oligomer Aggregates Amyloid fibrils
Secondary structure α-helices (42%), α-helices (30%), α-helices (21%),
β-sheets (3%) β-sheets (43%) β-sheets (54%)
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mice, PrPc is synthesized as a precursor of 254 amino acids while the human Prn-p
encodes a prion protein of 253 amino acids in length. During trafficking through
the secretory pathway of the cell, the N-terminal signal peptide is cleaved off in the
endoplasmatic reticulum (Hope et al., 1986) and 23 C-terminal residues demerge
upon addition of the GPI anchor at serine (Ser) 231 (Stahl et al., 1987). Cell culture
studies revealed that PrPc constitutively cycles between the cell surface and an
endocytic compartment with a transit time of approx. 60 min and more than 95%
of the internalized protein is recycled back to the cell surface (Shyng et al., 1993).
THE PATHOGENIC ISOFORM PrPSc AND REPLICATION MECHANISMS
In TSEs, the cellular prion protein PrPc can be converted into a pathogenic
isoform referred to as PrPSc that shows great resistance to radiation and nucleases
(Alper et al., 1967). The high proportion of β-sheets in PrPSc renders it insoluble and
markedly resistant to proteases (Table II) (Cohen and Prusiner, 1998). Digestion
with proteinuse K results in a 27–30 kDa fragment, termed PrPres (Bolton et al.,
1982). PrP27-30 is unusually stable at high temperatures and can only be inactivated
by protein denaturants that modify the structure of PrP27-30 (Prusiner et al., 1993).
After detergent and protease treatment, PrP27-30 was found to accumulate into
rod-shaped polymers that are insoluble in aqueous and organic solvents as well as
nonionic detergents. In contrast, PrPSc (the full-length infectious conformer of PrPc)
has a tendency to form aggregates but not amyloid fibrils (McKinley et al., 1991)
(Table II).
Given the same primary sequence of PrPc and PrPSc (Basler et al., 1986), the
different properties of PrPc and PrPSc seemed likely to involve posttranslational
modifications. Extensive biochemical investigations have failed to reveal any
covalent differences between PrPc and PrPSc (Stahl et al., 1993). By contrast,
spectroscopic studies demonstrated a conformational difference between PrPc and
PrPSc. PrPc has a high α-helical content of approx. 42%, with little or no β-sheets
(approx. 3%), whereas PrPSc contains approx. 30% α-helices and approx. 45%
β-sheets (Pan et al., 1993) (Table II). PrPSc formation is supposed to occur via the
interaction between PrPc and PrPSc, which is able to convert the host protein into a
likeness of itself (Griffith 1967; Bolton et al., 1982). The mechanism by which PrPSc
triggers further PrPSc production is unknown, although two major models have
been proposed. The catalytic model (Prusiner, 1991) proposes that the presence of
PrPSc catalyzes the conversion of PrPc to PrPSc. Alternatively, it has been proposed
that the formation of PrPSc is a nucleation-dependent process (Lansbury and
Caughey, 1995). The cellfree in vitro conversion process was shown to be consistent
with the nucleation-dependent polymerization mechanism of PrPSc formation and
inconsistent with the heterodimer mechanism (Caughey et al., 1995). Regardless of
the underlying mechanisms, there is more and more evidence supporting the initial
idea of self-replicating prions consisting of protein-only, which has in fact been
long debated. Although compelling evidence supports this hypothesis, generation
of infectious prion particles in vitro has not been convincingly demonstrated for a
long period of time. Thus, it was shown in 2004, by Legname and colleagues, that
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recombinant murine prion protein (including amino acid residues 89–230) produced
in E. coli can be converted into an infectious PrP form being able to cause a prion
disease-like phenotype in transgenic (PrP89-230 expressing) and, in the second
round, in wild-type mice (Legname et al., 2004). In addition, Castilla and colleagues
showed that PrP conversion can be mimicked in vitro by protein misfolding cyclic
amplification (PMCA), resulting in indefinite amplification of infectious PrPres as
shown by bioassays in hamsters (Castilla et al., 2005).
The precise subcellular localization of PrPSc propagation remains controversial.
There is evidence, however, that either late-endosome-like organelles or lysosomes
are involved (Mayer et al., 1992; Arnold et al., 1995). A role for lipid rafts in the
formation of PrPSc is deduced from the finding that both PrPc and PrPSc are present
in rafts isolated from infected cells (Baron and Caughey, 2003; Botto et al., 2004). It
was also shown that PrPc lacking the GPI anchor is converted into PrPSc (Chesebro
et al., 2005)
THE FUNCTION OF PrP
The exact physiological role of the cellular prion protein PrPc still remains ob-
scure, although some possible biological functions have been described. The pro-
posed functions include a neuroprotective function due to antiapoptotic activity
(Bounhar et al., 2001; Diarra-Mehrpour et al., 2004), a functional role in copper
metabolism due to its copper-binding capacity (Brown et al., 1997), involvement in
signal transduction (Koch et al., 1991; Mouillet-Richard et al., 2000), memory forma-
tion (Collinge et al., 1994), and neuritogenesis (Graner et al., 2000). Mice lacking PrP
(Prnp0/0) showed no obvious phenotype (Bueler et al., 1992), although they have
abnormalities in synaptic physiology (Collinge and Palmer, 1994) and in circadian
rhythm and sleep (Tobler et al., 1996). Prnp0/0 mice were shown to be completely
resistant to prion disease (Bueler et al., 1993). Several lines of PrP knockout mice
have been generated to unveil the function of PrPc (Weissmann and Flechsig, 2003).
The finding that lymphocytes express PrPc on the cell surface implicates a role
in lymphocyte activation (Cashman et al., 1990). Anti-PrPc antibodies cause partial
inhibition of mitogen driven T-cell proliferation giving evidence for a role in mod-
ulating T-cell responses (Bainbridge and Walker, 2005). The fact that PrPc is abun-
dantly expressed in the lymphoid tissue and acts as a signaling molecule on T-cells
implicates a role in the development and normal function of the immune system
(Mazzoni et al., 2005; Ballerini et al., 2006).
The molecular mechanism of PrP protection against oxidative stress is still
unclear, but PrP may reduce copper-mediated oxidative stress due to its copper-
binding activity (Vassallo and Herms, 2003). Since PrP knockout mice exhibit ap-
prox. 50% lower copper concentration in synaptosomal fractions than wild-type
mice, it was suggested that PrPc might regulate the copper concentration in the
synaptic region and may play a role in the reuptake of copper into the presynapse
(Kretzschmar et al., 2000).
Furthermore, it has been shown that PrPc harbors a copper/zinc-dependent
superoxide-dismutase (SOD) that provides PrPc with antioxidant activity. By dele-
tion of the octapeptide repeat region involved in copper binding, the SOD activity
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was abolished (Brown et al., 1999). In vivo experiments revealed that protein and
lipid oxidation is increased in skeletal muscle, heart, and liver in Prnp0/0 mice sug-
gesting a PrPc function related to cellular antioxidant defenses (Klamt et al., 2001).
PrPc is known to be attached to the plasma membrane through a glycosylphos-
phatidyl inositol (GPI) anchor and may act as a cell-surface receptor mediating cell-
surface signaling or cell adhesion. Recently, a coupling of PrPc to the nonreceptor
tyrosine kinase Fyn was observed (Mouillet-Richard et al., 2000). Furthermore, PrPc
has been described to regulate serotonergic receptor signaling and, thus, acting as
a protagonist for the homeostasis of serotonergic neurons (Mouillet-Richard et al.,
2005).
In addition, several experimental findings suggest a major role for PrPc in cell
survival or cell death. In a yeast two-hybrid system, PrPc was demonstrated to in-
teract selectively with the Bcl-2 protein (Kurschner and Morgan, 1995), that is a
suppressor of the programmed cell death. Recently, the antiapoptotic activity of
PrP has been shown in a human breast carcinoma cell line (Diarra-Mehrpour et al.,
2004). Cross linking of PrPc using monoclonal antibodies resulted in rapid and ex-
tensive apoptosis in hippocampal and cerebellar neurons suggesting that PrPc acts in
the control of neuronal survival (Solforosi et al., 2004). Expression of PrPc in gastric
cancer cell line led to an upregulation of Bcl-2 whereas p53 and Bax were downreg-
ulated (Liang et al., 2006). However, coaggregation of cytosolic PrP with Bcl-2 leads
to the induction of apoptosis (Rambold et al., 2006).
Despite all knowledge, there is some controversy on the protective function of
PrPc. It has been demonstrated that in some cell lines, the overexpression of PrPc
increases the susceptibility of these cells to staurosporine-induced apoptosis (Paitel
et al., 2002, 2003). In addition, it was proposed that endogenous cellular prion
protein sensitizes neurons to apoptotic stimuli through a p53-dependent caspase 3
mediated activation (Paitel et al., 2003, 2004).
INTERACTION PARTNERS OF THE CELLULAR PRION PROTEIN
More than 10 years ago, the existence of a cellular receptor for prions was
proposed. It was reasoned that the cellular prion protein PrPc would require a
transmembrane protein to trigger intracellular events (Shyng et al., 1994). Different
proteins (Table III) have been shown to interact with the cellular prion protein
including laminin (Graner et al., 2000), which is an extracellular matrix protein,
N-CAM (Schmitt-Ulms et al., 2001), a cell surface component with an important
role in neuronal aggregation, and tyrosin kinase Fyn implicating a role of PrP in
cell signaling (Mouillet-Richard et al., 2000).
Employing complementary hydropathy, a 66 kDa membrane protein that binds
PrPc both in vitro and in vivo was found (Martins et al., 1997) and it was reasoned
that this protein might act as a cellular prion protein receptor. However, the same
group identified this 66 kDa protein as stress-inducible-protein1 (STI1), playing a
role in neurite outgrowth and neuroprotection (Zanata et al., 2002). Parallel to this
study, we identified in a yeast two-hybrid screen, the 37 kDa laminin receptor pre-
cursor (LRP) as an interaction partner for the prion protein (Rieger et al., 1997).
Prions, Receptors, and TSE Therapy 113
Table III. Summary of Major Binding Partners for the Cellular Prion Protein, Their Proposed Func-
tion, and Subcellular Localization
PrPc binding
molecules Proposed function
Subcellular
localization Reference
Synapsin 1b Signal transduction Intracellular vesicles (Spielhaupter and
Schätzl, 2001)
Grb2 Signal transduction Intracellular vesicles (Spielhaupter and
Schätzl, 2001)
Pint 1 Unknown Unknown (Spielhaupter and
Schätzl, 2001)
Tyrosine kinase
Fyn
Binding/internalization Plasma membrane (Mouillet-Richard et al.,
2000)
Caveolin-1 Binding/internalization Caveolae/rafts (Mouillet-Richard et al.,
2000)
Clathrin Binding/internalization Clathrin-coated pits (Mouillet-Richard et al.,
2000)
CK2 Binding/internalization Caveolae/rafts (Meggio et al., 2000)
STI 1 Neuroprotection, neuronal
outgrowth
Cell surface (Zanata et al., 2002)
Bcl-2 Antiapoptotic/proapoptotic
function
Cytoplasm (Kurschner and
Morgan, 1995;
Sakudo et al., 2003;
Rambold et al., 2006)
p75 Binding/internalization Caveolae/rafts (Della-Bianca et al.,
2001)
Laminin Cell differentiation/cell
growth/movement ECM
formation
Cell surface (Graner et al., 2000)
GAGs Proposed role in prion
pathogenesis/receptor for
prions
Cell surface (Pan et al., 2002; Hijazi
et al., 2005)
HSPGs/HS Cofactor for PrPSc
synthesis/receptor for prions
Cell surface (Gabizon et al., 1993)
(Horonchik et al., 2005)
Co-receptor for PrPc (Hundt et al., 2001)
N-CAM Caveolae-like domain Caveolae-like domain (Schmitt-Ulms et al.,
2001)
Hsp60 Might influence PrP conversion Mitochondria (main)
(ER, Golgi,
secretory granules,
membrane
fractions)
(Edenhofer et al., 1996)
Nrf2 Unknown Unknown (Yehiely et al., 1997)
Aplp1 Unknown Cell surface (Yehiely et al., 1997)
37 kDa/67 kDa
Laminin
Receptor
(LRP/LR)
PrPc binding and internalization
(prion protein receptor)/PrPSc
binding and internalization
(PrPSc receptor)
Cell surface (Rieger et al., 1997;
Gauczynski et al.,
2001)
(Morel et al., 2005;
Gauczynski et al.,
2006)
NRAGE Neuronal viability Cytosol (Bragason and
Palsdottir, 2005)
Tubulin Intracellular trafficking Microtubular network
cytoskeleton
(Nieznanski et al., 2005)
ZAP-70 T-cell activation Glycosphingolipid-
enriched
microdomains
(Mattei et al., 2004)
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37 kDa LRP/67 kDa LR AND HEPARAN SULFATE PROTEOGLYCANES
AS RECEPTORS/CORECEPTORS FOR PrPc AND PrPSc
Further in vitro studies on neuronal and nonneuronal cells validated that both
forms of the laminin receptor, the 37 kDa LRP and the 67 kDa high affinity laminin
receptor act as the receptor for the cellular prion protein. Corresponding binding
domains on LRP/LR as well as on PrP were identified by yeast-two hybrid technol-
ogy (Hundt et al., 2001), revealing both a direct and an indirect, HSPG-dependent
binding site.
The 37 kDa LRP is thought to be the precursor of the 67 kDa LR, which
was first isolated from melanoma cells due to its high binding capacity to laminin
(Rao et al., 1983). Although LRP consists of a transmembrane domain (amino acid
residue 86–101, (Castronovo et al., 1991)), it is abundantly localized in the cyto-
plasm (Romanov et al., 1994). In mammalian cells, it has been demonstrated that
both the 37 kDa LRP and the 67 kDa LR are present in plasma membrane frac-
tions (Gauczynski et al., 2001). The exact mechanism by which the 37 kDa precur-
sor forms the mature 67 kDa isoform is up to now speculative. Data from the yeast
two-hybrid analysis showed that LRP failed to interact with itself (Hundt et al.,
2001), which would argue against homodimerization. Analysis of the membrane-
bound 67 kDa LR indicated that acylation of LRP is involved in the processing of
the receptor (Landowski et al., 1995) and the authors suggest that the 67 kDa form
consists of a homodimer of the LRP polypeptide modified by fatty acid chains. On
the contrary, a later study postulated that the 67 kDa LR is a heterodimer stabilized
by fatty acid-mediated interactions (Buto et al., 1998). Interestingly, mammalian
genomes contain multiple copies of the LRP gene, particularly 6 copies in murine
and 26 copies in the human genome (Jackers et al., 1996). Sequencing revealed that
over 50% of the 37 kDa LRP gene copies were pseudogenes most probably gener-
ated by retropositional events suggesting that the accumulation of several copies of
this gene might have given a survival advantage to the cell in the course of evolution
(Jackers et al., 1996).
Regarding the function of LRP/LR, the 37 kDa LRP appears to be a mul-
tifunctional protein (Fig. 2) involved in the translational machinery (Auth and
Brawerman, 1992) and has also been identified as p40 ribosome-associated protein
(Makrides et al., 1988). LRP has also been found in the nucleus, where it is tightly as-
sociated with nuclear structures (Sato et al., 1996) and binds to DNA through associ-
ations with histones H2A, H2B, and H4 (Kinoshita et al., 1998). The 37 kDa/67 kDa
LRP/LR has been described to act as a receptor for laminin, elastin, and carbohy-
drates (Ardini et al., 1998), as well as a receptor for Venezuelean equine encephalitis
virus (VEE) (Ludwig et al., 1996), Sindbis virus (Wang et al., 1992), and Dengue
virus (Tio et al., 2005) (Table III and Fig. 2). Very recently, LRP/LR has been
identified as a receptor for Adeno-associated Virus (AAV) serotypes 8, 2, 3, and
9 (Akache et al., 2006). Due to the colocalization of LRP/LR and PrP on the sur-
face of mammalian cells, a possible role of LRP/LR for PrP binding and internaliza-
tion was assumed. Cell-binding assays revealed, that the PrPc internalization process
represents an active LRP/LR-mediated event (Gauczynski et al., 2001). Due to the
identification of various LRP/LR isoforms, additional studies have been performed
to detect the isoforms that are present in the central nervous system and bind PrP.
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Fig. 2. Cellular functions of LRP/LR and model of the LRP/LR-/HSPG-dependent PrPc
and PrPSc binding and internalization. Upper panel: LRP/LR is associated to ribosomes
and is involved in the translation machinery (i), binds to nuclear DNA through its associ-
ation with histones contributing to the maintenance of nuclear structures (ii), and acts as
a receptor for laminin, elastin, and carbohydrates, as well as viruses and PrPc and PrPSc.
Lower panel: PrPc (green circle) anchored by glycosylphosphatidyl inositol (GPI) (green
bar) becomes internalized by LRP/LR (yellow ovals) (Gauczynski et al., 2001) utilizing
HSPGs (light green bars and black chain) as cofactors/coreceptors (Hundt et al., 2001).
PrPSc (purple squares) binds to the cell surface in a LRP/LR-(Gauczynski et al., 2006), and
heparan sulfate (black chain)/ HSPG- (Horonchik et al., 2005) dependent manner. The
PrP/LRP-LR/HSPG complex becomes internalized into endo-/lysosomes. LRP/LR (Morel
et al., 2005; Gauczynski et al., 2006) and heparan sulfates (Horonchik et al., 2005) medi-
ate presumably in synergy PrPSc internalization. Polysulfated glycans such as the heparan
mimetics HM 2602 and HM 5004 (red chain) block PrPSc binding to the cells by competing
with the binding to heparan sulfate and LRP/LR (Gauczynski et al., 2006). Pentosan poly-
sulfate (SP-54) and phycarin sulfate may have similar effects as the HMs (adopted from
(Gauczynski et al., 2006)). AAV denotes Adeno-Associated Virus.
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Several LRP/LR isoforms corresponding to different maturation states of the recep-
tor were identified, including a 44 kDa, 60 kDa, 67 kDa, and a 220 kDa form. All of
these isoforms were able to bind PrP, supporting a physiological role for the laminin
receptor/PrP interaction in the brain (Simoneau et al., 2003). A closer insight into
the fine cellular distribution of LRP/LR in the central nervous system was obtained
by using immunohistochemistry in adult rat brain (Baloui et al., 2004). It has been
shown that the 67 kDa LR is the major receptor form, which is expressed within the
cytoplasm and at the plasma membrane in most neurons and in a subset of glia cells.
In contrast, the 37 kDa LRP is much less abundant in adult than in postnatal central
nervous system and its expression is restricted to a subclass of cortical interneurons
known to be particularly sensitive to abnormal prion accumulation and rapidly de-
generate during early stages of CJD (Belichenko et al., 1999). In addition, recent
studies showed that LRP/LR is not only involved in the PrPc metabolism, but has
also a crucial role in prion propagation. Using antisense LRP RNA and small inter-
fering (si) RNAs specific for LRP mRNA, PrPSc levels in scrapie-infected neuronal
cells were reduced demonstrating the necessity for the laminin receptor LRP/LR
for PrPSc propagation in cultured cells (Leucht et al., 2003). Moreover, in a recent
study, it has been shown that bovine PrPSc is internalized by human enterocytes via
LRP/LR-mediated endocytosis (Morel et al., 2005) using the Caco-2/TC7 cell model
system. Analysis of the presence of PrPSc after supply of prion-contaminated brain
homogenate from different sources in Caco-2/TC7 enterocytes revealed that BSE
prions were specifically internalized and accumulate in human enterocytes, whereas
murine-adapted scrapie-prions were not endocytosed. PrPBSE-containing vesicles
visualized in these cells colocalized with LRP/LR in the subapical compartment.
PrPBSE internalization was blocked by the anti-LRP antibody W3 approving that
prion endocytosis in human enterocytes is mediated by the 37 kDa/67 kDa laminin
receptor LRP/LR. Even more recently, the specificity of prion binding in depen-
dency of the 37 kDa/67 kDa LRP/LR has been shown on BHK cells overexpressing
LRP (Gauczynski et al., 2006). This effect can be inhibited efficiently by the LRP-
specific polyclonal antibody W3 as well as by polysulfated glycans such as pentosan
polysulfate and heparan mimetics (Gauczynski et al., 2006). Moreover, it has been
shown that GAGs (Hijazi et al., 2005), especially heparan sulfate (Horonchik et al.,
2005) act also as receptors for PrPSc. Taken together, prions like other infectious
agents such as viruses may use LRP/LR and heparan sulfate as receptors, presum-
ably in synergy as suggested also in case of PrPc (Gauczynski et al., 2001; Hundt
et al., 2001), which also employs LRP/LR and HSPGs as receptors and coreceptors,
respectively (Fig. 2).
THERAPEUTIC STRATEGIES FOR THE TREATMENT
OF PRION DISEASES
Since variant Creutzfeldt–Jakob disease appeared, numerous strategies and tar-
gets have been proposed for a therapy of prion diseases, including:
1. stabilization of the structure of PrPc to prevent the transconformation from
PrPc to PrPSc
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2. interference of the binding of PrPSc to PrPc
3. inhibition of the formation of the abnormal form of PrP
4. prevention of PrP synthesis
5. destruction of PrPSc aggregates
6. inhibition of the prion protein receptor(s)
The inhibition of the PrPSc accumulation, however, is the most studied target.
There are a number of compounds that have been shown to efficiently interfere
with the PrPSc accumulation, such as Congo red (Ingrosso et al., 1995) and analogs
(Demaimay et al., 1997), certain cyclic tetrapyrrols such as porphyrins and ph-
talocyanines (Priola et al., 2000), sulfated polyanions such as dextran sulfate 500
(Farquhar and Dickinson, 1986), pentosan polysulfate (Caughey and Raymond,
1993) and suramin (Gilch et al., 2001), as well as polyene antibiotics such as AmB
and its derivative MS 8209 (Adjou et al., 1995) (Table IV). Many other compounds
have been identified to have an effect on the formation of pathological PrPSc in
vitro and in vivo, but only flupirtine, an analgetic, is possibly beneficial in humans
(Otto et al., 2004). To identify novel substances regarding a therapeutic potency,
assays for the screening of large compound libraries, e.g., a high-throughput assay
for the identification of drugs, which interfere with the PrPc/PrPSc interaction, were
developed (Bertsch et al., 2005). Although several substances have been identified
to date, which inhibit PrPSc formation, unfortunately most of them show only
Table IV. Summary of Major Components Exhibiting Therapeutic Antiprion Effects
Class of compounds Example Reference
Polysulfonated, polyanionic
substances
Dextran sulfate, (Farquhar and Dickinson, 1986;
Diringer and Ehlers, 1991)
suramin, (Gilch et al., 2001)
pentosan polysulfate, (Caughey and Raymond, 1993;
Farquhar et al., 1999;
Gauczynski et al., 2006)
heparan sulfate mimetics (Adjou et al., 2003; Gauczynski
et al., 2006)
Amyloidotropic
intercalators
Congo red (Caughey and Race, 1992; Poli
et al., 2004)
Polyene antibiotics Amphotericin B (AmB), (Pocchiari et al., 1987)
MS 8209 (Adjou et al., 1995)
Filipin (Marella et al., 2002)
Cyclic tetrapyrrols Porphyrines, phtalocyanines (Caughey et al., 1998; Priola et al.,
2000)
Polyamines DOSPA, (Winklhofer and Tatzelt, 2000)
SuperFect, polyethyleneimine (Supattapone et al., 2001)
Anthracyclines IDX (Tagliavini et al., 1997)
Phenothiazines Chlorpromazine (Achour 2002; Benito-Leon 2004)
Acridines/bis-acridines Quinacrine (Korth et al., 2001)
Designer peptides β-sheet breaker (Reilly 2000; Oishi et al., 2003)
RNA aptamers RNA aptamer Ap1/2/3 (antiprion
effect not proven)
(Weiss et al., 1997)
RNA aptamer DP7 (Proske et al., 2002)
RNA aptamer 60-3 (antiprion
effect not proven)
(Sekiya et al., 2006)
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significant effects when administered long before the clinical onset. At present,
there is no effective therapy for clinically affected TSE patients available, so that
TSEs usually culminate in death.
Another strategy was based on the finding that PrP-specific antibodies antago-
nize prion propagation both in vitro and in vivo (for a review, see (Buchholz et al.,
2006)). It was proven, that chronically scrapie-infected neuroblastoma cells have
been cured by a monoclonal antiprion protein (PrP) antibody (Enari et al., 2001). In
a murine model, treatment using this monoclonal antibody has delayed the devel-
opment of prion disease (White et al., 2003). Application of monoclonal antibodies
raised against recombinant PrP resulted also in a reduction of PrPSc level in mouse
neuroblastoma cells (Pankiewicz et al., 2006).
Since active immunization suffers from high costs, researchers have developed
passive immunization strategies although this issue deals with the problem of auto-
tolerance. Recently, it became obvious that the induction of a native PrPc-specific
antibody response (in contrast to a response against recombinant PrPc produced in
bacteria) may help to overcome tolerance. Novel strategies have been developed to
obtain such responses by passive immunization (Goni et al., 2005; Nikles et al., 2005).
Alternatively, single chain antibodies, which usually can be produced easier and
faster than full-length antibodies, revealed an antiprion effect in neuro-blastoma
cells (Donofrio et al., 2005).
For the treatment of neurodegenerative diseases such as Alzheimer’s disease,
AAV-mediated gene delivery has already been established (Zhang et al., 2003; Feng
et al., 2004; Hara et al., 2004; Sanftner et al., 2005).
THERAPEUTIC APPROACHES TARGETING LRP/LR
Polysulfated Glycanes
Polysulfated glycanes such as heparan mimetics (HMs) or pentosan polysul-
fate block PrPSc binding to target cells by interfering with the PrPSc-LRP/LR-HSPG
binding and internalization complex (Gauczynski et al., 2006) and prolong the sur-
vival times of scrapie-infected mice (Farquhar et al., 1999; Adjou et al., 2003). There-
fore, these substances are promising tools for the treatment of TSEs.
Transdominant Negative LRP Mutants
Recently, it has been shown that a LRP mutant encompassing only the extracel-
lular domain of LRP/LR (LRP102-295::FLAG) might act in a transdominant nega-
tive manner as a decoy by trapping PrP molecules (Vana and Weiss, 2006). In vitro
studies revealed that the LRP mutant is able to reduce the PrPSc accumulation in
scrapie-infected neuronal cells (Vana and Weiss, 2006) and, thus, might have poten-
tial for the development of a TSE therapy.
Antibodies
The PrP binding capacity of LRP offers strategies in therapeutic approaches
against prion diseases. Antibodies directed against LRP/LR such as W3 are able to
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block PrPSc propagation in cultured cells (Leucht et al., 2003), prohibit PrPBSE in-
ternalization by human enterocytes (Morel et al., 2005), and interfere with PrP27-30
binding to mammalian cells (Gauczynski et al., 2006). Therefore, antibodies directed
against the receptor might be powerful tools in the treatment of prion diseases.
However, this antibody format might not be suitable for a therapy in animals
or humans. Single chain antibodies are a promising alternative, which are already
in use for cancer treatments such as Herceptin® (De Lorenzo et al., 2004) for the
treatment of breast cancer (Zhou and Zhong, 2004). Although they consist of a
lower molecular weight (30 kDa) compared to the complete immunoglobulins, they
reveal a better tissue penetration and higher binding affinity. For therapeutic appli-
cation, scFv directed against 37 kDa/67 kDa LRP/LR might be passively delivered
by intracerebral injection directly into brain regions where massive PrPSc propaga-
tion takes place. In addition, permanent expression and secretion of scFvs might be
achieved by gene therapeutic strategies employing lentiviral or AAV-based vector
systems.
RNA Interference and Antisense RNA
A further strategy to interfere with PrPSc propagation is the knockdown of
LRP/LR by siRNA and antisense RNA technology. Successfull knockdown has
already been shown for PrP using Prn-p-specific sequences. Thus, the transfec-
tion of siRNA duplices corresponding to the murine Prn-p triggered specific Prn-p
gene silencing in scrapie-infected neuroblastoma cells and caused a rapid loss of
their PrPres content (Daude et al., 2003). Accordingly, it was shown in scrapie-
infected neuronal cells that transfection of either LRP antisense RNA or LRP-
specific siRNAs ablated LRP/LR expression and prevented PrPSc propagation in
scrapie-infected neuronal cells (Leucht et al., 2003), confirming a requirement of
LRP/LR for PrPSc propagation in cultured cells.
However, a permanent effect using RNAi may be achieved by lentivirus-
mediated gene transfer to specifically knockdown disease-relevant genes (Ralph
et al., 2005; Raoul et al., 2005). Therefore, a lentivirus-based RNAi gene therapy
strategy using HIV-derived vectors expressing LRP-specific siRNAs represents an
innovative approach in TSE treatment.
CONCLUSIONS
Prion diseases are rare diseases and the protein-only hypothesis (Bolton et al.,
1982; Prusiner, 1982) is an approved theory to explain the characteristics of TSEs.
However, the natural function of the cellular prion protein (PrPc) remains enig-
matic. A series of strategies for TSE treatment are currently under consideration.
The majority of these therapeutics target the prion protein itself, destabilize the
PrPSc structure, or interfere with the binding of PrPc to PrPSc. Nevertheless, no treat-
ment has been shown to prevent the appearance of clinical symptoms and death in
animal models or in CJD patients. In June 2004, the PRION-1 clinical trial (3 years)
was started to assess the activity and safety of quinacrine in human prion disease
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since there are no other drugs available that are considered suitable for human
evaluation. Thus, further work is essential to establish treatments that efficiently
medicate prion diseases.
The discovery of the 37 kDa/67 kDa laminin receptor (LRP/LR) as the cell
surface receptor for the cellular (PrPc) (Gauczynski et al., 2001) and a receptor
for infectious prions (Morel et al., 2005; Gauczynski et al., 2006) as well as GAGs
(Hijazi et al., 2005)/heparan sulfate (Horonchik et al., 2005) as receptors for PrPSc
and HSPGs as cofactors/coreceptors for PrPc (Hundt et al., 2001) opens new av-
enues for the development of alternative antiprion therapies. Antibodies directed
against LRP/LR (Leucht et al., 2003), small interfering RNAs directed against LRP
mRNA (Leucht et al., 2003), LRP mutants (Vana and Weiss, 2006), and polysulfated
glycanes interfering with the PrPSc/LRP/LR interaction process (Gauczynski et al.,
2006) represent alternative promising tools for the treatment of prion diseases.
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Maximilians-Universität München, Munich, GermanyAbstractTransmissible spongiform encephalopathies known as prion diseases are a group of fatal neurodegenerative disorders that
affect both humans and animals. The generally accepted principle of the disease is that the conversion of the cellular prion
protein (PrPc) into the disease associated isoform PrPSc leads to spongiform degeneration of the brain and amyloid plaque
formation. Until now no therapy leading to potential alleviation or even cure of the disease exists. It is therefore important to
develop therapeutic approaches for the treatment of TSEs since these infections are inevitably fatal and, especially in the case of
vCJD, they affect youngsters. Besides current conventional therapeutic strategies, this review summarizes new therapeutic tools
targeting the prion receptor LRP/LR.
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Prion diseases or TSEs are neurological disorders
associated with the aggregation of a pathologic
isoform of a host-encoded prion protein (PrP).
Conversion of the cellular prion protein (PrPc) into
the disease-associated form PrPSc leads to conforma-
tional changes resulting in aggregation and accumula-
tion. Deposition of this abnormal protein takes place
mainly in the brain and the lymphoreticular system,
accompanied with neuronal vacuolation (spongiosis)
and neuronal death. After extremely long incubation
times, affected individuals show progressive neuro-* Corresponding author. Tel.: +49 89 2180 76887;
fax: +49 89 2180 76999.
E-mail address: weiss@lmb.uni-muenchen.de (S. Weiss).
0378-1135/$ – see front matter # 2007 Elsevier B.V. All rights reserved
doi:10.1016/j.vetmic.2007.04.005logical symptoms terminating in death. Conventional
therapeutic approaches use anti-prion compounds
which can prolong incubation times but do not lead
to a cure. It has been demonstrated that prion
propagation in vitro requires the laminin receptor
(Leucht et al., 2003) implicating that approaches
downregulating LRP/LR are a promising alternative
strategy for the treatment of prion diseases.2. Prion diseases in humans and animals
Prion diseases involve rapid neurological decline,
accompanied by neuronal loss and spongiform
changes caused by accumulation of the aggregated
and misfolded prion protein. The most common type.
C. Zuber et al. / Veterinary Microbiology 123 (2007) 387–393388of human prion diseases, termed Creutzfeldt-Jakob
disease (CJD), can be classified into four categories:
sporadic (sCJD), inherited/familial (fCJD), iatrogenic
(iCJD) and variant (vCJD). Whereas it has been
suggested that the latter results from ingestion/
consumption of BSE-contaminated food (Bruce
et al., 1997), familial disorders (fCJD) are the
inheritance of autosomal-dominant mutations within
the Prn-p locus. Transplantation of tissues or injection
of hormones originating from individuals suffering
from CJD or the use of contaminated surgical
instruments resulted in the iatrogenic form of CJD.
Gerstmann–Sträussler–Scheinker syndrome (GSS),
fatal familial insomnia (FFI), its sporadic form (sFI)
and kuru are other human prion diseases.
Animal TSEs have been observed in different
species: Bovine spongiform encephalopathy (BSE) in
cattle, scrapie in sheep and goat, chronic wasting
disease (CWD) in cervids such as deer, elk or captive
mule and feline spongiform encephalopathy (FSE) in
cats or transmissible mink encephalopathy (TME). In
addition, some exotic diseases were observed includ-
ing exotic ungulate encephalopathy (EUE) and
primate spongiform encephalopathy (PSE). Transmis-
sion of BSE to pigs has been experimentally proven
(Wells et al., 2003). Recently, new forms of TSEs with
unusual characteristics e.g. an atypical scrapie case
(Nor98) (Benestad et al., 2003) have been discovered.
Apart from the existing species barrier, the different
modes of transmission are not yet understood.3. Prions and different forms of prion proteins
The term prion was defined by Stanley Prusiner as a
‘‘small proteinaceous particle that resists inactivation
by procedures which modify nucleic acids’’, suggest-
ing that a new agent exists beside the commonly
known pathogenic organisms such as bacteria, virus or
fungi (Prusiner, 1982). The infectious ‘‘agent’’, the
prion, and the exact infectious mechanism for prion
disorders is just as little understood as the mechanism
by which they kill neurons.
PrPc is an ubiquitous membrane-bound glycoprotein
attached to the cell surface by a glycosylphosphatidy-
linositol (GPI) anchor, expressed in many tissues and
cell types. Its conversion leads to the disease-associated
form PrPSc, which exhibits a higher b-sheet contentcorrelating with a high tendency to form aggregates.
PrPSc is characterized as insoluble and partially
resistant to proteases (Cohen and Prusiner, 1998).
Digestion of PrPc with protease K results in the
truncated form PrPres (a 27–30 kDa fragment) demon-
strating insolubility in aqueous and organic solvents as
well as in non-ionic detergents. Additionally, it is
completely resistant to proteases. PrPSc and PrP27-30
both have the tendency to form amyloid fibrils.4. The 37 kDa/67 kDa LRP/LR as the receptor
for PrPc
In a yeast two-hybrid screen we identified the
37 kDa laminin receptor precursor (LRP) as an
interaction partner for the prion protein (Rieger
et al., 1997). Further in vitro studies on neuronal
and non-neuronal cells proved that both the 37 kDa
LRP and the 67 kDa high affinity laminin receptor
function as the receptor for the cellular prion protein
(Gauczynski et al., 2001). Direct and indirect heparan
sulphate proteoglycane (HSPG)-dependent binding
domains on LRP/LR and on PrP have been identified
suggesting that HSPGs act as co-factors or co-
receptors for PrPc (Hundt et al., 2001). It has been
suggested that the 37 kDa LRP is the precursor of the
67 kDa form which was first isolated 1983 from
melanoma cells due to its high binding capacity to
laminin (Rao et al., 1983). The relationship between
the 37 kDa precursor form and the mature 67 kDa
isoform is still unknown. Regarding the function of
LRP/LR, the 37 kDa LRP appears to be a multi-
functional protein involved in the translational
machinery (Auth and Brawerman, 1992) and has also
been identified as a ribosome-associated protein
termed p40 (Makrides et al., 1988). LRP has also
been localized in the nucleus, where it is closely
associated with nuclear structures (Sato et al., 1996)
and binds to DNA through connections with histones
H2A, H2B and H4 (Kinoshita et al., 1998). The
37 kDa/67 kDa LRP/LR has been described as a
receptor for laminin, elastin and carbohydrates (Ardini
et al., 1998), as well as a receptor for Venezuelan
equine encephalitis virus (VEE) (Ludwig et al., 1996),
Sindbis virus (Wang et al., 1992), Dengue virus (Tio
et al., 2005) and Adeno-Associated Viruses (Akache
et al., 2006). In addition, studies have been carried out
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central nervous system and that bind PrP. Several
maturation states of the receptor were identified,
including a 44 kDa, 60 kDa, 67 kDa and a 220 kDa
form. All of these isoforms were able to bind PrP,
suggesting a physiological role for the laminin
receptor/PrP interaction in the brain (Simoneau
et al., 2003). Although LRP consists of a transmem-
brane domain (amino acid residue 86–101 (Castro-
novo et al., 1991)) it is abundant in the cytoplasm
(Romanov et al., 1994). In mammalian cells both the
37 kDa LRP and the 67 kDa LR are present in plasma
membrane fractions (Gauczynski et al., 2001).5. The role of LRP/LR in PrPSc propagation
LRP/LR not only acts as a receptor for the cellular
prion protein but also for the infectious PrP27-30, an
N-terminal truncated version of PrPSc (Gauczynski
et al., 2006). The importance of LRP/LR in PrPSc
propagation was verified using a polyclonal anti-LRP/
LR antibody termed W3 which was able to block and
prevent the binding of PrPSc and to cure scrapie-
infected neuroblastoma cells (ScN2a) from PrPSc
(Leucht et al., 2003).
LRP/LR-dependent binding of PrPc and PrPSc to
the cell surface (either alone or together with other co-
factors) is accompanied by internalisation which is
thought to occur in clathrin-coated pits. After this
receptor-mediated endocytosis the conversion of PrPc
molecules into the disease-associated form probably
takes place in endosomes, lysosomes or endolyso-
somes. Heparan sulphates also play an essential role in
prion uptake and cell infection (Horonchik et al.,
2005) suggesting that both the LRP/LR and heparan
sulphates act presumably in synergy for PrPSc binding
and internalisation.
The fact that LRP/LR is present in higher amounts
in several organs and tissues of scrapie-infected mice
and hamsters suggests a correlation between LRP/LR
levels and PrPSc propagation (Rieger et al., 1997).
Furthermore, expression studies revealed distribution
of the laminin receptor in the intestinal epithelial/
brush border confirming that the prion protein uptake
and therefore the infection is mediated and supported
by this receptor (Shmakov et al., 2000). After oral
exposure, TSE agents accumulate in lymphoid tissue,spleen, lymph nodes, tonsils, appendices and Peyer’s
patches. For this reason prion particles have to cross
the intestinal epithelial barrier. Besides the proposition
that M-cells are responsible for the uptake of prions
(Heppner et al., 2001) has also been suggested that
enterocytes are involved in this process, due to the fact
that bovine prions are rapidly endocytosed in the
presence of LRP/LR (Morel et al., 2005). By
preincubating the human enterocytes with the poly-
clonal anti-LRP/LR antibody, endocytosis of PrPBSE
was reduced.
Distribution studies in adult rats revealed that the
67 kDa LR form is highly present in brain regions,
classically associated with prion-related neurodegen-
eration, whereas the 37 kDa form was detected in a
subclass of interneurons known to be particularly
sensitive to abnormal prion accumulation and cell
death during the early stages of CJD (Baloui et al.,
2004).6. Conventional therapeutic strategies for the
treatment of TSEs
In recent years, various studies gave evidence that
substantial neuropathological changes (e.g. nerve cell
degeneration) already occur prior to the onset of
symptoms and might be related to PrPSc accumulation.
Accordingly, any effective intervention must aim to
start directly after inoculation. Unfortunately, no
diagnostic tests are available to detect the disease
prior to the onset of symptoms, except for individuals
carrying pathogenic mutations within the Prn-p gene.
Inhibition of PrPSc formation is the most studied target
and can be achieved through (i) inhibition of PrPc
synthesis or prevention of its transport to the cell
surface, (ii) stabilization of the PrPc structure to make
its conformational change unfavourable, (iii) destruc-
tion of PrPSc aggregates, (iv) reversion of PrPSc to a
protease-sensitive form and (v) inhibition of the prion
protein receptor(s).
A series of compounds efficiently interfere with
PrPSc accumulation, such as Congo red (Ingrosso
et al., 1995) and analogs (Demaimay et al., 1997),
certain cyclic tetrapyrrols (Priola et al., 2000) and
sulphated polyanions. Although many other com-
pounds have been identified, only flupirtine, an
analgetic, had beneficial effects on cognitive function
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anthracycline 40-iodo-40-deoxy-doxorubicin (IDX)
was able to delay clinical signs of the disease and
prolong the survival time in scrapie-infected hamsters
(Tagliavini et al., 1997). It was also shown that
quinacrine reduces the protease resistance of PrP
peptide aggregates and is able to inhibit the in vitro
conversion of the normal prion protein (PrPc) to the
abnormal form (PrPres) (Barret et al., 2003).
Chlorpromazine was reported to increase incubation
time in mice after intracerebral, but not intraperito-
neal, injection (Roikhel et al., 1984), but was less
effective in cell culture than quinacrine (Korth et al.,
2001). Unfortunately, most substances that inhibit
PrPSc formation show only significant effects when
administered long before the clinical onset of the
disease. Since no effective therapy for clinically
affected TSE patients is available these diseases are
inevitably fatal.
PrP-specific antibodies, a promising alternative
tool in TSE treatment, counteract prion propagation
both in vitro (Enari et al., 2001; Peretz et al., 2001;Fig. 1. Molecules inhibiting the PrP-LRP interaction and reducing the LR
protein (green circle) and the infectious PrPSc (green rectangle). After b
internalized into endo-/lysosomal compartments where the conversion of Pr
achieved by (I) trapping PrPSc by a LRP mutant (delTMD) encompassing th
(IIa) siRNAs and (IIb) antisense RNA directed against LRP mRNA, (III) an
binding sites and (IV) heparan mimetics interfering with the binding of PPerrier et al., 2004) and in vivo (Buchholz et al., 2006).
In a murine model, treatment with a monoclonal anti-
PrP antibody delayed the development of prion
disease (White et al., 2003). Application of mono-
clonal antibodies raised against recombinant PrP also
resulted in a reduction of PrPSc levels in infected
mouse neuroblastoma cells (Pankiewicz et al., 2006).
Paracrine secretion of single chain antibodies (scFv)
directed against PrPc revealed an anti-prion effect in
neuroblastoma cells (Donofrio et al., 2005).7. Therapeutic approaches targeting LRP/LR
7.1. Trans-dominant negative LRP mutants
Recently, it has been shown that an LRP mutant
encompassing the extracellular domain of LRP/LR
(LRP102-295::FLAG) might act in a trans-dominant
negative way as a decoy by trapping PrP molecules
(Fig. 1, I) (Vana and Weiss, 2006). In vitro studies
revealed that the LRP mutant is able to reduce theP/LR levels. LRP/LR (orange) is able to bind both the cellular prion
inding to the LRP/LR–HSPG complex the prion protein becomes
Pc to PrPSc might take place. Prevention of the binding to LRP/LR is
e extracellular domain (LRP102-295), downregulation of LRP/LR by
ti-LRP/LR antibodies (blue rectangles) competing with PrP for LRP
rPSc to the LRP/LR/HSPG complex.
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(Vana and Weiss, 2006) and might therefore represent
a promising novel tool in TSE therapy.
7.2. RNA interference and antisense RNA
A further strategy used to influence the PrPSc
propagation level is the knockdown of LRP/LR by
siRNA and antisense RNA technology. This has
already successfully been shown for PrP using Prn-p-
specific sequences. Thus, the transfection of siRNAs
corresponding to the murine Prn-p triggered specific
Prn-p-gene silencing in scrapie-infected neuroblas-
toma cells. This caused a rapid loss of their PrPres
content (Daude et al., 2003). Accordingly, it was
shown that transfection of either LRP antisense RNA
or LRP-specific siRNAs in scrapie-infected neuronal
cells results in downregulation of LRP/LR expression
and prevention of PrPSc propagation (Fig. 1, II)
(Leucht et al., 2003).
Furthermore, a permanent effect of knockdown of
disease-relevant genes using RNAi has been achieved
using a lentivirus-mediated gene transfer (Ralph et al.,
2005; Raoul et al., 2005). Recently it was shown that
lentivector-mediated RNAi efficiently suppressed the
prion protein and prolonged survival of scrapie
infected mice (Pfeifer et al., 2006). This suggests
that an alternative lentivirus-based RNAi gene therapy
approach using HIV-derived vectors expressing LRP-
specific siRNAs might represent another promising
approach in TSE treatment.
7.3. Antibodies directed against the LRP/LR
The PrP binding capacity of LRP offers strategies
in therapeutic approaches against prion diseases. The
curative effect of the polyclonal anti-LRP/LR anti-
body (W3) on scrapie infected N2a cells recommends
anti-LRP antibodies as therapeutic tools for the
treatment of prion diseases (Leucht et al., 2003).
On the molecular level this antibody (i) prevents the
binding of infectious prions to mammalian cells
(Fig. 1, III) (Gauczynski et al., 2006) and (ii) blocks
endocytosis of PrPBSE by enterocytes mediated by the
LRP/LR is inhibited after treatment with W3 (Morel
et al., 2005). Moreover W3 was able to prolong the
incubation/survival time in scrapie mice (Zuber et al.,
submitted).Since a polyclonal antibody format is not suitable
for a therapy in animals or humans the development of
single-chain antibodies directed against LRP/LR
provides a promising alternative therapeutic strategy.
Smaller (30 kDa) and with better tissue penetration,
they can be delivered via passive immunotransfer for
example intracerebrally into the brain region where
massive prion propagation takes place. So far, no
immune response or side reactions have been observed
after application of scFvs. In a murine scrapie model
passively delivered anti-LRP/LR single chain anti-
bodies reduced peripheral prion propagation (Zuber
et al., in press). To circumvent the problem of the short
half-life in organisms a permanent delivery of single
chain antibodies directed against LRP/LR may be
achieved by gene therapeutic strategies employing
AAV-based or lentiviral vector systems.
7.4. Polysulphated glycans
Polysulphated glycans such as heparan mimetics
(HM) or pentosan polysulphate interfere with the
binding of the infectious PrP27-30 to the LRP/LR–
HSPG complex and are therefore alternative promising
therapeutic tools (Fig. 1, IV) (Gauczynski et al., 2006).
Treatment of scrapie-infected mice with pentosan
polysulphate resulted in a prolonged incubation time
and even in the cure of two mouse strains infected with
two different scrapie strains (Farquhar and Dickinson,
1986). Moreover, it has been shown that GAGs (Hijazi
et al., 2005), especially heparan sulphate, (Horonchik
et al., 2005) also act as receptors for the infectious
PrPSc. Polysulphated glycans such as SP54 and PS3
(phycarin sulphate) also show an inhibitory effect on the
binding of PrP27-30 to LRP hyperexpressing BHK
cells (Gauczynski et al., 2006). Both pentosan
polysulphates and heparan sulphate mimetics are able
to prolong the incubation time in rodent models and
interfere with PrPSc propagation in neuronal cells due to
the inhibition of the LRP/LR dependent binding of
prions to target cells.8. Conclusions
So far, there is no TSE treatment available that is able
to cure affected individuals. Alternative therapeutic
strategies targeting LRP/LR might be promising since it
C. Zuber et al. / Veterinary Microbiology 123 (2007) 387–393392acts as the receptor for PrPc and PrPSc. Molecules
targeting the LRP–PrP interaction such as LRP mutants,
LRP/LR-specific antibodies and polysulphated glycans
or tools downregulating the LRP/LR levels such as
siRNAs and antisense RNAs might be effective in the
treatment of prion disorders.Acknowledgments
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Prion diseases are lethal for both humans and animals, and affected individuals die after 
several months following a rapid disease progression. Although researchers have 
attempted for decades to develop effective therapeutics for the therapy of human prion 
disorders, until now no efficient drug has been available on the market for transmissible 
spongiform encephalopathy (TSE) treatment or cure. Approximately 200 patients 
worldwide have died or suffer from variant Creutzfeldt–Jakob disease (CJD). Incidences for 
sporadic and familial CJD are approximately 1.5–2 per million per year and one per 
10 million per year, respectively, in Europe. This review summarizes classical and modern 
trials for the development of effective anti-TSE drugs, introduces potential effective delivery 
systems, such as lentiviral and adeno-associated virus systems for antiprion components, 
including antibodies and siRNAs, and presents vaccination trials. Most of the antiprion 
drugs target prion protein PrPc and/or PrPSc. Alternative targets are receptors and 
coreceptors for PrP, that is, the 37/67-kDa laminin receptor and heparan sulfate 
proteoglycanes. We review clinical trials for the treatment of TSEs and describe hindrances 
and chances for a breakthrough in therapy of prion disorders.
Expert Rev. Anti Infect. Ther. 5(4), 613–630 (2007)
Prion diseases & therapy
Prion diseases are a group of neurodegenerative
diseases affecting animals and humans [1]. Ani-
mal transmissible spongiform encephalopathies
(TSEs) occur as scrapie in sheep, bovine spong-
iform encephalopathy (BSE) in cattle, trans-
missible mink encephalopathy in mink (TME),
exotic ungulate encephalopathy (EUE) in zoo
animals and chronic wasting disease (CWD) in
elk and deer [1]. Human prion diseases include
kuru, Gerstmann–Sträussler–Scheinker syn-
drome (GSS), fatal and sporadic familial
insomnia (FFI/sFI) and Creutzfeldt–Jakob dis-
ease (CJD) [1]. CJD can occur in sporadic (s),
familial (f ), iatrogenic (i) and variant (v) forms
(TABLE 1). vCJD is thought to be caused by BSE
and represents a zoonotic disease [1]. The inci-
dence for sCJD is 1.5–2 per million per year [2].
Until April 2007, approximately 200 suspected
and confirmed cases of vCJD occurred world-
wide, most of them in the UK (164) and
France (22). Countries showing between one
and four vCJD cases include the Republic of
Ireland (4), the USA (3), Canada (1), Japan (1),
Portugal (1), Spain (1) and The Netherlands
(2) [201]. A clear correlation between the num-
bers of BSE cases and the numbers of vCJD
cases in individual countries is not visible,
since Germany with no reported case of vCJD
has 405 BSE cases (June 2007) [202]. Recent
findings on iatrogenic vCJD transmission via
blood and blood products caused major con-
cern in various countries and effective thera-
peutic or postexposure measurements are
urgently needed.
Human TSEs, such as CJD, are lethal, with
long incubation times (i.e., the time from the
day of infection to the first day TSE-relevant
symptoms occur). Survival (i.e., the time from
the day the first symptoms occur to the day of
death) varies between approximately 6 months
for sCJD and 15 months for vCJD. The average
age for vCJD patients is approximately 27 years
[201]. The youngest patient to date died at the age
of 14 years, the eldest at the age of 74 years [3,4].
Until now, no therapeutic is on the market
for the treatment or cure of prion diseases. In
addition, no vaccination against prion diseases
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is available. This article reviews therapeutic and vaccination
approaches for the treatment and prevention of prion diseases.
The effectiveness of a potential drug is, in principal, tested by
three systems: in vitro systems representing mainly scrapie
propagating cells, in vivo systems representing scrapie-infected
rodents or macaques, and finally clinical studies. Although a
series of drugs demonstrated convincing effects in vitro and
in vivo, those tested in clinical trials failed to show significant
effects on the prolongation of the incubation time or survival
in patients suffering from a TSE. The development of an
effective antiprion compound is challenging because the drug
has to penetrate the blood–brain barrier. Although many of
the compounds are effective in a cell culture system, they lack
any effect in vivo because of their low penetration into the
CNS. Moreover, a prerequisite for an effective treatment,
however, represents the development of a reliable preclinical
screening test to diagnose the disease at the preclinical stage
and initiate the treatment at an early stage of the disease.
Some progress has been made toward this, as shown in the
work by Malucci et al., suggesting that disease pathology and
symptoms might be reversible [5,6].
Polysulfonated, polyanionic substances
Dextran sulfate
The sulfated polyanion dextran sulfate 500 (DS500) is proven
to be an effective substance against TSEs in vivo (TABLE 2). A
single intraperitoneal injection leads to a dose-dependent
reduction of susceptibility to scrapie in mice and to a length-
ening of incubation time. The effective scrapie titer has even
been reduced by 90% [7]. However, DS500 is toxic in mice,
which leads to the question of whether this substance should
be tested in human prion diseases.
Suramin
Suramin is a polysulfonated aromatic urea derivative (TABLE 2). It
inhibits the scrapie prion protein (PrPSc) formation in vitro and
in vivo by inducing misfolding of cellular PrP (PrPc) in a post-
endoplasmic reticulum (ER)/Golgi compartment (FIGURE 1). The
protein is retargeted to acidic compartments, thereby preventing
PrPc from reaching the cell surface and the cellular compart-
ment(s) of conversion [8]. The derivatives of suramin are also
able to inhibit the PrPSc de novo synthesis and to induce aggrega-
tion and reduction of the half-life of PrPc without downregulat-
ing the PrPc cell surface expression. Therefore, a symmetrical
bipolar structure might be necessary [9]. 
Heparan mimetics
Heparan sulfate mimetics (HMs) belong to the group of
polysulfated glycans (TABLE 2). The HMs 2602 and 5004
block the PrPSc-37/67-kDa laminin receptor (LRP/LR)-
HSPG binding and internalization into target cells (FIGURE 1)
[10]. HM2602 was able to prolong the survival time in
scrapie-infected hamsters, whereas HM5004 does not have
any effects in vivo [11]. CR36 was efficient in reducing pro-
teinase K (PK)-resistant PrP (PrPres) in scrapie-infected cells
but had only a marginal effect on the survival time of mice
infected with BSE [12].
Pentosan polysulfate (SP54)
Pentosan polysulfate is a large polyglycoside molecule with
weak heparin-like activity (TABLE 2). It is able to prevent PrPSc
propagation in cell culture models (FIGURE 1) [13]. It may
inhibit the binding of PrPSc to LRP/LR by competing with
the coreceptor heparan sulfate [10]. In vivo, SP54 is able to
prolong the survival of scrapie-infected mice and even cures
two mouse strains (VM and CBA) infected with two defined
prion strains (22A and ME7) [14]. Orally or intraperitoneally
administered SP54 may not be very effective since the drug
may not cross the blood–brain barrier. Case studies for treat-
ment of vCJD in humans were published in which SP54 was
delivered by chronic intraventricular infusion. However, no
definite clinical benefit was observed [15,16]. Further clinical
studies are required to assess the efficacy of SP54 administra-
tion in vCJD and other prion diseases (see ‘Antiprion drugs in
clinical trials’ section).
Phosphorothioate oligonucleotides
Nucleic acids are known to interact with PK-sensitive PrP
(PrPsen) molecules. In cell-free assays, DNA binds to
recombinant PrP and, depending on their concentrations,
PrPsen aggregation is promoted or inhibited [17–19]. Natural
nucleic acids do not affect PrPres formation in scrapie-
infected neuroblastoma cells (ScN2a), but their degenerate
single-stranded phosphorothioated analogs (TABLE 2)
(FIGURE 1) are found to bind PrPc and inhibit PrPres accumu-
lation [20]. Phosphorothioate oligonucleotides (PS-ONs)
administered prophylactically significantly prolong survival
of scrapie-infected rodents [20]. Hydrophobicity and molecu-
lar size, but not the base composition of PS-ONs, are
important to efficiently interact with PrPc, implying an
interaction with an amphipathic site that influences conver-
sion. Thus, PS-ONs are not only an attractive new group of
agents in TSE therapy but may also help to identify the
mechanism for PrPres formation.
Table 1. Human prion disorders. 
Disorder Cause
Sporadic CJD Spontaneous?
Familial CJD PRNP mutation
Gerstmann-Sträussler-Scheinker syndrome PRNP mutation
Fatal familial insomnia PRNP mutation
Variant CJD Acquired
Iatrogenic CJD Acquired
Kuru Acquired
CJD: Creutzfeldt–Jakob disease; PRNP: Prion protein gene.
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Table 2. Summary of anti-infective drugs against prion disorders, their effects in vitro and in vivo and their suggested 
mode of action. 
Class of compounds Example Effect in vitro/in vivo Suggested mode of action Ref.
Polysulfonated, polyanionic and 
polycationic substances
Dextran sulfate +/+ Not known [7]
Suramin +/+ Induces aggregation and retargeting of 
PrPc to endocytic compartment
[8,9]
Pentosan polysulfate +/+ May inhibit internalization of PrPSc by 
competing with heparan sulfate and 
blocking the binding to LRP/LR
[10,13–16]
Heparan sulfate 
mimetics e.g., HM2602
HM5004
CR36
+/+ 
+/- 
+/-
Inhibits PrPSc internalization by 
competing with heparan sulfate and 
blocking the binding to LRP/LR
[10–12]
Phosphorothioate 
oligonucleotides
+/+ Binds to PrP and inhibit PrPres formation [20]
Amyloidotrophic intercalators Congo red +/+ May inhibit PrPSc propagation by 
overstabilization of the PrPSc molecule
[23–25,
27,28]
Polyene antibiotics Amphotericin B +/+ May inhibit endocytosis of PrPSc [29–35]
MS 8209 +/+ May inhibit endocytosis of PrPSc [29–35]
Filipin +/n.d. Reduces endocytosis of PrPsen [36]
Tetracyclines Tetracycline, 
Doxycycline*
+/+ Direct interaction with PrPSc leads to 
reduction of infectivity
[37,38]
Cyclic tetrapyrrols Porphyrines, 
Phtalocyanines
+/+ May inhibit PrPres formation [12,39–42]
Polyamines DOSPA +/n.d. Interferes with the accumulation of PrPSc [44]
SuperFect, 
Polyethyleneimine
+/n.d. Interferes with PrPSc propagation [43,142]
Spermine, Spermidine +/n.d. Prevents polymerization of recombinant 
human PrP to PrPSc
[45]
Anthracyclines IDX +/+ May prevent polymerization by binding 
to amyloid PrP
[48,49]
Phenothiazines Chlorpromazine +/n.d. Prevents PrPSc formation [50]
Acridines/bisacridines Quinacrine‡ +/- May prevent PrPSc formation [50–52]
Designer peptides !-sheet breaker +/+ Reverses conformational changes of 
pathogen PrP
[54]
RNA aptamers RNA aptamer Ap1/2 
(antiprion effect 
not proven)
+/- Specifically binds PrPc, but not PrPSc [55]
RNA aptamer DP7 +/n.d. Interferes with the de novo synthesis of 
PrPSc
[56]
Tyrosine kinase inhibitors STI571 +/n.d. Induces of the lysosomal degradation 
of PrPSc
[57]
*Currently recruiting for a placebo-controlled trial in Italy (Milan) and Germany (Göttingen) (A Randomized, Double-Blinded, Placebo-Controlled Study of the Efficacy of 
Doxycyclin in the Treatment of Sporadic Creutzfeldt-Jakob Disease).
‡Currently recruiting for a Phase II clinical trial (Novel Therapeutics For Prion Diseases: A Randomized, Double-Blinded, Placebo-Controlled Study of the Efficacy of 
Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease). 
IDX: Iododeoxydoxorubicin; LRP/LR: Laminin receptor; n.d.: Not determined; PrP: Prion protein.
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Congo red as an amyloidotrophic intercalator
Congo red (CR) (TABLE 2), a sulfonated azo dye that was origi-
nally used as a histologic stain for amyloids [21,22], was identified
to potently inhibit the PrPres accumulation in scrapie-infected
cells (FIGURE 1) without affecting the metabolism of PrPc [23].
Thus, the exact molecular mechanism of CR is not clearly estab-
lished. However, since CR binds to protein aggregates, it has
been proposed that CR inhibits prion propagation by overstabi-
lization of the PrPSc molecule [24]. Ingrosso and colleagues first
reported that in vivo administration of CR prolongs the incuba-
tion period of hamsters experimentally infected with scrapie. In
these studies, the maximal effect was observed when the scrapie
agent and CR were coinjected, suggesting that the timing of
drug administration is a key determinant [25]. Nevertheless, CR
has some properties that make it inappropriate as a therapeutic
candidate; for example, CR is not able to cross the blood–brain
barrier and it may be toxic after oral administration [26].
Therefore, a number of CR derivatives
were synthesized to overcome these unfa-
vorable properties and were tested for
their antiprion activity in vitro [27] and
in vivo [28]. In scrapie-infected hamsters,
subcutaneous injection of the CR analog
CR-A was shown to prolong the survival
time comparable to CR [28]. Nevertheless,
the adverse effects of these substances
make them currently unprofitable for the
treatment of human TSEs.
Polyene antibiotics
Polyene antibiotics, such as
amphotericin B (AmB) and its synthetic,
less-toxic derivative MS-8209 (TABLE 2),
are antifungal agents and have been evalu-
ated as anti-TSE agents in scrapie-
infected hamsters, delaying disease and
PrPSc accumulation [29,30]. In a murine
model of BSE and scrapie, both AmB and
MS-8209 were shown to prolong survival
times and delay the PrPres and glial fibril-
lary acidic protein accumulation [31,32].
These substances are thought to interact
with cholesterol present in mammalian
cell membranes disturbing the PrPSc
endocytosis [33], prevent the propagation
of the scrapie agent to the peripheral nerv-
ous system [34] or directly affect the con-
version of PrPc to PrPSc (FIGURE 1) [35].
Another polyene antibiotic, filipin
(TABLE 2), has also been shown to inhibit
PrPres formation in vitro. Filipin reduced
the endocytosis of PrPsen and led to a
massive secretion of fully matured PrPsen
and, thus, decreased the amount of PrPc
for the conversion process [36].
Tetracyclines
This antibiotic, which is produced in streptomyces, and its
derivative doxycycline (TABLE 2) have been shown to revert
abnormal physicochemical properties and to abolish neurotox-
icity of PrP peptides in vitro [37]. Based on these findings, it was
tested whether tetracyclines interact with PrPSc derived from
vCJD patients and from cattle infected with BSE. Incubation
of the infectious material with tetracycline and doxycycline
leads to a dose-dependent decrease in PK-resistant PrPSc
(FIGURE 1) [38]. Syrian hamsters injected with scrapie-infected
brain homogenate coincubated with tetracycline or doxycycline
showed a delayed onset of disease and a prolonged survival [38].
These data suggest a reduction of prion infectivity through a
direct interaction of the antibiotics with PrPSc. Thus, they are
potentially useful for the development of inactivation strategies
for BSE- or vCJD-contaminated material.
Figure 1. Schematic view of the proposed mode of actions of antiprion drugs, which are effective 
in vivo and in vitro. Heparan mimetics and pentosan polysulfate interfere with the PrPc and PrPSc binding 
to the 37/67-kDa laminin receptor (LRP/LR). Antibodies directed against PrPc or LRP/LR interfere with the 
PrPc binding to LRP/LR or PrPSc. Many anti-transmissible spongiform encephalopathy (TSE) drugs target the 
PrPc–PrPSc conversion, such as phosphorothioate oligonucleotides, Congo red, porphyrins, phtalocyanines 
(cyclic tetrapyrrols), anthracyclines (IDX), tetracyclines and polyene antibiotics. Some of them (e.g., polyene 
antibiotics) are thought to interfere with the PrP internalization process. The PrPc–PrPSc conversion process 
might take place either on the cell surface or within compartments of the endocytic pathway, such as 
endosomes, lysosomes and endolysosomes. Designer peptides might reverse conformational changes of 
PrPSc by breaking !-sheets. Suramin aggregates PrPc to a !-sheet PrPC structure, which is no longer 
available as a template for conversion to PrPSc. 
HSPG: Heparan sulfate proteoglycane; PrP: Prion protein; scFv: Single chain antibody. 
The image of PrPc (NMR structure) was modified from [141]. The model of PrPSc appears courtesy of Fred E 
Cohen, Department of Cellular & Molecular Pharmacology, University of California San Francisco (UCSF), 
USA [203].
Laminin receptor
HSPG (Coreceptor)
PrPC
scFv Full length
antibodies
Designer peptides
(!-sheet breaker iPrP13)
Modeled PrPSc
Suramin
• Phosphorothioate oligonucleotides
• Congo red
• Porphyrins, phthalocyanines
• Anthracyclines (IDX)
• Tetracyclines (tetracycline, doxycycline)
• Polyene antibiotics (AmB, MS8209)
• Heparan mimetics
• Pentosan polysulfate
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Cyclic tetrapyrroles
Tetrapyrrole compounds, which include porphyrins and
phtalocyanines, are known to bind selectively to proteins and
induce conformational changes (TABLE 2). Certain molecules
have been identified to inhibit the formation of PrPres in vitro
[39] and increased the survival of TSE-infected animals [40].
Among different tested compounds, phtalocyanine tetrasul-
fonate [40,41], meso-tetra(4-N-methylpyridyl)porphine iron (III)
[40], deuteroporphyrin IX 2,4-bis-(ethylene glycol) iron (III) [40]
and Fe(III)meso-tetra(4-sulfonatophenyl)porphine [42] were the
most potent inhibitors. Tetrapyrroles (FIGURE 1) have also been
shown to inhibit PrPres formation in a cell-free conversion
reaction, suggesting a direct interaction of the tetrapyrrole with
PrP molecules [39].
Polyamines
The finding that transfection of scrapie-infected mouse neuro-
blastoma (ScN2a) cells using the SuperFect reagent, which is a
mixture of branched polyamines, reduced the level of pre-exist-
ing PrPSc and led to the testing of several other polyamines
(TABLE 2) for their ability to interfere with PrPSc propagation in
chronically infected ScN2a cells. The branched polymers investi-
gated include polyethyleneimine, polypropyleneimine and
polyamidoamide dentrimers [43]. All these compounds have been
demonstrated to eliminate PrPSc in an in vitro assay using prion-
infected cells. Furthermore, the cationic lipopolyamine DOSPA
was shown to interfere with the accumulation of PrPSc in scrapie-
infected neuroblastoma cells [44]. Recently, it has been reported
that physiological concentrations of the aliphatic polyamines
spermine and spermidine (TABLE 2), which are involved in the cel-
lular metabolism and the stabilization of nucleic acids, prevent
the polymerization of human recombinant PrP to PrPSc in solu-
tion [45]. Since nucleic acids have been found to catalyze the con-
version of PrPc to the !-sheet conformation [17,46] and, most
recently, to infectious PrPSc employing protein misfolding cyclic
amplification and polyA RNA [47], the diminishment of biologi-
cal amines might lead to oligomerization and polymerization of
the PrPc and thus, application of polyamines in vivo might be a
promising therapeutical approach in TSEs.
Anthracyclines
Anthracyclins are a class of chemotherapeutic agents normally
used to treat a wide range of cancers (TABLE 2). Administration of
a derivative of doxorubicin, 4´-iodo-4´-deoxy-doxorubicin
(IDX), in a murine model of reactive amyloidosis reduced amy-
loid deposits [48]. In prion diseases, IDX was shown to bind to
PrP amyloid and prolonged the survival of scrapie-infected ham-
sters, when administered intracerebrally at the same time as the
scrapie agent [49]. It has been proposed that IDX binds to the
abnormal form of PrP, decreasing the availability of template
molecules for the conversion process of the normal PrP (FIGURE 1)
[49]. Owing to its cytotoxcity and limited ability to cross the
blood–brain barrier, IDX is inappropriate for treatment of
TSEs. However, owing to its antiprion activity, this substance
may act as a template for further compound development.
Phenothiazines
Phenothiazines represent compounds consisting of a tricyclic
structure and an aliphatic side chain at the central ring (TABLE 2).
Chlorpromazine was shown to inhibit PrPSc formation in
ScN2a cells at micromolar concentrations. After a 6-day treat-
ment, PrPSc was not detectable in ScN2a cells [50]. Since pheno-
thiazines have been used as antipsychotic drugs in humans for
approximately 50 years, their pharmacological profile is well
documented. Their ability to cross the blood–brain barrier des-
ignates these drugs as good candidates for clinical trials for the
treatment of CJD.
Acridines/bisacridines
Quinacrine is one of the most prominent drugs tested as a
therapeutic tool against prion diseases (TABLE 2). It is a tricyclic
antimalaria drug that has been used in humans for more than
60 years. Therefore, long-term experience in treatment is avail-
able and its pharmacological properties are well documented.
It is able to cross the blood–brain barrier and can be adminis-
tered orally. Quinacrine has an approximately tenfold higher
antiprion potency than chlorpromazine in a ScN2a cell assay
[50] and the S-quinacrine-enantiomer was found to have a
higher antiprion activity in preventing PrPSc formation than
the S-enantiomer [51]. However, in vivo studies of intraven-
tricular-administered quinacrine into Tg7 mice did not show
any prolongation effects [52] and even a paradoxical increase of
PrPres was observed when mice were treated with quinacrine
by the intraperitoneal route [53].
Nevertheless, it was under investigation in a Safety and Effi-
cacy Study (PRION-1: Quinacrine for Human Prion Disease),
which ended in March 2007 and, currently, patients are
recruited for a Phase II clinical trial (Novel Therapeutics For
Prion Diseases: a Randomized, Double-Blinded, Placebo-Con-
trolled Study of the Efficacy of Quinacrine in the Treatment of
Sporadic Creutzfeldt–Jakob Disease).
Designer peptides
!-sheet breaker peptides are a prominent group of designer
peptides that are known to interfere with the dimensional
structure of PrP (FIGURE 1 & TABLE 2). iPrP13, a 13-residue
!-sheet breaker peptide, is able to reverse the structural state of
PrPSc to a similar structure of PrPc in a chinese hamster ovary
cell culture assay [54]. In vivo, the infectivity of PrPSc-containing
material was decreased by 90–95% and the appearance of clini-
cal symptoms in scrapie-infected mice was delayed when the
infectious agent was incubated with iPrP13 prior to injection
[54]. Thus, these peptides might provide a useful tool to study
the PrP conformational changes during pathogenesis.
RNA aptamers
RNA aptamers were selected from large combinatorial libraries
in order to recognize target molecules with high affinity
(TABLE 2). The two aptamers AP1 and AP2 were identified to
bind specifically to murine, hamster and cattle PrPc but not to
native PrP27–30 from mice, suggesting that they recognize the
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PK-sensitive N-terminus of PrPc [55]. This finding might con-
tribute to the development of diagnostic tools to distinguish
between cellular and pathogenic PrP. Another promising
aptamer DP7 significantly reduced de novo-synthesized PK-
resistant PrPSc in ScN2a cells that express a chimeric
mouse–hamster–mouse PrP [56] and could, therefore, provide a
new class of therapeutic agents against TSEs.
Tyrosine kinase inhibitors
Interference with intracellular signaling has been assumed to
play a role in the conversion process of PrPc to its pathogenic
isoform. A screening of inhibitors of specific signaling path-
ways in prion-infected cells revealed that tyrosine kinase inhib-
itor STI574 (Gleevec®, imatinib mesylate) (TABLE 2) was effec-
tive against PrPSc propagation [57]. It was shown that STI574
decreases the half-life of PrPSc in ScN2a cells by inducing its
lysosomal degradation and, furthermore, the tyrosine kinase
c-Abl was proposed to be probably responsible for the anti-
prion effect of STI574 [57]. This novel class of compounds
might be a promising tool to investigate the role of cellular sig-
naling pathways in PrPSc propagation, as well as to develop
new therapeutic approaches with substances that are already
used for treatment of other human diseases. In this regard,
Gleevec is successfully established in the treatment of chronic
myeloid leukemia.
Antibodies as immunotherapeutics
Since antibodies are the most rapidly growing class of human
therapeutics, the development and design of these tools for
antagonizing prion infection have been investigated (TABLE 3).
There are only a few antibodies specifically targeting PrPSc;
for example, the 15B3 monoclonal antibody (mAb), which is
able to discriminate between the normal PrPc and the dis-
ease-associated form PrPBSE [58]; and 8G8, which also shows a
species-specific recognition for bovine PrPBSE [59,60]. Anti-
bodies directed against the repeat motif tyrosine–tyro-
sine–arginine were able to recognize the pathological isoform
of PrP [61]. However, none of the mentioned antibodies were
effective in interfering with prion propagation, although,
antibodies directed against PrPc aiming to interfere with
PrPSc propagation are permanently under investigation. Pri-
marily, the use of prion-knockout mice enabled the genera-
tion of anti-PrP antibodies that were formerly restricted to
immunotolerance. A difficulty for the design of antibodies
constitutes the PrP structure. While the C-terminus is well
defined (structured), the structure of the N-terminus part
remains poorly defined (nonstructured). Furthermore, it is
still unclear which PrP epitope exhibits the appropriate target
interfering with prion propagation. 
Antibodies directed against the C-terminal domain of PrP,
such as 6H4 (recognizing PrP epitope amino acids
[aa]144–152) [62], or the antigen binding fragment Fab
D18/D13 (recognizing aa132–156 and aa95–103, respec-
tively) [63] have been reported to inhibit PrPSc accumulation in
neuroblastoma cells, suggesting that the binding of mAb to
the corresponding epitope on PrPc inhibits the PrPc–PrPSc
interaction occupying their binding domains. In addition to a
complete cure, 6H4 protected N2a cells from a scrapie infec-
tion. By contrast, antibodies recognizing the octapeptide
repeat region that is suggested to be nonessential for prion
propagation [64] are able to antagonize PrPSc formation [65,66].
It can be concluded that the binding to mature PrPc on the
cell surface is necessary for inhibition of prion propagation.
Studies with polyclonal antibodies generated against dimeric
recombinant murine PrP in mice confirmed that crosslinking
of PrPc on the cell surface is important for PrPSc formation
[67]. Adjacent to therapeutic approaches, antibodies recogniz-
ing different epitopes have been generated to clarify the mech-
anism of PrPSc conversion and prion propagation, respectively.
One study dealing with hybrid-PrP antibody reagents suggests
that the PrP regions aa89–112 and aa136–158 are critical for
PrPc–PrPSc interaction [68]. 
Based on cell culture models, several in vivo studies have
been investigated. Prion pathogenesis has been prevented in
transgenic mice expressing anti-PrP 6H4 µ-chain [69]. Treat-
ment of scrapie-infected mice with mAbs termed ICSMs by
intraperitoneal injection resulted in a markedly reduced
peripheral PrPSc level and prion activity [70]. ICSM35 was
raised against the region aa91–110, whereas ICSM18 was
directed against the PrP epitope stretching from aa146 to
aa159. Treated mice remained healthy for more than 300 days
after continued administration starting from the point of max-
imal PrPSc accumulation. However, passive immunotransfer of
anti-PrP antibodies revealed no effect in the late incubation
period when clinical signs already have developed. In addition,
this therapy is efficient only if prions are inoculated into mice
by the intraperitoneal route. A postexposure prophylaxis using
mAbs 8B4 (residues aa34–52) and 8H4 (aa175–185) resulted
in a prolongation of the incubation period in scrapie-infected
mice [71].
Several groups reported the use of combinations of different
antibodies in cell culture. For instance, SAF34 directed against
the octapeptide repeat region and SAF61 recognizing residues
aa144–152 resulted in an inhibited PrPSc formation [66]. The
observed acceleration of PrPc degradation suggests that the dis-
appearance of PrPSc in cells is directly coupled to PrPc degrad-
ation by reducing its half-life [66]. Since the epitopes for SAF34
and SAF61 correspond to the two different binding sites on the
PrP for the 37/67-kDa LRP/LR [72], one possible mechanism
might be a disruption of the PrP–LRP/LR interaction resulting
in an impaired life cycle and degradation of PrPc. In addition,
the 37/67-kDa LRP/LR was confirmed as a receptor for nor-
mal PrPc [73] and infectious PrPSc [10], suggesting that antibod-
ies blocking the LRP–PrP interaction might be able to interfere
with prion propagation. Indeed, the polyclonal anti-LRP/LR
antibody W3 abrogates PrPSc propagation in scrapie-infected
N2a cells [74] and prolongs the survival time in rodents infected
intraperitoneally with scrapie [ZUBER C ET AL, UNPUBLISHED DATA].
A single chain anti-LRP/LR antibody (scFv), termed S18,
selected by phage display reduced peripheral PrPSc propagation
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in a murine scrapie model [75]. Considering essential functions
of PrP, for example, within neuroprotection or within signal
transduction pathways that might be impaired by anti-PrP
antibodies, inhibition of LRP/LR and not PrP by antibodies
might be an alternative strategy for therapeutic intervention in
prion diseases.
The exact mechanisms by which anti-PrP antibodies inter-
fere with PrPSc replication are still unclear. A recent screening
of mAbs for their capacity to antagonize prion infection in cell
culture suggests an epitope-independent mechanism concern-
ing more global effects on the PrP trafficking and/or trans-
conformation process [59]. Antibodies raised against recom-
binant PrPc were able to persistently clear neuroblastoma cells
(N2a) from PrPSc and to prevent de novo infection, due to the
interference in PrPSc formation both on the cell surface and
after internalization in the cytosol [76].
One has to consider that the induction of signal transduc-
tion pathways by PrP may be disrupted by the application of
anti-PrP antibodies. Therefore, the generation of antibodies
recognizing a PrP region that is not implicated in cell signal-
ing might be more favorable. Generally, no toxicity was
observed in cell culture studies involving anti-PrP antibodies.
However, it was reported recently that crosslinking of PrPc by
mAbs directed against the central amino sequence induced
neuronal apoptosis, suggesting that PrPc might act as an
essential protein in the cell [77]. Furthermore, PrPc itself
might play a critical role in prion neuropathology and
neuronal cell death.
In addition to polyclonal and monoclonal anti-PrP anti-
body strategies, alternative approaches are undertaken for
novel antibody designs. Phage display-based scFvs directed
against PrP were effective in cell culture models [78,79].
Moreover, scFvs derived from 6H4 expressed in a eukaryotic
system exert paracrine antiprion activity when cocultured
with ScN2a cells [80]. Antiprion intrabodies originated from
8H4 targeted to the ER lumen inhibited the transport of
PrPc to the cell surface, which resulted in blockage of PrPSc
accumulation [81]. Mice injected intracerebrally with PC12
cells expressing this intrabody developed no clinical scrapie
signs [81].
Active immunization/vaccination trials
Active immunization against prion disease has been at the
center of a variety of studies since it became evident that
humoral immune responses to the PrP can antagonize prion
disease, as described in detail in the previous section. The
studies using active immunization approaches, few of which
were able to prolong incubation times in animals, have been
summarized in detail previously [82]. However, the major
aspect of prion immunization has recently turned out to be
the induction of a response against the native form of PrP as it
is expressed, for example, on the surface of murine T cells.
Such responses have been predicted to be the key necessity in
successful vaccination against prion disease [83]. By contrast,
responses to recombinant PrP often failed to prolong incuba-
tion times in animals. The need to break tolerance thus
prompted researchers to develop elegant strategies starting
from antigen presentation via foreign immunogens, such as
retrovirus-derived particles [84] or an attenuated Salmonella
vaccine strain [85]. Recently, a DNA vaccine that combines
antigen expression with lysosomal targeting has been devel-
oped [86]. Handisurya and colleagues have recently published
a study in which papillomavirus-like particles were generated
that display a nine amino acid B-cell epitope of PrP,
DWEDRYYRE, resulting in potent conversion inhibitors
in vitro [87]. Taken together, the new generation of antiprion
Table 3. Antiprion antibodies, passive and active immunotherapeutic strategies. 
Antibody In vitro/in vivo studies Suggested mode of action Ref.
Monoclonal anti-PrP 6H4 +/+ (passive immunotherapy) Inhibition of the PrPc–PrPSc interaction by 
occupying their binding domains
[62,69]
scFv antibody 6H4 +/n.d. Inhibition of the PrPc–PrPSc interaction by 
occupying their binding domains
[81]
Anti-PrP mAb 8B4/8H4 n.d./+ (passive immunotherapy) Interaction with PrPc and/or PrPSc [71]
Antigen binding fragment Fab D18/D13 +/n.d. Inhibition of the PrPc–PrPSc interaction [63]
Antiprion mAb ICSM 18 +/+ (passive immunotherapy) Almost exclusive binding to PrPc [70]
Antiprion mAb ICSM 35 +/+ (passive immunotherapy) Recognize PrPSc in addition to PrPc [70]
SAF 34/61 +/n.d. Inhibition of PrPSc formation [66]
Antiprion intrabodies derived from 8H4 +/+ (cell therapy) Inhibition of the transport of PrPc to the cell surface 
thus blocking of PrPSc accumulation
[81]
Anti-LRP/LR polyclonal antibody W3 +/+ (passive immunotherapy) Interference with PrP-LRP/LR interaction [74]
scFv S18/N3 +/+ (passive immunotherapy) Interference with PrP-LRP/LR interaction [75]
LRP/LR: Laminin receptor; mAb: Monoclonal antibody; n.d.: Not determined; PrP: Prion protein; scFv: Single chain antibody.
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vaccines raise the promise to be of complete effectiveness,
compared with first-level vaccines developed on the basis of
recombinant PrP, by inducing a, so far barely understood,
antibody response against native PrP. 
An alternative strategy for the development of a vaccine to
reduce or prevent spread of CWD in domestic and wild popu-
lations of cervids was presented by Miller [88]. Five prion pep-
tides were tested in mice for their suitability to act as possible
CWD vaccines. Two of the peptides revealed a significant pro-
longation of survival in Rocky Mountain Laboratories-infected
mice. Since recently infectious prions have been detected in
body fluids of deer suffering from CWD [89], a vaccination
approach seems to be desirable.
Transdominant negative mutants
Several reports have discussed strategies for inhibiting PrPSc
accumulation. One major problem with drugs shown to exert
antiscrapie effects is their intrinsic property to induce a wide
variety of side effects [49,90]. Several PrP mutants have been
investigated for their therapeutic antiprion potential in vitro
[91]. Kaneko and collegues first showed that substitution of a
basic residue at position 167, 171 or 218 in the PrP prevents
PrPSc formation [91] and claimed that these PrP mutants
appear to act as dominant negative mutants by binding to
protein X more avidly than the wild-type PrP and thus ren-
dering it unavailable for the prion replication process. Mech-
anistically, Kaneko et al. argued that PrPc initially forms a
complex with protein X that might act as a molecular chaper-
one following PrPSc binding [91]. Alternatively, deleted PrP
molecules inhibiting the accumulation of PrPSc in a
transdominant fashion were designed [92]. Employing
scrapie-infected mouse N2a cells as a model system, it has
been shown that a deletion of eight amino acids in mouse
PrPc (PrPcdel114–121) abrogates the conversion of the
mutant protein into PrPSc. In addition, PrPcdel114–121
overexpression resulted in inhibition of PrPSc accumulation
[92]. Assuming that any side effects of PrPcdel114–121 should
be minimal compared with those of the chemical com-
pounds, an alternative therapeutic approach can be envisaged
using transdominant PrP mutants.
Further studies using transgenic mice expressing dominant
negative PrP mutants (Q167R and Q218K) demonstrated
that expression of dominant negative PrP strongly reduced
PrPSc accumulation in vivo [93]. Here, Perrier et al. generated
transgenic mice expressing PrP with either the Q167R or
Q218K mutation in wild-type mice or on a Prnp0/0 back-
ground. Following intracerebral prion inoculation into these
mice,  Tg(Q167R)Prnp+/+ and Tg(Q218K)Prnp+/+ mice
exhibit only low PrPSc levels or even no PrPSc accumulation
in the brain [93], supporting the possibility of producing
prion-resistant livestock.
Recently, in an animal model for iCJD, it has been shown
that after a 7-day-lasting intracerebroventricular administra-
tion of the dominant negative PrP mutant rPrP-Q218K, the
incubation period was prolonged from 117 to 131 days [94].
Delivery of PrP containing dominant negative mutations
has been achieved using lentiviral gene transfer [95]. By taking
advantage of ‘prion-resistant’ polymorphisms that naturally
exist in sheep and humans (Q171R and E219K), correspond-
ing residues were mutated in the murine Prnp gene (Q167R
and Q218K) and subcloned into lentiviral vectors. Trans-
duction of prion-infected N2a cells with lentiviral vectors car-
rying the dominant negative PrP mutants showed a strong
expression of the transgene and a potent inhibition of PrPSc
accumulation [95]. 
Since PrPc is a major cellular requirement for the propaga-
tion of infectivity [96], it represents an attractive therapeutic
target. However, identification of the 37/67-kDa LRP/LR as
the receptor for prions [10,60,73] suggested an alternative target
for the development of TSE therapeutics. Recently, it has
been shown that a LRP mutant encompassing only the extra-
cellular domain of LRP/LR (LRP102–295::FLAG) might act
in a transdominant negative manner as a decoy by trapping
PrP molecules [97]. In vitro studies revealed that the LRP
mutant is able to reduce the PrPSc accumulation in scrapie-
infected neuronal cells [97] and, thus, might have potential for
the development of a TSE therapy.
RNA interference approaches
Reduction of the 37/67-kDa LRP/LR level by RNA inter-
ference (RNAi) inhibits PrPSc accumulation in ScN2a and
ScGT1 cells [74], suggesting that LRP/LR represents a promis-
ing target for a gene delivery approach using siRNAs directed
against LRP mRNA.
Another target for siRNAs is the Prnp gene. Transfecting
scrapie infected N2a cells with siRNA duplexes directed against
the Prnp mRNA leads to downregulation of both PrPsen and
PrPres levels [98]. Recently, lentiviral gene transfer was used to
downregulate PrPc expression by delivering shRNAs into goat
fibroblasts, which were used to produce a cloned goat fetus by
nuclear transplantation. Analysis of the fetal brain tissue
revealed a significant downregulation of PrPc (>90%) [99].
Delivery of the shRNAs was even successful when the recom-
binant lentiviral vectors were injected into the bovine ova prior
to in vitro fertilization [99].
The group headed by Kretzschmar reported recently that
chronic ScN2a cells revealed an efficient reduction of PrPSc
levels after transduction with lentiviral shRNA512 [100]. Most
notably, the group mimicked the clinical situation by gener-
ating chimeric mice derived from lentivector-transduced
embryonic stem cells. These animals carried the lentiviral
shRNAs in a defined percentage of brain cells and expressed
reduced PrPc levels. Most importantly, in highly chimeric
mice, survival was significantly extended after scrapie infec-
tion, strongly suggesting that lentivector-mediated RNAi
represents an important approach for the treatment of prion
disorders [100].
Disablement of both Prnp alleles does not impair normal
development and behavior in mice [101]. Recently, PrPc-defi-
cient cattle were generated that appeared to be physiologically,
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histopathologically, immunologically and reproductively nor-
mal [102]. In addition, transgenic mice [tgN(NSEasLRP)2] were
constructed that showed a reduced LRP/LR level in hippo-
campal and cerebellar brain regions and no abnormal behavior
compared with control mice [103]. In addition, mice treated
with scFv S18 [75] or polyclonal antibody W3 (ZUBER C ET AL,
UNPUBLISHED DATA), both directed against LRP/LR by immuno-
transfer, revealed no side effects, suggesting that ectopic down-
regulation of LRP/LR in the brain or blocking the prion recep-
tor by antibodies has no phenotype. These findings lead to the
conclusion that gene silencing by RNAi targeting PrP and
LRP is a promising approach to retard disease progression,
especially in familial forms of prion diseases where an early
treatment is reasonable owing to a possible diagnosis at an
early stage of disease.
The 37/67-kDa LRP/LR as a target in therapy of prion diseases
37/67-kDa LRP/LR – originally identified as a PrPc interacting
protein [104] – acts as a receptor for the PrPc [73] and the infec-
tious PrPSc [10]. LRP/LR is required for the internalization of
BSE prions by human enterocytes [60]. We are developing a
series of therapeutics for the treatment of TSEs targeting
LRP/LR (reviewed in [1,105]): the polysulfated glycanes HMs
and pentosan polysulfate (SP54) (FIGURE 1) both interfere with
the binding of PrP27–30 to LRP/LR at the cell surface [10].
Antisense LRP RNA expressed in scrapie-infected neuronal
cells reduced PrPSc propagation [74]. siRNAs directed against
LRP mRNA also hamper PrPSc propagation in scrapie-infected
neuronal cells [74]. The lentiviral gene delivery system will be
employed to transfer siRNAs into animals. A transdominant
negative LRP decoy mutant termed LRP102–295::FLAG
impaired PrPSc propagation in scrapie-infected neuronal cells
[97]. Finally, antibodies directed against LRP/LR seem to be
powerful tools for the treatment of TSE. The polyclonal anti-
body W3 cured PrPSc-propagating cells from scrapie [74] and
prolonged the survival time in scrapie infected mice (ZUBER C ET
AL, UNPUBLISHED DATA). scFv antibodies directed against LRP/LR
(FIGURE 1) reduced peripheral PrPSc propagation by passive
immunization of mice [75] and through delivery of transgenes
encoding for scFvs into mice by recombinant adeno-associated
viruses (AAVs) (ZUBER ET AL. UNPUBLISHED DATA). 
Antiprion drugs in clinical trials
Symptomatic treatment
Given the wide range of symptoms and signs in CJD and cur-
rent limitations of causal therapy, symptomatic treatment
becomes extremely important. Antidementive drugs, such as
acetylcholinesterase inhibitors, were not tested systematically in
CJD patients, probably because, in most cases, the diagnosis is
made in advanced disease stages when dementia is severe. Many
CJD patients suffer from psychiatric symptoms, such as depres-
sion, anxiety, psychosis and hallucinations. Symptomatic treat-
ment spans a wide range of anxiolytic and antipsychotic drugs,
such as benzodiazepines or neuroleptics. Since muscle rigidity
and akinesia are frequent in the middle and advanced disease
stages, atypical neuroleptics should be used to minimize the
adverse effects. A symptomatic therapy exists for CJD-typical
myoclonus that responds well to clonazepam or valproate at a
standard dose.
Observational trials
So far, only a few case reports are available on therapeutic
measures that have an effect on the prognosis and course of the
disease [106]. Several compounds have been tested for their
potential as an antiprion drug. They belonged to distinct
classes, such as analgesic, antidepressant, antipsychotic, anti-
microbial and anticoagulant drugs. Most of them were tested
in observational trials only on a small number of individuals
and mainly case reports for these patients are available. These
studies are listed in TABLE 4 [107,109]. 
In vitro experimental results indicate that pentosan polysul-
phate (PPS) has an effect on PrP production, replication and
associated cell toxicity [110]. In animal experiments, PPS has a
prophylactic effect [52]. A major problem is that PPS is
believed not to cross the blood–brain barrier; therefore, the
compound has to be administered intraventriculary. This has
been performed in a number of individuals with vCJD and
sCJD [15,16,111]. There are controversial results of PPS in clin-
ical studies. Although prolongation of survival was not always
reported, this finding is hard to judge because this compound
has not been tested in a case–control study. PPS might still be
a candidate for a clinical trial since a significant effect was
observed in a murine model of scrapie, BSE and vCJD after
oral, intraventricular, intraperitoneal and intracerebral
administration of PPS [112].
Case–control trials
Controlled clinical trials using a prospective double-blinded
approach were conducted for flupirtine only [113]. Other
studies reported to date in the literature compared clinical
variables and survival times in treated patients and cohorts
with untreated CJD patients. Such trials are available for spo-
radic and vCJD patients using quinacrine and sCJD patients
using doxycycline. 
Table 4. Summary of case reports with anti-infective 
drugs used in prion diseases. 
Drug Ref.
Acyclovir [144,145]
Amantadine [109,146–151]
Amphotericin B [152]
Interferon [107,153]
Pentosan polysulfate [15]
Quinacrine [154–157]
Vidarabin [158]
Ludewigs, Zuber, Vana, Nikles, Zerr & Weiss
622 Expert Rev. Anti Infect. Ther. 5(4), (2007)
The flupirtine trial was conducted in 26 sCJD patients and two
iCJD patients [113]. A total of 13 patients were treated with
100 mg (300–400 mg) flupirtine daily; 15 controls received pla-
cebo. There was no difference regarding survival, that is, 107 days
for the treatment group and 106 for the controls. One of the
parameters used to monitor the disease progression was the change
in the ADAS-Cog score. Patients treated with flupirtine showed
significantly less deterioration in the dementia tests than patients
treated with placebo. The mean change in ADAS-Cog (baseline to
best) was +8.4 (±15.3) in the flupirtine group and +20.6 (±15.1)
in the placebo group (p = 0.02, one-sided t-test) [113].
Disease progression was evaluated in 30 sCJD patients and
two vCJD patients using 100 mg quinacrine three-times daily.
The data were compared with untreated 125 sCJD patients.
There was no significant difference on the mean survival time
between the treated and untreated groups [114].
According to cell culture and animal experiments, doxycyclin
may bind PrPSc directly, thus preventing further conform-
ational changes [38,115]. A limited number of patients with
sCJD were treated with doxycycline and an increased survival
in these patients compared with historical sCJD cases was
reported [116]. These preobservations have to be confirmed in a
prospective multinational study in Italy and Germany, which is
currently underway (TAGLIAVINI F, ZERR I, PERS. COMM.). No sys-
tematic studies are reported to date for establishment of this
treatment in routine clinical practice. 
Problems of clinical trials in CJD
Clinical diagnosis
There is a wide scope of clinical phenomenology in human
prion disease, regarding the age of onset, presenting features,
rate of progression and appearance of other clinical manifest-
ations [117–119]. Owing to clinical heterogeneity, the diagnosis
at early stages might be difficult. However, recent advances in
clinical diagnostic techniques, such as cerebrospinal fluid
(CSF) tests and MRI, enable the recognition of the disease at
earlier stages, but better tests are needed to identify patients as
early as possible, at best at the preclinical stage [120,121]. On
the other hand, clinical studies in patients with prion diseases
are hampered by various clinical presentations and variability
in the disease course, which are influenced by several factors,
such as age at onset, gender, molecular disease subtype and
Prnp codon 129 genotype [117,122].
At disease onset, the symptoms and signs are not specific;
however, during the disease course, almost all patients develop
rapid progressive dementia, ataxia, myoclonus and muscle tone
abnormalities. The prodromal phase is mainly characterized by
unspecific behavioral changes, fear, adynamia and dizziness,
which are frequently regarded as unspecific symptoms and no
suspicion of a prion disease is raised at that time. Many patients
complain of sleep disturbances or relatives might notice eating
abnormalities and weight loss. These signs, together with altered
social behavior and depressive mood changes, might point
toward an organic depression at this phase. Depression, fear and
aggression were reported as early psychiatric symptoms [123–127].
With the progression of the disease, patients develop cognitive
deficits and focal neurological signs, such as hemianopsia, cere-
bellar ataxia, pyramidal and extrapyramidal signs, myoclonus
and akinetic mutism. In the advanced stage of the disease, the
patients have lost contact with the environment, are usually bed-
ridden, akinetic and mute [128]. Muscle tone abnormalities (rigor
and/or spasticity) and myoclonus are mostly present. Patients of
the classical sCJD variant usually die within months or weeks
(median 6 months), whereas others (atypical cases) may survive
in this state for 1–2 years [122,129–131]. 
Differential diagnosis
Owing to the nature of the clinical symptomatology, the differ-
ential diagnosis of sCJD includes a large number of neuro-
logical and psychiatric diseases. The most frequent differential
diagnosis is Alzheimer’s disease [132–136]. The rapid disease
course, in particular, can rarely be discriminated from CJD
when myoclonus is present. Dementia with Lewy bodies and
vascular dementias are further diagnoses that are frequently
found as a differential diagnosis of CJD in elder patients [118].
Chronic encephalitis is often the differential diagnosis among
patients of younger age in both sCJD and vCJD. CSF tests and
MRI help to differentiate CJD from other neurodegenerative
and inflammatory conditions.
Phenotypic heterogeneity
Phenotypic variability in the clinical syndrome and neuro-
pathological changes in sCJD were recognized a long time ago
and some attempts were made to define disease subtypes
(such as Heidenhain variant or Brownell–Oppenheim vari-
ant). Based on new molecular diagnostic criteria, distinct clin-
icopathological phenotypes are defined by the codon 129 gen-
otype of Prnp together with the type of PK-resistant core of
the PrP (either as type 1 or 2). Some of clinicopathological
subtypes, formerly known as Heidenhain variant, could be
classified as homozygous for methionine (MM)-1/hetero-
zygous (MV)-1 subtype and Brownell–Oppenheim variant as
homozygous for valine (VV)-2 subtype [117]. 
The most frequent subtypes of sCJD are designated as
MM-1/MV-1 (the latter are often summarized as one
subtype because of clinicopathological similiarities), VV-2
and MV-2 (TABLE 5). Patients with MM1 (median age at
onset: 65 years [range 31–81 years]) subtype usually display
a short clinical disease course of several months and present
with rapid progressive myoclonic dementia. Patients with
VV2 subtype usually develop cerebellar ataxia for several
months and dementia is usually mild and becomes apparent
as the disease progresses, often at late disease stages. The dis-
ease course is prolonged (median 7 months). In MV2 sub-
type, the clinical presentation might vary between extrapy-
ramidal syndrome, ataxia and dementia. The slowly
progressive disease, which might span a period of up to
3 years, often hampers the diagnosis, since many other neu-
rodegenerative conditions might be taken into account
before CJD is suspected [117,126].
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The median disease duration reported for all forms of sCJD is
approximately 6 months [118,122,127]. However, the disease dura-
tion appears to vary with respect to the subtypes. The influence
of the genotype at codon 129 on disease duration is shown in
FIGURE 2. Patients who are homozygous for methionine have the
most progressive disease course, followed by those who are
homozygous for valine and heterozygous. The latter individuals
have the longest survival. In addition, patients who are younger at
disease onset might display a disease duration three-times longer
than elder individuals with the same genotype (FIGURE 3) [122,137].
Thus, age and codon 129 genotype have to be taken into account
when controlled clinical trials are undertaken in CJD patients.
Case identification
Although single prospective, double-blinded trials in CJD were
performed [113,114], clinicians face several difficulties with the
design. First, CJD is still a rare condition and the incidence rate is
1.5–2 per million per year [138]. Therefore, a monocentric
approach has to be chosen, ideally by centralizing the data in one
center experienced with case identification and diagnosis. Another
major problem is the rapid disease progression. Given a short sur-
vival in most patients, an early case identification is crucial to start
treatment. A specific problem has to be addressed when a clinical
trial has to be carried out in patients with dementia, which might
be severe at the time when the CJD diagnosis is made. It is impor-
tant that ethical issues concerning the trials, which will be carried
out on patients unable to give an informed consent, are addressed.
Disease progression
Dementia syndrome in CJD differs from other more common
neurodegenerative dementia, such as Alzheimer’s disease, but
has been poorly characterized and neuropsychological assess-
ment data are limited [124]. Commonly used dementia scales
were designed to monitor disease progression in Alzheimer’s dis-
ease and scales for vascular dementia and frontotemporal
dementia are also available [139]. However, these scales and scores
might not be suitable to monitor progression of the cognitive
decline in CJD patients; therefore, disease-specific scores have to
be developed. In addition, scores for monitoring other neuro-
logical abnormalities, such as ataxia, rigidity or myoclonus, also
have to be applied in clinical trials. Owing to the variability in
clinical syndromes and survival across molecular CJD subtypes,
scales might be weighted for single subtypes: ataxia is more
prominent in VV2 subtype and an ataxia scale might be more
useful to monitor the disease progression in this subtype,
whereas a score that involves neuropsychiatric assessment might
reflect disease progression for the MM1 subtype.
Conclusions
A series of anti-TSE drugs were effective in vitro (scrapie-infected
neuronal cells) and in vivo (mainly scrapie-infected rodent mod-
els). However, when administered in clinical studies, none of them
so far have revealed significant effects regarding a prolongation of
survival times in CJD patients or an improvement of the state of
health. A symptomatic therapy for CJD-typical myoclonus exists
Table 5. Molecular subtypes of sporadic Creutzfeldt–Jakob disease (clinical and pathological characteristics). 
Occurence Molecular 
disease subtype
Median age 
at onset, 
years (range)
Median duration, 
months (range)
Most prominent 
clinical 
signs/symptoms
Neuropathological features
Frequent MM1/MV1 65 (31–82) 4 (1–18) Dementia, cortical 
anopsia and myoclonus
Prominent involvement of occipital 
cortex, ‘synaptic type’ PrP staining
MV2 64 (53–76) 12 (4–27) Ataxia, dementia 
and extrapyramidal
Similiar to VV2, focal involvement 
of the cortex, amyloid-kuru plaques 
in the cerebellum, plaque-like focal 
PrP deposits
VV2 61 (40–76) 7 (3–18) Ataxia at onset and 
late dementia
Prominent involvement of 
subcortical structures, including 
brain stem nuclei, spongiosis often 
limited to deep cortical layers, 
plaque-like PrP staining, prominent 
perineuronal staining
Rare MM2-thalamic
MM2-cortical
52 (36–71)
64 (49–77)
16 (8–24)
16 (9–36)
Insomnia, dysautonomia 
at onset, later ataxia and 
cognitive impairment. 
Progressive dementia for 
several months
Atrophy of the thalamus and 
inferior olive, spongiosis may be 
absent or focal. Large confluent 
vacuoles with perivacuolar 
PrP staining
VV1 44 (19–55) 21 (17–42) Dementia at onset, 
later ataxia and 
extrapyramidal
Severe pathology in the cerebral 
cortex and striatum with sparing of 
brain stem nuclei and cerebellum
CJD: Creutzfeldt-Jakob disease; MM: Homozygous for methionine; MV: Heterozygous for methionine or valine; PrP: Prion protein; VV: Homozygous for valine. 
Data from German CJD Surveillance and according to [117,119,129–131].
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that responds well to clonazepam or valproate at a standard dose. A
safety and efficacy study with quinacrine ended in March 2007
and patients are currently being recruited for a Phase II clinical
trial. Pentosan polysulfate (SP54) was able to cure two mouse
strains from two scrapie strains. Clinical trials so far have led to
controversial results. HMs might represent alternatives to SP54.
Recently, Doh-ura reported prolonged survival times in CJD
patients after long-term cerebroventricular administration of the
drug [140]. Antibodies directed against PrP and LRP/LR revealed
significant effects in vivo and might be suitable for passive immu-
nization and vaccination strategies. Promising vaccination trials
were reported, including papilloma-like particles that display a
nine amino acid B-cell epitope of PrP resulting in potent conver-
sion inhibitors in vitro. Prion peptides may act as possible CWD
vaccines, which might protect exposed individuals from a CWD
infection in the USA. Each attempt to develop a therapeutic strat-
egy considers the development of an early (preclinical screening)
test. Until such a test is available, clinical studies in humans will be
hampered by the late diagnosis, when extensive neuronal damage
has already taken place. On the other hand, many factors have to
be taken into account for the analysis of the treatment outcome,
such as genetic background and heterogeneous disease course with
variable survival times. Disease-specific scores have to be developed
to monitor disease progression in single molecular disease subtypes. 
Expert commentary
vCJD patients are young and die at a mean age of approximately
27 years. All human TSEs, including the sCJD forms with an
incident rate of 1.5–2 cases per million per year, iCJD and the
familial forms, fCJD, fatal familial insomnia and GSS syndrome,
are lethal and survival times range between approximately
6 months in sporadic and a few years in genetic cases. No thera-
peutic for the causal treatment of human prion disorders is avail-
able on the market worldwide, and TSE patients are treated only
symptomatically. Even if the number of vCJD cases declines fur-
ther, the numbers of sporadic and familial human TSE cases will
stay constant or will even increase. Therefore, the development of
effective antiprion drugs is essential. 
It is hard to predict which of the drugs will show a significant
effect on the prolongation of survival in patients. Most of the
drugs target PrP. Since PrP does not seem to have essential func-
tions for the organism (PrP-knockout cows reveal no phenotype
[102]), depletion of PrP might also be tolerable for the human
body. An alternative target is LRP/LR, identified as a receptor
for PrPc and PrPSc. This receptor appears to be necessary for
organisms owing to its multifunctional role, such as cell adhe-
sion, growth and development (reviewed in [1,105]). However,
ectopic downregulation of LRP in the brain by using an anti-
sense RNA strategy revealed no phenotype [103], suggesting that
depletion of LRP in the brain is tolerable for the organism. In
addition, intraperitoneal treatment of mice with antibodies
directed against LRP/LR, such as W3 and scFv S18 [75], did not
reveal any side effects. Therefore, tools blocking LRP/LR might
be promising for the treatment of TSEs, especially when deliv-
ered by passive immunotransfer, ex vivo approaches (grafting of
antibody secreting myotubes) and gene delivery systems,
including recombinant lentiviral vectors. Here, antibodies
directed against LRP/LR, siRNAs directed against LRP
mRNA, transdominant negative LRP mutants and polysulfated
glycanes, such as SP54 or heparan mimetics, might be interest-
ing tools. In addition, siRNAs directed against PrP mRNA
Figure 2. Kaplan-Meyer survival time in Creutzfeldt-Jakob disease 
patients stratified by codon 129 genotype.  
MM: Homozygous for methionine; MV: Heterozygous for methionine and 
valine; VV: Homozygous for valine.
Reproduced from National TSE reference center, Göttingen, Germany.
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Figure 3. Kaplan-Meyer survival time in CJD patients stratified by age 
at onset. 
CJD: Creutzfeldt-Jakob disease.
Reproduced from National TSE reference center, Göttingen, Germany.
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delivered by lentiviral vectors [100] might be promising. The
development of preclinical screening tests is a prerequisite for
successful treatment of TSE patients. New approaches for the
identification of novel drugs for the treatment of TSEs might be
required, which target either novel components of the life cycle
of prions or well-known interaction partners of the PrP [1]. As
long as it is unclear whether CWD and sheep scrapie might cause
a zoonotic disease in humans, vaccination trials might be of
interest for those people coming in contact with cervids suffering
from CWD and/or sheep suffering from scrapie. 
Five-year view
Within the next 5 years, we will know whether classical anti-
prion drugs, such as SP54, HMs, quinacrine, doxycycline, or
others, will have the potential to prolong the survival time in
TSE patients. We consider the development of novel
antiscrapie drugs focusing on further essential components of
the life cycle of prions as important. One of the targets is the
37/67-kDa LRP/LR identified as a receptor for PrPc and PrPSc.
Here, antibodies, siRNAs and transdominant negative mutants
are currently tested for their antiprion activity in animal models
and, in case they are active, also in clinical studies.
A bottleneck in TSE therapy is the delivery system. Antibodies,
for instance, can be delivered by passive immunization, ex vivo
approaches (e.g., grafting of antibody-secreting muscle cells) and
gene delivery systems, including AAV and lentiviral vectors. Vac-
cination approaches include active immunization with PrP and
prion peptides, as well as DNA vaccination. Vaccination trials are
important, especially for those individuals in contact with ani-
mals suffering from a TSE to avoid the development of a
zoonotic disease.
siRNAs might represent further powerful therapeutic tools,
which can be directed against Prnp mRNA, LRP mRNA and
mRNAs encoding for further important proteins of the life cycle
of prions. Cutting-edge gene delivery systems might include lenti-
viral vectors, the AAV system or papilloma-like virus particles. A
better understanding of the life cycle of prions via identification
of all essential components for prion replication will reveal poten-
tial alternative targets for development of a powerful antiprion
drug. The development of preclinical screening systems seems to
be realistic within the next 5 years to enable an early preclinical
treatment of TSE patients with powerful antiprion drugs.
Acknowledgements
This work was supported by the European Commission (grant
NoE-NeuroPrion FOOD-CT-2004–506579, the Bundeminis-
terium für Bildung und Forschung (grant 01-KO-0514) and
the Deutsche Forschungsgemeinschaft (grant WE 2664/2–1).
Financial disclosure
The authors have no relevant financial interests related to this
manuscript, including employment, consultancies, honoraria,
stock ownership or options, expert testimony, grants or patents
received or pending, or royalties. 
Key issues
• Approximately 200 people worldwide have died or suffer from variant Creutzfeldt–Jakob disease (CJD) most likely caused by bovine 
spongiform encephalopathy.
• The incidences of sporadic and familial CJD are 1.5–2 per million/year and one per 10 million/year, respectively, in Europe.
• No therapeutic is on the market for the treatment of human transmissible spongiform encephalopathies.
• Most of the therapeutics target prion protein (PrP)c and/or PrPSc.
• Pentosan polysulfate (SP54) is the only drug that cured the mouse strains VM and CBA from scrapie strains 22A and ME7. There are 
controversial results with SP54 in clinical studies.
• The prion receptor 37/64-kDa laminin receptor (LRP/LR) is targeted by antibodies, polysulfated glycanes, siRNAs directed against 
LRP mRNA and transdominant negative mutants.
• No vaccination against prion disorders is currently on the market. Most antiprion vaccinations induce a response to PrP.
• A symptomatic therapy exists for CJD-typical myoclonus that responds well to clonazepam or valproate.
• Case reports were conducted with acyclovir, amantadine, amphotericin B, interferon, pentosane, quinacrine and vidarabin.
• Controlled clinical trials were performed with flupiritine only.
• Clinical diagnosis at early stages of CJD is possible with cerebrospinal fluid tests and MRI. Both techniques help to differentiate CJD 
from other neurodegenerative and inflammatory diseases.
• Preclinical screening tests are required to develop an effective therapeutic strategy, which can be initiated at the preclinical phase.
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Abstract: The 37 kDa/67 kDa laminin receptor (LRP/LR) represents a key player for cell 
adhesion, is associated with the metastatic potential of solid tumors and is required for 
maintenance of cell viability by preventing apoptosis. LRP/LR acts as a receptor for 
viruses such as Sindbis, Venezuelean Equine Encephalitis (VEE) virus, Adeno-
associated-viruses (AAV) and Dengue Virus, the latter causing 50 to 100 million 
infections in humans per year. LRP/LR acts further as a receptor for prions and represents 
a multifunctional protein subcellularly located to the nucleus, the cytoplasm and the cell 
surface. The receptor represents an alternative target for therapy of viral infections, 
cancer and prion disorders and might play additional roles in further neurodegenerative 
diseases such as Alzheimer’s disease. The species barrier in prion disorders might be at 
least in part determined by the presence of LRP/LR in enterocytes of the intestinal 
epithelium. Anti-LRP/LR antibodies, siRNAs directed against LRP mRNA, polysulfated 
glycanes such as pentosan polysulfate and heparan mimetics and LRP decoy mutants are 
promising tools for blocking or downregulating the receptor and may represent 
alternative therapeutics for the treatment of prion disorders.  
 
 
 
Key words: 37kDa/67kDa laminin receptor LRP/LR, prion protein PrP, 
neurodegenerative disease, HSPG, pentosan polysulfate, single chain antibody scFv, 
siRNA, species barrier, zoonotic disease, CWD, scrapie, BSE, therapy, cancer, 
Alzheimer’s Disease 
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1. The 37kDa/ 67kDa laminin receptor LRP/LR 
In a yeast two-hybrid screen, the 37 kDa laminin receptor precursor (LRP) was identified 
as an interaction partner for the prion protein [1]. Coinfection and cotransfection studies 
in insect and mammalian cells confirmed the interaction, and led to the assumption that 
LRP might act as the receptor for the cellular PrP [1]. Further in vitro studies on neuronal 
and non-neuronal cells validated the hypothesis and showed that the laminin receptor 
LRP/LR act as the receptor for the cellular prion protein [2]. Using the yeast two-hybrid 
system domains on PrP and LRP have been identified to be involved in the PrP-LRP 
interaction. Two binding domains for LRP on PrP were discovered: a direct binding 
domain (PrPLRPbd1, aa144-179) and an indirect one (PrPLRPbd2, aa53-93), which 
depends on the presence of heparan sulfate proteoglycans (HSPGs) that fuction as co-
factors or co-receptors for the binding of PrPc to the LRP/ LR [3]. Furthermore, the yeast 
two-hybrid system localized the direct PrP-binding domain on LRP between amino acid 
residues 161 and 180 [3] (Fig. 1). A second HSPG-dependent binding site, which has not 
been identified so far, might be located between amino acid 180 and 285. HSPGs are 
multifunctional macromolecules characterized by a core polypeptide to which 
glycosaminoglycans (GAGs) are covalently attached and have also been shown to act as 
initial attachment receptors for several viruses (Tab. 1) and are associated with Aβ 
deposits in Alzheimer’s disease (AD) [4]. 
The 37 kDa LRP is thought to be the precursor of the 67 kDa high-affinity laminin 
receptor (LR), which was first isolated from melanoma cells due to its high binding 
capacity to laminin [5]. Although the LRP has a transmembrane domain (amino acid 
residue 86-101, [3, 6]) (Fig. 1), it is abundantly localized in the cytoplasm [7]. In 
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mammalian cells, it has been demonstrated that both the 37 kDa LRP and the 67 kDa LR 
are present in plasma membrane fractions [2]. The exact mechanism by which the 37 kDa 
precursor forms the mature 67 kDa isoform is up to now still unclear. Data from a yeast 
two-hybrid analysis and a size exclusion chromatography on recombinant LRP showed 
that LRP failed to interact with itself [3], which is an argument against the hypothesis of 
a direct homodimerization. Analysis of the membrane-bound 67 kDa LR indicated, that 
acylation of LRP might be involved in the processing of the receptor [8]. Additional 
studies suggested that the 67 kDa LR might be a heterodimer stabilized by fatty acid-
mediated interactions [9]. Mammalian genomes contain multiple copies of the LRP gene, 
particularly 6 copies in the mouse and 26 copies in the human genome [10]. Sequencing 
revealed that over 50% of the 37 kDa LRP gene copies were pseudogenes most probably 
generated by retrotranspositional events. The finding of multiple pseudogenes for the 37 
kDa LRP might suggest that the accumulation of several copies of this gene might have 
given a survival advantage to the cell in the course of evolution [11].  
Interestingly, the 37kDa LRP appears to be a multifunctional protein involved in the 
translational machinery [12] and has also been identified as p40 ribosome-associated 
protein [13]. LRP has also been found in the nucleus, where it is tightly associated with 
nuclear structures [14]. The 37kDa/67kDa LRP/LR has been described to act as a 
receptor for laminin, elastin and carbohydrates [15] as well as a receptor for Venezuelan 
equine encephalitis virus [16], Adeno-associated Virus [17], Sindbis virus [18] and 
dengue virus [19] (Tab. 1). Recent studies investigated  the role of LRP/LR in the 
maintainance of cell viability and it has been shown that knockout of the laminin receptor 
via RNA interference induced apoptosis [20]. Due to the co-localization of LRP/LR and 
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PrP on the surface of mammalian cells, a possible role of LRP/LR for PrP binding and 
internalization was assumed. Using a cell-binding assay with recombinant PrP a LRP/LR 
dependent binding of PrP has been shown [2]. The strict LRP/LR specificity for the PrP 
binding could be confirmed in competition assays with different anti-LRP antibodies. 
Furthermore, it has been demonstrated, that the PrP internalization process represents an 
active receptor-mediated event [2]. Due to the identification of various LRP/LR isoforms, 
additional studies have been performed to detect the isoforms that are present in the 
central nervous system and bind PrP. Therefore, mouse brain fractions enriched in the 
laminin receptor were purified and overlay assays with recombinant PrP were performed 
[21]. Several LRP/LR isoforms corresponding to different maturation states of the 
receptor were identified, including a 44 kDa, 60 kDa, 67 kDa and a 220 kDa form. 
Furthermore, it could be demonstrated, that all of these isoforms were able to bind PrP, 
supporting a physiological role for the laminin receptor/PrP interaction in the brain [21]. 
A closer insight into the fine cellular distribution of LRP/LR in the central nervous 
system was reached by using immunohistochemistry in adult rat brain [22]. It has been 
shown, that the 67 kDa LR is the major receptor form, which is expressed within the 
cytoplasm and at the plasma membrane in most neurons and in a subset of glia cells [22]. 
In contrast, the 37 kDa LRP is much less abundant in adult than in postnatal central 
nervous system and its expression is restricted to a subclass of cortical interneurons 
known to be particularly sensitive to abnormal prion accumulation and rapidly degenerate 
during early stages of Creutzfeldt-Jakob Disease (CJD) [23]. In addition, recent studies 
showed, that LRP/LR is not only involved in the PrPc metabolism, but fullfills also a 
crucial role in prion propagation. Using antisense LRP RNA or small interfering (si) 
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RNAs specific for LRP mRNA, PrPSc levels in scrapie-infected neuronal cells were 
reduced indicating a necessity for the laminin receptor LRP/LR for PrPSc propagation in 
cultured cells [24].  
Due to the facts, that a (natural) infection with prions mostly occur via an oral route and 
that LRP/LR act as receptor for prions [2, 25] potential binding sites for PrP in the 
intestinal mucosa were examined. Tissue expression studies of the LR in human duodenal 
and jejunal biopsy samples led to the discovery, that this receptor is expressed in the 
apical brush border of small intestinal epithelial cells. Employing immunohistochemistry 
LR expression has also been observed in the perinuclear/Golgi apparatus region and in 
the Paneth cell secretory granules [26]. A colocalization with PrPc in the perinuclear 
compartment has recently been proven [27]. These findings suggest an involvement of 
LR in both secretory and endocytotic functions of human small intestinal epithelium. 
Moreover, it was speculated that the major implication of intestinal expression of the 67 
kDa LR may be an increased susceptibility to an oral infection with prions [26]. It has 
been demonstrated, that the oral transmission of infectious prion particles led to a rapid 
accumulation of PrPSc in Peyer’s patches [28]. PrPSc has also been detected in enterocytes 
of the villous epithelium of the small intestine of primates after oral exposure to prions 
[29]. Enterocytes represent the major cell population of the intestinal epithelium [30] and 
are known to actively participate in endocytosis. Since expression of PrPc was 
demonstrated to be necessary for prion replication, expression of the cellular prion 
protein in the gastrointestinal tract has been analyzed and indeed it has been shown that 
PrPc is present in human enterocytes [31]. These results led to the hypothesis that 
enterocytes might play an important role for the uptake of infectious prion particles. 
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Previously, it has been demonstrated that bovine PrPSc is internalized by human 
enterocytes via an LRP/LR-mediated endocytosis [32]. For a role in the uptake of 
pathogens from the gut, the 37 kDa/ 67 kDa LRP/LR must be internalized after ligand 
binding. In terms of internalization, it has been shown that the 67 kDa LR functiones as 
the major receptor for virus entry into mammalian cells [18]. Association of the laminin 
receptor with glycolipid-enriched microdomains in the cell membrane might lead to a 
clustering with other proteins in this region to provide a mechanism for internalization 
[33]. In summary, an important role of the 37 kDa/ 67 kDa LRP/LR in mediating binding 
and internalization of the prion protein and its involvement in pathological mechanisms 
was demonstrated. 
 
2. Role of LRP/LR as a target in prion diseases 
2.1. Antibodies as therapeutic tools 
Antibodies gained increasing attention in the development of therapeutics for human 
disease. Especially monoclonal antibodies are used in clinical trials and many of them 
already obtained the approval from the U.S. Food and Drug Administration (FDA) for 
therapy e.g. in cancer. Several anti-prion antibodies harboring different formats have 
already been developed antagonizing prion infection [34-38]. However, none of them 
achieved striking results, which render them suitable for application in human 
transmissible spongiform encephalopathies (TSEs). 
The 37kDa/67kDa laminin receptor represents the receptor for the cellular prion protein 
PrPc [2] and a receptor for the infectious PrP27-30 [25], implicating that LRP/LR might 
represent a valuable and alternative target for antibody development in prion disease 
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therapy [35, 39, 40]. Therefore, different antibody formats (Tab. 2, Fig. 2) directed 
against the LRP/LR have been developed to block or prevent binding and internalization 
of the prion protein and therefore a possible infection of cells. 
A polyclonal anti-LRP antibody termed W3 (Fig. 2) reduced the PrPSc propagation in cell 
culture [24], hampered the binding of BSE prions to human enterocytes [41] and 
prevented the binding of PrP27-30 to mammalian cells [25]. Passive immunotransfer of 
W3 into scrapie infected mice significantly reduced peripheral PrPSc propagation by 66% 
and prolonged the survival of scrapie infected mice 1.8-fold [42]. Since the amount of the 
polyclonal antibody W3 is limited, single chain Fv antibodies (scFv) have been selected 
via phage display on recombinant LRP [43]. Due to a smaller size (approx. 30 kDa) they 
display a better tissue penetration, might pass the blood brain barrier, and might therefore 
reach the brain, where prions replicate predominantly. Application of the anti-LRP scFv 
antibody termed S18 via passive immunotransfer into scrapie infected mice reduced PrPSc 
levels in the spleen by approx. 40%, indicating that the peripheral propagation is 
impaired (Fig. 2). The fact that incubation times and survival were not prolonged might 
be explained with the low stability and short half life (approx. 12 hours in blood) of the 
scFvs. To circumvent these problems, we developed a permanent delivery system based 
on recombinant Adeno-associated viral vectors (rAAV). rAAV mediated gene delivery is 
currently investigated in  clinical trials for human therapy. A recent study reported the 
administration of anti-PrP antibodies into scrapie infected mice via rAAV serotype 2, 
which resulted in a delayed onset of disease [44]. Intracerebral injection of rAAVs 
encoding for the anti-LRP/LR scFv antibodies S18 and N3 into scrapie infected mice 
efficiently reduced the peripheral PrPSc propagation by approx. 60% and 32%, 
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respectively [45]. This remarkable finding can be explained by the fact that trafficking of 
intracerebrally administered rAAV to the spleen occurred, resulting in a direct scFv 
expression and secretion [45].  
Although scFvs provide better tissue penetration and probably pass the blood brain 
barrier, a full length IgG format is much more stable in the organism and displays a 
longer half life up to 21 days. In contrast to the small scFvs, only the polyclonal anti-
LRP/LR antibody W3 prolonged survival in scrapie infected mice. Using an improved 
version of the scFv S18 (iS18), as a template for the antigen-binding regions, a full length 
IgG1-iS18 antibody has been engineered [46] and will be applied for prophylaxis and 
treatment of scrapie infected mice expecting a more pronounced effect regarding 
survival. 
The mode of action of the anti-LRP antibodies as a prion disease therapeutic, remains to 
be further investigated. Although an epitope mapping of the anti-LRP antibodies scFv 
S18 and full length IgG1-iS18 exhibits recognition at the very C-terminal part of LRP 
(Fig. 1) and not at the direct PrP binding site (aa161-180) [43, 46], the antibodies might 
act through sterical hindrance preventing the binding of infectious PrPSc to the receptor. A 
full length IgG format reveals higher stability in vivo and provides a higher affinity to the 
laminin receptor resulting in a probable more permanent prevention of the LRP/LR-PrPSc 
interaction. 
 
2.2. Pentosan polysulfate  
Pentosan polysulfate (PPS) is a large polysulfated glycane with weak heparin-like 
activity and has been shown to prevent PrPSc propagation in cell culture models [47]. 
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Recently, it has been proposed that PPS functions via inhibition of the binding of PrPSc to 
LRP/LR [25] (Fig. 2). In mouse models, PPS is able to prolong the survival time of 
scrapie infected animals or even cures of the mouse strains VM and CBA from 22A and 
ME7 prions, respectively [48]. Furthermore, survival time of scrapie-infected mice was 
increased using a combined treatment of PPS and Fe(III)meso-tetra(4-
sulfonatophenyl)porphine [49]. Orally or intraperitoneally administered PPS, however, is 
thought to be not strinkingly effective for the treatment of TSEs due to the assumed 
inability of the drug to cross the blood-brain-barrier [50]. Several case studies for the 
treatment of vCJD in humans were performed showing that delivery of PPS by chronic 
intraventricular infusion resulted in no definite clinical benefits [51, 52]. However, 
continuous intraventricular treatment of a 22-year-old vCJD patient with PPS over a 
period of 31 month resulted in a prolonged survival [53]. In addition, very recently the 
effect of continuous intraventricular infusion of PPS was investigated in seven UK 
patients suffering from human prion diseases. In this report, it has been demonstrated that 
a pentosan polysulfate therapy during 6 months extended the mean survival of all patients 
[54]. Nevertheless, further in vivo animal experiments and clinical studies, respectively,  
are required to assess the efficacy of PPS administration in variant Ceutzfeldt-Jakob 
Disease (vCJD) and other prion diseases. 
 
2.3. RNA interference approaches 
Since the 37kDa/67kDa laminin receptor (LRP/LR) has been identified to act as the cell-
surface receptor for the cellular prion protein [2] it was further discovered that limited 
expression of LRP inhibits PrPSc accumulation in scrapie infected neuronal cells (ScN2a 
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and ScGT1) [24]. Transfection of ScN2a and ScGT1 cells with vectors encoding for 
antisense LRP mRNA led to elimination of LRP expression concomitant with an absence 
of PrPSc propagation [24] (Fig. 2).  In addition, transgenic mice [tgN(NSEasLRP)] were 
generated showing a reduced LRP/LR level in hippocampal and cerebellar brain regions 
and no abnormal behavior compared to control mice [55]. Another approach to knock 
down LRP expression deals with small interfering (si)RNAs directed against the LRP 
mRNA. Transfection of ScN2a cells resulted in a strong downregulation of LRP 
correlating with a complete abolishment of PrPSc propagation 72 hours post transfection 
[24] (Fig. 2).  
These findings lead to the conclusion that post-transcriptional gene silencing of LRP by 
RNAi is a promising approach to delay PrPSc propagation. Further in vivo studies will 
reveal if permanent expression of siRNAs directed against the LRP mRNA might prolong 
incubation time and/or survival during scrapie infection. 
 
2.4. Transdominant negative laminin receptor mutant LRP102-295::FLAG  
The expression of cellular PrP (PrPC) is a major requirement of scrapie infection [56] and 
therefore represents a promising therapeutic target. However, identification of the 
37kDa/67kDa laminin receptor LRP/LR as the receptor for PrPC [2] and PrPSc [25, 41] led 
to an alternative target for the development of TSE therapeutics. Recently, it has been 
shown that an LRP mutant encompassing only the extracellular domain of LRP/LR 
(LRP102-295::FLAG) is secreted into the extracellular space and therefore might act in a 
trans-dominant negative manner as a decoy by trapping PrP molecules [57]. Baby 
hamster kidney (BHK) cells expressing and secreting the laminin receptor mutant show a 
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reduced binding of PrP 27-30, and in scrapie-infected neuronal cells the mutant is able to 
reduce the PrPSc accumulation [57] (Fig. 2). Thus, the transdominant negative LRP-
mutant might have potential for the development of a TSE therapy. An in vivo study with 
transgenic animals expressing the LRP mutant will reveal if the decoy mutant efficiently 
influences incubation time and/or survival during scrapie infection. 
 
3. Role of the 37 kDa/67 kDa laminin receptor LRP/LR in zoonotic diseases 
The phenomenon that the transmission of prion diseases from one species to another 
results in prolonged incubation times and survival compared to those of intraspecies 
transmission is called the “species barrier” [58]. This barrier is due to the variety of prion 
strains encompassing various infectious potential [59]. In natural animal populations the 
intraspecies transmission of prion diseases is much more efficient than an interspecies 
transmission [41], although these efficiencies can vary depending on the animal species, 
the used infectious agent and the route of infection: BSE and sheep Scrapie have a low 
intraspecies transmission efficiency [60, 61] whereas CWD is rapidly transmitted in 
captive deer populations [62] (Fig. 3). Until today, mechanisms underlying an 
intraspecies transmission remain unclear. But prions from one species are often less 
infectious to other species. This is thought to depend on differences in host prion protein 
sequences [63] (Fig. 4) but also may result from sequence differences of the 37 kDa/67 
kDa LRP/LR (Fig. 5). The species barrier of an interspecies transmission is sometimes so 
strong that peripheral injection, oral transmission and sometimes even an intracerebral 
inoculation with the agent causing a transmissible spongiform encephalopathy (TSE) fails 
to develop neurodegenerative signs. Nevertheless, susceptible hosts show clinical signs 
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when they are inoculated with brain homogenates of resistant species [63]. Bovine 
spongiform encephalopathy (BSE) is the only known TSE agent that was transmitted to 
humans causing the zoonotic disease vCJD [64]. Due to the fact that a natural infection 
with prions mostly occurs via oral uptake, like the transmission of BSE to human, further 
analyses were performed to study the initial prion uptake. Enterocytes represent the major 
cell population in the intestinal epithelium and express the 37 kDa/67 kDa LRP/LR on 
their cell surface. It was hypothesized that both enterocytes and the LRP/LR may play a 
major role in oral uptake of infectious prions and the species barrier. Shmakov and 
colleagues demonstrated that the 67 kDa LR is expressed in the apical brush border of the 
small intestine and in the perinuclear region of Paneth cell secretory granules[26]. These 
findings suggest that LRP/LR might play a crucial role in secretory and endocytic 
functions in the human small intestine epithelium and that the consequence of the 
expression of the 37 kDa/67 kDa LRP/LR may result in an increased susceptibility to oral 
infection with prions by LRP/LR mediated uptake by human enterocytes [26]. Studies of 
Morel et al. showed that bovine prions were specifically internalized by human 
enterocytes (Caco-2/TC7 cells) via the LRP/LR, whereas mouse-adapted scrapie prions 
were not endocytozed [41]. It has been demonstrated that BSE prion uptake was 
significantly reduced after preincubating the cells with the anti-LRP/LR antibody W3 
demonstrating that the 37 kDa/67 kDa laminin receptor is required for BSE prion 
internalization [41]. Other studies on oral and parenteral interspecies transmission in 
animals showed that BSE could be transmitted orally to sheep and goat [65], mink [66], 
mouse [67], but not to poultry [65]. Also pigs failed to be susceptible to oral BSE 
transmission [65], whereas a parenteral inoculation was successful [68] (Fig. 6). It still 
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remains unclear whether BSE is transmissible to humans and the mechanism of 
interspecies transmission is not elucidated, so far. But some interspecies interaction 
profiles of prions have already been elaborated employing yeast two-hybrid and 
conversion assays in vitro and transmission studies in vivo (Tab. 4). Further binding 
studies with prions of different species on bovine, porcine, cervid, ovine and human 
enterocytes, respectively, will help to unravel the species barrier in prion disorders and 
will prove whether different animal prions such as CWD or sheep Scrapie might cause 
further zoonotic diseases. 
 
4. LRP/LR as a drug target in cancer 
Both, the 37kDa LRP and the 67kDa LR play an important role in cancer. The 67 kDa 
isoform was first isolated from tumor cells [5] and is termed the high affinity receptor 
due to its strong binding capacity to laminin. Interaction of the LRP/LR with laminin, a 
major cell adhesion substrate, is crucial for the invasion of tumorigenic cells. There are at 
least two binding sites for laminin on LRP, one stretching from aa 205-229 and a second 
so called Peptide G sequence encompassing aa 161-180 [6] (Fig. 1) and comprising a 
heparin dependent laminin binding site [69-71], which is equivalent to the direct PrP 
binding site. The non-integrin laminin receptor LRP/LR is involved in the metastatic 
behavior of neoplastic cells compromising laminin mediated basement membrane 
attachment, accompanied by local degradation and cell movement. Overexpression of the 
67kDa LR has been detected in several cancer tissues (Tab. 3) including gastric cancer 
[72], colon carcinoma [73], colorectal carcinoma [74], cervical [75], breast [76], lung 
[77], ovary [78], pancreatic [79] and prostate cancer [80]. In addition to a proposed 
 15 
prognostic role in the metastatic tumor progression [81, 82], LRP/LR provides a suitable 
target for therapy in cancer. In a murine model it has been demonstrated that human 
fibrosarcoma cells pretreated with an anti-LRP antibody display less lung metastases 
compared to those injected with untreated cells [83]. Furthermore a suppressed LRP 
expression was followed by a reduced lung cancer cell proliferation and in vivo tumor 
formation [84]. 
All mentioned tools targeting the LRP/LR for prion disease therapy, are also suitable for 
a tumor intervening therapy. Blocking or downregulating LRP/LR, significantly reduced 
the invasive potential of tumorigenic human fibrosarcoma cells (HT1080) [46]. Anti-
LRP/LR scFv antibodies, the above mentionend full length format IgG, as well as 
heparan mimetics and pentosan polysulfate efficiently hamper the invasion through the 
perturbance of the laminin-LRP interaction on the cell surface [46]. These data suggest 
that tools targeting LRP/LR might represent effective alternative instruments to interfere 
with metastasis in cancer. Very recently, a critical role of LRP/LR for the maintainance 
of cell viability has been reported [20]. The fact that neoplastic cells such as HT1080 
reveal an increased LRP/LR level compared to non-tumorigenic cells [85] together with 
the finding that LRP/LR prevents apoptotic processes [20] suggests that the receptor has 
multiple effects in cancer development by supporting metastasis and inhibiting apoptosis. 
 
5. Role of LRP/LR in other neurodegenerative and infectious diseases 
5.1. Alzheimer’s Disease (AD) 
Alzheimer´s and prion diseases belong to the group of fatal neurological disorders. Both 
have in common to form amyloid plaques on neuronal tissues. In the case of Alzheimer´s 
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disease (AD) the cleavage of the amyloid β precursor protein (APP) is thought to be the 
crucial process causing AD by producing the Aβ-peptide (Aβ) [86]. In the non-
amyloidogenic pathway APP is cleaved by the α- and γ-secretase and the emerging 
soluble peptides are shedded into the extracellular matrix (Fig. 7). However, if the 
proteolytic processing of APP is performed by β- and γ-secretase, the emerging β-peptide 
(Aβ) which is secreted into the extracellular matrix, accumulates in amyloid plaques on 
neurons, accompanied by neurotoxic effects and neurodegeneration. Tau-fibres may 
additionally contribute to the development of the Alzheimer disease phenotype [87]. 
In prion diseases, misfolding of cellular prion protein (PrPc) to a proteinase K resistent 
and infectious isoform PrPSc is thought to be the causative pathogenic mechanism of 
TSEs. PrPc passes through the secretory pathway and is then anchored to the cell surface 
by a glycosyl phosphatidyl inositol (GPI) anchor. 
It has been shown that cellular PrP has a regulatory effect on the β-secretase cleavage of 
APP [88]. Overexpression of PrPc inhibited β-secretase cleavage and reduced Aβ 
formation in neuronal cells [88]. Vice versa downregulation of PrPc by RNAi leads to the 
secretion of increased amounts of Aβ into the cell culture medium [88]. Additionally, PrP 
is suggested to inhibit β-secretase (BACE1, β-site APP cleaving enzyme) activity 
involving interaction with glycosaminoglycanes [88].  
The 37kDa/67kDa LRP/LR has been shown to act as a receptor for both, PrPC [2] and the 
pathogenic isoform  PrPSc [25, 41]. LRP/LR interacts with PrP via an indirect binding 
domain depending on the presence of heparan sulfate proteoglycans (HSPGs) [25] which 
belong to the group of GAGs. LRP/LR and APP share the same subcellular localization 
on the cell surface. Therefore, it is conceivable that LRP/LR might be involved in 
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secretase mediated cleavage of App and shedding of APPsα, APPsβ and the β-peptide. 
 
5.2. Viral diseases 
As an initial step in viral diseases, most viruses enter the host cell by receptor-mediated 
endocytosis. Several protein receptors have been identified as initial virus attachment 
receptors including human immunodeficiency virus (HIV) which use the chemokine co-
receptors CCR5 and CXCR4 in addition to the CD4 receptor  [89] and the Epstein-Barr 
virus that is associated with infectious mononucleosis and the development of cancer, 
respectively, and use the complement receptor CR2 [90]. For alphaviruses, e.g. Sindbis 
Virus, the high-affinity laminin receptor has been described as major receptor in 
mammalian cells [18] (Tab. 1). Hamster cells, that overexpress the laminin receptor at the 
cell surface were more susceptible to a Sindbis virus infection compared to cells 
transfected with the antisense gene. Moreover, it has been demonstrated that the 67kDa 
laminin receptor also functions as the Sindbis virus entry receptor in mosquitos [18]. In 
addition, the 37kDa/67kDa laminin receptor has been identified as a receptor for (i) 
dengue virus, which is the causative agent of dengue fever and dengue hemorrhagic 
fever, in human liver cells [91], porcine kidney cells [19] and mosquito cells [92], 
respectively, and (ii) for several AAV subtypes [17] (Tab. 1). Thus, the identification of 
the 37kDa/67kDa LRP/LR as an initial entry receptor for mosquito-borne viral diseases 
opened up new vistas to establish a specific receptor-based antiviral prophylaxis and/or 
therapy. 
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ABBREVIATIONS 
 
LRP/LR    = laminin receptor precursor/laminin receptor 
PrP (PrPc, PrPSc, PrP27-30)  = prion protein (cellular form, scrapie form,  
protease-resiostant core) 
GPI     = glycosylphosphatidylinositol 
TSE     = Transmissible Spongiform Encephalopathy 
CJD, vCJD    = Creutzfeldt-Jakob Disease, variant  
Creutzfeldt-Jakob Disease 
BSE     = Bovine Spongiform Encephalopathy 
CWD     = Chronic Wasting Disease 
HSPG     = heparan sulfate proteoglycan 
GAG     = glycosaminoglycan 
PPS     = pentosan polysulfate 
siRNA     = small interfering ribonucleic acid 
AD     = Alzheimer’s Disease 
APP     = amyloid precursor protein 
Aβ     = amyloid beta protein (proteolytic fragment  
of APP) 
FDA     = U.S. Food and Drug Administration 
AAV     = Adeno-Associated Virus 
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Fig. (1). Functional domains of the 37kDa/ 67kDa laminin receptor LRP/LR. 
LRP/LR consist of 295 amino acids (aa) and belong to the group of Type II membrane 
proteins, spanning the plasma membrane once (aa 86-101) with its C-terminus exposed to 
the extracellular space.  PrP/ Laminin and Heparin/ Laminin binding sites have been 
characterized at aa positions 161-180 and 205-229, respectively. In addition, the scFv/ 
IgG1 antibody binding site has been mapped to aa 272-280. 
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Fig. (2). Therapeutic approaches targeting LRP/LR. 
LRP/LR (yellow oval) has been identified as receptor for cellular (dark green circle) and  
infectious prions (light green square). Several strategies can be employed to interfere 
with either the expression of LRP/LR (a, b) or binding of PrPSc (c-f). To ablate LRP/LR 
expression an antisense RNA (a) and a small interfering RNA (b) approach have been 
used resulting in prevention of PrPSc propagation in scrapie-infected cells [24]. Both the 
polyclonal anti-LRP/LR antibody W3 (blue immunoglobuline structure) (c) and the 
single chain (scFv) anti-LRP/LR antibody S18 (blue single chain antibody structure) (d) 
have been shown to interfere with the PrPSc propagation [24, 42, 43]. In addition, drugs 
such as pentosan polysulfate (PPS) (blue triangles) (e) were able to reduce PrPSc binding 
in vitro [25] possibly due to an inhibition of the LRP/LR-dependent binding of prions to 
the  cell. As an alternative therapeutic system, a LRP/LR decoy mutant (LRP102-
295::FLAG) (yellow semi-oval) (f) has been used to interfere with the PrPSc propagation 
in scrapie-infected neuroblastoma cells [57]. 
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Fig. (3). Intraspecies transmission efficiencies of TSEs. 
Experimental transmission of prion diseases have been performed to examine 
neuropathological profiles, risk factors and incidence rates. A long-term cohort study in 
cows investigating maternally-associated risk factors for BSE revealed a statistically 
significant risk of 10% for a transmission to the offspring [60]. For an intraspecies 
transmission of sheep scrapie, a rate of 25-40% has been calculated [62]. Chronic wasting 
disease (CWD) is naturally transmitted with remarkably efficacy of approximately 90% 
that has been studied in a captive mule deer herd [60]. 
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Fig. (4). Comparison of amino acid sequences of the direct and indirect PrP binding 
sites for LRP/LR in different species. 
PrP comprises two binding sites for LRP/LR, a direct (aa 144-179) and an indirect one 
(aa 53-93), that is medated by HSPGs [3]. (a) Sequence alignment for the direct PrP 
binding site in human, cervid, ovine, bovine and porcine PrP resulted in no sequence 
homology, whereas the (b) alignment for the indirect PrP binding domain for cervid, 
ovine, bovine and porcine PrP, respectively, revealed approximately 95% sequence 
identity (green). 
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Fig. (5). Comparison of amino acid sequences of the direct and indirect LRP/LR 
binding sites for PrP in different species. 
Binding of LRP/LR to PrP occurs via a direct binding site located between aa 161-179 
and an indirect HSPG-dependent domain encompassing aa 180-295 [3]. (a) Sequence 
alignment of the direct LRP/LR binding site for PrP resulted in complete identical 
sequences for the human, ovine, bovine and porcine proteins. (b) Human, ovine, bovine 
and porcine sequences, respectively, of the indirect LRP/LR binding domain showed 
approximately 90% homology (green). 
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Fig. (6). Oral and parenteral interspecies transmission of BSE. 
Obviously, a transmission of BSE to humans can not be tested due to ethical reasons. 
Oral transmission of the BSE agent (green arrows) has been performed succesfully to 
sheep and goats [125], minks [66], mice [67] and cows [126], respectively. However, 
several experiments demonstrated the existence of a species barrier for the oral 
transmission of TSEs (crossed green arrow), e.g. in elk and deer, pigs [127] and poultry 
[65], respectively, and parenteral transmission (= circumvention of the intestinal tract, 
crossed blue arrows) to elk. Interestingly, in pigs, a parenteral BSE transmission (blue 
arrow)  has been reported to be succesful [128]. Furthermore, the BSE agent has been 
effectively parenteral transmitted to cattle [126], sheep and goats [125], minks [Bradley, 
Paris Symposium, 1996] and deer [129]. 
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Fig. (7). Overview of the non-amyloidogenic and amyloidogenic APP pathway. 
(a) In the non-amyloidogenic pathway, APP (Amyloid β precursor protein) is 
proteolytically cleaved by the α-secretase (red arrow), member of the ADAM (a 
disintegrin and metalloprotease domain) family. A soluble fragment (sAAPα) is secreted 
into the extracellular space and the C-terminal domain stays membrane-bound. 
Afterwards the γ-secretase (blue arrow) cleaves within membrane-bound C-terminus and 
releases a soluble peptide (p3, light green cuboid) of approximately 3kDa. The γ-
secretase minimally consists of 4 individual proteins: the presenilins (aspartyl proteases) 
form the catalytic subunit, nicastrin, APH-1 (anterior pharynx-defective 1) and PEN-2 
(presenilin enhancer). (b) In the amyloidogenic pathway, APP is first cleaved by β-
secretase (green arrow) (BACE1, β-site APP cleaving enzyme), releasing a soluble 
fragment (sAPPβ) into the extracellular space, followed by γ-secretase cleavage. 
Thereby, the amyloid β peptide (Aβ, dark green), which is the primary constituent of 
Alzheimer’s Disease (AD), is shed off the cell surface and aggregate in the brain od AD 
patients. 
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Tab. 1. General conspectus of LRP/LR and HSPGs as initial attachment receptors 
for viruses 
Viruses using LRP/LR as 
receptor 
Reference Viruses using HSPGs as 
receptors 
Reference 
Dengue Virus  
(Serotype 1, 2, 3) 
[19] Adeno-Associated Virus  
(Serotype 1,6) 
[93] 
Sindbis Virus [18, 94] Adenovirus (Serotype 2, 5) [95] 
Venezuelean Equine 
Encephalitis Virus  
[16] Human Papilloma Virus [96] 
Adeno-Associated Virus  
(Serotype 2, 3, 8, 9) 
[17] Hepaptitis B Virus 
Hepatitis C Virus 
[97] 
[98] 
  Human Immunodeficiency 
Virus 
[99] 
  Murine Leukaemia Virus [100] 
  Herpes Simplex Virus Type 1 [101] 
  Pseudorabies Virus [102] 
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Tab. 2. Anti-LRP/LR tools as therapeutics in prion diseases 
 
Effect in vivo Anti-LRP/LR 
tools 
Effect in 
vitro 
Application in 
vivo 
 
Peripheral 
PrPSc 
propagation 
Incubation 
time 
survival 
Reference 
Antibodies 
Polyclonal 
antibody W3 
blocks PrPSc 
propagation 
and cures 
scrapie 
infected 
cells 
passive 
immunotransfer 
via i.p. 
injection 
reduced by 
66% 
no 
prolongation 
1.8 fold 
prolongation 
[42] 
passive 
immunotransfer 
via i.p. 
injection 
reduced by 
40% 
no 
prolongation 
no 
prolongation 
 
[43] Single chain 
Fv antibody 
scFv S18 
n.d. 
delivery by i.c. 
injection of 
rAAV 
reduced by 
60% 
no 
prolongation 
no 
prolongation 
[45] 
Laminin receptor decoy mutant 
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LRP102-
295::FLAG 
Reduces 
PrPSc 
propagation 
in 
transfected 
N2aSc+ 
cells  
 
 
Generation of 
transgenic mice 
in progress in progress in progress [57] 
3 Strategies downregulating LRP/LR expression 
Antisense LRP 
RNA 
Prevents 
PrPSc 
propagation 
in 
transfected 
ScMNB 
cells 
Generation of 
transgenic mice 
n.d. n.d. n.d. [24, 55] 
LRP-specific 
siRNAs 
Prevents 
PrPSc 
propagation 
in 
transfected 
N2aSc+ 
cells 
i.c. injection of 
lentiviral 
particles 
expressing 
siRNAs (gene 
therapy) 
in progress in progress in progress [24] 
 
Anti-LRP/LR tools blocking or downregulating the 37kDa67kDa LRP/LR were applied 
in cell as well as in animal studies to investigate their potential in prion diseases. 
i.p. intraperitoneal; i.c. intracerebral, n.d. not determined; ScN2a+ Scrapie infected mouse 
neuroblastoma cells; ScMNB Scrapie mouse neuroblastoma cells; 
peripheral PrPSc propagation was determined analysing the PrPSc content in the spleen of 
scrapie infected mice 90 days pot infection; incubation time describes the time span from 
 29 
the scrapie infection until the mice display the first TSE relevant symptoms (Ataxia of 
gait, tremor, rigidity in the tail or difficulty righting from a supine position). Survival 
represents the time span from the day one of the four TSE symptoms occur until the day 
two of these symptoms are observed for three days. 
 
 
Tab. 3. Expression of the 67kDa LR has been reported in human tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human tumors with LR expression Reference 
Colorectal carcinoma [74] 
Colon cancer  [103] 
Cervical preneoplastic and neoplastic squamous 
epithelial lesions 
[75] 
Gastric adenocarcinoma  [104] 
Breast carcinoma   [76, 105] 
Acute myeloid leukemia (AML) [106] 
Human laryngeal sqamous cell carcinoma [107] 
Human small cell lung cancer [108] 
Prostate cancer [80] 
Ovarian carcinoma [78] 
Uterine adenocarcinoma  [109] 
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Tab. 4. Comparison of interspecies interactions in the Yeast Two-Hybrid System with 
interconversion studies by in vitro Conversion and transmission in transgenic and 
non-transgenic animals. 
PrP 
species 
PrP 
species 
Interspecie
s 
interaction
s by yeast 
two-hybrid 
system 
Interconversio
n by in vitro 
conversion 
assays 
Interspecies 
transmission 
in transgenic 
mice 
Interspecies 
transmission in 
animals 
Human Cattle + + [110]       +  [64, 111]    + [112-114] 
Sheep Cattle + + [115]   + [116, 117]    + [118, 119] 
Sheep Human + + [110]       + [116]             n.d. 
Hamster Human - -        n.d. 
Via guinea pigs 
[120] 
Hamster Cattle - - [115]        n.d. - [65] 
Cervid Cattle n.d. n.d.        - [121] n.d. 
Cervid Human n.d. n.d.     - [121, 122] n.d. 
Cervid Sheep n.d. n.d.       + [122] n.d. 
Mouse Human n.d. + [123]        - [124] n.d. 
Mouse  Sheep n.d. n.d.       + [124] n.d. 
Mouse Hamster n.d. n.d.       + [124] n.d. 
 
“+” : Interaction in described system 
“- “ : No interaction in described system 
“n.d.” : not determined 
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AbStrACt
We identified the 37kDa/67kDa laminin receptor (LRP/LR) as a cell surface receptor 
for the cellular prion protein (PrPc) and the infectious prion protein (PrPSc). Recently, we 
showed that anti‑LRP/LR antibody W3 cured scrapie infected N2a cells. Here, we demon‑
strate that W3 delivered by passive immunotransfer into C57BL/6 mice reduced the PrPSc 
content in the spleen significantly by 66%, demonstrating an impairment of the peripheral 
PrPSc propagation. In addition, we observed a 1.8‑fold increase in survival of anti‑LRP/LR 
antibody W3 treated mice (mean survival of 31 days) compared to preimmune serum 
treated control animals (mean survival of 17 days). We conclude that the significant effect 
of anti‑LRP/LR antibody W3 on the reduction of peripheral PrPSc propagation might be 
due to the blockage of the prion receptor LRP/LR which is required, as previously shown 
in vitro, for PrPSc propagation in vivo.
IntroduCtIon
Transmissible spongiform encephalopathies (TSE) are a group of neurodegenerative 
protein-misfolding diseases, also known as prion diseases affecting both animals including 
scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting 
disease (CWD) in elk and deer as well as humans (e.g., Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker (GSS) syndrome and fatal familial insomnia (FFI)) (for 
review see refs. 1–4). Affected individuals display rapidly progressive symptoms due to 
various effects such as gliosis, astrocytosis, neuronal loss and spongiosis.
TSEs are associated with an abnormal form of the prion protein, termed PrPSc. The 
conversion of the host encoded PrPc into the disease associated isoform (PrPSc) results in 
accumulation which is perpetuated by an autocatalytic process.5,6 Although various thera-
peutic approaches have already been developed (for review see refs. 7–11), no treatment 
was available until now, which is able to cure affected individuals. The first successful 
approach in antibody-based therapies was the passive immunotransfer of a monoclonal 
anti-PrP antibody which cured rodents peripherally infected with PrPSc.12 Besides mono-
clonal antibodies targeting the prion protein,13,14 also single chain anti-PrP antibodies are 
currently investigated for a TSE therapy.15
Among many interaction partners identified for PrPc,10,16-18 the non-integrin 37/67 
kDa laminin receptor (LRP/LR) has been discovered as a receptor for both the cellular 
PrPc 19,20 and the disease associated PrPSc.21,22 Downregulation of LRP/LR by antisense 
LRP RNA or siRNAs directed against LRP mRNA abrogates PrPSc propagation in ScN2a 
cells.23 Secretion of a transdominant negative LRP mutant also abolishes PrPSc propag-
tion in neuronal cells.24 A polyclonal anti-LRP/LR antibody termed W3 interferes with 
PrP27-30 cell binding21 and internalization of bovine PrPSc by human enterocytes.22 
Most notably, W3 has been shown to cure PrPSc propagating cells from scrapie.23 In order 
to investigate whether W3 is able to hamper prion propagation in vivo, we delivered W3 
into mice by passive immunization. Spleen analysis confirmed a significant reduction in 
peripheral PrPSc propagation in W3 treated mice. Moreover, W3 treated mice revealed 
a 1.8-fold increase in survival (the time span from the day one of the four TSE-relevant 
symptoms occur until the day mice show two of the four TSE-relevant symptoms over 
three days25) compared to the control group injected with preimmune serum. Our results 
suggest that LRP/LR plays an important role for PrPSc propagation in vivo and that 
targeting LRP/LR is a relevant strategy for therapy in prion diseases.
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www.landesbioscience.com Prion 207
©2
008
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
In Vivo Effects of LRP/LR Antibody W3 
MAterIAlS And MetHodS
Antibodies and preimmune serum. In order to get the polyclonal 
anti-LRP antibody pAb W3, we immunized albino rabbits [(New 
Zealand; ZRL:kbl (nzw)br; Charles River Breeding Laboratories, 
Wilmington, Massachusets)]. One mililiter of a mixture of GST::
LRP fusion protein expressed in E. coli system26 and CWS adjuvant 
(RIBI adjuvant, Sigma) was subcutaneously injected into rabbits 
(see ref. 27). After 28 days, animals were boosted and after additional 
14 days the animals were immunized a third time. Eleven days later 
200 ml of blood were collected and coagulated for one hour at 37°C 
and incubated over night at 4°C followed by two centrifugation steps 
ten minutes at 9,000 rpm and 10.500 rpm at 4°C. Purification was 
done using a protein A sepharose column (Pierce, Rockford, Illinois). 
W3 was selected from several anti-LRP sera tested for recognition 
efficiency of LRP/LR by FACS and western analysis.27 Preimmune 
serum was obtained from rabbit prior to immunization.
Passive immunotransfer of anti‑LRP/LR antibody W3 into mice. 
Animals were maintained and treated in accordance with ethical 
guidelines of Bavaria. Experiments were approved by the Regierung 
von Oberbayern (Munich, Germany, Ar.: 209.1/211-2531-83/04). 
For infection studies C57BL/6 mice were injected intraperitoneally 
(i.p.) with a total amount of 1 mg of W3 or preimmune serum. 
Treatment was performed once per week over a period of 12 weeks. 
One week after the first antibody injection mice were inoculated i.p. 
with 100 ml 10% RML Scrapie homogenate. The time span from 
the day of RML inoculation until one of the four symptoms: ataxia 
of gait, tremor, difficulty righting from a supine position and rigidity 
in the tail occured (termed as symptom onset) and survival (the time 
span from the day one of the four TSE-relevant symptoms occur 
until the day mice show two of the four TSE-relevant symptoms 
over three days25) were monitored. In all monitoring procedures the 
investigators were blinded as to the experimental groups individual 
mice belonged to.
Analysis of PrPSc and total PrP levels in the spleen of RML 
inoculated mice. Ninety days post RML inoculation six mice per 
group were sacrificed for analysis of peripheral PrPSc propagation. 
Spleens were collected and homogenized in PBS buffer. Adjusting 
the total protein amount to 200 mg, samples were digested with 
Proteinase K to a final concentration of 20 mg/ml for 60 minutes 
at 37°C. Samples were analysed on a 12% SDS PAGE and 
blotted onto a PVDF membrane. Immunodetection was performed 
using SAF83 as the primary and anti-mouse-POD conjugate 
(Jackson Immunoresearch) as the secondary antibody. Blots were 
developed using an enhanced chemiluminescence system (Perkin 
Elmer Lifescience) and exposed on Kodak Biomax light films. 
Quantification of the western blot signals was carried out by densi-
tometric measurements using the Image J software. To determine the 
total PrP amount, spleen samples were treated as described for the 
PrPSc detection but without a Proteinase K treatment. For total PrP 
detection SAF32 was used as the primary and anti-mouse-IgG-POD 
as the secondary antibody.
Analysis of PrPSc and total PrP levels in the brain of terminal 
mice. Mice were sacrified after two of the four characteristical 
TSE symptoms25 were detected for a period of three days. Total 
brain samples of six mice per group were collected and homog-
enized in PBS buffer. Protein levels were adjusted to 200 mg per 
sample and digested with Proteinase K to a final concentration 
of 20 mg/ml for 60 minutes at 37°C. The PrPSc content was 
determined by analysis on a 12% SDS PAGE and blotted onto a 
PVDF membrane. Immunodetection was performed using SAF83 as 
the primary and anti-mouse-IgG-POD (Jackson Immunoresearch) 
as the secondary antibody. Blots were developed using an enhanced 
chemiluminescence system (Perkin Elmer Lifescience) and exposed 
on Kodak Biomax light films. Quantification of the western blot 
signals was carried out by densitometric measurements using the 
Image J software. To determine the total PrP amount total brain 
samples were treated as described for PrPSc detection in the absence 
of Proteinase K treatment. Detection for total PrP was carried 
out using SAF32 as the primary and anti-mouse-IgG-POD as the 
secondary antibody.
Statistical analysis. Statistical analyses were performed employing 
a Student’s t test with two tailed distribution and two-sample 
unequal variance.
reSultS
Anti‑LRP/LR antibody W3 reduces peripheral PrPSc prop‑ 
agation. One milligram per week of anti-LRP/LR antibody W3 and 
preimmune serum was intraperitoneally injected into scrapie infected 
mice for a period of 12 weeks (Fig. 1). One week after the first 
injection mice were intraperitoneally inoculated with RML Scrapie 
homogenate and monitored for symptom onset (incubation times) 
and survival (Fig. 1). W3 and preimmune serum treated mice were 
controlled daily and showed normal behavior till they were sacrificed. 
No side effects were detectable at any time points.
Western blot analysis of the spleen of W3 treated mice 90 days post 
inoculation revealed a significant reduction of the PrPSc level by 66% 
compared to the preimmune serum treated mice (Fig. 2A and B), 
suggesting that W3 reduces significantly peripheral PrPSc propaga-
tion. The amount of total PrP (PrPSc plus PrPc) was reduced by 
approx. 40% (Fig. 2C and D) in W3 treated mice, suggesting that 
PrPc levels remain unaffected by the antibody treatment.
Anti‑ LRP/LR antibody W3 prolongs the survival in scrapie 
infected mice. Anti-LRP/LR antibody W3 treated mice did not 
show a prolongation of incubation times compared to the preim-
mune serum treated control group (Fig. 3A and Table 1). However, 
the anti-LRP/LR antibody W3 treated mice revealed a mean survival 
of 31 days, which represents a 1.8-fold prolongation of the survival 
in comparison with the preimmune serum (mean survival 17 days) 
treated control group (Fig. 3B, C and Table 1).
At the terminal state the PrPSc level in the brain of W3 treated 
mice was reduced by 17% compared to preimmune serum treated 
mice (Fig. 4A and B), whereas W3 and preimmune serum treated 
mice showed no alteration in the total PrP content (Fig. 4C and D), 
suggesting that PrPc levels remained unaltered in both experimental 
groups.
dISCuSSIon
At present no therapeutic strategy is available for the treatment 
of TSEs which cures prion diseases.8,9,11,28,29 Since the laminin 
receptor acts as a receptor for PrPc,30 and PrPSc,21 LRP/LR exhibits 
a promising target for therapeutic strategies in prion diseases. The 
anti-laminin receptor polyclonal antibody W3 was well efficient 
in vitro by curing scrapie propagating cells from PrPSc.23 In order 
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Figure 2. Analysis of total PrP and PrPSc levels in the spleen of scrapie infected mice treated with polyclonal anti‑LRP antibody W3 and preimmune serum 
90 days post infection. LRP/LR antibody W3 and preimmune serum was intraperitoneally injected into C57BL/6 mice for 12 weeks. C57BL/6 mice were 
intraperitoneally inoculated with RML prions (10%) one week after the first antibody/preimmune serum injection. (A) Spleen of C57BL/6 mice were collected 
90 days post infection and analyzed for the PrPSc content after Proteinase K digestion by Western blotting using anti‑PrP antibody SAF 83. Western blot 
analysis of the PrPSc levels in the spleen of three W3 and three preimmune serum treated mice are shown. b‑actin was used as a loading control (detection 
by an anti‑b‑actin antibody). (B) Densitometric measurements of Western blots from six spleens per group revealed a significant reduction of the PrPSc level 
by 66% in the W3 treated group compared to the preimmune serum treated group, for which the PrPSc level was set to 100% (*p < 0.05). Quantification 
of PrPSc signals were normalized by b‑actin levels. Quantification of the western blot signals was carried out by densitometric measurements using the Image 
J software (mean + SD). (C) Spleen samples of C57BL/6 mice (collected 90 days post infection) were analyzed for quantification of the total PrP content 
by western analysis using anti‑PrP antibody SAF 32. Western blot analysis of the PrP levels (in the absence of Proteinase K) in the spleen of three W3 and 
three preimmune serum treated mice is shown. b‑actin was used as a loading control (detection by an anti‑b‑actin antibody). (D) Densitometric measurements 
of western blots from six spleens per group revealed a reduction of total PrP content by 39% in the W3 treated group compared to the preimmune serum 
treated group, for which the total PrP level was set to 100% (p < 0.2). Quantification of total PrP signals were normalized by b‑actin levels. Quantification 
of the western blot signals was carried out by densitometric measurements using the Image J software (mean + SD).
Figure 1. Schematic overview of the passive immunotransfer modalities. One milligram of antibody (either W3 or preimmune serum) per C57BL/6 mouse 
was intraperitoneally injected seven days prior to intraperitoneal inoculation with 10% RML brain homogenate. Antibodies injections (i.p.) were performed 
at doses of 1 mg per week for a period of 11 weeks. Treatment was terminated 77 days post inoculation. Ninety days post inoculation, animals were 
sacrificed for analysis of the PrPSc and total PrP content of the spleen. Incubation times represent the time span from the day of RML inoculation until one of 
the four symptoms occur: ataxia of gait, tremor, difficulty righting from a supine position and occurrence of rigidity in the tail. Survival represent the time 
span from the day one of the four TSE‑relevant symptoms occurs until the day mice show two of the four TSE‑relevant symptoms over three days.25 At this 
time point mice were sacrificed followed by determination of the PrPSc and total PrP content in the brain.
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to prove an in vivo effect of W3 on (1) 
peripheral PrPSc propagation and (2) 
prolongation of survival, we passively 
transferred W3 into C57BL/6 mice by 
intraperitoneal injections followed by 
i.p. RML prion inoculations. W3 treated 
mice revealed a significant reduction 
(66%) of the peripheral PrPSc propaga-
tion compared to preimmune serum 
treated mice as analyzed by determining 
the PrPSc levels in the spleen. Total PrP 
levels (PrPSc plus PrPc) in the spleen were 
reduced by approx. 40%, suggesting that 
W3 treatment has no or only a weak 
influence on the reduction of PrPc levels 
in the spleen.
In addition, W3 treated mice 
revealed a 1.8-fold increase in survival 
(31 days) compared to the preimmune 
serum treated control group (17 days), 
suggesting that W3 also hampers PrPSc 
propagation in the central nervous system 
contributing to prolongation of survival. 
Moreover, this is of potential interest for 
treatment of CJD patients because the 
effects were observed during the clinical 
stages, when mice had already neurolog-
ical symptoms (prolongation of survival 
time from onset of the disease to death). 
Due to the limited amount of the poly-
clonal antibody W3, which was raised 
against LRP in a rabbit,27 we could not 
elongate the antibody treatment over the 
12 weeks treatment period and could not 
increase the number of animals and/or 
the dose of antibody applied (1 mg) which all together might have 
resulted in an even more obvious effect on the increase in survival. In 
contrast to survival, incubation times were not affected. We assume 
that by increasing the antibody amount and the time period of treat-
ment, the incubation time might also be prolonged. Application of a 
monoclonal anti-PrP antibody in mice with 2 mg of antibody twice 
a week resulted in a delayed onset of the disease.12 Many promising 
anti-prion drugs which are effective in vitro failed to be active also 
in vivo (reviewed in ref. 9). Among them, are the antimalaria drugs 
mefloquine31 and quinacrine.32 In contrast, W3 is effective both 
in vitro23 and in vivo. Currently, the efficacy of doxycyclin in the 
treatment of CJD is under investigation in observational studies in 
Milano (Italy) and Göttingen (Germany). First data indicate that 
administration of doxycyclin might prolong the survival by two-fold. 
In the German study on 23 patients, the survival was prolonged 
from four months (median in sCJD) to eight months. Whether the 
prolongation time is due to a specific prion effect, will be tested in 
a prospective double blind study. No conclusions can be drawn, 
Figure 3. Symptom onset (Incubation times) and survival in scrapie infected C57BL/6 mice treated with poly‑
clonal anti‑LRP antibody W3 and preimmune serum. C57BL/6 mice were intraperitoneally inoculated with 
RML prions one week after the first antibody/preimmune serum injection and monitored for the occurrence 
of characteristic TSE symptoms. Symptom onset (Incubation times) represents the time span from the day 
of RML inoculation until the day one of the four symptoms appear: ataxia of gait, tremor, difficulty righting 
from a supine position and occurance of rigidity in the tail.25 Survival represents the time span from the 
day one of the four symptoms occurs until the day mice show two of the four TSE‑relevant symptoms over 
three days.25 At this time point, mice were sacrificed. (A) Kaplan‑Meier curve (symptom onset) showing 
percent of animals free of symptoms dependent from days post RML inoculation. 20% of the W3 treated 
animals revealed a prolonged symptom onset compared to the preimmune serum control group (p < 0.2). 
(B) Kaplan‑Meier curve (symptom onset plus survival) showing percent of animals alive dependent from 
days post RML inoculation. (C) Survival (days) of W3 and preimmune serum treated animals. The median 
revealed a 1.8‑fold prolonged survival for the W3 treated group compared to the control group injected 
with preimmune serum (p < 0.19) (mean + SD).
Table 1	 Incubation	times	and	survival	of	scrapie	infected	mice	treated	with	W3	and	preimmune	serum
experimental  Incubation times,  Survival, days  Incubation times +  number of Mice  
Group days (Mean+/‑ Sd) (mean+/‑ Sd) Survival, days (Affected/ Inoculated) 
   (mean+/‑ Sd)
preimmune serum 169,5 ± 1,2 17,5 ± 7,2 187,8 ± 10,6 6/6
W3    171 ± 1,78  31,4 ± 16 (1.8‑fold          202,2 ± 18,4       5/5 
      increase in survival)  
LRP/LR antibody W3 and preimmune serum was intraperitoneally injected into C57BL/6 mice (1 mg per week) for a period of 12 weeks. C57BL/6 mice were intraperitoneally inoculated with RML prions one week after 
the first antibody/preimmune serum injection. Incubation times represent the time span from the day of RML inoculation until one of the four symptoms occur: ataxia of gait, tremor, difficulty righting from a supine 
position, and occurrence of rigidity in the tail.25 Survival represent the time span from the day one of the four TSE-relevant symptoms occurs until the day mice show two of the four TSE-relevant symptoms over three 
days.25 At this time point mice were sacrificed.
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however, regarding a potential prolongation of incubation times in 
CJD patients by doxycyclin. A combination therapy with doxycyclin 
and antibodies targeting LRP/LR might have some additive or even 
synergistic effects.
On the molecular level LRP/LR specific antibody W3 blocks 
(1) PrPc binding to neuronal cells,30 (2) PrP27-30 binding to 
mammalian cells21 and (3) BSE prion internalization by human 
enterocytes,22 suggesting that the antibody interferes with PrPc and 
PrPSc internalization processes prohibiting as a consequence PrPSc 
propagation, which might occur in compartments of the endocytic 
pathway rather than on the cell surface (for review see refs. 8 and 10). 
In scrapie infected mice, we show that W3 is able to interfere 
efficiently with peripheral PrPSc propagation, which takes place 
in organs of the lymphoreticular system such as the spleen. At the 
time point when the animals were sacrificed (at the day when two 
TSE-associated symptoms appeared for three days25) the detected 
PrPSc levels in the brain were not significantly different between W3 
treated and preimmune serum-treated mice, suggesting that PrPSc 
propagation was not delayed in the brain of W3 treated animals. 
The total PrP content at the terminal state in the brain of mice 
treated with W3 and preimmune serum was unchanged, suggesting 
that also PrPc levels in the brain were not affected by W3 treatment.
Taken together, this pilot study revealed important results regarding 
an antibody therapy or post-exposure prophylaxis with W3 resulting 
in a signifcant reduction of peripheral PrPSc propagation and a slight 
prolongation of survival. Since we started the antibody treatment seven 
days prior to PrPSc inoculation and terminated the treatment 77 days 
post PrPSc inoculation (long before first symptoms occur) (Fig. 1), 
we preformed in this study a post-exposure prophylaxis rather than 
a therapy, which is usually initiated at the stage when first symptoms 
appeared.
Since the amount of W3 is limited, we generated in a parallel study 
single chain antibodies (scFv) directed against LRP/LR by phage 
display.33 Passive immunotransfer of the scFv S18 by intraperitoneal 
injections into scrapie infected mice also resulted in a reduction of 
the PrPSc level in the spleen by approx. 40% without a significant 
prolongation of incubation times and survival.33 W3 reduced PrPSc 
levels in the spleen significantly by 66% and slightly prolonged the 
survival 1.8-fold. One of the reasons for the slightly better efficacy of 
W3 compared to scFv S18 might be the longer half-life of full-length 
IgGs in the blood (approximately 14 days) compared to single chain 
antibodies (approximately 12 hours). The amount of antibody 
(1 mg per week) was the same for both studies although the duration 
of antibody treatment was different (eight weeks for scFv S18 versus 
12 weeks for W3). A polyclonal serum raised against a specific antigen 
(here LRP/LR) contains approximately 5–10% antibodies directed 
against this antigen.34 Therefore approximately 50–100 mg of LRP/
LR specific antibodies per week were injected in the present study, 
Figure 4. Analysis of total PrP and PrPSc levels in the brain of scrapie infected mice treated with polyclonal anti‑LRP antibody W3 and preimmune serum 
at the terminal state. LRP/LR antibody W3 and preimmune serum was intraperitoneally injected into C57BL/6 mice for 12 weeks. One week after the first 
antibody/preimmune serum injection C57BL/6 mice were intraperitoneally inoculated with RML prions (10%). (A) Mice were sacrificed after showing two 
of the four characteristical TSE symptoms25 over three days (terminal state) and total brain was analyzed for the PrPSc content (after Proteinase K diges‑
tion) by Western blot analysis using anti‑PrP antibody SAF 83. PrPSc levels in total brain samples of three W3 and three preimmune serum treated mice 
are shown. b‑actin was used as a loading control (detection by an anti‑b‑actin antibody). (B) Densitometric measurements of Western blots from six brain 
samples per group revealed a reduction of PrPSc levels by 17% in the W3 treated group compared to the preimmune serum treated group, for which the 
PrPSc level was set to 100% (p < 0.3). Quantification of PrPSc signals were normalized by b‑actin levels. Quantification of the Western blot signals was car‑
ried out by densitometric measurements using the Image J software (mean + SD). (C) Total brain samples of terminal C57BL/6 scrapie infected mice were 
analysed for the total PrP content (in the absence of Proteinase K) by Western blot analysis using anti‑PrP antibody SAF 32. Total PrP levels in total brain 
samples of three W3 and three preimmune serum treated mice are shown. b‑actin was used as a loading control (detection by an anti‑b‑actin antibody). 
(D) Densitometric measurements of western blots from six brains per group revealed approx. equal levels in both groups (p < 0.2). Quantification of total 
PrP signals were normalized by b‑actin levels. Quantification of the Western blot signals was carried out by densitometric measurements using the Image J 
software (mean + SD).
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i.e. 10 to 20-fold less compared to the scFv S18 trial (1 mg/week), 
suggesting that full-length IgG molecules are more potent than scFv 
fragments in passive immunotherapy.
Our results demonstrated that the polyclonal antibody W3 
significantly impaired PrPSc replication in the spleen. These findings 
are an incentive to pursue with studies of antibodies directed against 
LRP/LR to obtain more effective results on the neuroinvasion phases 
of the infection. Passive immunotransfer studies with improved 
versions of the single chain antibody S18, as well as full-length IgG 
versions thereof might represent promising regimens for an efficient 
treatment of prion diseases.
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bstract
Transmissible spongiform encephalopathies are a group of neurological disorders associated with the deposition of PrPSc, an abnormal form of
he cellular prion protein PrPc. The 37 kDa/67 kDa laminin receptor (LRP/LR) has been identified as a prion receptor and several lines of evidence
trongly suggest that this protein plays a role during prion pathogenesis. Here we report the selection of recombinant single chain antibodies (scFvs)
irected against LRP from naı̈ve and synthetic phage scFv libraries for therapeutic application. Western blotting and FACS analysis confirmed
specific LRP/LR recognition pattern of the two selected scFvs S18 and N3. Both scFvs specifically interfered with the PrP/LRP interaction in
itro. High yield production of the scFvs of approx. 1 mg/L of culture medium was achieved in E. coli. Passive immunotransfer of the scFv S18
ntibody reduced PrPSc levels by approx. 40% in the spleen of scrapie infected C57BL/6 mice 90 days post scFv injection, suggesting that scFv
18 interferes with peripheral PrPSc propagation, without a significant prolongation of incubation and survival times.
2007 Elsevier Ltd. All rights reserved.
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. Introduction
Prion diseases describe fatal neurodegenerative diseases (for
eview (Aguzzi and Weissmann, 1998; Lasmézas and Weiss,
000; Prusiner, 1998; Weissmann, 2004), lacking any effective
herapeutic treatment (for review Vana et al., 2007; Weissmann
nd Aguzzi, 2005; Zuber et al., 2007). This group of infectious
isorders includes Creutzfeldt–Jakob disease (CJD) in humans,
ovine spongiform encephalopathy (BSE) in cattle and chronic
asting disease (CWD) in cervids. The causative agents do not
epresent classical pathogens such as bacteria or viruses but are
nfectious proteins. The infectious scrapie prion protein (PrPSc)
epresents an abnormally folded isoform of the cellular prion
rotein (PrPc). A key event in the disease pathology is the con-
∗ Corresponding author. Fax: +49 89 218076999.
E-mail address: weiss@lmb.uni-muenchen.de (S. Weiss).
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oi:10.1016/j.molimm.2007.04.030ody; Prion disease therapy
ersion of PrPc into PrPSc that accumulates in the brain (for
eview: Weissmann, 2004). The conversion process is thought
o take place in a compartment of the endocytic pathway after
nternalization (Arnold et al., 1995) or at the cell surface (Kaneko
t al., 1997) where PrPc locates GPI anchored.
We identified the non-integrin 37 kDa/67 kDa laminin recep-
or (LRP/LR) as the cell surface receptor for PrPc (Gauczynski
t al., 2001b) and showed that it is required for PrPSc propaga-
ion in scrapie infected cells (Leucht et al., 2003). Bovine prions
re endocytosed by human enterocytes via LRP/LR (Morel et
l., 2005) and moPrP27-30 binds LRP/LR dependent to mam-
alian cells confirming that LRP/LR acts as a receptor for
nfectious prions (Gauczynski et al., 2006). Molecular tools
locking the LRP/LR represent alternative therapeutic agents
or the treatment of TSEs (for review Vana et al., 2007; Zuber et
l., 2007). These include a trans-dominant negative LRP mutant
Vana and Weiss, 2006), polysulfated glycanes (Gauczynski et
l., 2006), siRNAs directed against LRP mRNA (Leucht et
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l., 2003), which can be delivered by lentiviral vectors (Vana
nd Weiss, 2006) and antibodies directed against LRP/LR (for
eview Vana et al., 2007; Zuber et al., 2007). Polyclonal anti-
RP antibodies (Rieger et al., 1997) are able to interfere with
i) PrPBSE internalization (Morel et al., 2005), (ii) PrP27-30 cell
inding (Gauczynski et al., 2006), (iii) PrPSc propagation in cul-
ured neuronal cells (Leucht et al., 2003) and (iv) prolong the
urvival time in scrapie infected mice 2.3 fold (Zuber et al.,
ubmitted). These findings recommend anti-LRP antibodies as
romising alternative tools in the prophylaxis and/or therapy of
rion diseases. Since polyclonal antibodies are due to their lim-
ted amounts and their relative high molecular weight (approx.
50 kDa) inappropriate for long-term therapeutic applications,
e selected monoclonal single chain antibodies (scFv) (Bird et
l., 1988) directed against LRP, termed N3 and S18, by phage
isplay (Clackson et al., 1991). Both scFvs were produced in
igh amounts in E. coli, interfered with the PrP/LRP interaction
rocess and sc Fv S18 reduced peripheral PrPSc propagation in
crapie infected mice.
. Materials and methods
.1. Phage display selection ELISA screening
Three rounds of selection were performed on a GST::LRP
usion protein expressed in Baculovirus infected Sf9 cells
Rieger et al., 1997). Approximately 1012 phages from
ach library were incubated with polystyrene immobilized
ST::LRP. Unspecifically bound phages were removed by sev-
ral washing steps. Bound phages were eluted and used for
nfection of E. coli XL1 Blue cells. Cells successfully transduced
ith phagemids encoding scFvs were selected for ampicillin
esistance and subsequently infected with M13K07 helper phage
o generate phage progeny displaying scFv for the following
n vitro selection. After the third round of selection individ-
al colonies were grown in LB medium (100 g/mL ampicillin,
0 g/mL tetracycline) at 30 ◦C. Cells were harvested by cen-
rifugation and resuspended in 200 mM Tris–HCl, pH 7.5, 20%
ucrose, 1 mM EDTA. During incubation on ice the outer mem-
rane is destroyed so that soluble periplasmic proteins including
he scFv are released into the liquid. After removal of cellular
ebris, crude extracts were tested in ELISA for scFv antibody
ragments binding GST::LRP fusion protein.
Detection of scFv bound to immobilized GST::LRP
200 ng/well) was carried out using an anti-His HRP-conjugate
Qiagen, 1 g/mL). The signal was developed with the tetram-
thyl benzidine solution (TMB) (KPL) and detected at 450 nm
fter termination of the reaction with 0.5 M H2SO4.
.2. ScFv expression and purification
The clones S18 and N3 were subcloned as NcoI–NotI restric-
ion fragments into the vector pSKK2 (Le Gall et al., 2004)
esulting in the plasmids pSKK2-S18 and pSKK2-N3, respec-
ively. The clone C9 encoding for a scFv antibody directed
gainst preS1 a hepatitis B coat protein (Persing et al., 1987)
as subcloned into pSKK2 resulting in pSKK2-C9. The con-
m
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tructs were transformed into E. coli RV308 and plated onto 2YT
gar containing 100 g/mL ampicillin and 50 mM glucose. For
xpression, bacteria were cultured at 26 ◦C in 2 YT medium sup-
lemented with ampicillin and glucose until an optical density
etween 0.6 and 0.8 at a wavelength of 600 nm was achieved.
fter centrifugation bacterial pellets were resuspended in YTBS
edium supplemented with 1 M d-sorbitol and 2.5 mM betaine
ith 0.2 mM IPTG and grown at 21 ◦C overnight. The cells
ere resuspended in 50 mM phosphate buffer pH 8, 300 mM
aCl containing 20 mM imidazole, -mercaptoethanol and
rotease inhibitors (PMSF, aprotinin, leupeptin). After snap-
reezing in liquid nitrogen, the lysate was digested 1 h with
mg/mL lysozyme and centrifuged at 4 ◦C 14,500 rpm for 1 h.
he supernatant was incubated with Probond nickel-chelating
esin (Invitrogen). Beads were washed with the buffer described
nd finally eluted with 50 mM phosphate buffer pH 8, 300 mM
aCl and 250 mM imidazole. For their application in animal
xperiments, scFvs were further purified by size exclusion chro-
atography using a sephadex S200 column and filter sterilized.
.3. Expression of LRP::FLAG in the Semliki-Forest-Virus
SFV) system
Expression of mouse and human LRP::FLAG employing
he SFV system was described previously (Gauczynski et al.,
001b). Briefly, SFV based vectors carrying mouse or human
RP::FLAG were used. Recombinant SFV-1 RNAs were gen-
rated by in vitro transcription and transfected into BHK cells
y electroporation.
.4. FACS analysis (flow cytometry)
Cell suspensions were prepared in PBS, 2% fetal calf serum,
0 mM EDTA, 0.01% sodium azide (FACS buffer). For flow
ytometry, cells were incubated with the primary antibody
t concentrations of ∼1 g/106 cells for 15 min at room tem-
erature and washed in FACS buffer before incubation with
ITC-conjugated anti-myc or anti-rabbit antibodies for 15 min
t room temperature. After washing in FACS buffer, data acqui-
ition and analysis were performed with an EPICS XL-MCL
Coulter) flow cytometer. For each condition, 5000 cells were
ounted. A polyclonal anti-gal-3 antibody (Gauczynski et al.,
001b) and the scFvs N3 and S18 were used as primary anti-
odies.
.5. Western blot analysis
Cells were lysed in 10 mM Tris–HCl pH 7.5, 10 mM NaCl,
0 mM EDTA, 0.5% Triton X-100 and 0.5% sodium deoxy-
holate. Equal amounts of cellular proteins were resuspended
n SDS sample buffer and heated to 95 ◦C for 5 min. Samples
ere analysed on a 12% SDS-polyacrylamide gel and blotted
nto a polyvinylidene difluoride membrane, blocked with 5%
ilk and incubated with the primary antibodies N3, S18 (diluted
:1000 to a final concentration of 1 g/mL) or anti-LRP 43512
diluted 1:5000 to a final concentration of 0.5 g/mL). The scFvs
ere detected with an anti-c-myc antibody (Santa Cruz 1:1000
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o a final concentration of 1 g/mL), followed by a peroxi-
ase conjugated anti-mouse antibody (Santa Cruz 1:5000 to a
nal concentration of 0.5 g/mL). Detection was performed by
nhanced chemiluminescence (Perkin-Elmer Life Sciences).
.6. Epitope mapping
The entire sequence of human LRP was covered by 92 differ-
nt synthetic peptides of 15 amino acids length. The N-terminus
f each peptide was shifted with respect to the previous peptide
y three amino acids, leading to an overlap of 12 amino acids.
ynthesis was performed on a cellulose membrane (AIMS,
raunschweig) using Fmoc chemistry (PyBop/NMM activa-
ion, Trt/tBu/Pbf/Boc side chain protection) according to the
POT-synthesis method of Frank (1992) using a spotting robot
Syro, MultiSynTech GmbH, Witten, Germany). Detection was
erformed as described for western blotting.
.7. KD estimation by ELISA
Two hundred nanograms of GST::LRP per well in 800 mM
aHCO3 pH 8.6 has been coated on a Nunc immunoplate Max-
sorb and incubated over night at 4 ◦C. After three washing
teps with PBS/0.1% Tween 20, 300 L per well of blocking
olution (2% milk in PBS pH 7) was added for 2 h at room tem-
erature. After three washing steps (PBS/0.1% Tween) serial
ilutions (1:5) on anti-LRP scFv S18 starting with 100 g/mL
ere added, incubated for 1 h at room temperature followed
y three washing steps (PBS/0.1% Tween). Detection was per-
ormed by adding anti (His)5-HRP (1/1000), followed by four
ashing steps (PBS/0.1% Tween) and one washing step (PBS).
ifty microlitres per well of solution mix (TMB peroxidase sub-
trate (KPL) and peroxidase substrate solution B (KPL) ration
:1) was added to start the substrate reaction, which was deter-
ined by adding 50 L 0.5 M H2SO4. Equilibrium dissociation
onstants KD were estimated by fitting the experimental values
each anti-LRP scFv S18 concentration was added in triplicate)
o equation Y = BmaxX/(Kd + X) for one-site binding (hyperbola)
sing the software program PRISM (GraphPad Software, San
iego, CA).
.8. Generation of recombinant proteins
pGEX-4T (Amersham) was used for GST expression
nd pGEX-2T-huPrP23-230 for GST::huPrP23-230 expression.
uPrP23-230 was cloned into pGEX2T as described for the
onstruction of pGEX2T-haPrP23-231 (Weiss et al., 1995). The
DNA fragment encoding huLRP (aa 1–295) was amplified by
CR and subcloned via BamHI and EcoRI into the expression
ector pGEX-4T. GST, GST::huPrP23-230 and GST::huLRP
ere produced in E. coli BL21 cells as described for GST and
ST::haPrP (Weiss et al., 1995). These proteins were purified
y glutathione-sepharose affinity chromatography (Amersham
iosciences). GST::LRP was digested with 5 units biotinylated
hrombin (Thrombin Kit, Novagen). The supernatant was incu-
ated with streptavidin agarose beads to remove the recombinant
hrombin according to the manufacturer’s instructions.
3
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.9. Pull-down assay
Four micrograms of LRP were pre-incubated with 100 g
cFv. GST::PrP beads, GST beads and unloaded beads were
rst saturated with bovine serum albumine for 1 h. Twenty-five
icrolitres of beads were then added to the reaction in a final vol-
me of 350 L binding buffer (50 mM Tris–HCl pH 8, 300 mM
aCl, 0.025% NP40) for 1 h at room temperature. The beads
ere washed four times in the same buffer. Bound proteins were
luted directly in SDS-loading buffer for SDS-PAGE analysis.
.10. Animal experiments
All animal experiments were approved by the Bavarian Gov-
rnment (Az: 209.1/211-2531-83/04).
.10.1. Analysis of peripheral PrPSc accumulation
Three groups of six C57BL/6 female mice were injected
ntraperitoneally with 100 L of a 10% RML brain homogenate
repared from the brains of terminally sick mice. The mice were
reated intraperitoneally once a week with one mg of antibodies
S18 or C9) diluted in PBS or a total period of 8 weeks, the
rst treatment being given one day prior to RML prion inocu-
ation. Control mice were treated with PBS. Ninety days after
rion inoculation, mice were sacrificed and spleens were homog-
nized in PBS to 10% (w/v). The homogenates were adjusted
o 5 mg/mL and digested with 50 g/mL of proteinase K (1 h,
7 ◦C). One hundred and fifty micrograms of total protein were
nalysed by western blotting using the antibody SAF83. Undi-
ested lysates were used as a loading control. The density bands
btained were analyzed using NIH software.
.10.2. Analysis of the incubation and survival times
Three groups of C57BL/6 female mice were intraperitoneally
njected with S18, C9 and PBS followed by inoculation with
ML prions. The same conditions were applied as for the
nalysis of the peripheral PrPSc accumulation described above.
ncubation times represent the time span from the day of RML
noculation until one of the four symptoms: ataxia of gait, tremor,
ifficulty righting from a supine position, and rigidity in the tail
ccurs. Survival times represent the time span from the day one
f the four symptoms occurs until the day mice show two of the
our TSE-relevant symptoms over 3 days (Sethi et al., 2002). At
his time point the mice were sacrificed.
.10.3. Investigation of side effects caused by scFvs
To investigate side effects of scFv, 2 groups of 6 C57BL/6
ice were injected with PBS or S18 during 8 weeks. The
nimals were sacrificed 4 and 8 weeks or 120 days after begin-
ing of treatment, blood was collected in EDTA and analysed
or immune cell content (Vet-Med-Labor, Munich). Different
rgans (liver, brain, kidney, spleen) were collected and analysed.
. Results.1. Selection of anti-LRP scFvs by phage display
Specific phage display fragments binding to GST::LRP were
elected from a naı̈ve and a synthetic phage scFv library
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Fig. 1. Selection of scFvs by phage display. Clones of each library ((a) naive library; (b) synthetic library) were analysed for their ability to bind GST::LRP by ELISA.
(c) Unique clones were used for the detection of recombinant GST and GST::LRP by western blotting. (d) Selection summary: a BstNI fingerprinting of the DNAs of
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he 13 clones selected from the naı̈ve library revealed 10 identical clones. One c
ll clones tested recognized specifically GST::LRP. Due to their strong antigen
aı̈ve library, S: synthetic library.
Schwarz et al., 2004). After three rounds of affinity selection on
ST::LRP, 47 individual clones from each library were selected
o test their ability to recognize GST::LRP by ELISA. 66% of
he selected clones from the naı̈ve library and 53% from the
ynthetic library showed positive signals (Fig. 1a–c).
The selected antibodies clearly recognized GST::LRP but not
ST (Fig. 1c), demonstrating that the antibodies specifically rec-
gnized the LRP part of the fusion protein, in contrast to the poly-
lonal antibody W3 which was generated by immunization of
nimals with the GST::LRP fusion protein. A BstNI fingerprint-
ng of the DNAs of the 13 clones selected from the naı̈ve library
howed that 10 clones were identical. One clone was identified
wice and another one revealed an individual restriction pattern
Fig. 1d). Due to their strong antigenic recognition, we selected
he scFv clones S18 and N3 for further characterization.
.2. Specific recognition of native and denatured LRP by
cFvs S18 and N3
The scFvs S18 and N3 were expressed in E. coli and puri-
ed by IMAC. Up to 1 mg scFv per L of culture medium
as achieved. The purified antibodies migrated with molec-
lar weights of approx. 35 kDa as analysed by SDS-PAGE
Fig. 2a).
Purified S18 and N3 specifically recognized both mouse
RP::FLAG and human LRP::FLAG overexpressed in BHK
ells employing the Semliki Forest Virus (SFV) sytem as well
s the endogenous LRP (Fig. 2b). In contrast to S18, N3 also
ecognized the 67 kDa LR form (Fig. 2b), which does not impli-
ate a general inability for S18 to recognize the 67 kDa form on
a
b
w
(
was identified twice and another one revealed an individual restriction pattern.
gnition, scFv clones S18 and N3 were selected for further characterization. N:
ther cell types. The FACS profiles obtained with both scFvs
emonstrate a specific recognition of cell surface LRP/LR in
RP overexpressing BHK cells (Fig. 2c), suggesting that both
cFvs recognize LRP/LR on the cell surface under native con-
itions. Taken together, these results indicate that N3 and S18
pecifically recognize the denatured and the native form of LRP
n the cell surface.
.3. Epitope mapping of scFvs S18 and KD estimation
The scFv S18, used for animal experiments due to its bet-
er recognition of native moLRP (Fig. 2c), was subjected to an
pitope mapping. Three dots were detected for S18 (Fig. 3a),
hereas no signals were detected for scFv C9 (data not shown).
ne intense dot observed for S18 is related to an unspecific
ignal. Comparing the signal positions with the correspond-
ng peptide sequence, we identified the epitope stretching from
mino acid 272–280 of LRP. This epitope locates within the
xtracellular domain of huLRP (Fig. 3b) (Hundt et al., 2001). In
ddition a KD value of 5.1 × 10−9 mol/L for the binding of scFv
18 on GST::LRP has been estimated by ELISA.
.4. ScFvs S18 and N3 interfere with PrP/LRP interaction
GST::huPrP23-230 interacts with huLRP in vitro (Fig. 4)
nalyzed by pull-down assay. In contrast to the control anti-
ody C9, both scFv antibodies S18 and N3 after pre-incubation
ith huLRP blocked the GST::huPrP23-230/huLRP interaction
Fig. 4).
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Fig. 2. scFvs N3 and S18 specifically detect denatured and native LRP/LR. (a) SDS-PAGE analysis of purified scFvs expressed in E. coli. Proteins were visualized by
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of C57BL/6 mice with scFv S18 confirmed no side effects. We
determined the PrPSc levels in the spleen, 90 days after RMLoomassie brillant blue staining. (b) BHK cells were transiently transfected with
moLRP), respectively. Cell lysates were analysed by western blotting, using N
ells transfected as described in (b) were analysed by FACS using scFvs N3, S1
.5. ScFv S18 reduced PrPSc accumulation in the spleen in
murine scrapie model by passive immunotransferWe chose scFv S18 for animal experiments due to its better
ecognition of moLRP on the cell surface (Fig. 2c). Pretreatment
ig. 3. Epitope mapping of scFv S18. (a) Membranes encompassing the huLRP
equence were hybridized with S18. The sequence of the peptides detected and
he amino acid positions are indicated. (b) Schematic representation of LRP. The
ollowing binding sites are indicated: direct binding site to PrP (aa 161–179)
Hundt et al., 2001), a suggested indirect HSPG-dependent binding domain
or PrP (aa 180–285) (Hundt et al., 2001), scFvS18 recognizes the epitope aa
72–280.
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NA (mock), SFV huLRP::FLAG RNA (huLRP) and SFV moLRP::FLAG RNA
or the monoclonal anti-LRP antibody 43512 (control). (c) Non-permeabilized
he anti-gal-3 antibody.nfection, which corresponds to the plateau phase of PrPSc accu-
ulation. S18 treated C57BL/6 mice revealed a reduction of the
ig. 4. S18 and N3 block the PrP/LRP interaction in vitro. (a) GST::huPrP
mmobilized on sepharose glutathione beads was incubated with recombinant
RP in presence or absence of scFvs as indicated. GST immobilized on beads
nd unloaded beads were employed as negative controls. After elution, LRP
ound on beads was analysed by western blotting using N3 for detection. (b)
uantitative analysis of western blots performed by densitometric evaluation of
he LRP level in three independent experiments.
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Fig. 5. Spleen analysis of mice inoculated with prions after intraperitoneal treatment with PBS, scFvC9 or scFvS18. Each group consists of six animals. (a) Analysis
of PrPSc levels (after PK digestion) in the spleen has been performed 90 days after scrapie inoculation by western blotting. Shown are the PrPSc levels of three mice
of each group injected with PBS, C9 and S18, respectively. (b) Densitometric measurements of western blots from six spleens per group revealed a reduction of the
PrPSc level by 40% in the scFv S18 treated group compared to the PBS treated group, for which the PrPSc level was set to 100%. Quantification of the western blot
signals was carried out by densitometric measurements using the Image J software.
Table 1
Incubation and survival times of scrapie infected mice treated with scFv C9, scFv S18 and PBS
Experimental group Incubation times (occurence of first
TSE symptoms, days) (mean ± S.D.)
Survival times, days
(mean ± S.D.)
Incubation + survival times, days
(mean ± S.D.)
Number of mice
(affected/inoculated)
PBS 177 ± 0 14.4 ± 9.5 191.4 ± 8.9 10/10
C9 170 ± 2.7 27.6 ± 3.2 197.6 ± 1.3 6/6
S18 182.4 ± 8 17.8 ± 6.2 200.2 ± 14.2 5/5
Incubation times represent the time span from the day of RML inoculation until one
position, and rigidity in the tail occurs. Survival times represent the time span from th
TSE-relevant symptoms over three days (Sethi et al., 2002). At this time point the mi
Fig. 6. Incubation plus survival times of scFv treated mice after RML inocula-
tion. PBS treated mice show mean incubation plus survival times of 191.4 (±8.9)
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ays post infection, whereas the S18 and C9 group show incubation plus survival
imes of 200.2 (±14.2) and 197.6 (±1.3) days, respectively. For definitions of
ncubation and survival times see footnote of Table 1.
rPSc content in the spleen by approx. 40% (Fig. 5b), suggest-
ng that S18 hampers peripheral PrPSc propagation. However,
he reduction of peripheral PrPSc propagation did not result in a
ignificant prolongation of the incubation and survival times in
crapie infected mice (Fig. 6, Table 1).
. Discussion
Among the numerous molecules harboring an anti-prion
ctivity (for review Gauczynski et al., 2001a; Vana et al., 2007)
ntibodies represent promising tools for prion diseases therapy.
ntibodies against PrP inhibit PrPSc propagation in cell cul-
ure (Enari et al., 2001; Pankiewicz et al., 2006; Peretz et al.,
001; Perrier et al., 2004) and also in mice (Heppner et al.,
a
o
a
t
of the four symptoms: ataxia of gait, tremor, difficulty righting from a supine
e day one of the four symptoms occurs until the day mice show two of the four
ce were sacrificed.
001; Peretz et al., 2001; White et al., 2003). Recently, scFv
ntibodies directed against specific epitopes of PrPc have been
eveloped (Adamson et al., 2006). However, anti-TSE strategies
argeting PrP have been contested, since PrP antibodies injected
nto the brain of mice led to rapid neuronal apoptosis (Solforosi
t al., 2004). Therefore, LRP/LR, acting as a receptor for both
rPc and PrPSc (Gauczynski et al., 2006; Morel et al., 2005),
epresents an alternative promising target for therapy in prion
iseases.
We selected and characterized two single chain antibodies
scFvs) N3 and S18 directed against LRP/LR. The epitope for
18 on LRP has been located within the extracellular domain
f LRP (aa272–aa280) (Hundt et al., 2001), a prerequisite for
he interference capacity of the antibody with the extracellular
ocated PrP.
We investigated whether the single chain antibody S18
hows inhibitory effects on prion replication in vivo by pas-
ive immunotherapy. S18 reduced PrPSc levels in the spleen by
pprox. 40%, demonstrating that the antibody has the capac-
ty to interfere with peripheral prion propagation. However, the
18 mediated reduction of the peripheral PrPSc propagation was
ot concomitant with a significant prolongation of the incuba-
ion and survival times in scrapie infected mice treated with
cFv S18. One reason for that might be the short half life of the
ntibody, which we calculated with approx. 12 h in the blood
f animals implicating a daily scFv delivery. A more frequent
pplication of higher amounts of the antibody for a longer period
f time might be required to obtain a certain type of threshold to
chieve a regression of the disease reflected in prolonged incuba-
ion and/or survival times. Gene transfer resulting in a permanent
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n vivo expression of scFv provides an alternative delivery sys-
em (Afanasieva et al., 2003; Arafat et al., 2002). A recent work
eported that anti-PrP single chain antibodies expressed in mam-
alian cells exert a paracrine anti-prion activity (Donofrio et al.,
005). Therefore it might be interesting to consider a bi-therapy
ssociating anti-LRP and anti-PrP scFvs to improve anti-prion
reatment.
The capacity of the selected scFvs to block the PrP/LRP inter-
ction in vitro (i) and the anti-prion effect on the peripheral PrPSc
ccumulation in a murine model (ii) recommend anti-LRP scFvs
s efficient tools in therapy of prion disorders.
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The 37/67 kDa laminin receptor (LRP/LR) acts as a receptor for prions providing a promising
target for the treatment of prion diseases. Recently, we selected anti-LRP/LR single-chain
antibodies (scFvs) and proved a reduction of the peripheral PrPSc propagation by passive
immunotransfer into scrapie-infected mice. Here, we report the development of an in vivo gene
delivery system based on adeno-associated virus (AAV) vectors expressing scFvs-S18 and -N3
directed against LRP/LR. Transduction of neuronal and non-neuronal cells with recombinant
(r)AAV serotype 2 vectors encoding scFv-S18, -N3 and -C9 verified the efficient secretion of the
antibodies. These vectors were administered via stereotactic intracerebral microinjection into the
hippocampus of C57BL/6 mice, followed by intracerebral inoculation with 10 % RML at the
same site 2 weeks post-injection of rAAV. After 90 days post-infection, scFv-S18 and -N3
expression resulted in the reduction of peripheral PrPSc propagation by approximately 60 and
32 %, respectively, without a significant prolongation of incubation times and survival. Proof of
rAAV vector DNA in spleen samples by real-time PCR strongly suggests a transport or trafficking
of rAAV from the brain to the spleen, resulting in rAAV-mediated expression of scFv and thereby
reduced PrPSc levels in the spleen are most likely due to blocking of the prion receptor LRP/LR
by scFv.
INTRODUCTION
Prion diseases are fatal lethal neurodegenerative diseases
affecting humans and animals (for review see Weissmann,
2004; Zuber et al., 2007a). None of the affected individuals
can be treated or cured effectively (Ludewigs et al., 2007;
Vana et al., 2007; Weissmann & Aguzzi, 2005). The
abnormal form of the prion protein, PrPSc, is frequently
associated with infectivity and propagates mainly in the
brain and the lymphoreticular system (LRS). Accumulation
of the aggregated PrPSc leads to neuronal death. PrPSc is
distinct from the host protein PrPC by its biochemical
properties such as proteinase K sensitivity and insolubility,
but harbours the same amino acid sequence. The
generation of PrPSc from PrPC involves conformational
changes accompanied by modifications in the secondary
structure of the protein (for review see Aguzzi &
Weissmann, 1998; Prusiner, 1998; Weissmann, 2004).
The 37/67 kDa laminin receptor (LRP/LR) is a multi-
functional protein (i) playing an important role in cell
adhesion, movement and growth of many cell types, (ii)
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acting as a receptor for some subtypes of adeno-associated
virus (AAV), alphaviruses and dengue virus, (iii) playing
an important role in cancer progression and metastasis (for
review see Gauczynski et al., 2001a; Nelson et al., 2008;
Rieger et al., 1999) We recently showed that blockage or
downregulation of LRP/LR in neoplastic cells prevents
invasion of these cells into neighbouring tissues, suggesting
that LRP/LR plays a major role in cancer metastasis (Zuber
et al., 2008b) and (iv) finally, LRP/LR represents a key
player in prion infection (Ludewigs et al., 2007; Vana et al.,
2007; Zuber et al., 2007a). LRP has been shown to act both
as the PrPC (Gauczynski et al., 2001b) and PrPSc receptor
(Gauczynski et al., 2006) and is responsible for bovine
PrPSc internalization by human enterocytes (Morel et al.,
2005). The fact that LRP levels are increased in organs of
the LRS and central nervous system (CNS) such as spleen
and brain of infected animals (Rieger et al., 1997) strongly
suggests that this receptor is not only essential for prion
uptake after oral infection but also plays an important role
for PrPSc propagation and prion pathogenesis in the
peripheral nervous system, including the LRS and CNS.
Additionally, several laminin receptor isoforms have been
found in mouse brain all binding to PrP (Simoneau et al.,
2003). LRP/LR, plays a key role as a cell surface receptor for
prions, was also recently found to interact with PrP in the
perinuclear compartment and in part with a mutated PrP
lacking the signal sequence in the nucleus (Nikles et al.,
2008). LRP/LR attracts more and more attention as a target
for therapy in prion diseases and cancer. Multiple strategies
on LRP inactivation have been shown to be successful by
inhibiting PrPSc propagation in vitro: (i) downregulation of
LRP via antisense or siRNA strategies completely blocks
PrPSc propagation (Leucht et al., 2003) and delays the
incubation time in scrapie-infected mice (H. Ludewigs and
others, unpublished data), (ii) a trans dominant-negative
LRP mutant interferes with PrPSc propagation in ScN2a
cells (Vana & Weiss, 2006), (iii) polysulfated glycanes block
the PrPSc–LRP/LR interaction and strongly reduce PrPSc
binding (Gauczynski et al., 2006) and (iv) the anti-LRP
antibody, W3, abrogates PrPSc accumulation in scrapie-
infected cells (Leucht et al., 2003) and prevents binding and
internalization of PrPBSE prions (Morel et al., 2005). W3
reduces peripheral PrPSc propagation significantly by 66 %
and prolongs the survival in scrapie-infected mice by 1.8-
fold (Zuber et al., 2007b). Many of these anti-LRP/LR tools
particularly antibodies, siRNAs and polysulfated glycanes
interfere with the laminin–LRP/LR interaction, which
results in a reduced invasive potential of neoplastic cells,
recommending these tools as powerful therapeutics in the
treatment of cancer, especially metastasis formation (Zuber
et al., 2008b).
Monoclonal antibodies are attractive therapeutic agents
and at least 21 of them obtained FDA approval for
therapeutic use in patients (Reichert et al., 2005;
Waldmann, 2003). Nevertheless immunotherapy is limited
by the immunogenicity of murine-derived antibodies and
the restricted tissue penetration. Single-chain antibodies
(scFv) as an alternative system have been developed to
circumvent such problems. In contrast to entire immu-
noglobulins, scFv are much smaller in size, which allows
them to penetrate into tissues and lacking the Fc part they
do not provoke an immune response (for review see Sanz et
al., 2005). We recently described the selection of anti-LRP
scFvs termed S18 and N3 from a human antibody library
by phage-display (Zuber et al., 2008a). Employing a passive
immunotransfer approach, scFv-S18 reduced PrPSc depos-
ition in the spleen of infected mice by approximately 40 %
(Zuber et al., 2008a). However, intraperitoneal injection of
the antibody did not significantly prolong the incubation
times and survival (Zuber et al., 2008a) was most likely due
to the short half-life of scFvs in the blood (approx. 12 h or
less) and probably due to insufficient amounts that had
been administered (1 mg per week). In addition, due to the
low stability, scFvs might have failed to cross the blood–
brain barrier and therefore have failed to reach the brain
where most of the prion agent propagates. To circumvent
these limitations, we exploited a gene therapeutic approach
based on the recombinant (r)AAV vector system. Due to its
non-inflammatory and non-pathogenic nature, we chose
the AAV system for in vivo delivery of scFvs-S18 and -N3 to
achieve a permanent expression of the antibodies from
neuronal cells. Up to now 12 serotypes have been identified
named AAV type 1–12 (for review see Wu et al., 2006)
(Schmidt et al., 2006), AAV serotype 2 is the best
characterized one and is conventionally utilized as a gene
therapy vector. This serotype offers a series of advantages
including, e.g. transduction of a wide variety of cell types
and low immunogenicity after in vivo application (Tal,
2000). Furthermore, the vector genome persists for
extended periods of time enabling long-term transgene
expression.
AAV received increasing attention as a promising candid-
ate for gene therapy and at least 13 gene therapeutic
approaches are currently under investigation in clinical
trials worldwide (see http://www.clinicaltrials.gov).
Applications of AAV to treat Parkinson’s disease are
actively studied in experimental models (Hayashita-Kinoh
et al., 2006; Luo et al., 2002). AAV was efficiently used to
target the Prn-P gene (Hirata et al., 2004) and PrPC was
overexpressed by adenovirus-mediated gene targeting
(Shyu et al., 2005).
rAAV2-mediated delivery of PrPC-specific scFvs targeting
the prion protein delayed the onset of prion pathogenesis
in mice (Wuertzer et al., 2008). Here, we provide the proof
of principle for a successful AAV-mediated gene therapy
targeting the prion receptor LRP/LR by anti-LRP/LR scFvs.
To examine which AAV serotype is suitable for the
transduction of neuronal cells, we determined transduction
efficiencies for serotypes 2, 3 and 5 based vectors in two
neuronal cell lines, N2a and GT1, using the green
fluorescent protein as the marker gene. The highest
transduction efficiency was achieved by AAV-2 (data not
shown). Consequently, we constructed rAAV-2 vectors
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encoding anti-LRP scFv-S18, -N3 and -C9, respectively.
The cDNAs encoding anti-LRP scFv-N3 and -S18 and the
anti-preS1 (coat protein of the hepatitis B virus) scFv-C9
were subcloned from the expression vector pSKK2-N3,
-S18 or -C9 (Le Gall et al., 2004) into the mammalian
expression vector pSecTag2B (Invitrogen) to attach the Igk
leader sequence (Coloma et al., 1992) for antibody
secretion, a carboxy-terminal myc tag for immunodetec-
tion, a polyhistidine tag and a CMV promoter, resulting in
the vectors pSecTag2B-N3, -S18 and -C9, respectively. The
cDNA sequences were then cloned into the XbaI restriction
site of the AAV vector plasmid pSub/CEP4 (Wendtner
et al., 2002), resulting in the vector plasmids pSub/CEP4-
N3, -S18 and -C9, respectively. Transfection of N2a cells
with these vector plasmids confirmed that all recombinant
scFvs-N3, -S18 and -C9 were expressed and secreted into
the medium (Fig. 1a). Detection of scFvs was achieved by
using a murine anti-c-myc tag antibody. rAAV-2 vectors
coding for scFvs were generated by triple transfection of the
vector plasmid pSub/CEP4-N3, -S18 or -C9, respectively,
the packaging plasmid pRC (Wendtner et al., 2002) and the
adenoviral helper plasmid pXX6 (Xiao et al., 1998). Vector
production and purification was performed as described
previously (Hacker et al., 2005) and followed by a heparin
affinity chromatography step for further purification and
concentration of the vector preparation. All three viral
plasmid preparations (rAAV-S18, rAAV-N3 and rAAV-C9)
used within the animal experiments were analysed for their
capability to express the transgene in neuronal (N2a and
GT1) and non-neuronal (HeLa) cells. scFv-S18 was
released into the medium as depicted in the Western blot
of supernatants obtained 3 and 6 days post-transduction
from N2a and GT1 cell cultures, respectively (Fig. 1b).
Furthermore, expression and secretion of all three scFvs-
N3, -S18 and -C9 by rAAV-transduced HeLa cells was
verified (Fig. 1c).
To investigate the therapeutic feasibility, scrapie-infected
mice were microinjected with rAAV-N3, -S18 and -C9,
respectively. PrPSc accumulates mainly in the CNS and
particularly high amounts have been detected in the
hippocampus. For that reason, we decided to target this
region of the brain by stereotactic microinjection. A
volume (56109) of genomic particles was injected
intracerebrally (i.c.) into each mouse and the presence of
the secreted scFv-N3 was confirmed 30 days post-injection
by immobilized metal ion affinity chromatography
(IMAC) purification (Fig. 2a). Briefly, homogenates were
diluted in 6 M guanidium-HCl, 0.1 M Na2HPO4/
NaH2PO4 pH 8, sonicated and incubated with 100 ml
Ni2+ beads (Probond resin; Invitrogen) in the presence of
10 mM imidazole. After extensive washing, beads were
eluted in SDS sample buffer and analysed by Western
blotting.
A volume of 10 % RML scrapie homogenate was
administered into the same area of the brain 2 weeks after
rAAV microinjection to allow mice to recover from the
application procedure. Neither the intracerebral micro-
injection of the rAAV nor the viral particles themselves had
any obvious effect on the behaviour of the mice. To
examine the peripheral PrPSc propagation, spleen samples
were analysed 90 days post-infection (p.i.) by Western
blotting. Spleens were homogenized and 200 mg total
protein was digested with proteinase K (final concentration
of 20 mg ml21) for 30 min at 37 uC. We observed a
reduced PrPSc content in mice treated with rAAV-N3 by
approximately 32 % compared with the control group
(rAAV-C9). Furthermore, rAAV-S18-injected mice dis-
played a significant PrPSc reduction by approximately 60 %
(Fig. 2b, c), suggesting that both antibodies hampered
peripheral PrPSc propagation. In addition, the presence of
the scFv-S18 and -C9 encoding DNA sequences in the
spleen were verified by real-time PCR (Fig. 2d). The
reduced PrPSc level might therefore be due to the presence
of the scFvs encoded by the rAAV-2s, which had trafficked
or had been transported from the brain to the spleen. Since
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Fig. 1. (a) Expression and secretion of scFvs-N3, -S18 and -C9 in
N2a cells after transfection with AAV vector plasmids pSub/CEP4-
N3, -S18 or C9, respectively. Mock, transfection with the pSub/
CEP4 vector plasmid only. After transfection (48 h), medium and
N2a cell lysate were immunoblotted and analysed with an anti-c-
myc antibody (Santa Cruz Biotechnology) for the presence of
scFvs. (b) Transduction of N2a and GT1 cells with rAAV-S18
results in the secretion of scFv-S18. Depicted are supernatants
collected 3 and 6 days post-transduction, respectively. (c)
Secretion of scFv-S18, -N3 and -C9 after rAAV-N3, -S18 and -
C9, respectively, transduction with the corresponding rAAV
vectors from HeLa cells. Supernatants were analysed by immuno-
blotting 72 h post-transduction. Detection was performed with an
anti-c-myc antibody.
Delivery of scFvs directed against LRP/LR by rAAV
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heparan sulfate proteoglycans (HSPGs) have been reported
to act as initial attachment receptors for AAV-2
(Summerford & Samulski, 1998) concomitant with the
fact that the spleen exhibits high HSPG levels (Murdoch et
al., 1994; Wrenshall & Platt, 1999) we speculate that the
administered rAAVs might have crossed the blood–brain
barrier and targeted the spleen followed by transgene
expression, resulting in the hampering effect on peripheral
PrPSc propagation by the expressed scFvs. In addition to
the primary receptor HSPG, the administered AAV-2
might have also used the LRP/LR as a receptor, since it has
been reported that LRP/LR can act as a receptor for AAV
serotype 2 (Akache et al., 2006).
Although we observed a significant reduction in the PrPSc
level in the spleen of mice after i.c. RML inoculation post-
microinjection with rAAV-S18, incubation times and
survival were not significantly affected (Table 1). This
correlates with an earlier study, describing an unaltered
incubation period in splenectomic hamsters intracerebrally
infected with ‘Chandler’ scrapie strain (Kimberlin &
Walker, 1977). These hamsters lacking spleens displayed
%paper no. vir83670 charlesworth ref: vir83670&
Fig. 2. (a) Detection of scFv-N3 in the brain of C57BL/6 mice 30 days post-stereotactic microinjection of rAAV-N3. Crude
brain homogenates were IMAC purified. scFv-N3 expression was detected with an anti-c-myc antibody. (b) Reduction of PrPSc
levels in the spleen of RML-infected C57BL/6 mice 90 days post-infection. Spleen homogenates from six mice per group
(rAAV-C9, negative control; rAAV-S18, rAAV-N3) were analysed after proteinase K digestion for determination of PrPSc levels
by Western blotting employing the SAF83 antibody (1 : 5000). Four individual spleen samples from each treated group are
shown. A reduced PrPSc content is observed in the rAAV-S18- and -N3-treated mice. b-Actin was used as a loading control.
For this, a corresponding amount of non-proteinase K digested spleen homogenates was analysed by Western blotting using
an anti-b-actin antibody. (c) Densitometric quantification of Western blot signals was performed using Image J software. Six
individual spleen samples per group (rAAV-C9, negative control; rAAV-S18, rAAV-N3) were analysed by Western blotting and
the density of the PrPSc signals were determined. The mean density of all collected spleen samples (six individual spleen
samples per group) was plotted as a histogram. The PrPSc content of rAAV-C9-injected mice was set to 100 %. PrPSc values
determined from the rAAV-S18-treated group (six individual spleen samples, n56) were compared with the control group
(rAAV-C9, n56) using a Student’s t-test and revealed significantly reduced PrPSc levels by approximately 60 % (P50.04).
Spleen samples from rAAV-N3-treated mice display a reduction in the PrPSc level by approximately 32 %. (d) Real-time PCR
analyses on spleen DNA extracted 90 days post-infection. To examine the presence of the rAAV-2 in the spleen, primer pairs
that amplify a small part within the corresponding scFv encoding DNA sequences were used. A part of the scFv-C9 DNA
sequence (approx. 271 bp, white arrow) was amplified from DNA isolated from spleen homogenates of a rAAV-C9-treated
C57BL/6 mouse (lane 1). Real-time PCR analysis from DNA from spleen homogenate of an unrelated C57BL/6 mouse (lane 2).
The PCR product from the vector plasmid pSub/CEP4-scFv-C9 encoding the respective scFv-DNA sequence is shown as a
positive control (lane 3). Spleen DNA from two different rAAV-S18-treated mice (lanes 4 and 5) display positive signals for
scFv-S18 DNA sequence (approx. 239 bp). The signal in lane 6 represents an unspecific PCR product of spleen DNA from an
unrelated control mouse. The signal in lane 7 describes the positive control for the amplified part of the scFv-S18 encoding
DNA sequence of pSub/CEP4-S18. GAPDH-PCRs from DNA from a spleen served as a quantitative standard and displayed
no significant differences in the DNA quality used for the specific PCRs.
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a prolongation in the incubation time only if they were
infected intraperitoneally. We conclude therefore, that a
reduction in the peripheral PrPSc propagation observed in
the spleen does not necessarily implicate a prolonged
survival or incubation time after intracerebral inoculation
with RML prions.
Furthermore, the rAAVs might not have reached all the
relevant brain cells supporting prion propagation. AAV-2
infects a restricted region near the injection site of the
brain, which is believed to result from rapid HSPG-
mediated uptake of AAV-2 particles by neurons (Bartlett
et al., 1998; Wang et al., 2003). Multiple injection
approaches into both hippocampal hemispheres might
increase the expression of the scFvs. It is also possible to
combine intracerebral treatment with systemic delivery to
inhibit PrPSc invasion in peripheral organs and the CNS
simultaneously. In the rAAV study described by Wuertzer
et al. (2008), which resulted in a delayed onset of the prion
disease due to the expression of anti-PrP scFvs, mice were
infected intraperitoneally. We might therefore have
observed an effect on the incubation time or survival if
we would have used this route of infection.
The fact that we observed a reduction in PrPSc levels in the
spleen without a prolongation of incubation times or
survival, provides further evidence for the assumption that
PrPSc levels in spleen and brain do not correlate with
infectivity. Several reports discuss the absent link between
infectivity or disease progression and high titres of
proteinase K-resistant PrPSc (Lasmezas et al., 1997).
Manson and colleagues demonstrate in a 101TG mouse
model that infectivity is not automatically linked with the
presence of PrPres (Manson et al., 1999). Although no or
low levels of the disease-associated PrP were found,
Gerstmann-Straussler-Scheinker syndrome was followed
by the development of clinical transmissible spongiform
encephalopathy (TSE) signs. Moreover tissues containing
little or no proteinase K-resistant PrP can be infectious
with high titres of TSE infectivity (Barron et al., 2007).
Taken together, the load of PrPSc does not automatically
predict disease progression. To examine whether also the
infectivity is reduced concomitant with the observed
reduction in PrPSc levels in the spleen of rAAV-treated
mice expressing scFvs directed against LRP/LR, a potential
infectivity titre of the spleen has to be determined by
employing bioassays.
We described here a promising gene therapeutic approach
employing rAAVs encoding scFvs targeting LRP/LR. Single
microinjections of rAAV carrying scFv sequences directed
against LRP/LR into the brain resulted in the expression of
the therapeutic antibody followed by a significant reduc-
tion by approximately 60 % of the PrPSc level in the spleen
of rAAV-S18-treated mice. This result is in line with our
previously reported studies: passive immunotransfer of the
polyclonal anti-LRP/LR antibody W3 (Zuber et al., 2007b)
and the scFv-S18 (Zuber et al., 2008a) both resulted in a
reduction of the PrPSc content in the spleen, indicating that
anti-LRP/LR antibodies reduce peripheral PrPSc propaga-
tion. Despite the significant reduction of the PrPSc content
in the spleen achieved by all three delivery approaches, a
prolongation of the survival of scrapie-infected mice was
only achieved by the treatment with the polyclonal
antibody W3 (Zuber et al., 2007b). This might be explained
by the higher stability of full-length IgGs in the organism
(half life up to 21 days in blood) compared with scFvs (half
life less than 12 h in blood). Both half life and stability of
the scFvs have to be improved to achieve an even more
pronounced therapeutic effect for the treatment of prion
diseases or the availability has to be improved by stable
expression from a vector genome.
In summary, the AAV system either used for expression of
scFvs directed against PrP (Wuertzer et al., 2008) or LRP/
LR represent a powerful delivery system for the treatment
of prion disorders targeting the prion protein or its LRP/
LR receptor.
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Table 1. Incubation times and survival of scrapie-infected C57BL/6 mice treated with rAAV-C9, -S18 and -N3
Incubation time represents the time span from the day of RML inoculation until one of the four characteristic TSE symptoms: ataxia of gait,
tremor, difficulty righting from a supine position or rigidity in the tail, occurs. Survival represents the time span from the day one of the four
symptoms occurs until the day mice showed two of the four TSE-related symptoms over 3 days (Sethi et al., 2002). At this time point mice were
sacrificed.
Experimental
group
Incubation times
(days, mean±SD)
Survival
(days, mean±SD)
Incubation times plus
survival (days, mean±SD)
No. mice
(affected/inoculated)
rAAV-C9 125.3±1.9 27±3.4 152±3.7 6/6
rAAV-S18 128.6±3.7 20.1±14.92 148.6±15.7 7/7
rAAV-N3 126.7±7.4 6.5±1.7 133.2±7.9 4/4
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mice were anaesthetized and placed in a stereotaxic apparatus (SR-6N
Narishige).
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Abstract 
Enterocytes, a major cell population of the intestinal epithelium, represent one of the 
major entry barriers of prions after oral exposure. We employed enterocytes of human, 
bovine, porcine, ovine and cervid origin and incubated them with brain homogenates 
from cervids, sheep and cattle suffering from CWD, Scrapie and BSE, respectively. We 
confirmed the recently published finding that BSE prions colocalized with the prion 
receptor 37 kDa/67 kDa LRP/LR on human enterocytes (Caco2 TC-7 cells) supporting 
the hypothesis that BSE caused the human zoonotic disease vCJD. CWD and sheep 
scrapie prions also co-localized with LRP/LR on human Caco-2/TC-7 cells suggesting a 
possible oral transmissibility of CWD and sheep scrapie prions to humans. Further 
interspecies colocalization studies revealed that CWD might not be transmissible to 
cattle, pigs and sheep and sheep scrapie might be transmissible to cattle which might 
have caused BSE but not to cervids and pigs. 
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Introduction 
Transmissible spongiform encephalopathies (TSEs) are a group of lethal neurodegenerative 
disorders affecting both humans and animals. In contrast to other “protein misfolding 
diseases” such as Alzheimer’s or Huntington’s disease, prion diseases are known to be 
infectious. According to the protein only hypothesis (Griffith, 1967; Prusiner, 1989) an 
abnormal form of the cellular prion protein (PrPc), the PrP Scrapie (PrPSc) is thought to be the 
major infectious constituent (Prusiner, 1982). PrPc is suggested to be converted to PrPSc which 
accumulates in the central nervous system (CNS) resulting in neuronal loss and spongiform 
degeneration in the brain. 
TSEs can be transmitted within one animal species (intraspecies transmission) or 
among different species (interspecies transmission). An oral transmission of prion disease has 
been widely observed, e.g. BSE (Bovine Spongiform Encephalopathy) has been suggested to 
originate from the consumption of sheep Scrapie contaminated cattle food (Wilesmith et al., 
1988). In addition, it has been demonstrated that the ingestion of BSE-tainted meat resulted in 
the development of human variant CJD (Creutzfeld-Jacob-disease) (Bruce et al., 1997), 
showing a transmissibility of BSE prions to humans. Extensive experimental transmission 
studies of prions to other animal species have been performed (Bruce et al., 1994; Chesebro, 
2003), resulting in altered incubation times and survival or in an inablility to transmit the 
disease (Collinge et al., 1995; Pattison, 1965; Scott et al., 2005; Wells et al., 2003) that is 
known as “species barrier”. Beside the variety of prion strains and their structural differences, 
the route of infection plays also an important role in the species barrier. In pigs, it has been 
shown that there are intracerebrally and intraperitoneally infectable with the BSE agent, 
whereas an oral infection and disease transmission failed (Wells et al., 2003). Currently, BSE 
and vCJD represent orally acquired TSEs, but little is known about the mechanisms 
underlying the infection process. After ingestion of prion-contaminated food, the TSE causing 
agent has to cross the intestinal epithelial cell barrier, where both M-cells (microfold cells) 
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(Heppner et al., 2001) and enterocytes are proposed to mediate the prion uptake and transport 
(Okamoto et al., 2003) (Morel et al., 2005). Enterocytes are the major cell population in the 
intestine (Booth and Potten, 2000) expressing PrPc on their surface (Morel et al., 2004). It has 
been reported, that a protease resistant prion protein is transcytosed across human enterocytes 
independently of endogenous PrPc expression (Mishra et al., 2004) referring to a receptor-
mediated prion uptake. Furthermore, the 37 kDa/67 kDa laminin receptor LRP/LR is 
expressed on the apical brush border of enterocytes (Shmakov et al., 2000) and has been 
shown to be responsible for the binding of both PrPc (Gauczynski et al., 2001) and infectious 
prions (Gauczynski et al., 2006). Moreover, recent studies on human enterocytes (Caco-
2/TC7) revealed an LRP/LR-dependent binding and internalization of bovine prions (PrPBSE), 
that could be blocked by preincubation with the anti-LRP/LR antibody W3 (Morel et al., 
2005), previously reported as a therapeutic tool in a murine Scrapie model (Zuber et al., 
2007b). 
The spread of CWD (Chronic Wasting Disease), a prion disease affecting free ranging 
cervids, represents a severe risk in some regions of North America and parts of Canada due to 
hunting and consumption of their meat. Although animal transmission experiments propose a 
species barrier for CWD prions to humans (Kong et al., 2005), oral transmission of CWD to 
humans via contaminated food cannot be excluded and remains to be examined.  
In the present study, we examined a possible oral transmission of prions by culturing different 
enterocyte species in the presence of brain homogenates originating from prion infected 
cervids, cattle and sheep. Furthermore, the role of the laminin receptor LRP/LR in prion 
protein uptake was investigated using confocal immunofluorescence analysis. Interestingly, 
fluorescence labelling of the CWD prion protein revealed a colocalization with LRP/LR on 
human enterocytes, providing evidence for a possible oral transmissibility of CWD to humans 
resulting in a new zoonotic disease. In addition, sheep Scrapie prion proteins was also bound 
to and colocalized with LRP/LR on human enterocytes suggesting an oral transmission of 
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sheep Scrapie to humans. Taken together, we provide (i) a cell culture model to study in oral 
transmission of TSEs and (ii) further evidence for an important role of the 37 kDa/67 kDa 
LRP/LR in prion uptake on enterocytes. 
 
RESULTS 
LRP/LR levels on human and animal enterocytes  
Since the LRP/LR has been identified as a receptor for PrPc (Gauczynski et al., 2001) and 
PrPSc (Gauczynski et al., 2006), respectively, we examined whether the laminin receptor level 
might correlate with the ability of prion protein uptake. As a prerequisite, cell surface 
LRP/LR levels of five different enterocyte species were measured using FACS analysis 
(Figure 1). A relatively high LRP/LR surface level has been observed on human (72.01 %), 
,cervid (66.34 %) and bovine enterocytes (40,78 %), respectively, compared to ovine (3.69 %) 
and porcine (16.05%) enterocytes (Table I). 
 
PrPCWD is colocalized with LRP/LR on human enterocytes  
To investigate whether CWD prions might bind LRP/LR-dependent, human enterocytes 
(Caco-2/TC7) were cultured in the absence or presence of CWD- infected or non-infected 
brain homogenate for 2 hours and subsequently stained for LRP/LR and CWD prions 
(PrPCWD), respectively. Immunofluorescence analysis revealed that CWD brain derived PrP is 
detectable and colocalizes with LRP/LR on the cell surface of Caco-2/TC7 cells (Figure 2 E-
G). In parallel, cervid prion protein from healthy brain can be also found to bind to human 
enterocytes in a LRP/LR mediated manner (suppl. Figure S2 E-G). Cervid enterocytes were 
used as a positive control and revealed a clear colocalization of LRP/LR with PrPCWD (Figure 
2 A-C) and LRP/LR with cervid prion protein (suppl. Figure S2 A-C). In contrast, on porcine 
enterocytes no colocalization of LRP/LR and PrPCWD (Figure 2 I-K) and PrPc (suppl. Figure 
S2 I-K), respectively, was observed. Additionally, both bovine and ovine enterocytes 
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displayed no surface-colocalization of PrPCWD with LRP/LR (Figure 2 M-O and Q-S) and 
cervid PrPc (suppl. Figure S2 M-O and Q-S), respectively. Immunofluorescent background 
signals were estimated by the signal of the secondary antibodies alone (data not shown). To 
exclude that the PrP signal resulted from any unspecific antibody recognition, cells were 
stained with 8G8 in the absence of brain homogenates (Figure 2D, H, L, P, T). 
 
Sheep Scrapie PrPSc is colocalized with LRP/LR on human and bovine enterocytes  
We cocultured human and animal enterocytes with ovine brain homogenate from both non-
infected and sheep Scrapie-infected animals.. Following staining of the 37 kDa/67 kDa 
LRP/LR and ovine PrPSc,respectively, we observed a colocalization of PrPSc with LRP/LR on 
the cell surface of Caco-2/TC7 cells (Figure 3 E-G). Ovine PrPc was also colocalized with 
LRP/LR on human, bovine and ovine enterocytes (suppl. Figure S3 E-G), respectively, 
concluding that both ovine PrPSc and PrPc bind to human enterocytes in a LRP/LR dependent 
manner.  
Additionally, binding of ovine PrPSc (Figure 3 M-O) and PrPc 
(suppl. Figure S3 M-O) on bovine enterocytes might occur via LRP/LR. In contrast, cervid 
enterocytes displayed no clear colocalization of LRP/LR with ovine PrPSc (Figure 3 A-C) and 
PrPc (suppl. Figure S3 A-C). Also porcine enterocytes failed to bind PrPSc (Figure 3 I-K) as 
well as ovine PrPc (suppl. Figure S3 I-K) LRP/LR-dependent. As an intraspecies control, 
ovine enterocytes were used,  revealing a cell surface colocalization of LRP/LR and both 
ovine PrPSc (Figure 3 Q-S) and PrPc (suppl. Figure 3S Q-S).  
 
PrPBSE is colocalized with LRP/LR on human and bovine enterocytes  
Human, cervid, bovine, ovine and porcine enterocytes, respectively, were incubated with BSE 
infected brain homogenate (PrPBSE) following LRP/LR and PrPBSE staining. 
Immunofluorescence studies revealed a colocalization of both LRP/LR and PrPBSE on Caco-
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2/TC7 cells (Figure 4 E-G). Bovine enterocytes that were used as positive control displayed a 
clear colocalization of PrPBSE with the laminin receptor on the cell surface (Figure 4 M-O). In 
contrast, porcine enterocytes (Figure 4 I-K) as well as cervid and ovine enterocytes showed no 
colocalization of PrPBSE and LRP/LR (Figure 4 M-O and Q-S).  
 
DISCUSSION 
In the present manuscript, we established an enterocyte cell culture model to study the oral 
route of prion infection. Brain homogenates originating from healthy and prion-diseased 
animals were applied to human and animal enterocytes, respectively, and the LRP/LR 
dependent PrP binding was studied employing immunofluorescence analysis. Enterocytes 
represent the model of choice, since this cell type has been demonstrated to bind and 
internalize BSE prions via the 37 kDa/67 kDa LRP/LR (Morel et al., 2005), suggesting an 
important implication in the oral transmission of prion diseases. Different enterocyte species 
were employed to investigate LRP/LR-dependent binding of different prion strains. 
Colocalization of BSE prions with LRP/LR on Caco-2/TC7 cells confirmed the 
LRP/LR mediated endocytosis of bovine prions (Morel et al., 2005), providing evidence for 
the important role of enterocytes together with LRP/LR in the oral transmission of BSE to 
humans. In contrast, no colocalization of BSE derived prions with LRP/LR on porcine 
enterocytes confirms that pigs are not orally infectable with BSE prions (Wells et al., 2003). 
BSE prions do also not colocalize with LRP/LR on cervid and ovine enterocytes suggesting 
that cervids and sheep might not or only scarcly orally infectable with BSE. 
Colocalization of CWD and sheep scrapie prions with LRP/LR on human enterocytes 
suggests a potential risk for an oral transmission of CWD and sheep scrapie to humans, which 
might result in a new zoonotic disease. In contrast, CWD prion proteins failed to colocalize 
with LRP/LR on bovine and ovine enterocytes, which might suggest that CWD cannot be 
transmitted orally to cattle and sheep. 
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Sheep scrapie prions colocalize with LRP/LR on bovine enterocytes confirming the 
transmission of sheep scrapie to cattle originating in the development of BSE. In contrast, 
sheep scrapie prions do not colocalize with LRP/LR on cervid and porcine enterocytes, 
suggesting that cervids and pigs cannot become orally infected with sheep scrapie.  
FACS analyses revealed that 72.01 % of human, 66.34% of cervid, 40.78% of bovine, 
16.05% of porcine and 3.69% of ovine enterocytes, respectively, express LRP/LR on the cell 
surface (Table I). However, all enterocytes bind CWD, sheep scrapie and BSE prions (Fig.2, 3 
and 4 B, F, J, N, R) but only in a few cases the prions colocalize with LRP/LR (Table 1). We 
conclude that the expression level of LRP/LR does not determine whether prions of a specific 
species can target LRP/LR followed by internalization. Although prion proteins and LRP/LR 
molecules are highly conserved among different mammalian species, defined amino acid 
alterations within the prion protein and the laminin receptor molecules (sequence comparison 
from www.expasy.org, data not shown) might determine whether both molecules can 
specifically interact on the cell surface. We proved in addition, that the anti-PrP specific 
antibody 8G8 did not recognize endogenous PrP (Fig. 2, 3 and 4, D, H, L, P, T) and is 
therefore specific for the infectious PrP employed in our studies. 
Cellular cervid, sheep and bovine (data not shown) PrPc reveal the same colocalization 
pattern as infectious CWD, sheep scrapie and BSE prions on human and animal enterocytes 
(supplementary Figures S2 and S3, respectively), demonstrating that endogenous PrP show 
the same binding behaviour to LRP/LR compared to their infectious counterparts. 
Although we cannot exclude that prions might use alternative infection pathways 
besides the LRP/LR mediated PrP internalization into enterocytes such as M-cells (Ghosh, 
2002) which might also mediate prion uptake, which further leads to prion propagation in the 
gut associated lymphoid tissues (GALT) (Glaysher and Mabbott, 2007, review Press et al., 
2004), we have strong evidence that enterocytes represent a major cell population in the 
intestine, responsible for LRP/LR dependent BSE prion binding and internalization (Morel et 
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al., 2005) and, as shown in this manuscript, for LRP/LR dependent CWD and sheep scrapie 
binding. 
Since CWD and sheep scrapie prions might enter the human body via the oral route 
and may cause a zoonotic disease, tools targeting LRP/LR such as, polysulfated glycanes, 
siRNAs or antibodies (Ludewigs et al., 2007; Vana et al., in press; Vana et al., 2007; Zuber et 
al., 2007a) might provide alternative therapeutics or prophylactics for intervention of orally 
aquired TSEs. 
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METHODS 
Isolation of primary ovine enterocytes. A female Leine sheep (provided by B.Brenig, > 18 
months of age) was euthanized by intravenous injection of T61® and Narcoren®. Since it was 
a pregnant sheep the duodenum of the fetus was also isolated. A segment of the duodenum 
was taken, from the fetus and the adult animal, distal to the pylorus within 5 min after 
euthanasia and rinsed with Krebs-Ringer buffer (containing 25 mM HEPES) to remove feed 
particles. Duodenum was cut into 1 cm pieces and split longitudinally. Duodenal segments 
were digested in PBS containing 0.8 U/ml collagenase, 0.8 U/ml dispase and 5 mM CaCl2, 30 
min at 37 °C. The mucosa was scrapped off carefully from underlying musculature using a 
scalpel and digested additionally for 10 min at 37 °C in PBS with 0.8 U/ml dispase and 5 mM 
CaCl2. Mucosal enterocytes were separated from other cells by sequential filtration through a 
1000-µm and a 300-µm sieve. The filtrate was centrifuged at 200 x g for 5 min and washed in 
PBS with 100 U/ml penicillin/100 µg/ml streptomycin. The resulting pellet was resuspended 
in Medium 199, with Earle´s salts, 2mM L-Glutamin, 25 mM HEPES, 15 % feltal calf serum 
(FCS) and 50 µg/ml gentamicin (Gibco Invitrogen). Cell yield and viability was determined 
using a hemacytometer and 0.4 % trypan blue. 4-6 x 105 cells/cm2 were seeded on 6-cm petri 
dishes in Medium 199.  
Cell culture. Caco-2/TC7 cells (human enterocytes) (provided by M. Rousset) were grown in 
DMEM, 4500 mg l-1 D-glucose, 2 mM Glutamax, 20 % fetal calf serum (FCS), 1 % 
penicillin-streptomycin and 1 % non-essential amino acids (Gibco Invitrogen). FBJ cells 
(bovine enterocytes) (provided by R. Riebe) were maintained in DMEM:MEM with Hank´s 
salts (1:1), 1000 mg l-1 D-glucose, 2 mM Glutamax, 10 % FCS, 1 % penicillin-streptomycin, 1 
% non-essential amino acids (Gibco Invitrogen) and 500 mg l-1 NaHCO3. DWM-R cells 
(cervid enterocytes, provided by R. Riebe) were cultured in IMDM:F12 Nutrient Mix (1:1), 2 
mM Glutamax and 10 % FCS (Gibco Invitrogen). IPEC-J2 cells (porcine enterocytes, 
provided by B. Brenig) were cultured in DMEM:F12 Nutrient Mix (1:1), 1000 mg l-1 D-
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glucose, 2 mM Glutamax, 5 % fetal calf serum, 1 % penicillin-streptomycin, 1 % non-
essential amino acids, 0.1 % Insulin-Transferrin-Selenium and 5 ng ml-1 Epidermal growth 
factor (Gibco Invitrogen). After two days growing in Medium 199 fetal ovine enterocytes 
were grown in MEM with Earle´s salts, 25 mM HEPES, 10 % FCS, 50 µg/ml gentamicin and 
2 mM L-glutamin, whereas adult enterocytes were cultured in IMDM:F12 Nutrient Mix (1:1), 
2 mM Glutamax and 10 % FCS (Gibco Invitrogen). All cell types were grown at 37 °C with 5 
% CO2.   
Brain homogenate preparation. Brains samples from infected cattle (BSE, provided by 
B.Brenig), white tailed deer (CWD) and sheep (Scrapie) (both provided by J. Richt) were 
homogenized to 20% (w/v) at 4°C in PBS. 
FACS analysis. Cultured cells were detached with 1 mM PBS/EDTA, centrifuged at 1200 
rpm at 4 °C for 10 min and fixed in 4 % paraformaldehyde (4 °C). The cell surface LRP/LR 
levels of each cell type were stained by the single chain anti-LRP/LR antibody scFv S18 
(Zuber et al., 2008). scFv C9, an antibody against hepatitis B surface protein, was used as 
negative control. Primary antibodies were diluted 1:50 in FACS buffer (0.01 % sodium azide, 
20 mM EDTA, 2 % FCS in 1x PBS) and incubated for 1 h at 4 °C. After three washing steps 
cells were incubated with the secondary antibody c-myc-FITC (1:50, Santa Cruz) and 
resuspended in FACS buffer for analysis.  
Immunofluorescence. Cells were fixed with 4 % paraformaldehyde, and permeabilized with 
0.3 % Triton X-100. The primary antibody (8G8) and the secondary antibodies (Alexa Fluor® 
488 goat anti-mouse IgG (H+L), Alexa Fluor® 633 goat anti-rabbit IgG (H+L), Molecular 
Probes, Invitrogen) were diluted in PBS/0.3 % Triton X-100. Cells were incubated overnight 
at 4 °C with primary antibodies (1:150) followed by incubation with secondary antibodies 
(1:300). Immunofluorescence backgrounds were estimated by the signal obtained in cells 
incubated with non-infectious brain homogenates or by the fluorescence of infected cells 
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when secondary antibodies were applied alone. Examination was done by confocal 
fluorescence microscopy (Zeiss LSM 510). 
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FIGURES 
 
 
 
 
Figure 1: Detection of cell surface LRP/LR levels on human and animal 
enterocytes by FACS analysis. (A) Human (Caco-2/TC7), (B) cervid (DWM-R), (C) 
ovine (DOMI-1), (D) bovine (FBJ) and (E) porcine (IPEC-J2) enterocytes were 
analyzed for LRP/LR surface level. While cervid and human enterocytes revealed a 
high LRP/LR level, porcine enterocytes showed low levels of the laminin receptor on 
the surface. Almost undetectable LRP/LR levels were observed in ovine enterocytes. 
LRP/LR levels were detected using the anti-LRP/LR scFv S18 antibody (blue curve). 
As negative control the anti-CD19 Hd37 antibody was employed (green curve). 
20,000 cells were counted per single experiment. One representative experiment out 
of five is shown for each cell line.    
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Figure 2: Binding and colocalization of CWD prions with LRP/LR on human and 
animal enterocytes. Staining of the 37kDa/67 kDa LRP/LR on cervid (A), human 
(E), porcine (I), bovine (M) and ovine (Q) enterocytes with the anti-LRP/LR antibody 
W3. A localization of the receptor on the cell surface and inside the cells can be 
observed. Staining of cervid prions (PrPCWD) on cervid (B), human (F), porcine (J), 
bovine (L) and ovine (R) enterocytes with the anti-PrP antibody 8G8. The merge of 
both stainings shows a colocalization of LRP/LR and PrPCWD on cervid (C) and human 
(G) enterocytes but not on porcine (K), bovine (O) and ovine (S) enterocytes, 
respectively. As a control of the specificity of the PrP staining was carried out by 
incubation of cells with 8G8 in the absence of infected and noninfected brain 
homogenates (D, H, L, P, T). All cells were incubated with 50 µg protein  
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Figure 3: Binding and colocalization of sheep Scrapie prions with LRP/LR on 
ovine, human and bovine enterocytes. The 37kDa/67 kDa LRP/LR on cervid (A), 
human (E), porcine (I), bovine (M) and ovine (Q) enterocytes was stained with the 
anti-LRP/LR antibody W3. Localization of sheep PrPSc was detected using the anti-
PrP antibody 8G8. The merge of both pictures shows a colocalization of LRP/LR and 
shPrPSc on human (G), bovine (O) and ovine (R) enterocytes. No colocalization was 
observed on cervid (C) and porcine enterocytes (K). All cells were incubated with 50 
µg protein. As a control for a specific PrP staining cells were stained with 8G8 in the 
absence of infected and noninfected brain homogenates (D, H, L, P, T). 
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Figure 4: Binding and colocalization of BSE prions with LRP/LR on human and 
bovine enterocytes. Cervid (A-D), human (E-H), porcine (I-L), bovine (M-P) and 
ovine (Q-T) enterocytes were incubated with BSE infected brain homogenate. 
LRP/LR was detected with the W3 antibody and BSE prion were stained using the 
8G8 antibody. A colocalization of the laminin receptor and BSE prions on the cell 
surface is observed on human (G) and bovine (O) enterocytes in contrast to cervid 
(C), porcine (K) and ovine (S) enterocytes. All cells were incubated with 50 µg 
protein.  
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Table I Colocalization of cellular and infectious prion proteins of different species with 
LRP/LR on the cell surface of human and animal enterocytes.  
  
 Human 
(Caco-2/TC7) 
Bovine 
(FBJ) 
Cervid 
(DWM-R) 
Porcine 
(IPEC-J2) 
Ovine 
(DOMI 1) 
CWD /  
cervid PrPc + - + - - 
shScrapie / 
ovine PrPc + + - - + 
BSE /  
bovine PrPc + + - - - 
Cell surface 
LRP/LR levels 
72.01 % 40.78 % 66.34 % 16.05 % 3.69 % 
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Supplementary Figures 
 
Figure S2. Binding of cervid prion protein on cervid and human enterocytes. 
Intracellular and cell surface staining of the 37kDa/67 kDa LRP/LR on cervid (DWM-
R) (A), human (Caco-2/TC7) (E), porcine (IPEC-J2) (I), bovine (FBJ) (M) and ovine 
(DOMI 1) (Q) enterocytes with the anti-LRP/LR antibody W3. Staining of cervid prion 
protein (cervid PrPC) on cervid (B), human (F), porcine (J), bovine (N) and ovine (R) 
enterocytes was carried out with the anti-PrP antibody 8G8. The merge of both 
stainings shows a colocalization of LRP/LR and cervid PrPC on cervid (C) and human 
(G) enterocytes but not on porcine (K), bovine (O) and ovine (S) enterocytes. Cervid 
enterocytes were used as internal positive control for the binding of cervid prion 
protein to enterocytes. All cells were incubated with 50 µg protein. Incubation of all 
samples with the secondary antibody only leads to negative signals (D, H, L, P, T). 
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Figure S3. Binding of ovine prion protein on ovine, human and bovine 
enterocytes. Cervid (A-D), human (E-H), porcine (I-L), bovine (M-P) and ovine (Q-T) 
enterocytes were incubated with non-infected ovine brain homogenates. Staining for 
the 37 kDa/67 kDa LRP/LR was performed using the anti-LRP/LR antibody W3. 
Detection of ovine prion protein was done using the anti-PrP antibody 8G8. In 
contrast to cervid (C) and porcine enterocytes (K) a colocalization of ovine prion 
protein and LRP/LR was detected on human (G), bovine (O) and ovine (S) 
enterocytes. Ovine primary enterocytes were used as internal positive control for the 
binding of cervid prion protein to enterocytes. All cells were incubated with 50 µg 
protein. Incubation of all samples with the secondary antibody only leads to negative 
signals (D, H, L, P, T). 
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0022-2836/$ - see front matter © 2008 EThe 37-kDa/67-kDa laminin receptor precursor/laminin receptor (LRP/
LR) acting as a receptor for prions and viruses is overexpressed in various
cancer cell lines, and their metastatic potential correlates with LRP/LR
levels. We analyzed the tumorigenic fibrosarcoma cell line HT1080
regarding 37-kDa/67-kDa LRP/LR levels and its invasive potential.
Compared to the less invasive embryonic fibroblast cell line NIH3T3, the
tumorigenic HT1080 cells display approximately 1.6-fold higher cell-surface
levels of LRP/LR. We show that anti-LRP/LR tools interfere with the
invasive potential of HT1080 cells. Anti-LRP/LR single-chain variable
fragment antibody (scFv) iS18 generated by chain shuffling from parental
scFv S18 and its full-length version immunoglobulin G1-iS18 reduced the
invasive potential of HT1080 cells significantly by 37% and 38%,
respectively. HT1080 cells transfected with lentiviral plasmids expressing
small interfering RNAs directed against LRP mRNA showed reduced LRP
levels by approximately 44%, concomitant with a significant decrease in the
invasive potential by approximately 37%. The polysulfated glycans
HM2602 and pentosan polysulfate (SP-54), both capable of blocking LRP/
LR, reduced the invasive potential by 20% and 35%, respectively. Adhesion
of HT1080 cells to laminin-1 was significantly impeded by scFv iS18 and
immunoglobulin G1-iS18 by 60% and 68%, respectively, and by SP-54 and
HM2602 by 80%, suggesting that the reduced invasive capacity achieved by
these tools is due to the perturbation of the LRP/LR–laminin interaction on
the cell surface. Our in vitro data suggest that reagents directed against
LRP/LR or LRP mRNA such as antibodies, polysulfated glycans, or small
interfering RNAs, previously shown to encompass an anti-prion activity by
blocking or downregulating the prion receptor LRP/LR, might also be
potential cancer therapeutics blocking metastasis by interfering with the
LRP/LR–laminin interaction in neoplastic tissues.
© 2008 Elsevier Ltd. All rights reserved.Edited by J. Karn Keywords: laminin receptor; prion; cancer; metastasis; therapyess: weiss@lmb.uni-muenchen.de.
ymethylated dextran; LRP/LR, laminin receptor precursor/laminin receptor; GAG,
lobulin G1; scFv, single-chain variable fragment antibody; HEK, human embryonic
line; HSPG, heparan sulfate proteoglycan; FACS, fluorescence-activated cell sorting;
P, matrix metalloproteinase; DMEM, Dulbecco's modified Eagle's medium; HRP,
lenediaminetetraacetic acid.
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531Anti-LRP/LR Tools Inhibit Invasion of HT1080 CellsIntroductionThe 37-kDa/67-kDa laminin receptor precursor/
laminin receptor (LRP/LR), a nonintegrin cell-
surface protein, has been reported to correlate
with the aggressiveness of cancer cells, particularly
with their invasive potential and metastatic poten-
tial, which have been investigated intensively in
various studies.1,2 Overexpression of the 67-kDa
LR form is correlated with the metastatic potential,
suggesting that the receptor might play an impor-
tant role in the development of the metastatic
phenotype.3
Besides several relevant physiological functions
such as adhesion or angiogenesis,4,5 LRP/LR acts as
the receptor for the cellular prion protein,6 infectious
prions,7 and several viruses such as the dengue
virus,8 the Venezuelan equine encephalitis virus,9
the Sindbis virus,10 and the adeno-associated virus
serotypes 2, 3, 8 and 911 (for a review, see Refs. 12–
14). Interestingly, the Sindbis virus is known to infect
mammalian cells via the 67-kDa LR. A recent gene
therapeutic strategy, using this virus, has raised
considerable interest since it is known to attack
and kill selectively metastatic cells without adverse
effects.15
Several isoforms of the nonintegrin LR have been
identified,16 whereas the 37-kDa LRP and the 67-
kDa LR are the dominant isoforms present in most
cell types. The mechanism by which the 67-kDa LR
evolves from the 37-kDa LRP form is still not
clarified. Although mRNA and protein expression
levels have been examined, the relationship between
LRP and LR and the molecular nature of the 67-kDa
LR remains unclear. The full-length gene encoding
the 37-kDa precursor has been isolated, encoding
for the 295-amino-acid LRP.17 However, the com-
position of the 67-kDa high-affinity LR remains
unsolved.
The 67-kDaLR reveals a high affinity to laminin,18 a
majorglycoprotein of the basementmembrane,which
is involved in the attachment, spreading, migration,
and differentiation of normal and neoplastic cells.
Two binding sites are present on the LRP for laminin.
A sequence termed peptide G (LMWWML, amino
acids 161–180) on LRP/LR represents the laminin
binding site and might induce conformational
changes mimicking the effect of the entire re-
ceptor.19,20 The resulting proteolytic cleavage of
laminin-1 promotes tumor cell migration.3 The
second binding site stretches from amino acid 205
to 229 at the carboxy terminus of LRP and binds the
β1 chain of laminin.2 The interaction between
laminin and the tumorigenic cell is a prerequisite
for basement membrane invasion andmetastasis.18,21
Laminin also mediates the interaction of malignant
cells and the immune system.22 The laminin–67-kDa
LR interaction (i) enhances the ability of tumori-
genic cells to invade, (ii) leads to an increased
expression of the 67-kDa form,23 and (iii) results in
an activation of proteolytic enzymes and their
regulators.24Here, we examined the potential of anti-LRP/LR
tools to influence the invasion and metastatic
potential of the tumorigenic human fibrosarcoma
cells HT1080. These cells revealed a higher expres-
sion of the 37-kDa LRP on the cell surface
compared to the nontumorigenic mouse embryonic
fibroblast cell line NIH3T3, suggesting that LRP/
LR contributes to the invasive potential of tumori-
genic cells. Furthermore, HT1080 cells represent the
model cell system of choice for invasion assays.
Anti-LRP/LR-specific antibodies such as the par-
ental single-chain variable fragment antibody (scFv)
S18,25 the polyclonal W3,26,27 and the polysulfated
glycans7 are known to block LRP/LR acting as a
prion receptor. Anti-LRP/LR antibodies such as the
single-chain anti-LRP/LR antibody scFv iS18, its
full-length version immunoglobulin G1 (IgG1)-iS18,
and the polysulfated glycans HM2602 and pento-
san polysulfate (SP-54) significantly inhibit the
invasion of HT1080 cells. HT1080 cells transfected
with recombinant lentiviral plasmids expressing
small interfering RNAs (siRNAs) directed against
LRP mRNA revealed reduced levels of LRP,
concomitant with a significantly reduced invasive
behavior. These data suggest the important role of
LRP/LR for the invasive potential of the tumori-
genic HT1080 cells. The reduction of the invasive
potential of HT1080 cells by our anti-LRP/LR tools
obviously results from inhibition of the laminin–
LRP/LR interaction on the cell surface. Anti-LRP
tools may therefore act as alternative potential
agents for an antimetastatic therapy.Results
HT1080 cells reveal increased cell-surface
LRP/LR expression levels compared to the
nontumorigenic cell line NIH3T3
To investigate the correlation of the LRP/LR
expression profile and the invasive potential of
HT1080 cells, we compared the LRP/LR levels on
HT1080 and NIH3T3 cells displaying a less invasive
behavior. For detection of LRP/LR, we used the
single-chain antibody termed scFv S18, recently
characterized for recognition of the 37-kDa LRP on
mouse neuroblastoma cells (N2a).25 Fluorescence-
activated cell sorting (FACS) analysis revealed an
approximately 1.6-fold higher LRP/LR level on the
surface of HT1080 cells (63%) compared to NIH3T3
cells (39%) (Fig. 1a). Although scFv S18 recognized
the 37-kDa LRP form by Western blotting only
(Fig. 1c), the fact that the antibody recognizes the
67-kDa LR form by FACS cannot be excluded.
Total LRP/LR levels determined by FACS analysis
in permeabilized cells displayed a similar LRP/LR
level in both cell lines (Fig. 1b). This finding
correlates with the results obtained by Western
blot analysis. Cell lysates of HT1080 and NIH3T3
revealed no significant difference in the total 37-
kDa LRP content (Fig. 1c).
Fig. 1. Expression of the 37-
kDa/67-kDa LR on HT1080 and
NIH3T3 cells. (a) FACS analysis
was carried out using S18, an anti-
LRP scFv recognizing the 37-kDa
LRP on the cell surface. HT1080
cells displayed higher LRP levels on
the surface (63%, thin gray curve)
compared to the nontumorigenic
cell line NIH3T3 (39%, thick gray
curve). Cells were stained with scFv
HD37 as a negative control (black
curve) as well as with the secondary
antibody only to detect background
binding (dotted gray line). Data are
representative of three independent
experiments comprising cells from
different cultures. (b) FACS analysis
of LRP on permeabilized cells using
the anti-LRP scFv S18. HT1080 and
NIH3T3 cells displayed nearly simi-
lar total LRP levels (black curve: HD37 staining, negative control; thin gray curve: HT1080, 74%; thick gray curve:
NIH3T3, 64%). (c)Western blot analysis of HT1080 andNIH3T3 cell lysates revealed similar total LRP levels. The anti-LRP
antibody scFv S18 was used for detection of the 37-kDa LRP. The blot is representative of at least three independent
analyses including cell lysates from different cell cultures. β-Actin was used as a quantitative loading control.
532 Anti-LRP/LR Tools Inhibit Invasion of HT1080 CellsAnti-LRP/LR antibodies (scFv iS18) generated
by chain shuffling from parental scFv S18 and
its full-length version IgG1-iS18 significantly
reduce the invasive potential of HT1080 cells
We examined the invasion of HT1080 cells in the
presence of antibodies directed against LRP/LR.
From S18, a previously described single-chain anti-
LRP antibody,25 we generated an improved version
termed iS18 by chain shuffling, which revealed an
approximately 10-fold lower Kd (5.6×10
− 10 M)
compared to the parental S18 (Kd=5.1×10
−9 M)25
for binding to glutathione S-transferase (GST)∷LRP.
scFv iS18 has been expressed in Escherichia coli in
high yields (approximately 1 mg/l culture medium)
and purified to homogeneity (Fig. 2a). IgG1-iS18 has
been expressed in human embryonic kidney (HEK)
293 cells in high yields (5 mg/l culture medium) and
also purified to homogeneity (Fig. 2b). Epitope
mapping of IgG1-iS18 identified the epitope stretch-
ing from amino acid 272 to 280 of LRP (Fig. 2c),
demonstrating that the improved IgG1-iS18 recog-
nizes the same epitope as the parental scFv S18.25
The epitope (amino acids 272–280) does not match
with the binding site for laminin-1 to LRP, which
stretches from amino acid 161 to 18019,20 (Fig. 2d).
Preincubation of HT1080 cells with 0.2 μg/μl of
scFv iS18 resulted in a significant reduction in the
number of invasive cells by 37% (p=0.01) (Fig. 3)
compared to HD37, which had an even adverse
effect, which, however, is not significant. Both scFv
HD37 directed against the human B-cell-surface
receptor CD19 and scFv C9 directed against the
hepatitis B surface protein preS1 failed to signifi-
cantly decrease the number of invasive HT1080 cells
(Fig. 3). Treatment of cells with full-length IgG1-iS18
revealed a significant reduction in the number ofinvading cells by 38% (p=0.03) compared to non-
treated cells (Fig. 3). We did not observe significant
effects on the reduction of invasion by antibody
concentrations below 0.2 μg/μl (scFv iS18) and
0.5 μg/μl (IgG1-iS18).
HT1080 cells transfected with recombinant
lentiviral plasmids expressing anti-LRP siRNAs
reveal reduced LRP/LR levels and display
reduced invasive potential
Transfection of HT1080 cells with recombinant
lentiviral plasmids pENTR-siRNA-LRP 4, -LRP 7,
and -LRP 9 reduced LRP levels in these cells by 53%,
36%, and 41%, respectively (Fig. 4a), concomitant
with a significant reduction by 36%, 39%, and 37%,
respectively (p=0.014), of the number of invading
cells (Fig. 4b). Note that this value is comparable to
the invasion of the nontumorigenic cell line NIH3T3.
Transfection of HT1080 cells with pENTR-siRNA-
lamin A/C revealed no effect on the LRP expression
level and its invasive potential (Fig. 4). pENTR-
siRNA-lamin A/C-transfected cells show the same
invasive behavior compared to nontransfected cells
(data not shown).
The heparan mimetic HM2602 and the pentosan
polysulfate SP-54 reduce the invasive potential
of HT1080 cells
Heparan sulfate proteoglycans (HSPGs) play a
critical role in cancer growth and tumor metastasis28
and act as coreceptors for PrPc binding to LRP/LR.6
Since the polysulfated glycans such as the heparan
mimeticHM2602 and the pentosan polysulfate SP-54
interfere with the LRP/LR-dependent binding of
infectious prions, presumably by blocking LRP/LR,7
Fig. 2. Overexpression of anti-LRP/LR-specific antibodies. (a) ScFv iS18 overexpressed in E. coli RV308 through IPTG
induction and subsequently purified via His affinity purification according to the production of scFv S18.25 Lanes 1–4,
eluted fractions after incubation with nickel-chelating resin (Invitrogen) reveal purified scFv iS18 at approximately 35 kDa
by Coomassie staining. (b) IgG1-iS18 overexpressed in HEK293 cells (EBNA) and secreted into the medium was purified
via protein A Sepharose. Lanes 1–9, eluted fractions from protein A Sepharose reveal IgG1-iS18 (heavy and light chain at
approximately 55 and 25 kDa, respectively) by Coomassie staining. (c) Epitope mapping of the recognition of IgG1-iS18
on human LRP. The anti-LRP/LR antibody IgG1-iS18 recognizes the peptide TEDWSAAPT stretching from amino acid
272 to 280 on the human LRP sequence. This correlates with the recognition pattern of scFv S18 on LRP.25 Dots numbered
86, 87, and 88 indicate the spotted peptide sequence of huLRP (amino acids 263–283). (d) Schematic representation of the
human 37-kDa LRP. The laminin binding site is indicated (161–180); the binding epitope of IgG1-iS18 (amino acids 272–
280) corresponds to the epitope recognized by scFv S18/scFv iS18. TMD, transmembrane domain.
533Anti-LRP/LR Tools Inhibit Invasion of HT1080 Cellswe investigated whether these carbohydrates might
influence the invasive potential of tumorigenic cells.
SP-54-treated cells displayed a significant reductionFig. 3. Effect of anti-LRP single-chain antibodies and
IgG antibodies on the invasion of HT1080 cells. HT1080
cells were preincubated with anti-LRP scFv iS18, scFv C9,
and, as a negative control, HD37 at concentrations of
0.2 μg/μl or with IgG1-iS18 and IgG1-HD37 (negative
control) at concentrations of 0.5 μg/μl prior to application
onto the matrigel chamber. Invasive cells were stained
with toluidine blue, and after extraction of the dye,
absorbance was measured at 620 nm. NIH3T3 cells
displayed a less invasive behavior (51%) since they are
nontumorigenic. The percentage of untreated HT1080
cells (w/o antibody) that invaded the matrigel was set to
100%. Treatment with scFv iS18 reduced the invasion of
HT1080 cells by 37% (*p=0.01) compared to cells treated
with scFv HD37. Cells treated with IgG1-iS18 displayed a
significantly reduced invasion by 38% (*p=0.03) com-
pared to cells treated without antibody. Experiments were
performed in triplicate; data are representative of three
independent experiments. One experiment included six
wells per experimental series.in the number of cells that invaded the matrigel by
35% (p=0.0001) (Fig. 5). We did not observe
significant effects on the reduction of invasion by
SP-54 concentrations below 0.2 μg/μl. HM2602
reduced the invasive potential of HT1080 cells by
20%. An unspecific carboxymethylated dextran
(CMD) had no effect on the invasive potential of
HT1080 cells (Fig. 5).
HT1080 cell adhesion to laminin-1 is blocked by
anti-LRP/LR tools
To elucidate the molecular mechanism by which
the anti-LRP/LR reagents interfere with the invasion
of HT1080 cells, we analyzed their potential to block
the binding of HT1080 cells to laminin-1. Laminin-1-
mediated adhesion was significantly blocked after
preincubation of HT1080 cells with anti-LRP scFv
iS18 by approximately 60% (p=0.00001) and full-
length IgG1-iS18 by 68% (p=0.001) (Fig. 6a and c). In
addition, pretreatment of cells with SP-54 or the
heparan mimetic HM2602 significantly decreased the
laminin-1-dependent attachment by 79% and 81%
(p=0.0002), respectively, compared to nontreated cells
(Fig. 6d). CMD, which had no effect on the invasion of
HT1080 cells, did not significantly influence the
adhesion of the cells to laminin-1 as well (Fig. 6d).
Anti-LRP/LR antibodies are noncytotoxic on
HT1080 and NIH3T3 cells
Cell viability in the presence of anti-LRP anti-
bodies and cell count were assessed by trypan blue
Fig. 4. HT1080 cells transfected with siRNA expressing
lentiviral plasmids downregulating LRP display a
reduced invasive behavior. (a) Western blot analysis of
LRP level in HT1080 cells transfected with siRNA
expression vectors pENTR-siRNA-LRP 4, -LRP 7, and
-LRP 9, respectively. The 37-kDa LRP was detected 24 h
after transfection by anti-LRP antibody S18. Compared to
cells transfected with the control vector pENTR lamin A/
C (lane 1), cells transfected with pENTR-siRNA-LRP 4,
-LRP 7, and -LRP 9 show reduced LRP levels (lanes 2–4) by
53% (siRNA 4), 36% (siRNA 7), and 41% (siRNA 9),
respectively. β-Actin was used as a quantitative loading
control. (b) HT1080 cells transfected with pENTR-siRNA-
LRP 4, -LRP 7, and -LRP 9, respectively, downregulating
LRP, exhibit a decreased invasion rate analyzed 24 h after
transfection with the corresponding lentiviral plasmids by
36%, 39%, and 37%, respectively (*p=0.014), which is
comparable with the less invasive NIH3T3 cells (56%).
HT1080 cells transfected with pENTR-siRNA-lamin A/C
were set to 100% invasion rate. One experimental series
was investigated sixfold.
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effect of the antibodies used up to a concentration of
0.2 μg/μl. After 24 h of incubation time, the
antibodies had no effect on proliferation or cell
viability, confirming that neither scFv iS18 nor IgG1-
iS18 is toxic to HT1080 and NIH3T3 cells.Fig. 5. HT1080 cells treated with the heparan mimetic
HM2602 and SP-54 revealed a less invasive potential.
HT1080 cells were preincubated with HM2602, SP-54, and
CMD as a negative control at concentrations of 0.2 μg/μl.
Cells were applied onto a matrigel-filled transwell, and
invasion was determined by measurement of toluidine-
blue-stained cells at 620 nm. SP-54 reduces the invasion by
35%, significantly (**p=0.0001) comparable to the less
invasive NIH3T3 cells. HM2602 decreased also the
invasive potential of HT1080 cells by 20%. The percentage
of untreated HT1080 cells that invaded the matrigel was
set to 100%. One experiment included six wells per
experimental series. Three independent experiments
were performed.Discussion
The metastatic potential of the 37-kDa/67-kDa
LRP/LR has been recently investigated in various
studies, indicating its important role in cancer
progression. For dissemination and de novo blood
vessel formation, invasive and metastatic cells have
to cross basement membranes. Overexpressed in
tumorigenic cell lines, the 67-kDa LR acts through
the proteolytic cleavage of laminin-1, which is a
relevant event in basement membrane degradation3
and within the migration process. The 67-kDa LR29
and the 37-kDa LRP30 mediate laminin-induced cell
attachment. An important role for the 37-kDa LRP intumor progression has been described in the
treatment of mice with lung cancer cells displaying
a reduced 37-kDa LRP level due to an introduction
of antisense LRP/p40 mRNA. Mice subcutaneously
inoculated with these cells displayed a prolonged
survival,30 suggesting that the 37-kDa LRP might
influence cell adhesion, tumor progression, and the
metastatic potential.
In some other cancers, αVβ3, α6β4 and other
integrins are clearly overexpressed, and their sup-
pression significantly reduces metastasis, as shown
recently for breast cancer metastasis.31 These integ-
rins may interact, for example, with laminin-5 or
with fibronectin and other basement membrane
components. As mentioned above, LRP/LR plays
an important role in laminin-1 cleavage, resulting in
basement membrane degradation3; another very
important process of extracellular matrix degrada-
tion favoring tissue invasion is related to the action
of equally overexpressed matrix metalloproteinases
(MMPs), which are turned on through integrins.
HT1080 cells, used in this article for laminin-1–LRP/
LR adhesion studies and invasion assays, over-
express MMP-2 and MMP-9 via an integrin–fibro-
nectin interaction.32
In this article, we investigated the effect of tools
directed against the 37-kDa LRP in invasion assays
and laminin-1-mediated cell adhesion. To investi-
gate whether tumorigenic fibrosarcoma HT1080
cells reveal increased LRP/LR levels compared to
the nontumorigenic embryonic fibroblast cell line
NIH3T3, we performed Western blot and FACS
analyses. HT1080 cells revealed an approximately
1.6-fold higher LRP/LR cell-surface expression level
Fig. 6. Cell attachment to laminin-1 is inhibited by anti-LRP/LR tools. (a) HT1080 cells were incubated with anti-LRP
scFv iS18 and scFv C9 as a negative control. Cells were applied onto a 96-well plate, either coated with laminin-1 or
uncoated (w/o laminin-1), for 1 h at 37 °C. After the attached cells were extensively washed with PBS, they were stained
with 0.1% crystal violet and absorbance was measured at 570 nm. Untreated cells (HT1080 only) attached to laminin-1
were set to 100%. Cells attached to the uncoated plate (w/o laminin-1) represent the background binding. Preincubation
with scFv iS18 (0.2 μg/μl) resulted in a significantly reduced adhesion of cells to laminin-1 by 60% compared to scFv C9-
treated control cells (***p=0.00001). (b) Representative photograph of laminin-attached HT1080 cells stained with 0.1%
crystal violet. This image was taken prior to extraction of the color and measurement of the absorbance at 570 nm. The
staining correlates with the percentage of laminin-attached cells. Row 1 represents HT1080 cells only; rows 2 and 3 display
cells preincubated with scFv C9 and scFv iS18, respectively, before application to the laminin-1-coated well. (c) HT1080
cells were incubated with IgG1-iS18 and IgG1-HD37, respectively (each 0.2 μg/μl), before they were applied to the
laminin-1-coated plate. Untreated cells attached to laminin-1 were set to 100%. IgG1-iS18-treated cells revealed a reduced
adhesion to the plate by 68% (**p=0.001). (d) HT1080 cells preincubated with 0.2 μg/μl of HM2602 and SP-54,
respectively, and subsequently added to the laminin-1-coated well. Attachment of cells is reduced by 79% and 81%,
respectively (***p=0.0002). One experiment included 6 wells per experimental series. Three independent experiments
were performed.
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genic cell line displayed a reduced invasive behavior
observed in the applied invasion studies, we suggest
a relationship between the lower 37-kDa LRP/LR
level on the cell surface and the invasive potential.
We want to point out that in all invasion studies
performed, the NIH3T3 cells reveal a lower invasive
potential compared to the tumorigenic HT1080 cells.
Some of our anti-LRP/LR tools (e.g., anti-LRP
antibodies scFv iS18 and IgG1-iS18 and pentosan
polysulfate) reduced the invasive potential of
HT1080 cells even below the invasion rate of the
nontumorigenic NIH3T3 cells. The relatively high
invasion rate (50–80%) observed in the reported
nontumorigenic NIH3T3 cell line might be due to a
transformation that has been reported to occur
spontaneously in cell culture.33,34
Although cell-surface staining by FACS demon-
strates a higher LRP/LR level for HT1080 cells, the
total LRP/LR content did not differ significantly as
analyzed by Western blotting, which might be due
to the high intracellular LRP levels localized in the
translational machinery35 and the nucleus.36 How-
ever, since the laminin–LRP/LR interaction takesplace on the cell surface, only the cell-surface level of
LRP/LR is thought to be crucial for the tumorigenic
potential of cells. Although scFv S18 mainly
recognizes LRP by Western blotting, FACS analysis
employed for cell-surface detection of the receptor
cannot reveal which of the LRP/LR isoforms are
detected on the cell surface.
Anti-LRP/LR antibodies scFv iS18 and IgG1-iS18
significantly reduced the invasive potential of
HT1080 cells by 37% and 38%, respectively, and
were shown to significantly inhibit laminin-1-
mediated cell attachment by 60% and 68%, respec-
tively, suggesting that the inhibition of LRP/LR–
laminin-1 binding on the cell surface contributes to
the reduction of the invasion. Recently, we showed
that transfection of siRNAs directed against LRP
mRNA efficiently downregulates LRP/LR expres-
sion, resulting in a reduction of PrPSc propagation in
neuronal cells.26 In order to investigate whether
reduced LRP/LR levels in tumorigenic cells also
diminish the invasive potential, we transfected
HT1080 cells with recombinant lentiviral plasmids
expressing siRNAs directed against LRP mRNA.
Indeed, transfection of HT1080 cells with lentiviral
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expressing siRNAs directed against LRP mRNA
resulted in downregulation of the 37-kDa LRP level
by approximately 44%, concomitant with a signifi-
cant reduction by 37% of HT1080 cells invading the
matrigel.
Since the downregulation of the invasiveness by
pENTR-siRNA-LRP 4, -LRP 7, and -LRP 9 (approxi-
mately 37%) is similar to the effect of anti-LRP/LR
antibodies scFv iS18 and IgG1-iS18 (reduction by
37% and 38%, respectively) and given the fact that
LRP expression is reduced by approximately 44%,
these data suggest that transfection may primarily
affect cell-surface expression of LRP/LR. Our data
suggest that reduction of the LRP/LR levels in
tumorigenic cells by an siRNA approach might
represent an alternative strategy for reducing the
metastatic potential of tumor cells.
HSPGs are sulfated polyanions, either secreted or
membrane bound, which consist of a protein moiety
to which various sulfated glucosaminoglycans
(GAGs) are attached. HSPGs play a critical role in
the regulation of tumor progression, invasion, and
metastasis28 and contribute to cell adhesion.37
Depending on the protein core, GAGs, GAG-
associated molecules, or tumor-cell-specific factors
may reveal tumor-promoting or -suppressing
activities.38 Therefore, various treatment strategies
targeting HSPGs have been developed.38,39 HSPGs
act as coreceptors for PrPc,40 and polysulfated
glycans such as heparan mimetics and pentosan
polysulfate (SP-54) are able to inhibit the LRP-
mediated prion uptake, most likely by blocking
LRP/LR on the cell surface.7 Therefore, we tested the
influence of polysulfated glycans on the LRP/LR-
mediated invasion and the LRP/LR–laminin-1
binding on HT1080 cells. The pentosan polysulfate
SP-54 and the heparan mimetic HM2602 signifi-
cantly reduced the invasion of HT1080 cells by 35%
and 20%, respectively. SP-54 and HM2602 signifi-
cantly decreased the binding of HT1080 cells to
laminin-1 by approximately 80%, suggesting that the
reduction of the invasive potential of HT1080 cells by
these polysulfated glycans is due to the blockage of
the laminin-1–LRP/LR interaction on the cell sur-
face. It is also conceivable that anti-LRP/LR-tool-
treated HT1080 cells may migrate slower through
the matrigel or adhere more slowly to laminin-1. The
slightly better effect of SP-54 (81%) on the inhibition
of the laminin–HT1080 adhesion compared to
HM2602 (78%) can hardly explain the fact that SP-
54 reduces HT1080 invasion by 35% compared to the
reduction of invasion (20%) by HM2602.
Since it has been reported that laminin interaction
with the 67-kDa LR promotes invasion,24 we
analyzed, employing an adhesion assay, whether
our anti-LRP/LR reagents, for example, anti-LRP/
LR-specific antibodies and polysulfated glycans,
block the binding of cells to laminin-1-coated plates.
We show that our anti-LRP/LR-specific antibodies
scFv iS18 and IgG1-iS18 block the adhesion of
HT1080 cells to laminin-1 by 60% and 68%,
respectively. The polysulfated glycanes HM2602and SP-54 interfere with the laminin-1–HT1080
adherence by even 80%. If one would deduce the
background binding of HT1080 cells to noncoated
plates, which represents 30%, anti-LRP/LR antibo-
dies and polysulfated glycanes would almost
completely block laminin-1-specific binding. This
correlates with the finding that a higher LRP/LR
expression level corresponds to a higher adhesion to
laminin.29 Our data suggest that the reduction of
invasiveness of HT1080 cells achieved by our anti-
LRP/LR tools might be due to the interference of the
laminin-1–LRP/LR interaction on the cell surface.
The exact mechanism by which our anti-LRP tools
such as antibodies and polysulfated glycans func-
tion, for example, influencing the MAPK signaling
cascade induced through laminin, sterical blockage
of the laminin binding site, or directly occupying the
binding site for laminin, has yet to be examined. For
cancer therapy, maybe a combination therapy
targeting (i) LRP/LR, (ii) the interaction of αVβ3
or α6β4 with laminin-5 or with fibronectin,31 and
(iii) the integrin–fibronectin interaction leading to
overexpression of metalloproteinases32 might be, at
least for some types of cancer, very effective.
The significant reduction in the invasive potential
of HT1080 cells due to the blockage/inhibition of the
37-kDa/67-kDa LRP/LR or the downregulation of
LRP suggests an alternative strategy in cancer
treatment. A previous study confirmed that passive
delivery of scFvs into mice revealed no side effects25
and that a polysulfated glycane (HM PI8841) is
currently being tested in a clinical phase III trial. (i)
Transfer of anti-LRP/LR antibodies by passive
immunization, (ii) application of polysulfated gly-
canes such as SP-54, and (iii) gene delivery of
siRNAs directed against LRP mRNA by appropriate
gene delivery systems such as lentiviral vectors into
tumorigenic animals will demonstrate whether our
anti-LRP/LR tools might be potential therapeutics
for the treatment of cancer.Materials and Methods
Cell culture and conditions
Human fibrosarcoma cells (HT1080) and mouse
embryonic fibroblast cells (NIH3T3) were cultured in
Dulbecco's modified Eagle's medium (DMEM) high
glucose (4.5 g/l) (Invitrogen Gibco) supplemented with
10% fetal calf serum, nonessential amino acids, and
penicillin/streptomycin at 37 °C in a humidified 5% CO2
atmosphere.
Reagents and antibodies
Matrigel™ originating from the mouse Engelbreth–
Holm–Swarm tumor was obtained from Sigma (Munich,
Germany). For cell adhesion assays, laminin-1 was
purchased from Sigma. The anti-LRP/LR antibody scFv
S18 and C9 (scFv directed against the hepatitis B cell-
surface protein preS1) were overexpressed in E. coli RV308
according to Zuber et al.25
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An improved version of the scFv S18,25 termed scFv
iS18, was generated by permutations of residues in the
CDR3 of the light chain. An scFv phage display library
of 8×107 different clones with retained S18 VH and
permutated light chains was cloned. The light chains
contained complementarity determining region 3 regions
with stretches of four to seven random amino acids
[CNSR (N)4–7 VLFG]. Four rounds of selection were
performed using biotinylated GST∷LRP fusion protein
expressed in baculovirus-infected Sf9 cells42 as a target.
To increase the stringency, we reduced by 10-fold the
antigen concentration in every panning round, starting
with a concentration of 10 nM in the first round. Prior to
every selection round, the library was consecutively
preadsorbed to polystyrene-coated GST and streptavi-
din-coated paramagnetic beads (Dynal, Oslo, Norway)
in order to remove binders to these proteins. The
streptavidin-coated beads were used to capture the
biotinylated antigen and bound phage. After extensive
washing, bound phage particles were used for infection
of E. coli XL1-Blue cells without preceding elution. Cells
successfully transduced with phagemids encoding scFvs
were selected for ampicillin resistance and subsequently
infected with M13K07 helper phage to generate phage
progeny displaying scFv for the following selection
round. After the fourth panning round, individual scFvs
were expressed and tested for their binding ability as
described.25 scFv iS18, revealing the highest affinity, was
subcloned into an expression vector, expressed, and
purified as described for scFv S18.25 The Kd of iS18 was
estimated by ELISA according to Zuber et al.25 as
5.6×10−10 M (parental scFv S18: Kd=5.1×10
−9 M25).Generation of full-length IgG1-iS18 and IgG1-HD37
The full-length antibody IgG1-iS18 was constructed as
follows. The variable domains of the light chain and heavy
chain were amplified individually by PCR and cloned
separately into two different mammalian expression
vectors containing the respective human constant
domains. The vectors pEU1.2 and pEU4.2 were kindly
provided by Cambridge Antibody Technology,43 repre-
senting an integrated vector expression system for the
eukaryotic expression of antibodies or their fragments
after selection from phage display libraries.43 IgG1-iS18
was transiently expressed in HEK293 cells. Antibodies
were purified from the supernatant by protein A
Sepharose. Approximately 5 mg of IgG1-iS18 was
synthesized per 1 l of culture medium.
IgG1-HD37, directed against the human B-cell-surface
receptor CD19, was used as a negative control. IgG1-
HD37 was expressed in HEK293 cells and purified
according to IgG1-iS18. Approximately 8 mg of protein
was produced per 1 l of culture medium.
For cell attachment studies and invasion assays, the
heparan mimetic HM2602 and pentosan polysulfate (SP-
54)7 were used in concentrations of 0.2 μg/μl (20 μg per
100 μl cell suspension containing 104 cells). CMD7 was
used as a negative control.Epitope mapping
To determine the binding site of IgG1-iS18 to LRP, the
entire amino acid sequence of human LRP was spotted
onto a membrane and immunodetection with IgG1-iS18was performed as described for Western blotting. For
detection of the bound IgG1-iS18, a horseradish
peroxidase (HRP)-coupled secondary anti-human anti-
body (1:10,000) was used. The membrane encompasses
92 different synthetic peptides with a length of 15
amino acids. The N terminus of each peptide was
shifted with respect to the previous peptide by 3 amino
acids, leading to an overlap of 12 amino acids. Synthesis
was performed on a cellulose membrane (AIMS,
Braunschweig) using Fmoc chemistry (PyBop/NMM
activation, Trt/tBu/Pbf/Boc side-chain protection)
according to the SPOT-synthesis method of Frank44
using a spotting robot (Syro, MultiSynTech GmbH,
Witten, Germany).
FACS analysis
For determination of LRP/LR expression, cells were
detached in phosphate-buffered saline (PBS)/1 mM ethy-
lenediaminetetraacetic acid (EDTA) to prevent trypsiniza-
tion of LRP/LR on the cell surface, fixed with 4%
paraformaldehyde, and resuspended in FACS buffer
containing 0.01% sodium azide, 20 mM EDTA, and 2%
fetal calf serum in 1× PBS. For cell-surface staining of
LRP/LR, cells were incubated with the first antibody scFv
S18 (dilution 1:50 in FACS buffer) or scFv HD37 as a
negative control, on ice, for 1 h followed by three washing
steps and additional incubation with a fluorescein-
isothiocyanate-coupled anti-c-myc antibody (Santa Cruz)
(dilution 1:50 in FACS buffer) for 1 h on ice to detect the c-
myc tag coupled to the scFvs (see Ref. 25). For detection of
total LRP/LR, cells were permeabilized in 100% methanol
for 20 min at room temperature and treated further as for
detection of LRP/LR surface staining. Measurements and
evaluation were performed using a Beckman Coulter
EPICS flow cytometer and software. Data were collected
from three independent experiments comprising cells
from different cultures.
Western blotting
For determination of total LRP/LR levels, cells were
detached in PBS/1 mM EDTA and resuspended in lysis
buffer (10 mM Tris/HCl, pH 7.5, 10 mM EDTA, 100 mM
NaCl, 0.5% Nonidet-P40, and 0.5% desoxycholate). Thirty
micrograms of total protein was subjected to SDS-PAGE
and blotted onto a polyvinylidene difluoride membrane.
After the membrane was blocked in 10% horse serum in
PBS containing 0.1% Tween for 1 h, it was incubated with
S18 as the primary antibody for LRP/LR recognition.
After three washing steps in PBS/Tween, the membrane
was incubated with the secondary anti-c-myc (to detect the
c-myc tag on the scFvs) and a third anti-mouse-HRP-
coupled antibody for 1 h. For quantitative loading control,
the membranes were incubated in parallel with an anti-β-
actin antibody (1:5000, Sigma) followed by an HRP-
coupled anti-mouse antibody (1:10,000, Jackson Immu-
noResearch). The membranes were developed by
enhanced chemiluminescence reagents (Perkin Elmer
Life Sciences).
Transfection of HT1080 cells with recombinant
lentiviral plasmids expressing siRNA directed against
LRP mRNA
Cells were seeded into six-well plates the day prior to
transfection. Transfection with plasmids encoding for
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4, -LRP 7, and -LRP 9 (Ludewigs, H. et al., unpublished
data) was done using gene porter reagent 2 (Peqlab)
according to the manufacturer's instructions. As a
negative control, cells were transfected with pENTR-
siRNA-lamin A/C directed against lamin A/C mRNA
(control) (Invitrogen).
Invasion assay
This assay, also termed chemoinvasion assay, is used
to detect and quantify the capacity of the cells to invade
a matrigel-coated transwell chamber. Culture inserts
(Nunc, 8 μm pore size) were filled with Matrigel™
diluted in DMEM (Gibco) and set into a 24-well plate
filled with serum-containing medium (DMEM). Conflu-
ent cells were adjusted to 106 cells per 100 μl of cell
suspension, resuspended in serum-free media, and
applied onto the matrigel-filled transwell chamber.
After 18 h incubation, noninvasive cells were scraped
off with a cotton swab and invasive cells were fixed and
stained with toluidine blue. The dye was solubilized by
incubation at 37 °C in a 1% SDS solution for 1 h, and
samples were measured at 620 nm using an ELISA
reader. The fraction of invasive cells was calculated as
follows: % invasion=number of invasive cells×100/total
number of cells. One experiment comprised 6 wells per
experimental series. Each experiment was repeated at
least in triplicate, which includes different plates contain-
ing cells from another culture.
Cell adhesion assay to laminin-1
The adhesion assay was performed on 96-well plates
coated with laminin-1 (0.2 μg/μl) (Sigma) at 4 °C
overnight. To ensure that cells can only bind to laminin-
1, we used plates without precoating (for suspension cell
culture). In addition, to detect potential unspecific
binding of cells, we used plates without laminin-1
precoating in parallel. Surfaces were blocked with 1%
bovine serum albumin in PBS for 1 h at 37 °C. HT1080
cells in serum-free medium were added to wells (104
cells/well) followed by incubation for 1 h at 37 °C. To
examine the influence of the anti-LRP/LR antibody, we
preincubated cells for 10 min with scFv iS18 (0.2 μg/μl)
and scFv C9 (0.2 μg/μl, as a negative control) or with
IgG1-iS18 (0.5 μg/μl) and IgG1-HD37 (0.5 μg/μl, as a
negative control). In case of heparan studies, CMD was
used as a control. After the attached cells were
extensively washed with PBS, they were fixed in 3.7%
formaldehyde and stained with 0.1% crystal violet. The
pigment was extracted with 33% acetic acid for 5 min,
and the absorbance was measured at 570 nm as an
indicator of cells attached to laminin-1. One experiment
comprised 6 wells per experimental series. Each experi-
ment was repeated at least in triplicate including different
plates and cells from another culture.
Evaluation of in vitro cytotoxicity of anti-LRP/LR
antibodies and siRNAs directed against LRP mRNA
HT1080 cells were cultured in the presence of anti-LRP
antibodies for 2 and 24 h. The maximum concentration of
the antibodies used was 0.2 μg/μl (20 μg per 104 cells).
After the viable cells were stained with trypan blue, they
were counted and compared to cells treated without
antibody. HT1080 cells transfected with pENTR-siRNA-LRP 4, -LRP 7, and -LRP 9 displayed normal growth
behavior at least 1 week after transient transfection.
Data analyses and statistics
Statistical analyses were performed using a Student's t
test. p-Values of less than 0.05 were considered significant.
Values were expressed as mean+SD.Acknowledgements
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ABBREVIATIONS 
 
1-character code for amino acids 
A  alanine  
C  cytseine 
D  aspartic acid  
E  glutamic acid 
F  phenylalanine 
G  glycine 
H  histidine 
I  isoleucine 
K  lysine 
L  leucine 
M  methionine 
N  asparagine 
P  proline 
Q  glutamine 
R  arginine 
S  serine 
T  threonine 
V  valine 
W  tryptophane 
Y  tyrosine 
 
%      percentage 
37 kDa LRP     37 kDa laminin receptor precursor 
67 kDa LR     67 kDa laminin receptor 
aa      amino acid 
AAV      adeno associated virus 
approx.      approximately 
APP      amyloid precursor protein 
BBB      blood brain barrier 
BSE      bovine spongiform encephalopathie 
Caco-2/TC7     human enterocytes 
cDNA      complementary deoxyribonucleic acid 
CHO      chinese ovary hamster cells 
CJD (sCJD, vCJD, fCJD, iCJD) Creutzfeldt-Jakob disease (sporadic, variant, familial, 
iatrogenic form of CJD) 
CLD caveolae-like domains 
CNS central nervous system 
C-terminal carboxyterminal 
Cu2+ copper (II) ion 
CWD Chronic wasting disease 
DNA desoxyribonucleic acid 
Dpl doppel 
DWM-R cervid enterocytes 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
ER endoplasmatic reticulum 
EU European Union 
EUE Exotic ungulate encephalopathy 
FBJ fetal bovine enterocytes  
Fab antigen-binding Fragment 
Fc constant region of Ig 
FFI      Fatal familial insomnia 
FSE      Feline spongiform encephalopathy 
GAG      Glycosaminoglycan 
GPI      glycosyl-phosphatidyl-inositol 
GSS      Gerstmann-Sträussler-Scheinker Syndrome 
h      hour 
hGH      human growth hormone 
hGNH      human gonadotropin 
HM      Heparan sulfate mimetic 
Hsp      heat shock protein 
HSPG      Heparan sulfate proteoglycan 
HT1080 human fibrosarcoma cells 
Ig Immunoglobulin 
IPEC-J2 duodenal jejunum piglet cells 
kb kilobase 
kDa kilodalton 
M Molar 
MCX-7 human breast carcinoma cells 
µg microgram 
mg milligram 
ml milliliter 
mRNA messenger RNA 
N2a mouse neuroblastoma cells 
NIH3T3 mouse fibroblast cells 
NMR nuclear magnetic resonance 
N-terminal amino-terminal 
PCV polymerase chain reaction 
PK proteinase K 
PRNP prion protein gene 
PrPc cellular Prion protein 
PrPSc prion protein scrapie 
PrP0/0 prion protein knock out  
PrPres protease resistant form 
CtmPrP/NtmPrP transmembrane forms of the prion protein 
PS pentosan polysulfate 
rER      rough endoplasmatic reticulum 
RNA ribonucleic acid 
ROS reactive oxygen species 
SAF scrapie associated fibrils 
scFv single chain fragment variable 
ScN2a scrapie infected mouse neuroblastoma cells 
SDS sodium dodecylsulfate 
SDS-PAGE SDS polyacrylamide electrophoresis 
sFI  sporadic familial insomnia 
Sho shadow of the prion protein, shadoo 
siRNA small interfering RNA 
SOD      superoxid dismutase 
ST-1 stress inducible protein 
Tg transgeneic/transgene 
TME      Transmissible mink encephalopathy 
TSE transmissible spongiform encephalopathy 
UK United Kingdom 
US/USA United States of America 
VH variable heavy chain of Ig 
VL variable light chain of Ig 
VEE Venezuelan enquine encephalitis virus 
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